### UNITED STATES DISTRICT COURT FOR THE DISTRICT OF MASSACHUSETTS

	)
JOHN HANCOCK LIFE INSURANCE	)
COMPANY, JOHN HANCOCK	
VARIABLE LIFE INSURANCE	)
COMPANY, and MANULIFE INSURANCE	)
COMPANY (f/k/a INVESTORS	)
PARTNER LIFE INSURANCE	)
COMPANY),	) CIVIL ACTION NO. 05-11150-DPW
Plaintiffs,	)
	)
V.	)
	)
ABBOTT LABORATORIES,	)
	)
Defendant.	)
	)

### <u>AFFIDAVIT OF STEPHEN J. BLEWITT</u> <u>CONTINUATION OF EXHIBITS</u>

### PLs' MB



Interoffice Correspondence

From: Matt Russell PPD R&D Finance

D-404, AP9 Ext. 5-3482

Date: March 2, 2001

TO:	Bob Funck	D-404 AP9	Mike Higgins	D-404 AP9
	Tom Woidat	D-404 AP9	Mike Comilla	D-404 AP9
	Kirnes Holland	D-404 AP9	Paula Bourland	D-404 AP9
	Mischelle Vidakovic	D_404 A PQ		

Subject: 2001 PLAN FINAL Reference Package

Attached you will find a copy of the 2001 PLAN FINAL Reference Package. This package has consolidated many of the key schedules we used in the PLAN. Hopefully, this will make referencing numbers from the PLAN easier for everyone. Please let me know if you have any questions.

шсиих



## 2001 PLAN

FINAL Reference Package

Data as of February 16, 2001

### 2001 PLAN Reference Package

### Table of Contents

Descriptions	Page #
FINAL OpCost (As of 2/9/2001) - Summary Pages - Monthly Gaiting - Grant Gaiting - All Other OpCost Pages	1-5 6-11 12-17 18-27
Key Issues in 2001 - Plus/Minus List - Funded/Unfunded Studies by Compound - Key Statistics (Final Venture Pkgs.) - Spending by Phase of Development	28 29-30 31-46 47-48
Target Detail/Book Pages to Division  R&D Summary Global/Domestic Split (Page 100) Global Al Split (not submitted to Div.) Corp. Submission vs. FINAL PLAN Targets McKinsey Expense Summary (Potential Savings) R&D Executive Summary	49 50 51 52 53 54-55
Other Miscellaneous Schedules - PLAN Gaiting Rollforward (Gross & Net) - Project Funding by Phase - Expense Summary (Al/PPD Splits) - Detall of "Other"	56-57 58 59 60
Task Backup/Rollforwards	61-62
Headcount	63-68
Capital - Final PLAN - Task Related	69-72 73
Balance Sheet	74-75
Depreciation	76
Floorspace	77-79
Miscellaneous Fixed Expenses (Burden File)	80-84
Key Unfunded List	. 85

Note: IDV's were issued in a separate package on 1/5/2001.

LNGROUP/Russel/(Title Pages for Packages/(Table of contents ref. pkg.ids)/Sheeti

**ШСШ**У

# FINAL Opcost

шана

Operating Cost Statement								
(\$000)					<del> </del>			
			Book!		[	Ì		
		09/25/00 FINAL	ORACLE 2001	10/24/2000	12/01/00-1/30/00 CURRENT		FINAL	DI PLAN
	ZOOO ACTUALS		,	PRIOR		TOTAL	2001	VS'
	ASTUALS	DO AGU	PLAN	ADJS	ADJ5	ADJS	PLAN	DO AGU
Pharmacoulical Discovery	134,725	134,688	145,324	_	(4,688)	(4,688)	140,636	(5,948
-New Technology (accil # 742-505)	17,438	16,160	16,914	-	(4,488)	(4,468)	12,445	3,714
Yotal Pharmaceutical Discovery	152,153	150,848	162,238		(9,156)	[9,156]	153,002	(2,734
	[				1	• • • •	·	
Drug Safety Evaluation		8,269	***					11.4
-Experimental Science	7,541	970	10,126	-	(1,507)	(1,507)	8,619	(330
-Drug Safety Grants	ا ۔۔۔۔ا	5,693	1,640 5,588	-	(1,012)	(1,012)	628	342 561
-Clirical Drug Analysis	5,788	5,593 171	385		(459) (185)	(459) (185)	5,129 200	
-Drug Safety Grants	6,821	7,950	7,207	-	(740)		6,469	6
-Todoslogy -Drug Safety Grants	انتشرا	3,511	2,188	-	(702)	(740) (702)	1,485	7. 7. 2.025
-Pathology	3,817	2,901	3,597	-	127	127	3,724	纠织新
-Drug Safety Grants		605		_	220	220	220	A 74 1975
Comparative Medicine	11,152	10,963	11,219	•	(197	(197)	11,022	部扩充
Admin & Strateoic	850	915	P94		(87)	(87)	907	STY SER
-Strategic & Exporatory Science	3,377	3,423	3,787	_	(345	(345)	3,442	
Total Drug Salety Evaluation	39,175	41,134	42,520		(3,208)	(3,208)	39,312	7 1,622
			,	_	(-,	(4,200)	,7	
Hodical Attains	1 1				i f	ŀ		建筑
- Genetics/Admin	4,161	4,819	5,645	-	(2,703)	(2,703)	2,942	計量概
- Nedical Services	6,996	6,675	7,454	-	(58)	(56)	7,398	
- Clinical Pharm	ا ا	1,358		-		1		
- Outcomes Res/Admin	1,430		1,542	-	201	201	1,743	
- Phasa IV	8,201 20,788	8,137	5,645 21,285		61	51	6,706	5 21 6 (589
Total Medical Allairs	, 20,760	16,789	21,200	-	(2,497)	[2,497]	18,789	
Information Mgmt & Technology				'	: <b>1</b>	1	i	
- Resource Management	-	_	_	_			_	
- Client Management	1,654	2,055	2,471	-	ल	m	2,454	1000
- Technology Management	44,502	44,763	48,529	_	(1,484)	[1,484]	47,945	1,72,202
- Emerging Tech Mgt	-		_		l l	[		3.76
- I M & T Admin	715	558	840				64D	· (196 (202
Total information Migral & Technology	46,571	47,376	51,840		(1,491)	(1,491)	50,349	A 100
Development Operations						- 1		
- Data Management	6,404	8,529	10,487	_	(835,5)	G.360	7,119	F15170
- Statistics	8,009	8,077	6,026		(1,590)	(1,590)	5,436	1541
- Abbott Res & Lib into Syca-ARLIS	3,093	3,243	3,607	_	(555)	(556)	3,251	
Total Development Operations	10,566	10,649	22,320	1	(5,514)	(5,514)	16,806	3,043
						`` ]	-	<b>A.E. S.T.</b>
Vonture Management -Cardiovescular/Dishetes (CD)	55	172	122					46.3
-Anti - Infective	5,783	5,381	P.439	-	(122) (707)	(122]		
-Anti - Veral	13,597	9,491	10,203	-	252	(707) 202	8,732 10,485	(P.25)
-Ansigssia/CCM	2,373	2,247	3,334	_	2414	2414	5,748	100
-Urology .	2,529	2,650	3,750		(1,729)	(1,729)	2,021	
-Molecular Therapeutics	2,639	3,102	4,,,,,	-	(1,,,2.5)	(		
-Neuroscience/Oxingiones			_	_	_	-		
-Oncology & Transplant (Cancer Morn)	6,450	6,655	6,574	]	810	810	7,384	图形 #28
Total Venture	33,726	29,708	73,022		925	925	34,350	15 5 (4.842
				_	1	,		1.11
Administration	16,853	18,312	20,312	_	(680)	(680)	19,652	130
Pharm Analytical R&D	62,454	63,142	62,721	_	(838,6)	(2,860)	58,853	2,7,28
•		9,000		_			•	
Regulatory Affairs	9,119	9,000	10,070	-	(648)	(648)	9,422	
Phase-1 Center	8,990	8,585	14,065		(4,398)	(4,398)	9,570	Ew (1,085
Total Functional	409,706	406,751	440,797		(30,512)	(30,512)	410,285	1
Ine Lambin	1		-40,191	i -	(30,512)	(34,512)	4 (U,285	
htī - Матромиг	3,550	3,988	6,567	(2,452)		(2,462)	4,105	
Clinical Grants						1		1
-Domestic	103,780	109,231	139,785	~ .m			444 55	4.00
-Adjustment	, ,,,,,,,	(B46	143,765	(26,467	4,710	(21,757)	118,028	10 (0 70) 1646
Total Clinical Grants	103,780	108,385	139,785	(25,467	4,710	D1 757	118 028	
			1 .	\ <i>a</i> ,+01	4,/10	(21,757)	1 10,020	
Services Purchased	52,599	57,834	53,226	(5,127	(9,527)	(15,854)	47,272	
SPD Purchases	54,991	G1,921	図,457	(5,110	(4,922)	(\$0,D3Z)	53,435	.245,10,486
Corporate Task	_	_	8,100		(001,50)	(8,100)		
•	ן ו				1	1		
Judgment - Internal	-	(10,930)	3		12,977	33,954	6,060	1100
Judgment - Published	j -	(3,642	(30,100)	5,000	15,300	Z0,300	003,8)	16 E 15
Gabbill reimburament from Commen	<u>.</u>	_	_	İ			_	13725
		_	, -	-	"	-	_	陸網網
Hand Post/Flash to Actual Adjustment	1		-	Ì	-	-	-	THE PERSON
Other Project Changes:	1		ł	ł			Ì	經驗以
		<u> </u>						1.1.1.1.1
Total Project Changes (For Exp Call)	-		_	-	-		-	m 125.1
	نصيبا			<u> </u>	ļ			1. 54.77.25.77.
Total Gross Expense	E24,636	626,307	663,948	(14,189	(20,374)	(34,563)	629,385	111.77
Services Sold	(249,043)	(251,517	(253,911)	(2,411	12,304	C25,2	(744 018	(A. 12)
				1	1			-F4.2
Net Total	375,593	374,730	410,037	(16,600	(070,63)	[24,570]	385,367	7-04-2 110-63
Targita ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) (	, 375,593	374,730	410.037	ينست تبريزون ا	2: 4 (8.070)			34(0.E)

MGHLY CONFIDENTIAL ABBT 0037513

	U	ú	ú	ı
,			4	

(2000)								
1			Book I					
	2000	09/25/00 FINAL	DRACLE 2001	10/24/2000 PRIOR	12/01/00-1/30/00 CURRENT	TOTAL	2001	DI PLAN
	ACTUALS	DD AGU	PLAN	ADJS	ADJS_	ADJB	PLAN	DO AGU
Patents & Trademark	5,564	6,585	5.976	74		74	6,050	· (485
Saletita Copy Charges	556	555	549	(10)		(10)	5239	-16
Corp Admin Fixed	4,880	4,995	5,126	102	217	319	5,445	(450)
Corp Cost Pools	5,031	5,175	5,231	(102	(59)	(161	5,070	. , 105
CHIAD Services Purchased Fixed (AHD)	193	197	197	(1)		m	196	
PPD Ops Fixed Allocations	2,607	2,522	3,232	_		-1	3,232	_ @10
CENG - Fixed Maintenance from PPD O	948	947	899			_	889	-48
CHEN Variable (EWRS)	323	141	147	-		-	147	/ (6
CMIS - Purchasing	697	697	733	14		14	747	(50)
CHMS Telecommunications	118	116	110	2	12	14	130	(14)
Fixed L. C. Exp - Atimin Services	415	410	427	m	(হা	(6)	421	15 - 09
Corp Eng EHS Food Allocation	559	<u>658</u>	· 591				597	
TOTAL CORPORATE ALLOCATION	21,869	21;678	23,230	78	165	243	23,473	11,595
CMIS - Unit of Activity, Fixed - Other	3,012	2,263	3,681	(747	(447	(5,194	2,857	(404
CARS - Unit of Activity, Fixed - Aegis	2,062	2,690	2,100	-		[	2,100	757.700
PPD Personnel DQA47	2,512	2,458	2,600		] 1	1	2,801	30.04
PPD Mig Ops - Allocation	60	60	60	3		3	53	32.10
PPD Ops QA Int Sycs/Reg Affairs	1,438	1,438	1,942	-			1,942	(504)
PPD Ops Returned Goods	130	131	136	-			136	. is
Project Expense (\$1MM)	10.815	11.208	11.208	<u>(B14</u>	1	(4,109)	<u>7,099</u>	4 109
TOTAL BURDEN FILE	41,898	42,324	45,137	(1,280		(5,056	40,081	Z,243
SPD Plief Plant Stack Card SPD Busk Direct	20,926 24,905	20,960 33,681	21,195 32,992	4,632 (12,674		3,302	24,497 17,328	11.517 11.553
Excess Capacity Stack Card	9,160	9,280	5.280	2,932	(602)	2,330	11,610	.315. (T 220)
Subtotal SPD (Other than TAP)	54,991	63,921	63,467	[5,110	. (4,922	[\$0,032	53,435	30 485
Grant/Out of Pocket Purchases: TAP Buts Drug (D-TAP)	47	125	125	(41		(41)	84	334
TAP - SPD Manpower & Bulk (D-453)	211	450			1	(205	245	205
Pharmacogenetics — ADD Allocation Misc Expense	-	_					-	
Subtotal (For Exp Cat)	228	675	575	(246	_	(245)	329	334
Other Purchases				<u> </u>				13.7.5.0.1
Ctarl Once-A-Day (Global Al Marpower) Corp Drug User Fees	10,189 1,918	11,393 1,951			1	(3,914) (831)	7,763 1,207	744
Patent to Operations (search services)	200	200		_	]		-	200
D-A54 Poor Space (not in functionals) D-A54 Deprec (not in functionals)	377	405 1,864	4	-	162	182 (49)	182 2,984	223
Molecular Probus	(6)	7	7	-	1	(,,,	7	100
Inventory transfer for Protease 2nd Gen	877	. (5,726 8,287		r5,000		(5,000)	_	(5,726) 15 8 287
SDG/Other Clinical Supplies (Tricia Geran -PPO Op	•	200			.)	(0,000	200	1-3
Angle Charges	228					- '	-	1
Library (D441) to CHAIS OA (D44N) to Operations	1,387	1,448					1,500	- C51
Sangstat (Cyclosporine)	_	(2,400		∮	. 360	350	-	12 400
Sangstat (Sangcya) Gabbiti Royally	] =	967	]	] -	-	_	] [	
RitonaviriLeRoche Combo			} _			-	-	
NOVO Sotiemeni Motabolox	(1,500			-	·[	***	-	(1,500
FLAP/Vanguard	(818)	(818	4 ~	] -		_	-	(818
Sanoli Cost Sharing w/Gabbil Ci charge from OPS (Clin Val Mgr) + \$4	]	(150		-	1	-	-	150
Contract Management System	47			] "	`	1	-	20.0
HPD R&D Purchased	411	L .		.{		-	-	
Yale Univ Sunivan Patent Staples Rebates	(68		] :	:		] _	] ]	<b>FERR</b>
Trianglo receipt \$2,935 +\$325 tor1999	(3,482		(5,38	· -	.] .	.)	(5,38	12,457
Serfindolo License Comdisco	2,440	2,440		1	1	-	1 -	2440
Hydrocadone (IDV-in from HPD)	-	.[	] [	4,02			] -	
CRD Rebates	(381	1 -	-	. (3,000		(3,000		
Gabitel Reimbursement from Commord Other	38		<u> </u>		1,400	1,400	<u> </u>	
Subjects) (For Exp Cat)	10,473	14,93	\$ \$7,57	(4,60	1 (6,05	110,65	6,86	2 . 8,073
Grand Total	107,590	121,75	126,69	(11,23	7) (14,74)	) (25,98I	100,70	

memx CONFIDENTIAL ABBT 0037514

Pharmaceutical Products Research & Develop Services Sold (\$000)

1	·	<del></del> -	Book (		·			
		09/25/00	ORACLE	10/24/2000	12/01/00-1/30/00	i	1	D1 PLAN
	2000	FINAL	2001	PRIOR	CURRENT .	TOTAL	2001	VS.
	ACTUALS	DOAGU	PLAN	ADJS	ADJS	ADJS	PLAN	DO AGU
								17 13
General Benefit		_ [					186,670	. 17
-Global Pharmaceutical	183,768	183,768	193,857	4,813	[12,000]	(7,187)	186,070	(2,902)
Direct Sister Benefit						لخمم	2.384	2,094
-R&D Sci Serv.	3,619	4,478	2,571	55	(242)	(187)		21.27
-Direct Service	4,125	3,794	3,975	(175)		(175)	3,800 6,184	2.088
Total Direct Support	7,744	8,272	6,545	(120)	(242)	(362)	0,104	
Total int'l Sister Div.	191.512	182,040	200,403	. 4.693	(12.242	(7,549)	192,654	610
TAP Judgment (Positive Controls)		-	-					
TAP Busk Drug (D-TAP)	17	125	125	(41)	3 J	(41)	B4	
TAP - SPD Manpower & Bulk	211	450	450	(205)	1 .	(205)	245	<b>美国智</b>
TAP - All Other	20,715	23,359	20,170	(575)	261	(314)	19,856	华色证3,503
Total TAP (Incl. Judgment)	20,943	23,834	20,745	(821)	261	(560)	20,185	
m. of the man of the same		1			1 1			
Domestic Sister Divisors:	9,442	10,575	9,689	(950)	95	(855)	8,834	<b>新联州</b>
HPD	2,268	1,896	2,340	43	1 1	43	2,383	487
ADD	4,312	4,584	4,810	(719)	      818	99	4,909	經濟學型
SPO	186	663	1,851	40	3	104	1,855	7772
ROSS	186	39	1,051	1			42	<b>福温</b> 斯
CPB		71	69	5	] "]	5	74	呼吸到巴
MIS	59	'''	69		; [	. 3		
AHD	-	-		1	1	·}	-	
CHMS Library Services	20	2				-		
Corp. Eng. Subtot <del>al</del>	16,300	17,930	18,801	(1,581	977	[E04]	18,197	
Other Sister Divisons:			•	l	1			
Corp. Admin.	1				}	1		<b>多時記</b>
-Corp. Admin.	71	42	23	1		1	24	
-Tan Rate Diff	481	451	485	'	1		485	120
-Symposken Expense	155	165	165		l		165	<b>技器是100</b>
Subtotal CHAD	687	658	673	1	-	1	674	医
	)			1		1 1		
PPD Product R&D:			12.096		i	119	12,215	
Mig Support (MC,PM)	14,283	10,780			'} -	113	263	
Mfg Support (PV)	124	285	263	-	1	-	200	
PPD Marketing (P5,P6)	4,658	5,414	4,920	- 1	(1,300)	(1,300)	3,620	Jan. 794
Subtotal Other	19,065	16,479	17,279	119	(1,300	(1,181)	16,098	1.381
				1		1		
VAT Refund	537	537			.1	_	_	537
PARD Services Sold Impact (Judgement)			(3,990	d _	.	{	(3,990	3.990
Rounding	(1)	(1)	, , ,	1 : -	1	\		E CONTRACTOR
· · · · · · · · · · · · · · · · · · ·								SHARING COLOR
Grand Total	249,043	251,577	253,911	2,411	(12,304	(9,893)	244,018	7,559
Memor.				<del> ,:</del>			40	<del>,</del>
INPUT Global Al from DetRoll file	N/A	183,76B	193,857	N/A	. N/A	N/A	186,670	1 :
Calculated above	N/A	183,768	193,857	N/A	. N/A	N/A	186,670	'
Key Check (s/b 0)	N/A		<del></del>	N/A	N/A	N/A		:
INPUT From J:\Drive File	N/A	210,626	219,877	N/A	N/A	N/A	211,72	1 1
Calculated above	N/A	210,628	219,877	N/A	N/A	N/A	211,72	<b>'</b>
Key Check (s/b 0)	N/A_	(2)		N/A	. N/A	N/A		<del> </del>
Sister Division Amount								
INPUT From DetRoll file	<b>N/A</b>	67,809	64,044	AUA.	NΔVA	N/A	61,33	
Calculated above	NA	67,809	60,054	N/A	N/A	N/A	57,34	3
Key Check (s/b 0)	N/A	***	3,890	N/A	N/A	N/A	3,89	7
Sister Division Reconciliation							<b></b>	
Sister Division Memos -Oracle	N/A	67,809 49,144	60,054 E7 254	N/A N/A	N/A N/A	N/A N/A	57,34 104,22	4
BP - Blue Plans . DC - Div Computing/Systems	N/A N/A	13,730	57,354 13,850	N/A	N/A	N/A	20,07	p
DO - Department Overhead	N/A	50	50	N/A	N/A	N/A	5	0
GO - Global Delivery	N/A	328,237	345,312	N/A	N/A	N/A	299,56	4
GD - Global Discovery	N/A	96,719	90,107	N/A	NA	ÀΛΑ	94,82	
P1 - Pharmacoutical Products	N/A	44,693	59,654	N/A	N/A	N/A	38,96 5.46	
TG - Triangle	- N/A	3,011	5,481	N/A N/A	N/A N/A	N/A N/A	, 5,46	1
TAP Pass Thru & Buik Drug not in Ora Other Judgement .	c N/A N/A	-	-	N/A	N/A	N/A	3,99	ō
Total	NA	<i>603,3</i> 93	631,842	N/A	N/A	N/A	524,50	5
INPUT Total Per Oracle	N/A	600,093	631,253	NA	N/A	N/A	624,47	1
	N/A	3,300	589	N/A	N/A_	N/A		4

HIGHLY CONFIDENTIAL ABBT 0037515

2001 PLAN
Pharmaceutical Products Research & Development
Clinical Grants
(\$000's)

07/18/01 09:07 AM

	2000 ACTUALS	09/25/00 FINAL 00 AGU	Book 1 ORACLE 2001 PLAN	10/24/2000 1 PRIOR ADJS	12/01/00-1/30/00 CURRENT ADJS	TOTAL ADJS	FINAL 2001 PLAN	OTPLAN
PPD SERVICE:								
Tiagabine/Gabitril Omniœf	(80)	2,600	1,900 4,800	(2,000)	(1,900) 200	(1,900) (1,800)	3,000	202600 3000
Depakote/Depakene	15,319	14,589 (45)	11,174	•••	(1,733)	(1,733)	9,441	512B
r-Pro-UK Fenofibrate (Foumier)	( <b>45</b> ) 799	(160)	2,250		(2,211)	(2,211)	39	(99)
Hematin	407	200	 200		600	600	600 200	(600)
PharmacoGenetics (Genset)	***	200	200	•••		•••	200	
TOTAL PPD SERVICE	16,400	17,184	20,324	(2,000)	(5,044)	(7,044)	13,280	22204
GLOBAL SERVICE:		•						
Ritonavir ABT-538	2,715	4,382	1,752	•••	(508)	(508)	1,244	5188
Protease 2nd Gen ABT-378 Dopamine	30,884	30,362	13,379	•••	9,196	9,196	22,575	77.87
KCO ABT-598	***		***	•••	380	380	380	200
ABT-594 (formerly CCM)	2,106	2,800	13,760 1,628	(13,051)	356 (1,628)	(12,695) (1,628)	1,065	7735
ABT-089 (formerly ChCM) Clarithromycin	2,314	4,448	4,210		(1,270)	(1,270)	2,940	7600
Ketolide ABT-773	23,093	23,137	46,382		1,023	1,023	47,405	(24·25B)
Prokinetic Macrolide - Dom Zileuton & 2nd Generation	•••	 1	***	***	***		•••	
BPH ABT-980	13,855	14,058	16,678	(11,416)	(5,262)	(16,678)		2058
Cyclosporine H2G (Medivir)	7,831 63	7,560	1,300	•••	(307)	(307)	993	200
Endothelin ·	2,056	2,440	8,794		10,457	10,457	19,251	
NS 49 Nippon Shinyakyu ABT-23 Bimoclomol (Biorex)	357	633			•••	***		
Anti-Mitotic ABT-751		•••	2,091	•••	(1,066)	(1,066)	1,025	25
Hytrin		•••	***		•••	•••	÷	
FTI (Famesyltransferase) MMPI (Metalloprotease)	116	231	1,346		(228)	(228)	1,118	
Taxane			4 740		(50)		1,621	
TSP Peptide Quinolone	843 680	968 638	1,710 5,000	•	(89)	(89)	5,000	4962
Cox II	157	131	784	•••	(653)	(653)	131	
Neuraminidase Adjustment (EVR)	123	(846)	•••		•••	•••		846
TOTAL GLOBAL SERVICE	87,203	90,942	118,814	(24,467)	10,401	(14,066)	104,748	
MISC:								
Vitamin D Analog/Iron Dextran Isotretinoin/Norvir Investigation	•••	76	•••	•••		•••	•••	
Adjustments	•••		•••			•••	***	
Dexmedetomidine/Zemplar (HPD	177	183	647	•••	(647)	(647)		183
Tranxene Reformulation Biaxin Reformulation			 /,		-	•••		
	177	259	647		(647)	(647)	••	259
GRAND TOTAL GRANTS	103,780	108,385	139,785	(26,467)	4,710	(21,757)	118,028	<b>系統領(9)643)</b>

ABBT 0037516

2001 PLAN Pharmaceutical Products Research & Development Operating Cost Statement (\$000)

02/19/01 D8:07 AM

. ,		09/25/00	Book! ORACLE	10/24/2000	12/01/00-1/30/00		FINAL	OTPLAN
	2000	FINAL	2001	PRIOR	CURRENT	TOTAL	2001	14.WS.43
	ACTUALS	00 AGU	PLAN	ADJS	ADJS	ADJS	PLAN	100AGU
SDG/Other .	B77	1,500	3,000	(3,000)		(3,000)		<b>到期的0</b> 0
HIV/Knoll/QD/Other		1,000						000
Aegis Insurance		952	•••		·	\ ·		1205
Genset#1		500						
IT Productivity Projects			2,000	(2,000)	(	(2,000)	<b>,</b>	
Neurosearch FTE \$2530, depr \$20					1			
Coactinon						1	•	[6] [1] [1]
SPD IDV Liponavir	•	. 607	•••		1		•••	
Triangle R&D					ł		•	
Data Management Absorbtion		1,078		• '	1	[		
Other New Products		2,650			}			THE SECOND
Quinolone In License Payment	· .	]			1			
Division Task	Į.			•••	ļ		•••	
HPD R&D Purchased	}	1	•••		1	1	ļ	
		•			}	1		
Total SDG/Other	877	8,287	5,000	(5,000	<u> </u>	(5,000		8,287

HIGHLY CONFIDENTIAL ABBT 0037517

PPRD FUNCTIONAL EXPENSE								•					COTACT No COTACT	
RECONCILIATIONS MONTH - \$ 2001 PLAN	η. 													
	01 PLAN	MAL	FEB	MAR	APR	MAY	JUNE	JULY	AUG	SEPT	OCT_	NOV		TOTAL
Discovery Deals * (742-505)	12,448		625	2,015	250 11,527	625 11,575	2,015 11,614	250 11,614 :	525 11,982	2,015 12,018	250 12,038	825 12,056		12,448 40,536
All Other Discovery* Subtotal Pharmacounical Discovery	153,082	11,481	11,481	11,507						<del></del>		<u> </u>		53,082
DRUG SAFETY			•											
Experimental Science	8,819	6239	697 52	714 52	715 52	718 52	732 52	733 52	734 52	721 53	722 53	723 53	723 53	8,619 628
Drug Safety Grants (742-200) Clinical Drug Analysis	628 5,129	52 423	423	424	425	425	431	432	432	428	428	429	429	5,129
Drug Salety Grants	200	17	17 525	17 537	17 537	17 538	17 544	17 645	17 548	16 542	16 543	16 544	16 544	200 6,459
Textcology  Drug Safety Grants	8,489 1,485	524 124	124	124	124	124	124	124	124	124	124	124	12Z	1,488
Pathology	3,724	299 · 18	300 18	307 18	307 18	308 18	319 16	32D 18	320 18	310 19	33 I	311 19	312 18	3,724 220
Drug Safety Grants Comparative Medicine	220 •11,022	915	916	917	B \$7	818	878	819	818	920	920	921 76	921	11,022
Admin & Strategic	907 5,442	75 284	75 284	75 265	75 285	75 285	75 290	76 290	78 291	78 287	76 287	268	77 268	3,442
Stratopic & Exploratory Science	59,312	3,210	3,220	3,259	3,261	3,265	3,309	3,315	3,318	3,284	3,287	1,292	3,292	38,312
Substal Drug Safety MEDICAL AFFAIRS	23,42	4,2,10		•										
Administration (Clip Res - CNS)	2,942	226	227	227	247	248	255	255 820	256 521	250 623	250 524	251 625	250 627	2,942 7,358
Medical Services Outcomes Research	7,398 1,743	598 • 124	601 124	612 138	614 139	617 139	618 153	153	154	154	154	155	156	1,743
Phase IV	6,708	497	526	548	558	557	567	573	575	576	<u>. 577</u> _		578	5,706
Subtotal Medical Affairs .	18,789	1,443	1,478	1,523	1,558	1,561	1,593	1,601	1,608	1,503	1,605	1,609	1,611	18,789
(nformation Mgmt & Technology					•					٠.				_
Resource Management Client Management	2.484	203	204	204	205	205	205	206	207	207	207	208	203	2,464
Technology Management	47,D45	3,578	.3,321	3,472	3,351 70	3,518 70	3,433 70	3,784 70	3,673 70	3,642 70	4,554 71	4,492 71	5,229 71	47,045 840
IM&TAdmin	840		5,594	3,745	3,628	3,793	3,708	4,060	3,950	3,919	4,632	1,771	G,503	50,349
Subtotal Information Mgml & Tech  Development Operations	50,349	3,848	3,204	40	3,024	4,132		4,	-,	•				
Data Manapement	7,118	588	589 526	590 527	591 628	592 530	593 539	594 541	595 542	596 543	697 544	597 545	597 548	7,119 6,435
Statistics Abbott Ros & Lib Info Svcs-ARLIS	5,438 3,251	525 256	268	266	248	249	258	256	256	257	257	24B	426	3,251
Subtrizi Development Operations	16,808	1,378	1,381	1,383	1,387	1,371	1,388	1,391	1,393	1,395	1,396	1,390	1,569	16,808
VENTURE MANAGEMENT	•	•												
Cardiovastular/Diabetes (CD)	8.732	453	457	488	478	480	 4B1	482	3,482	484	485	485	485	6,732
Anti-Infective Anti-Viral	10,485	857	868	889	870	871	672	873	873	874	875	878	877	10,485 5,748
Analgesia/CCM	5,748 2,021	494 157	499 167	499 167	499 168	500 168	501 °	. 501 189	450 189	451 169	451 169	451 170	457 170	2,021
Urology Molecular Therapoutics	2,021	-	-	_	_	_	_	_		-		-	-	-
Neuroscience Oncology	7,384	इत	- 578	579	594	617	652	67B	629	637	632	622	635	7,384
Subletal Venture	34,350	2,558	2,579	2,582	2,610	2,638	2,574	2,853	5,603	2,609	2,612	2,815	2,619	34,350
Administration	19,652	1,628	1,829	1,631	1,533	1,535	1,637	1,639	1,841	1,643	1,645	1,847	1,646	19,652
PARO	58,853	4,890	4,881	4,967	4,939	4,071	5,045	4,991	5,042	4,992	5,059	5,045	4,031	58,853
Regulatory Affairs	B.422	673	699	768	786	788	800	B11	812	814	815	B17	631	9,422
Phase-1 Center	9,670	784	772	777	B12	813	815	816	817	819	620	821	824	9,670
TOTAL FUNCTIONAL	410,285	31,857	32,339	34,155	32,367	33,043	34,598	33,141	96,788	35,112	34,358	34,688	37,862	410,285
		287	369	205	267	389	246	452	452	452	431	411	144	4,105
International Manpower Clinical Grants	4,105 118,028	8,273	8.232	10,105	10,458	10,628	11,508	9,804	10,811	10,016	6,787	10,766	1D,648	118,028
OA54 Services Purchased	100,707	9,075	9,075	8,268	8,742	6,252	6,807	6.252	8,252	8,113	8,717	8,717	8,337	100,707
Corporate Task	,,,,,,,,	-				-	-,	_			٠		•••	_
Judgment - Internal	6,060	5,668	2,909	1,944	1,289	2,290	4,725	(1,565)	(3,054)	(2,135)	599	(1.383)	(5,227)	6,060
· •	[9,800]	-	(917)	(617)	(817)	(817)	(817)	(לופן	(817)	(916)	(816)	(816)	 (815)	(508,6)
Judgment - Published Gabbil reimbursement from Cons	, (3,000) n	(01//	(2117	(011)	(511)	(2.17)	(511)		(,				_	-
Hand Post/Plash to Actual Adjustmen		_		_										
		-		_										
Other Project Changes:		_		_	-			-	-	•	-			
Gross PPD R&D Expense	629,385	54,338	52,107	53,860	52,324	53,763	57,165	49,267	52,413	50,742	50,077	.52,383	50,846	629,385
QASS Bervices Bold		(21,165)	-		•		(21,963)	(190,81)		(507, 21)	(19,579)	(20,455)	(19,977)	(244,018)
				33,006	31,998	33,048	35,202	30,206	32,408	31,039	30,498	31,928	989,00	385,367
Net PPD RED Expense	385,367		31,892	98,071	n		100,248			83,653		-	93,395	F-17-11-11
Mamor: Quarterly Net Expense						33,048	35,202	30,206	32,408	31.039	30,498	31,028	30,969	
			** ***											
The line is input; palyment plays to the #.	385,367	33,173 8.51%	31,892 8,28%	33,008 8.56%	31,928 8.3D%	8.58%	9.13%	7.84%	8.41%	8.05%	7.91%	8,29%	8.04%	205 200
Then have in Arrive purignment plays to that if,	385,267								8.41%	8.05%				385,367
Then have in injusting partyments plays in the S.  The noting of these bounders and state of the Posts and the second of the State Posts and t		B.51%	8,28%	8.56%	8.3D%	8.58%	9.13%	7.84%			7.91%	6,29%	8.04%	
To not impact bease from the authority expect only Yold Po 2000 Final AGU		8.51% 	8.28% 	35,911	8.30%	8.58% 32,058	9,13%		27,124 27,124	29,769 29,386	7.91%	8.29% 27,355	26,418 27,512	374,730 375,593
The not report from time for solvening report and Yard Pio 2000 Firmal AGU 2000 Actually (Adjusted for Thrombo 1999 Actually (Adjusted for Thrombo		8.51% 32,133 32,133 21,427	8,28% 30,404 30,494 23,693	35,911 35,911 25,358	8.3D% 33,138 33,138 24,205	8.58% 32,058 32,058 25,870	9.13% 45,704 45,704 24,288	7.84% 28,013 28,013 25,642	27,124 27,124 24,018	29,769 29,386 23,961	7.91% 25,703 27,095 28,343	27,355 27,115 27,940	26,418 27,512 40,595	374,730 375,593 315,443
"Do not super! beans beam for and-not; request order Yards Pea 2000 Firstal AGU 2000 Achtachts		8.61% 	8,28% 30,404 30,404 23,693	35,911 35,911 25,358	8.30% 33,138 33,138 24,205	8.58% 32,058 32,058 25,870	9.13% 45,704 45,704 24,288	7.84% 28,013 28,013 25,642	27,124 27,124 24,018	29,769 29,386 23,961	7.91% 26,703 27,095 28,343	27,355 27,115 27,940	26,418 27,512 40,595	374,730 375,593

HIGHLY CONFIDENTIAL ABBT 0037518

PPRD FUNCTIONAL EXPENSE RECONCILIATIONS YTD - \$ 2001 PLAN	;. 										<del></del> -	<del></del> .	EUTHON MAIN AN
	101 PLAN	, MAL	FEB	MAR .	APR .	MAY	JUNE	JULY	AUG	SEPT	oct	NOV	DEC
Discovery Doals * (742-505) AD Other Discovery *	12,446 140,638	11,461	625 22,942	2,64D 34,449	2,890 45,976	3,515 57,551	5,530 69,165	5,780 80,779	6,405 92,741	8,420 104,759	8,670 116,795	9,295 128,851 ·	12,446 140,638
Subtotal Pluminecoutical Discovery	153,082	11,461	23,567	37,089	48,855	B1,066	74,695	86,559	99,145	113,178	125,485	138,148	153,082
DRUG SAFETY			1,385	2,100	2.815	7,531		4,996	5,730	0,451	7,173	7,896	8,619
Experimental Science Clinical Drug Analysis	8,619 5,129	589 423	848	1,270	1,695	2,120	4,263 2,551	2,983	3,415	3,843	4,271	4,700	5,129
Toxicology	6,469	524 299	1,049 599	1,586 906	2,123 1,213	2,681 1,621	3,205 1,840	3,750 2,160	4,296 2,480	4,838 2,790	5,301 3,101	5,925 3,412	6,489 3,724
Pathology Comparative Medicine	3,724 11,022	916	1,632	2,749	3,686	4,584	5,502	6,421	7,340	5,260	8,180	10,101	11.022
Admin & Strategic	907 3,442	75 284	150 <i>5</i> 68	225 853	300 1,138	375 1,423	450 1,713	526 2,003	602 2,294	678 2,581	754 2,868	830 3,156	907 3,442
Strategic & Exploratory Science Subtotal Drug Safety	39,312	3,210	6,430	9,689	12,850	18,215	19,524	22,839	26,157	29,441	32,728	36,020	38,312
MEDICAL AFFAIRS	,	4,210	0,	-,			,		,	,			
Administration (Clin Res - CNS)	2,942	226	453	680	927	1,175	1,430	1,685	1,941	2,191	2,441	2,692	2,942
Modical Services Outcomes Research	7,398 1,7 <b>43</b>	596 124	1,197 248	1,809 388	2,423 525	3,040 654	3,658 B17	4,278 970	4,899 1,124	5,522 1,278	6,148 1,432	6,771 1,587	7,398 1,743
Phase IV	6,706	497	1,023	1,589	2,125	2,682	3,249	3,822	4,397	4,873	5,550	6,128	6,706
Subtotal Medical Affairs	18,789	1,443	2,921	4,444	5,000	7,581	0,154	10,755	12,381	13,964	15,589	17,17B	18,789
Information Mgmt & Technology													•
Resource Management Client Management	2.454	203	407.	611	816	1,021	1,228	1,432	1,639	1.B46	2,053	2,261	2,464
Technology Management I M & T Admin	47,045 848	3,576 59	6,897 138	10,369 207	13,720 277	17,238 347	20,671 417	24,455 487	28,128 557	31,770 627	38,324 698	40,816 769	47,045 840
Subtotal Information Mgmt & Yech	50,349	3,848	7,442	11,187	14,813	18,806	22,314	26,374	30,324	34,243	39,075	43,B46	50,349
Development Operations													
Data Management .	7.119	588	1,277	1,767	2,358	2,950	3,543	4,137	4,732	5,328	5,925	6,522	7,119 6,436
Statistics Abbuti Res & Lib Info Svcs-ARLIS	6,436 3,251	525 266	1,051 532	1,578 798	2,106 1,048	2,638 1,295	3,175 1,551	3,716 1,807	4,258 2,063	4,801 2,320	5,345 2,577	5,890 2,825	3,251
Substated Development Operations	16,608	1,378	2,780	4,143	5,51D	6,891	8,269	9,860	11,053	12,449	13,847	15,237	15,806
VENTURE MANAGEMENT													
Cardiovyscutar(Diabetes (CD) Anti-Infective	8,732	. 453	620	1,388	1.887	2.347	2.626	3,310	6,792	7,276	7,781	8,247	8,732
Anti-Vinsi	10,465	867	1,735	2,804	3,474	4,345	5,217	6,090	6,963	7,837	8,712	9,588	10,485
Analgesia/CCM Urology	5,748 2,021	494 167	993 334	1,492 501	1,991 888	. 2,491 837	2,992 1,005	3,493 1,174	3,943 1,343	4,394 1,512	4,845 1,881	5,296 1,851	5,748 2,021
Molocular Thorapoutics		-	-			-	***			-	-	· -	-
Neuroscience Oncology	7,384	577	1,755	1,734	2,328	2,945	3,597	4,225	4,854	5,485	6,117	6,749	7,384
Solutional Venture	34,350	2,658	5,137	7,719	10,329	12,885	15,639	18,292	23,895	26,504	29,116	167,16	34,350
Administration	19,652	1,526	3,255	4,686	6,519	8,154	9.791	11,430	13,071	14,714	16,359	18,006	19,652
PARD	58,853	4,890	9,771	14,738	19,677	24,648	29,593	34,684	39,726	44,718	49,777	54,822	58,853
Regulatory Affairs	8,422	673	1,372	2,138	2,924	3,722	4,522	5,333	6,145	6,959	7,774	8,591	9,422
Phase-1 Center	9,670	764	1,536	2,313	3,125	3,938	4,753	5,589	6,385	7,205	8,025	8,845	9,570
TOTAL FUNCTIONAL  Mama: % of Total Func, and, Disc De	410,285 als	31,852	64,191 16,0%	98,348 24,1%	130,713 32.1%	163,756 40.3%	198,354 48,5%	231,495 56,7%	268,284 65.8%	303,376 74.1%	337,735 82.7%	372,423 91.3%	410,285 100.0%
International Manpower	4,105	287	657	852	1,148	1,519	1,765	2,217	2,688	3,120	3,551	3,961	4,105
Clinical Grants	118,028	6,273	16,505	26,610	37,066	47,592	59,198	619,002	79,813	69,E29	96,616	107,3B2	118,028
OA54 Services Purchased	100,707	9,075	18,150	26,418	35,160	43,412	50,319	58,571	66,823	74,838	83,853	92,370	100,707
Corporate Task	-			_	_		_				_		-
Judgment - Internat	6,060	5,688	8,576	10,520	91,809	14,098	18,823	17,25B	14,205	12,070	12,809	11,287	6,060
Judgment - Published	(9,600)	(B17)	(1,634)	(2,451)	(3,268)	(4,085)	(4,902)	(5.719)	(6,536)	(7,352)	(8,168)	(8,984)	(9,800)
Gabibil reimbursoment from Commen		-			-	٠				•••	_	_	-
Hand Post/Flash to Actual Adjustmen	ı <u>.</u> .	_	-		_		_	_					-
Other Project Changes: .		_			•	•		_	_		_	_	
Gross PPD R&D Expense	629,385	54,338	106,445	160,305	212,629	265,392	323,557	372,824	425,237	475,979	\$26,056	578,439	629,385
QA55 Services Sold	(244,018)	(21, 165)	(41,380)	(62,234)	(82,560)	(103,275)	(125,238)	(144,299)	(164,304)	(184,007)	(203,586)	(224,041)	(244,018)
Not SPD RED Sweens		23,173											385,367
Noi PPD R&D Expense													

PPRD SERVICES PURCHASED RECONCILIATIONS MONTH - S ZODI PLAN

• •	OS PLAN	JAN	FE8	MAR	APR	MAY	JUNE	JULY	AUG	SEPT	ост	NOV	DEC	TOTAL
Pateritz & Tredomark	6.050	504	504	504	504	504	504	504	504	504	504	504	506	6,050
	5,445	454	454	454	454	454	454	454	454	454	454	454	451	5,445
Corp Admin Fixed	5,070	423	423	423	423	423	423	423	423	423	423	423	.417	5,070
Corp Cost Pools		45	45	45	45	45	45	45	45	45	45	45	44	539
Satelite Copy Charge	539				16	16	16	16	16	16	16	16	20	196
CHMD Services Purchased Food (AHD)	196	. 16	16	16					269	269	269	269	273	3,232
PPD Ops Fixed Allocations	3,232	269	269	269	269	269	269	269						
CENG - Flood Maintenance from PPO O	899	75	75	75	75	75	75	75	75	75	75	75	74	899
CHEN Vertable (EWRS)	147	12	12	12	12	12	12	12	. 12	12	12	12	15	147
CMIS - Purchasing	747	62	52	1	62	62	62	62	62	62	62	62	65	747
CHMS Telecommunications	130	11	11	11	11	11	11	11	11	11	11	11	. 8	130
Floord L.C. Exp Admire. Services	421	35	35	35	35 ·	35	35	35	35	35	35	35	35	421
Corp Eng EHS Fixed Allocation	597	50	50	<u>50</u>	<u>50</u>	50	<u>50</u>	50	50	50	50	<u>50</u>	<b>9</b> 7.	<u>597</u>
TOTAL CORPORATE ALLOCATION	23,473	1,956	1,956	1,956	1,955	1,856	1,956	1,956	1,956	1,856	1,956	1,956	1,957	23.A73
CAMS - Unit of Activity, Food - Other	2.667	222	222	222	272	222	222	222	222	222	222	222	725	2,667
CMIS - Unit of Activity, Flood - Angis	2,100	175	175	175	175	175	175	175	175	175	175	175	175	2,100
PPD Personnel DOA47	2,601	217	217	217	217	217	217	217	217	217	217	217	214	2,601
PPD Mig Ops - Allocation	63	5	5	5	5	5	5	5	5	5	5	5	8	ಐ
PPO Ops QA Inf Svcs/Reg Affairs	1,942	162	162	152	162	162	162	162	162	152	162	162	150	1,942
PPD Ops Returned Goods	136	11	11	11	11	11	11	11	11	11	11	11	15	136
Project Expense	7.099	592	592	592	592	592	592	592	592	592	592	592	597	7.099
TOTAL BURDEN FILE	40,0B1	3,340	3,340	3,340	3,340	3,340	3,340	3,340	3,340	3,340	3,340	3,340	3,341	40,081
SPD Pilot Pient Stack Cord	24,497	2,042	2,042	2,042	2,042	2,042	2,042	2,042	2,042	2,042	2,042	2,042	2,035	24,497
SPD Bulk Direct (Chem/Ferm)	17,328	1,444	1,444	1,444	1,444	1,444	1,444	1,444	1,444	1,444	1,444 958	1,444 <u>958</u>	1,444 952	17,328 11,610
Excess Capacity Stack Certi Subtotal SPD (Other than TAP)	<u>11.610</u> 53,435	<u>968</u> 4,454	9 <u>68</u> 4,454	<u>968</u> 4,454	<u>958</u> 4,454	<u>968</u> 4,454	<u>968</u> 4,454	<u>968</u> 4,454	<u>968</u> 4,454	<u>968</u> 4,454	4,454	4,454	4,441	53,435
TAP Busk Drug (D-TAP)	84	7	7	7	7	7	7	7	7	7	7	7	7	84
TAP - SPD Marpower & Bulk (D-453)		20	20	20	20	20	. 20	20	20	20	20	20	25	245
Pharmacogenetics — ADD Attocation Misc Expense	_		-			_					***			-
Subtotal (For Exp Cat)	329	27	<b>Z7</b>	य	टर	27	27	27	27	27	27	27	32	329
Other Purchases:		973	973	973	973	483	483	483	483	483	483	483	487	7,763
Ctari Once-A-Day (Global Al Manpower Corp Drug User Fees	7,763 1,207	3/3	-			-	_	_	-	1,207			-	1,207
Patent to Operations (search services)	•••	-			15	15	15	15	 15	15	15	15	17	182
D-AS4 Floor Space (not in functionals) D-AS4 Deprec (not in functionals)	182 2,984	15 249	15 249	. 15 249	249	249	249	249	249	249	249	249	245	2,984
Molecular Probes	7	-	•••			-	-		<b></b> .				7	7
inventory transfer for Proteste 2nd Ger SDG/Other	١		_			· <del>-</del>	_	_	_	-			-	
Clinical Supplies (Tricia Geran -PPD Or	200	17	17	17	17	17	17	17	17	16	16	16	16	200
Aegis Charges Library (D441) to CHMS	_		_	_					_					
DA (D44N) to Operations	1,500	-		•			-		•••	-			1,500	1,500
Sangstat (Cyclosporine) Sangstat (Sangsya)						_	-		•••					
Gabitri Royalty	_	-					-			•••	•••			•••
Ritoravir/LaRoche Combo		-		-		•••	***			***				
NOVO Settlement Metabolox			***	_		•••							. <b></b>	
FLAPNænguard			-				•••	-	•••	***			-	
Sanofi Cost Sharing w/Gabbil		•••		•••			-			-:-		·		
Cli charge from OPS (Clin Val Mpr) + \$ Triangle receipt \$2,935 +\$325 for 1999				(807	, 🗓		(1,345)			(1,345			. (1,884)	(5,381)
Comdisco	***	_		-	•			-	-	-	-			
Hydrocodone (IDV-in from HPD)	~ ~~	-	-	-	(333)	(333)	(333)	(333	(333)	(333	) (33-	4) (334	i) (334)	(3,000)
CRO Rebates Gabbin Reimbursement from Commen	(3,000) ≓ 1,400		_	·	(000)	,	. (0.0)	,,	, (555)		45			1,400
Other	-		-										·	
Grand Total	100,707	9,075	9,070	8,268	8,742	B,252	6,907	8,252	8,252	8,113	8,71			100,707
					=				<del></del> -	*********			: <del></del>	200cc220
					(2,537)	•								

HIGHLY

PPRD SERVICES PURCHASED RECONCILIATIONS YTD - \$ 2001 PLAN

	'01 PLAN	JAN	FEB	MAR	APR	MAY	JUNE	JULY	AUG	SEPT	OCT	NOV	DEC
Pateryls & Tradomark	6,050	504	1,008	1,512	2,016	2,520	3,024	3,528	4,032	4,536	5,040	5,544	6,050
	5,445	454	908	1,362	1,816	2,270	2,724	3,178	3,632	4,D86	4,540	4,994	5,445
Corp Admin Fixed	5,070	423	848	1,269	1,692	2,115	2,538	2,961	3,384	3,807	4,230	4,653	5,070
Corp Cost Pools	539	45	90	135	180	225	270	315	360	405	450	495	539
Satelite Copy Charge	196	16	32	4B	64	80	. 96	112	128	144	160	176	196
CHMD Services Purchased Fixed (AHD)	3,232	269	538	807	1,076	1,345	1,514	1,883	2,152	2,421	2,690	2,959	3,232
PPD Ops Fixed Allocations	699	75	150	225	300	375	450	525	600	57\$	750	825	899
CENG - Fixed Maintenance from PPD O	147	12	24	35	48	60	72	84	96	108	120	132	147
CHEN Variable (EWRS)	747	62	124	188	248	310	372	434	496	558	620	682	747
CMIS - Purchasing	130	11	22	33	44	55	. 66	π	88	99	110	121	130
CHMS Telecommunications	421	35	70	105	140	175	210	245	280	315	350	385	421
Fixed L C Exp - Admin. Services		. 60	100	150	200	250	300	<u>350</u>	400	450	500	550	597
Corp Eng EHS Fixed Attocation	597	1,956	3,812	5,868	7,824	9,780	11,736			17,504	19,560	21,516	23,473
TOTAL CORPORATE ALLOCATION	23,473	1,336	444	588	688	1,110	1,332	1,554	1,776	1,998	2,220	2,442	2,667
CMIS - Unit of Activity, Flood - Other	2,657	175	350	525	700i	875	1,050	1,225	1,400	1.575	1,750	1,925	2,100
CMIS - Unit of Activity, Fixed - Acqis	2,100		434	651	858	1,085	1,302	1,519	1,735	1,953	2,170	2,387	2,601
PPD Personnel D0A47	2,601	217	10	15	20	25	30	35	40	45	50	55	53
PPD Mig Ops - Allocation	63	_	374	485	648	B10	972	1,134	1,296	1,458	1,620	1,782	1.942
PPD Ops QA Inf Svcs/Reg Alfaba	1,942	162			44	510 55	66	77	BB	99	110	121	136
PPD Ops Returned Goods	136	11	22	33	.,		3,552	4.144	4.736	5.328	5.920	6.512	7.099
Project Expense	7.099	592	1.184	1.776	- <u>7.368</u> 13,360	2.960 16,700	20,040	23,380	26,720	30,060	33.400	36,740	40,081
TOTAL BURDEN FILE	40,081	2,340	6,680	10,020	•	10,700	12,252	14,294	16,336	18,378	20,420	22,462	24,497
SPD Pilot Plant Stack Card SPD Bulk Direct (Chem/Ferm)	24,497 17,328	2,042 1,444	4,084 2,888	6,126 4,332	8,168 5,776	7,220	8,864	10,108	11,552	12,996	14,440	15,884	17,328
Exense Capacity Stack Card	11,610	968	1.936 8,908	2.904 13,352	3,872 17,816	4.840 22.270	<u>5,808</u> 25,724	<u>6,776</u> 31,178	7.7.44 35.632	<u>8.712</u> 40,086	<u>9.680</u> 44,540	10,648 48,994	11.610 53,435
Subtotal SPD (Other than TAP)	53,435	4,454 7	14	21	28	. 35	42	49	56	63	70	π	B4
TAP Bulk Drug (D-TAP)  TAP - SPD Marpower & Bulk (D-453)	84 245	20	40	60	B0	100	120	140	160	180	200	220	245
Pharmacogenetics - ADD Allocation		-			••		•••	_	77				_
Misc Expense Subtotal (For Exp Cal)	329	27	· 54	81	108	135	162	189	215	243	270	297	329
Other Purchases:		•••				=				6,3D9	6,793	7,276	7,763
Clari Once-A-Day (Global Al Marepower Corp Drug User Fees	7,763 1,207	973	1,947	2,920	3,893	4,376	4,860	5,343	5,826	1,207	1,207	1,207	1,207
Patent to Operations (search services)		٠	-	45	<b></b>	 75	 90	105	120	135	150	165	162
D-A54 Floor Space (not in functionals) D-A54 Deprec (not in functionals)	162 2,984	15 249	3D 49B	,-	996	1,245	1,494	1,743	1,992	2,241	2,490	2,739	2,884
Molecular Probes	7		_				-		•••	-		•••	7
Inventory transfer for Professe 2rid Ger SDG/Other	· P			-	·-	-	_				***		
Clinical Supplies (Tricks Geran -PPD D	p 200	. 17	34		68	B5	102	119	136	152	168	184	200
Angis Charges Library (D441) to CHMS	***			· -		-			_		-	•••	1,500
QA (D44N) to Operations	1,500		••			-			-			•••	1,500
Sangstat (Cyclosporine) Sangstat (Sangcya)			-		· -	-	_		-	•••	-		
Gabitrii Royalty	_		-	<del>.</del>		-							•••
Ritonavir/LisRoche Combo NOVO Settlement			_	·			_	· •••		_		_	
Metabolex			_			-	-						-
FLAP/Vanguard Sanofi Cost Sharing w/Gabtril			-						_		_		-
Clicharge from OPS (Clin Val Mgr) + \$	4						 (2,152	2) (2,152)	(2,152)	(3,497	) (3,497	(3,497)	(5,381)
Triangle receipt \$2,935 +\$325 for 1999 Comdisco	(5,381					(607	, 12,132	بر اجرانکدا 	, (c, 100)	- (-,-51	. (21,301	. ,,	
Hydrocodone (IDV-in from HPD)	-				·		. /900		 (1,565)	(1,998	3) (2,332	(2,666	(3,000)
CRO Rebates Gabitril Reimbursement from Commer	(3,000 남 1,400					(666	) (999	a) (1,332) 	, (1,000)		. 467	934	1,400
Other	.,			-			-						
Grand Total	100,707	9,078	18,15	1 26,41	35,161	43,413	50,32	58,573	66,825	74,938	E3,656	92,373	100,707

нена

PPRD SERVICES SOLD RECONCULATIONS MONTH - \$ 2001 PLAN

													<del></del>		
	101 PLAN	MAL	FEB	MAR	APR	MAY	JUNE	JULY	AUG	SEPT	OCT	NOV	DEC	TOTAL	
% RATE - ACTUALS															
% RATE - MONTHLY PROJECTION			•		_	_	_				***	_	_	_	
			-		_			_	_				_		
Consulative % Rate			_	-	_	-			_	-					
% RATE - ADJUSTED PROJECTION											•				
AI GLOBAL PHARMACEUTICAL	186,670	16,385	15,435	16,074	15,546	15,935	17,183	14,280	15,224	14,922	14,795	15,674	15,214	186,670	•
Direct Sister Benefit		•													
R&D Scientific Service (fixed)	2,384	199	199	199	199	189	199	199	199	199	199	199	185	2,384	
Direct Service	3,800	317	317	317	317	317	317	317	317	<u>317</u>	317	<u>317</u>	313	3,800	
Total Direct Sister Benefit '	6.184	516	516	516	516	518	515	516	516	516	516	516	508	6,184	
	192,854	16,901	15,951	16,590	16,062	16,451	17,699	14,796	15,740	15,438	15,314	16,190	15,722	192,854	
Total Inti Sister Division	192,634			•	•	-	-	•	•	,	·	•			
TAP - SPD Marpower	245	20	20	20	20	20	20	20	20	20	20	20	25	245	
TAP - Judgment (Positive Controls)	_		-	-	Ξ.	=	=	=	=	=	Ξ.	7	7	84	
TAP - Bulk Drug	64	7	7	7	7.	7	7	7	7	7	7				
TAP - All Other	19,858	<u>1.655</u>	1,655	1,855	<u>1,655</u>	1.655	1,655	1,655	1.655	1,655	<u>1,855</u>	1,855	1.651	19,858	
Total TAP	20,185	1,582	1,652	1,512	1,682	1,582	1,682	1,682	1,582	1,562	1,682	1,682	1,683	20,185	
Domestic, Sister Divisions							•					***			
HPD	5,B34	738	736	738	738	736	736	736	736	736	736	736	738	8,834	
ADD .	Z,383	199	199	189	189	199	199	199	. 199	199	199	199	194	2,383	
SPD	4,909	409	409	409	409	409	409	409	409	409	409	409	410	4,909	
ROSS	1,955	163	163	163	163	163	163	163	163	163	163	163	162	1,955	
CPD	42	4	4	4	4	4	4	4	4	4	4	4	(2)	42	
MIS	74	6	6	6	6	6	6	6	8	6	6	6	B	74	
AHD (AHS Abbott Health Systems)	_	_	_		_	_	_	•••		_	-	_	-	-	
CHMS Library Charges	_	_		_	_	-	_	·	•••	-	_	_	-	-	
Corp Eng	-	-	***		15.	44	172		424		414	***	434	***	
Total Domestic Sister Division	18,197	1,517	1,517	1,517	1,517	1,517	1,517	1,517	1,517	1,517	1,517	1,517	1,510	18,197	
Other Sister Divisions:															
Corp Administration											_	_	_		
Corp. Admin.	24	2	2	2	2	2	2	2	2	2	2	, Z	2	24	
TAP Rate Diff (Fixed)	485	40	40	40	40	40	40	40	4D	40	40	40	45	485	
Symposium Expense (Fixed)	165	14	14	14	54	14	14	14	14	14	14	14	· 11	<u>165</u>	
Subtotal CHAD	674	86	56	56	56	56	56	56	56	56	56	56	58	674	
PPD Product R&D					·								. 047	12.215	
Mig Support (MC.PM)	12,215	1,018	1,01B	1,018	1,018	1,016	1,018	1,018	1,018	1,018	1,018	1,018	1,017		
Mig Support (PV)	263	22	22	22	22	22	22	22	22	22	22	22	21	263	
PPD Marketing (P5,P5) (Inc Cephalon)	3,520	302	302	302	302	302	302	302	302	302	302	302	298	3,620	
Subtotal Other	16,098	1,342	1,242	1,342	1,342	1,342	1,342	1,342	1,342	1,342	1,342	1,342	1,336	16,098	
VAT Refund					_		_	_		_				***	
PARD Services Sold impact (Judgema	(3,990)	(333)	(333)	(333)	(333)	(333)	(333)	(332)	(332)	(332)	(332)	(332)	(332)	(3,990	)
	. (3,000)	(223)	(222)	()	(000)	1	()		(/	(	-	,,	` _	-	
Rounding														<del></del>	
GRAND TOTAL	244,018	21,165	20,215	20,854	20,326	20,715	21,953	19,061	20,005	19,703	19,579	20,455	19,877	244,018	
														- r	
Memo: Excluting Global - \$		4,7B0	4,78D	4,780	4,780	4,780	4,780	4,781	4,7B1	4,7B1	4,781	4.781	4,763	57,348	
Quarterly - \$				14,340			14,340			14,343			14,525	57,348	,
Excluding Global - % of Qir				25.0%			25.0%			25.0%			25.0%		
Excluding Global - % Dec										-			8,3%		
Preferred Current - 10 DEG			•			,									

HIGHLY

PPRD SERVICES SOLD RECONCILIATIONS YTD - \$ 2001 PLAN


	'DI PLAN	MAL	FEB	MAR	APR	MAY	JUNE	JULY	AUG	SEPT	DCT	NOV	DEC
AI GLOBAL PHARMACEUTICAL	186,670	16,385	31,820	47,894	62,440	79,375	96,658	110,838	126,062	140,984	155,782	171,455	186,670
Direct Sister Benefit													
R&D Scientific Service (fixed)	2,384	199	398	597	796	995	1,194	1,393	1,592	1,791	1,990	2,189	2,384
Direct Service	3,800	317	634	951	1,268	1,585	1,902	2,219	2,536	<u> 2,853</u>	<u>3,170</u>	3,487	3.BOO
Total Direct Sister Benefit	5,184	516	1,032	1,548	2,064	2,580	3,096	3,612	4,128	4,544	5,160	5,676	6,184
Tatal Intl Sister Division	192,854	15,901	32,852	49,442	65,504	81,955	99,854	114,450	130,190	145,528	160,942	177,132	192,854
TAP - SPD Manpower	245	20	40	60	80	100	120	140	160	180	200	220	245
TAP - Judgment	-	-	_	-	-	-	-	-		_			
TAP - Bulk	84	7	14	21	28	35	42	49	58	53	70	77	B4
TAP - All Other	19,856	1,655	3,310	4,965	6,620	<u>8,275</u>	<u>8,930</u>	11,585	13,240	14,895	16,550	18,205	18,856
Total TAP	20,185	1,582	3,384	6,046	6,728	8,410	10,092	11,774	13,456	15,138	16,820	18,502	20,185
Domestic Sister Divisions										•			•
HPD	8,834	736	1,472	2,208	2,944	3,68D	4,416	5,152	5,888	8,524	7,360	B,096	B,834
ADD	2,383	199	398	597	796	995	1,194	1,393	1,592	1,791	1,990	2,189	2,383
SPD	4,908	409	818	1,227	1,636	2,045	2,454	2,863	3,272	3,681	4,090	4,499	4,909
ROSS	1,955	163	326	489	652	B15	978	1,141	1,304	1,467	1,630	1,783	1,955
CPD	42	4	8	12	15	20	24	28	32	36	40	44	42
MIS	74	6	12	18	24	30	35	42	48	54	60	66	74
AHD (AHS Abbott Health Systems)	-	_		_	_				•••	•		-	
CHMS Library Charges	_	_	_	٠ _				***		100	***	-	_
Corp Eng		#12	414	125	-	221	***	an.	-	ш	446	_	-
Total Domestic Sister Division	18,197	1,517	2,034	4,651	6,068	7,585	9,102	10,519	12,136	13,553	15,170	16,687	18,197
Other Sister Divisions:							•						
Corp Administration													
Corp., Admin.	24	2	4	6	8	10	12	14	16	18	20	22	24
TAP Rate Diff	485	40	80	120	160	200	240	280	320	350	400	440	485
Symposium Expense	165 674	<u>14</u> 56	<u>28</u>	42	<u>56</u>	70	<u>B4</u>	<u>98</u>	112	126	140	<u>154</u>	<u>185</u>
Subtotal CHAD	674	56	112	168	224	280	336	392	448	504	560	616	674
PPD Product R&D													
Mig Support (MC,PM)	12,215	1,01B	2,036	3,054	4,072	5,090	6,108	7,126	8,144	8,162	10,180	11,198	12,215
Mfg Support (PV)	263	22	44	68	88	110	132	154	175	198	220	242	253
PPD Marketing (P5.P6) (Inc Cephalon)	3,620	302	504	905	1,208	1,510	1,812	2,114	2,416	2,71B	3,020	3,322	3,620
Subjectal Other	15,098	1,342	2,684	4,026	5,368	6,710	8,052	8,394	10,736	12,078	13,420	14,762	16,098
VAT Refund	_	_	_	·			_					_	_
PARD Services Sold Impact (Judgeme	(3,990)	(333)	(666)	(999)	(1,332)	(1,665)	(1,898)	(2,330)	(2,662)	(2,994)	(3,326)	(3,658)	(099,5)
Rounding	,	(F-0)	-	_	_	***	-	•	-		· · ·	_	
GRAND TOTAL	244,018	21,165	41,380	62,234	52,560	103,275	125,238	144,299	164,304	184,007	203,586	224,041	244,018
GRAND IDIAL	277 <sub>1</sub> 010	====	===		====	1001213			104000		2001-30		

mgmx

RD CLINICAL GRANTS SCONCILLATIONS MONTH - \$ 01 PLAN														0.01 AL	
•	D1 PLAN		FEB.	MAR	APR	MAY	TUNE	. שועץ	AUG	5EPT	oct	NOV	DEC	DEC	TOTAL
PD SERVICE :														٠	
zyabino/Qabitri	_		_	_	· _	_	_		~		600	600	600	-	3.000
merican epakato/Depakane	3,000 8,441	723	(80)	1,179	1,180	1.180	1,180	1,180	600 1,181	600 608	373	373	172	Ξ	8,441
Pro-UK-	_	=	-	-	-	-	-		-	_	_	_	_	_	29
enoSprato (Fournier)	39 500	39	120	120	120	120	120	_	_	Ξ	_	_	•••	_	600
emailn hermacoGenei≔s (Gensei)	200	Ξ	-	20	20	20	20	20	20	20	20	20	20		200
OTAL PPD SERVICE	12,285	762	32	1,310	1,320	1,320	1,320	7,200	1,801	1,228	993	532	892	-	13,260
LONAL SERVICE:	•														
litonavir ABT-538	1,244	299	(142)	109	109	109	109	109	109	109 1.953	108 1,896	801 868,7	105 1,996	-	1,24
rotease 2nd Gen ABT-378	22,575	120	1,518	1,892	2,001	2,243	2,239	2,168	2,155	1,103	1,086	(,250	1,150	_	
)opemine	380	-			_	_	_	_	-	_	_	190	190	_	38
CO ABT-598 UBT-594 (formorly CCM)	1,065	100	30	101	120	120	120	120	120	120	48	48	18	-	1,06
R1-033 (formarly ChCyt)	1,,		_		_	_	_	_	-		_=	259	259	-	2.04
Larithromyclo	2,940	172	172	200	260	260	250	260	260	259 3.386	259 323	3.595	3,596	-	47.40
etolide ABT-773	47,405	4.647	4,847	4,825	4,950	4,960	4,960	3,403	3,403	2,386	323	7,083	200	_	40,40
rokinale Macrofida - Dom	-	-	-	-	-		_	_	_	_	_		_	_	
Seuton & 2nd Constition		_	-	-	_	_	_	_	_	_		_	-	_	
PH ABT-980	990	454	35	125	115	115	35	35	35	34			-	-	8:
cyclesporina i2G (Medivir)		_	-	-	-	-		==	<b>=</b>	=			2,178	-	18.25
indothelin	18,251	1,005	1,035	1,075	1,035	1,035	1,540	1,897	1,897	1.697	2,179	2,179	2,170	=	15,50
IS 49 Nopon Shinyakyu ABT-Z	3	-	_	-		_	-	***	_	-		_	_	_	
Simoctomat (Biorex)	1,025	-	-		73	75	125	125	125	125	125	125	125	_	1,0
UNI-AUTONI: ABT-751	1,023		-						-		-	_		_	
Hyteln FTI (Famesytransferes)	-	· <u>-</u>	_	=	=	_	_	_	_	_	-			-	
MMPI (Motalisprotesse)	1,118	64	64	64	54	54	114	114	114	114	114	114	114	=	
Taxano		116	116	116	88	115	165	. 166	166	185	185	185	76	-	1,5
TSP Peplide	1,621 5,000	229	159	159	309	209	209	209	628	626	477	894	894	-	5,0
Quinolone Cox II	131	E5	66				_	_	_	-	_	_	-	-	
Hauraminidase	-	_		_	_	_		_	-	-	-	-	-	-	
Adjustment (EVR)	-	_	_	-	-		-	-							
TOTAL GLOBAL SERVICE	104,748	7,511	8,290	8,786	2,135	1,306	10,145	8,604	8,010	8,788	5,794	8,772	9,654	-	. 104,7
MISC:												_	_		
Vitamin D Analog/Iron Daxtran	-	-	-		-			· -	_	_		_			-
teotreiminin/Nords investigation Adjustments	-	_	_	_	_	_	_		_			-	_		-
Augustricaus Descriedotomicina/Zemplar (HF	ם כי	_		-	_	-	••					-	_	•	-
Transme Reformulation	_	_		-	-	-	-		-		-	_	-		-
Biaxin Reformulation		_		20,610	-	_	32.50	; -		30.63	: <b>-</b>	_	28,195	i '	
GRAND TOTAL GRANTS	118,028	6,273	8,232	10,105	10,450	10,626		9,104	10,81		6,787	10,750	10,840 23.99		118,0 700
- Quarterly Percentages Actuals							11 50								
	restruments		STORES	45019786	5.59H38	रवस्थान्द्रभि	TEIONE	8 502	10,65		37,79			505	
Total Global Grants Total Other Domostic Grants			洲岛		海田	320	307 1 32	的治验	35200	27.07					
Total Other Grants				duka ya		1	300	70.70	THE REAL	3-140-1		COLUMN TO	THE COL		- V 5 55
													SHALL SHALL	英語的	200
Total Grants  Key Checks (2/b )  Brant System (Excel as of 1/2)	) ENGINE			70	411		商品		20 m	322	海影	問語		2000	1000
Brant System (Excel as of 1/2)	ALL THUS THE	227									115,000	2)-050	17222	3) 13 5/1	10
Difference	-	TOTALDER		CC-TAIL N		DESCRIPTION OF	10000	NAME OF TAXABLE	10000010	20072	THE PERSON NAMED IN				

/2


PRID CLINICAL GRANTS ECONCILIATIONS - YTD \$ 001 PLAN	ī- 												
	DI PLAN	HAL	FEB	MAR	APR	MAY	JUNE	JULY	AUG	SEPT	OCT	NOV	DEC
PD SERVICE:													
ispablne/Gabitrii		-	-	-	-	-	-	-	600	1,200	1,500	2.400	3,000
mnicel epskote/Depskone Pro-UK	3,000 9,441	723	635	1,014	2,894	4,174	5,154	6,534	7,715	6,323	6,696	9,069	9,441
enofibrate (Fourtier)	39	39	39	39	39	39	39	19	39	39	39	39	239
ematin	600	_	120	240	360	480	600	500	600	600	600	600	600
hamiscoGenetics (Gensel)	200	-			-40	- 60	- 50	100	120	140	150	150	200
OTAL PPD SERVICE	13,280	762	794	2,117	3,433	4,753	6,073	7,273	9,074	10,302	11,205	12,288	13,280
LOBAL SERVICE:													
Bonavir ABT-538	1,244	299	157	266	375	484	593	702	611	920	1,028	1,135	1,244
rolozse 2nd Gan ABT-378	22,575	120	1,938	3,830	5,531	8,074	10.313	12,479	14,634	16,567	18,583	20,579	22,575
opumine CD ABT-598	380	-	-			-	-	-	_	-	_	190	380
BT-594 (formarly CCM)	1,065	100	130	231	251	471	591	711	831	1251	289	1.047	1,065
IT-029 (formerly ChCM)	-		,	-			-				-		.,
arithmanyuin	2,940	172	344	504	864	1,124	1,384	1,644	1,904	2,163	2,422	2,681	2,940
notide ABT-773	47,405	4,647	2,694	14,619	19,579	24,539	29,489	32,902	36,305	39,691	40,014	43,709	47,405
kinefe Macrolide - Dom	-	-	-	_	-	-	-	_	-	_	_	-	_
urion & 2nd Generation	•	-	_	_	-	_	-	-		-	-	-	-
YK ABT-980 Closporing	193	454	499	824	739	854	859	974	859	993	993	693	893
G (Modivir)			747					-			-		-,20
dothelia	18251	1,035	2,070	3,105	4,140	5,175	7,024	8,921	10,815	12,715	14,894	17,073	19,251
49 Nippon Shinyakiyu ABT-23		_	_	· -	_	_	· -	_	_		_	_	-
noclornol (Biorna)		_	_	-	75	150	275	400	575	650	775	800	1,025
S-Milotic ABT-751 Vin	1,025	-	_	-	15	130	2/5	400	525	650	115	900	1,025
vru) NPI (Mateloprotesso)	1,118	64	128	122	256	320	434	548	862	776	890	1,004	1,118
CERT C		_	-	_	_	-	-	_	_	_	_		_
SP Pepside	1,521	116	232	345	436	552	718	884	1,050	1,215	1,360	1,545	1,621
imotona	5,000	229 65	388	547	856 131	7,065 101	1,274	1,483	2,109	2,725	3,212	4,106	5,000
nr II merminidase	131		131	131	131	131	131	131	131	131	131	131	131
şustment (EVR)	Ξ	_	=	=	_	_	_	_	_	_	-	-	_
OTAL GLOBAL SERVICE	104,748	.7,611	15,711	24,497	23,633	62,939	53,125	81,729	70,739	79,527	85,321	95,094	104,748
tamin D Analog/bon Dextran	_	_	_	_	_	_	-	_	_	_	_	_	
oralisation symplement	-	_	_	-	-	-	-	-	-	_	-		-
justmonts	-	-	-	-	-	_	-	-	-	-	-	_	-
consistentialistic (HPD process Reformulation	-	-	-	_	-	_	-	-	-	-	-	-	-
exin Reformulation	=	_	=	_	_	_		=	_	=	_	_	_
	-		_	_	_	_	-		-	_	_	_	_
RAND TOTAL GRANTS	118,028	8.273	16,505	26,610	37,065	47,692	59,198	69,002	79,813	89,829	PG,616	107,382	118,028



HIGHLY


				ייי איז ורג, וה		<b>4</b> _	e ·	De .	year surg
	3	101 101 101 101 101 101 101 101 101 101	March March March March March March March		10-4-0	17	EXTREMENDATION	CHARLES	BENEFA
	Ī	13	A 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1		11 Per-00	1	raiser.	No.	110 970 114 100 115 100 116 100 116 100 117
	ŧ	101 169 102 178 111 1049 31 1118 6DYM Med 6DYM ACC	# 1#E4 #####		:	1111	SERVER		111 111 111 111 111 111 111 111 111 11
	14	22-211	9-22-522-25		-	*			
	11	11.1	# \$5%###################################		=	2111	1		1,110 1,10 1,
		SPECTER					2000	200	
GZALVO) QCST AJK	11	11111	11111111111		Ē	E iii	TO WELL		
4 £	2.5	11			٠,	011	Name of the last o		 Siferes
	Į		•			1 911		TOTAL DE	i ii
	ł				1.		Name of the least	THE PARTY.	
	£	副							ineral interest
	ī	** ** ** ** ** ** ** ** ** ** ** ** **			•		Marson I		ii.
	1	# 1 1 MAN			1		PATECLES.	NAME OF THE OWNER, OWNE	iii iiii jiidaa
	2	= 1 212			'		NESCON.		THE SHOPE
	Ę	TOTAL PART INTERNITURATE NUMERA PRESENTATIVA PROGRAMMA PART PROGRAMMA PROGRA			1		(EXPERIMENT)	nnon na mandalan da katan da k Banan da katan da ka	
	Ė	# 2 1			1			TE SAN	
	- Ł	:::			١.			SEED	111
	į	* 8 1 100			,	SECTION .		T. Salaki	111 111 21000
		# 1 1 BB			=			NAME OF TAXABLE PARTY.	
	2	# 15 E				REAL PROPERTY.			111
	į	ZVENT.					STATE		
		ressen					THE SEC		
	į						and a		PERSONNEL BOTH IN A SERVICE OF THE PERSONNEL OF THE PERSO
	Project Harns	CETOFFANT HORALING CHARLES CONTRACTOR CONTRACTOR CONTRACTOR CATEGORY CONTRACTOR CATEGORY CATE					STATE OF	THE REAL PROPERTY.	BITT AND NA COME IN AUTH IN AUTH BIRTHEN
		CANTER OF CONTRACT	2222222222				200	NACOTATION	11 200 UL
		CTCLOST CTCLOST CTCLOST CTCLOST	### ##################################			200	TENESTE:	TERMON	DIPAGO DI
							H-24/32	25525	450 H
	Į	MATERITIA LAS FAMBARCOCIOCA RE LAS FAMBARCOCIOCA RE TEDATRIC TELESPERI TEDATRICA TELESPERIA DEPONA PEDO TELESPERIA DEL TELESPERIA DEL TELESPE	_ E		1980 1980 1980 1980 1980 1980 1980 1980		HE SHE		MANUAL MA
mama	كمثم كمدالهاهم	CLOSFOI TOTOSFOI AT BENGE	FRANK TIPE. Cal. Arm Tip Tip Tip Tip Tip Tip Tip Tip Tip Tip			PRANT		Canadra,	ANT AND
A Develo	Ì	HALLICERTIFE HALLICERTIFE HALLICERTIFE HALLICERTOPICAL RES HALLICERTOPICAL HAL	HINDING BIT OF THE STATE OF THE			PROPERTY PRO	THE STATE OF	ACCESS MEDICAL GROUP, LTD IN PERSONALITY CAMPETERS	PORT TO THE PORT OF THE PORT O
darent.		MULTI-CERTIFE LAB MULTI-CERTIFE LAB MULTI-CERTIFE ROUTING PK ABEOTT-BANGE	ARDITO-GINE ARDITO		ENGINEERI Erreft Date	ESPECTA	SHEET STATES	ACCESS	DEFALOR VARIOUS VARIOU
Pharmacteritori Producto Rosessch & Development Oranto System	1.	1 4 4 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5	Marcos Marcos Marcos Marcos Marcos Marcos Marcos Marcos Marcos Marcos Marcos Marcos Marcos Marcos Marcos Marcos Marcos Marcos Marcos		962599 WOO 238	ROPE OF THE SHOET CHARLES AND THE STATE OF T		163588 WA ACCESS MIDICAL GROUP, LTD	Column   C
rited Pro	§ -	AN A			7 X	OFFICE OFFI	765.55	N/A	
Pharmoceurical Ozante Grafem	101 PLAN	(ch.118 197119 197199 197199 197199	101937 107108 107108 107108 107118 107118 107118 107118		TERRITA 101411	NI W	SECTION	01563	107588 107588 107588 107588 10778 1177 1177 1177 1177 1177 1177 1
£ 6	ñ	272555 7	3 *********	四一流流流	0 <u>4</u> 2	to s	组	- 5	* trssrs: # [

MOHIN CONFIDENTIAL ABBT 0037527



HIGHLY

9/



HIGHLY
CONFIDENTIAL
ABBT 0037529

PPRD GREYBOOK RECONCILIATIONS MONTH - \$				•									COLUMN I	
1001 PLAN	GLOBAL											•		
CHARGES TO PROJECTS:	'DI PLAN		FEB .	MAR.	APR	MAY	JUNE .	JULY	AUG	SEPT	ост	NOV	DEC	TOTAL
					<del></del> -		<del></del> -			<del></del> -				
Memo: Global Key Check		_				39.837	42.958	35.700	38,080	37,305	36.995	39,185	38,034	466,675
Skobai	486,675	40,963	38,588	40,185	38,865	38,831	42,838	35,700	30,000	ىسىر دى	20,000	44,100	50,004	400,015
Direct Service	105,362	8.262	8.406	8.56Ż	8,348	8,813	9,094	8,454	8,240	B,324	7,969	8,085	11,807	105,362
PPD Service Sister & Takeda	57,348	5,113	5,113	5,113	5,113	5,113	5,113	5,113	5,113	5,113	5,113	5,113	1,105	57,348
TOTAL GROSS EXPENSE	629,385	54,338	52,107	52,B6D	52,324	53,763	67,165	49,267	62,413	50,742	50,077	62,383	50,946	629,385
				— ·										
LESS SISTER DIVISION CHARGES:	_													
******	192,854	16,901	15,951	16,590	16,062	16,451	17.699	14.796	15,740	15,438	15,314	18,190	15,722	192,854
A/ Total TAP Phann. Inc.	20,185	1,682	1,682	1,682	1,682	1,682	1,882	1,682	1,682	1,682	.1,682	1,682	1,683	20,185
HPD	8,834	736	735	736	736	736	736	738	736	736	736	736	738	8,834
ADD	2,383	189	199	199	199	199	199	199	199	199	199	199	194	2,383 4,909
SPD	4,909	409	409	409	409	409	409	409	409	409	409	409	410 162	1,855
ROSS	1,955	163	163	163	163	163	163	163	163	163	163	153		42
CPD '	42	4	4	. 4	4	4	4	4	4	4	8	6	(Z) B	74
CMIS '	74	6	5	6	6	6	6	6	6 1,398	1,398	1,398	1,398	1,394	16,772
Other Sister Division	16,772	1,398	1,398	1,398	1,398	1,398	1,398	1,298				<u> </u>		
TOTAL CHARGES OUT	248,008	21,498	20,548	21,187	20,659	21,048	22,296	19,293	20,337	20,035	19,911	20,787	20,309	248,009
PARD SERVICES SOLD IMPACT (Judgement)	3,990	333	333	333	333	333	333	332	332	332	332	332	332	2,890
NET PPRO EXPENSE	385,367	33,173	31,892	33,006	31,998	33,048			32,408		30,498	31,928	50,969	385,367
	<del></del>	فنسب				<del></del>								
ACTUALS PER GREYBOOK (JORIVE) VARIANCE/KEY CHECK		(33,173)	(31,892)	(303,006)	G1,998)	(33,048)	(35,202)	(30,206)	(32,408)	(31,039)	(30,498)	(31,925)	(30,969)	(385,367
ACTUALS PER KIRNES/DIANA									_	-		-	-	-
VARIANCE/KEY CHECK		(33,173)	(31,892)	(33,006)	(31,898)	(33,048)	(35,202)	(30,208)	(32,408)	(31,039)	(30,498)	(31,928)	(30,969)	(385,367
Memo: 2000 Actuals		32,133	30,404	35,911	33,138	32,058	45,704	28,013	27,124	29,386	27,095	27,115	27,512	376,593
Memo:		46 884	15,951	16,590	16,062	16,451	17,699	14,796	15.740	15,438	15,314	16,190	15,722	192,854
AI 2001 PLAN (12/08/00)		16,801 10,645	15,951		14,474	18,424	17,281	17.959	15,360	19,401	19,301	16,441	15,581	
Al Final 2000 AGU		14,040	14,304		17,717	10,424	11,201	.,,,,,,	10,000	10,101	,			•
Net PPRD Expense	104	704	3Qt	40lt	Total		10tr	2001 PL	AN Favi(L	Infav) vs. 40tr	Total	ł		
and the sale of th	1 <u>0t</u>	2 <u>01</u> 100,248					104	5740	245		<u> </u>	1		
2001 FLAN (12/08/00) % of total	98,071 25.4%	26.0%	24.3%	24.2%										
		***	D4 D22	0D 470	471 700		377	10.652	10.7/7	(47 040	(10,637	ļ		
2000 Final AGU % of total	98,448 26.3%	110,900 29.6%			374,730 100,1%		377 0.4%			-16.1%	-2.8%			
	98,448				375,593		377	10,652	19.130	(11,673	9,774			•
2000 Actuals			-				0.4%				-2.6%			
% of total	26.2%	29.5%	22.5%	21.6%	100.036		U.476	2.07	-10.072	12.25		J		

mgmX

												•	• •
PPRD GREYBOOK RECONCILIATIONS YTD - \$													COMPANIA DOG 7 AM
2001 PLAN	GLOBAL									· 	·		<del></del>
CHARGES TO PROJECTS:	101 FLAN	JAN	FEB	MAR	APR	MAY	JUNE	JULY	AUG	SEPT	<u>ост</u>	NOV	DEC
Global	466,675	40,963	79,551	119,738	158,601	198,435	241,395	277,096	315,156	352,461	389,456	428,641	458,675
Direct Service PPD Service Sister & Takeda	105,352 57,348	8,262 5,113	16,668 10,226	25,230 15,339	33,576 20,452	42,389 25,565	51,483 30,678	59,837 35,791	69,177 40,904	77,501 46,917	85,470 51,130	83,555 56,243	105,362 57,348
TÖTAL GROSS EXPENSE	629,385	54,338	106,445	160,305	212,629	266,392	323,557	372,824	425,237	475,978	526,056	578,439	629,385
LESS SISTER DIVISION CHARGES:	_						:						
A) Talai'	192,854	16,901	32,852	49,442	85,504	81,955			130,190	145,628 15,138	160,942 16,820	177,132 18,502	192,854 20,185
TAP Pharm, inc. HPD	20,185 8,834	1,682 736	3,364 1,472	5,046 2,208 597	6,728 2,944 796	8,410 3,680 995	10,092 4,416 1,194	11,774 5,152 1,393	5,888 1,592	6,624 1,791	7,360 1,990	8,096 2,189	B,B34 2,383
ADD SPD	2,383 4,909 1,955	199 409 163	398 818 326	1,227	1,636 652	2,045 815		2,B63	3,272		4,090 1,630	4,499 1,793	4,909 1,855
ROSS CPD CMIS	42 74	4,		1:2	16 24	20 30		28 42	32 48	36 54	40 60	44 66	42 74
Other Sister Division	16,772	1,398	2,796	4,194	5,592	6,990	8,388	8,786	11,184	12,582	13,960	15,376	16,772
TOTAL CHARGES OUT	248,008	21,498	42,D46	63,233	63,892	104,940	127,236	146,629	166,966	187,001	206,912	227,699	248,008
PARD SERVICES SOLD IMPACT (Judgement)	3,990	333	686	999	1,332	1,685	1,998	2,330	2,662	2,994	3,326	3,658	3,990
NET PPRO EXPENSE	385,367	33,173	65,065	98,071	130,069				260,933		322,470	354,398	385,367

L'IGROUPPLANNINGIZ001 PLANZ001 FINAL OpcostWK4

HIGHLY CONFIDENTIAL ABBT 0037531

Communication   Communicatio	ن. Modelling Factor: .input # months actuals in cell	below			PLAN	ELOPMENT	г						627 PGS 68257 AM	
Part	0 Modelling Calculations are in Relics & pink hight Modelling Factor: Input total Global \$'s in cell b 456.675								AUG	SEPT	OCT			TOTAL
Seed Demonst 1, 12, 12, 12, 13, 12, 13, 13, 13, 13, 13, 13, 13, 13, 13, 13	Giotal: Discovery Deals Gensal Payments	ō	Đ	D	0	Đ	. 0	0	D	0	0	0	0	. 0
10 Other (see Schedisch bescheit al Memo 1)	Other Global Grants Global SPD	7,511	8,200	8,786	9,136	9,306	10,186	8,604	9,010	8,788	5,794	9,773	9,654	104,748
Construction   1.00	Sublotal - Identified Global Expenses	11,434	12,748	14,724	13,309	13,854	16,124	12,777	13,558	14,726	9,957	14,321	16,721	164,263
August to Freedom Al Editors   1,000	All Other (see allocation basis at Memo 1) Complete of activities and the second	ar ib	i, i 110:		Pa			0.750	24,836 44,836		in di A			Quitanity.
Tright Carbon   49,873   36,986   49,167   19,067   19,	Total Global as Calculated Adjust to Frozen Al Salfoud Income in Section of the Calculation of the Modelling Factor: If freezing Al salious, Imput 1.	1,208 30,963	(964) 208/5885	194	470	79	33	(632)	(334)	(562)	1,000	175	(667)	D
Demonstic Formath	Total Global  Communication  Communi	(4006a) ((6385)	79,55E (31,620)	147,099) 147,099)	(57,00) (67,40)		29 (7.95) (1865-54)	1977 0963 1110 1110 11	(125 062) (125 062)	7752 46 FT 4740 2841	389 456 155 7821	1928,641) 217,114,601	466 675 (186 670)	
Motion 7,302 8,176 7,045 6,828 7,295 7,576 7,095 7,240 6,997 6,777 8,880 6,522 05,716 Total Domestic 6,595 8,799 8,895 8,679 8,146 8,427 8,765 8,572 8,556 8,001 8,417 8,148 105,562	Domestic: Domestic Grants Domestic SPD													
Troub Domestic  8,595 8,739 8,895 8,879 8,146 8,427 8,765 8,767 8,765 8,767 8,765 8,772 8,656 8,301 8,417 8,149 105,3x2  Minon 1 1. Troub 161 PPD R3D Expense 131,773 31,872 33,005 31,989 33,046 35,222 30,205 32,400 31,079 31,624 11,6	Subtatal - Identified Domostic Expenses	1,293	563	1,850	1,851	1,851	1,851	1,731	2,332	1,759	1,524	1,524	1,517	(88,382)
Memon 1:  Total Nite PD REID Expense  12,173 31,852 33,006 31,993 33,046 33,207 30,206 32,403 11,019 30,488 31,528 30,000 38,537  Total Nite PD REID Expense  (1,233) (6,50) (1,635) (	All Other	7,302	8,176	7,045	6,828	7,295	7,576	7,055	7,240	6,897	6,777	6,893	6,632	65,716
Teach Mart Pip RED Exponse   33,173   31,872   33,065   31,993   33,046   35,202   32,055   32,055   31,039   30,488   31,202   30,205   31,101   30,101	Total Domestic	8,595	8,739	8,895	8,679	8,146	9,427	8,765	9,572	· B,656	8,301	8,417	6,149	105,362 -
Calculating prefilmancy calconductions from TRH protein parkings   Calculating prefilmancy calconductions from the protein parking   Calculating prefilmancy calconductions   Calculating prefilmancy calculating   Calc	Memo 1: Total Not PPD RED Expense Less 100% of Identified Domestic Exp (above) Less 60% of Identified Global Exp (above) All Other Not yet Calendarized (Allocation base)	(1,293) (6,650)	(563) (7.649)	(1,850) (6,834)	(1,851) (7,985)	(1,851) (8,312)	(1,851) (9,674)	(1,731) (7,656)	(2,332) (8,135)	(1,759) (8,836)	(1,524) (5,980)	(1,524) (8,593)	(1,517) (10,034)	(19,645) (98,558)
I) Input maturals to detailed model. Confirm that not RAD lies to J drive (PALPLAL WAS).	Street, while united by the production that so will be				9 12 2 2 2									
Minko sure calendarization shorts (column B in Called Grants, Firm Expense, 5 year Purchased, Sves Sold) are painfulground arrestal from Op Coat Solnt	Input actuats to detailed model. Conform that net     Input items puting into "identified Global Expensi     From analysts: Discovery New Technology, Gr     We can guesstimate Discovery functionals	R&D Hes es" and "a ants, SPO	to J drive landified D , License ;	(P&L\P&U omesti≂ E	xpenses"	Shocks								
Monified Global Expenses (Net)   5,850   7,649   8,834   7,985   6,312   9,674   7,586   8,135   8,836   5,980   8,593   10,033   98,557   Identified Dementic Expensors   1,293   553   1,850   1,851   1,851   1,651   1,731   2,332   1,759   1,524   1,524   1,571   19,646   Paymal Agustinent for PLAN   0   200   400   600   800   1,000   1,200   1,400   1,600   1,800   2,200   1,200   1,200   1,200   1,200   1,200   1,000   1,800   1,800   2,200   1	4) Make sure calendarization sheets (column B in G 50) are putting corned arrural Firm Op Cost 5 5) Model Quantum Profile 5) Model Quantum Profile 5) Model net R&D calendarization below. (Imputs a 7) For APU praiminary estimates, March = Fasts, A For ASSI preliminary estimates, July = Flash (II in Fig. 1) and (II in Fig. 1).	iaited Gra Sunt re in blue. pril = Plas ot availeb	Plugabi + Blue F s, use AP	other to ac lan impac U + BP), A	chieve qtr ! !ugus! = !	ty profile APU+ Blue	Plan Imp	act.	der Fara					
Identified Domestic Expension   1,289   553   1,850   1,851   1,851   1,851   1,731   2,332   1,759   1,244   1,524   1,524   1,517   19,545   Payrold   0   200   400   600   800   1,000   1,200   1,400   1,600   1,800   2,000   2,200   13,200   Adjustment for PLAN   0   0   0   0   0   0   0   0   0						•				8.835	5.980	6.593	10.033	98.557
Subtotal - Identified Nat Expenses	identified Domestic Expenses Payroli Adjustment for PLAN	1,293 0 0	563 200 0	400 0	1,851 600 O	1,851 800 D	1,851 1,000 0	1,731 1,200 0	2,332 1,400 D	1,600 0	1,800 D	2,000	2,200 0	13,200 D
All Other - see (a) for Actuals														D
Not ReD 33,173 31,692 33,006 33,173 31,692 33,006 33,006 33,007 32,008 33,007 3	•													
Comparison   Com					,						D	Đ		
Chargest   Plant   Color   C														
2001 PLAN (12/08/00) 98,071 100,248 93,653 93,395 385,367  Blue Plant 0 0 0 0 0 0  Changes 0 0 0 0 0  TED 0 0 0 0 0  TBD 0 0 0 0 0  Other (DIP) 0 0 0 0 0  Other (DIP) 9 0 0 0 0  Changes 93,855 93,395 385,367	Diagram and Salay and Sala		30,404	35,911	注意 33,138	報酬報 32,058	(日本) 45,70	0#55211670 4 28,013	27,124	29,769	26,703	1945 27,355	26,418	374,730
Changes: 0 0 0 0 0 0 TED 0 0 0 0 0 0 TBD 0 0 0 0 0 0 TBD 0 0 0 0 0 0 Other (DIP) 0 0 0 0 0 Other (DIP) 9 0 0 0 0 Other (DIP) 9 0 0 0 0 0 Other (DIP) 9 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0		10tr 98,071	2 <u>01</u> 100,248	30 <u>v</u> 93,653		<u>Tetal</u> 385,367								
Financial PLAN 0 0 0 D	Changes: TBD TBD Other(DIP)	6	) 0 ) 0 ) 0	0 0 0	0	0 0 0 1 0								
IIICHIA.	Total Expecised PLAN  Expects of PLAN					•								

HIGHLY CONFIDENTIAL ABBT 0037532 PHARMACEUTICAL PRODUCTS RESEARCH & DEVELOPMENT 2001 PLAN GLOBAL AI CALENDARIZATION

DULUT AM

			<u>.</u>		<del></del>								
	MAL	FEB	MAR	APR	MAY	JUNE	JULY	ALIG	SEPT	DCT	NOV	DEC	TOTAL
Global Al	16,385	15,435	16,074	15,546	15,835	17,183	14,280	15,224	14,922	14,798	15.674	15,214	186,670
Total Fixed Al Total Direct Al	199 317	199 317	199 317	199 317	189 <b>31</b> 7	199 317	199 317	189 317	199 317	199 317	189 317	195 313	2,384 3,890
Total Al Support	515	516	518	516	516	516	516	516	516	516	516	508	6,184
Total Global	16,901	15,951	16,590	16,062	16,451	17,699	14,796		15,438	15,314	16,190	15,722	192,854
2000 AGU Global Al	10,645	14,364	14,799	14,474	16,424	17,281	17,969	15,360	19,401	19,301	16,441	15,581	192,040

(

(

1

451

103

962

4,441

13,349

23

5,390

1,225

<u>53,435</u>

2

449

102

968

4,454

67 H G/01

00:07 AM

Filed 01/28/2008

PPRD SERVICES PURCHASED - SPD RECONCILIATIONS MONTH - \$

Giobal Other - ABT 378 IV Global Other - Misc PMP Global Other - Misc (Add'ti Warehou

Protease 2nd Gen to PPNC

Unit of Activity Charges Global Other-Misc. MJH Adjust

**New Projects** 

New Projects

Total SPD

Excess Capacity

449

102

968

4,454

23

5,390

1,225

11,610

<u>53,435</u>

2

448

102

968

4,454

... 2

449

102

968

4,454

13,382

z

448

102

988

4,454

2

449

102

968

4,454

... Z

44B

102

4,454

13,362

2

449

102

4.454

... 2

449

102

4,454

... 2

449

102

968

4,454

13,362

2

448

102

968

4,454

HIGHLY

PPRD SERVICES PURCHASED - SPD RECONCILIATIONS YTD - \$ 2001 PLAN

02/19/01

														····
		1411	FEB	MAR	APR	MAY	JUNE	JULY '	AUG	SEPT	ОСТ	NOV	DEC	TOTAL
TOTAL FIXED AND DIRECT CHARGES	'01 PLAN	JAN .	rep	WAL.	~~~ .		JUNE	JUC:	700					TOTAL
DIRECT CHARGES														
PASS THROUGH CHARGES:				•								٠.		
Protease 2nd Gen (ABT 378)					4,992		7 400	B.736	9.984	11,232	12,480	13,728	14.970	14,970
.Macrolide (ABT 773)	14,970	1,248	2,496	3,744		6,240	7,488	5,735	9,004	11,232	12,400	14,720	14,570	
Macrolide (ABT 773) Pediatric	•			***		***		•••				***		
Macrolide (ABT 773) LV.	-								•••					
Cholinergic Channel Modulator BPH Backup								-		-		•	***	•••
Endothelin	683	57	114	171	228	285	342	399	456	513	570	627	683	583
NPS-1776	490	41	82	123	164	205	246	287	328	369	410	451	490	490
Quincione	5,762	480	950	1,44D	1,920	2,400	2,880	3,36D	3,840	4,320	4,800	5,280	5,762	5,762
Cancer - Anil Mitotic (Eisal-7010)	1,172	98	198	294	392	490	588	686	784	882	980	1,078	1,172	1,172
Clari 140H		***		•••	•••		•••		•	-				
Cancer - Angiogenesis	2,753	229	458	687	916	1,145	1,374	1,603	1,832	2,061	2,290	2,519	2,753	2,753
Clari IV	4,297	358	715	1,074	1,432	1,790	2,148	2,506	2,854	3,222	3,580	3,938	4,297	4,297 1,700
Ctari Process Improvements	1,700	142	284	426	588	710	852	994	1,136	1,278	1,420	1,562	1,700	
New Products		•••	•••	***	•		***					•	***	•••
Misc Process Impv (ery Danisco)	31.827	2,653	5,306	7,959	10,612	13.265	15,918	18,571	21,224	23.877	26,530	29,183	31,827	31,827
Subtotal Pass Through	31,021	2,033	3,000	1,555	10,012	13,200	13,510	10,511	21,227	Enini i	20,000	20,100	0.1027	,-2,
							•							
DISCOVERY														
Natural Products Discovery			₩.	•	•••	***	•		٠					
Palents & Trademarks	370	31	62	93	124	155	186	217	248	279	310	341	370	370
Miscellaneous (Depr adjusted here)		***							:-	4 000		Z,398	2,621	2,621
Discovery Special Labs	2,621	218	436	654	872	1,090	1,308	1,526	1,744	1,962	2,180 2,490	2,398	2,821	2,991
Subtotal Discovery	2,991	249	498	747	996	1,245	1,494	1,743	1,992	2,241	2,490	4138	2,891	2,001
OTHER												•		
Dom Other-Ery Proc Imp	389	31	62	93	124	155	186	217	248	279	310	341	359	369
Global Other - Clari I	_				***		***					•••	-	•••
Global Other - Clarl IV												•••	•••	
Global Other - ABT 378 IV	-		•••	•••	•••	•••					•••		•••	***
Global Other - Misc PMP	•••					•••		•••	:-	•••			23	23
Global Other - Misc (Add'ti Wareho	ų 23	2	4	6	8	10	12	14	16	1B	20	22	23	23
Protease 2nd Gen to PPNC				4047	- 700				n 500	4 045	4 400	4,939	5,390	5,390
New Projects	5,390	449	898	1,347	1,796	2,245	2,694	3,143	3,592	4,041	4,490 1,020	1,122	1,225	1,225
New Projects	1,225	102	204	306	40B 3,872	510	612 5,808	714 6,776	816 7,744	918 8.712	9,680	10,648	11,610	11,610
Excess Capacity	11,610	968	1,936	2,904	•	4,840	•		-	•			71,010	
Unit of Activity Charges	•••	•••			•••	***	***	•••	,	•••	•••	•••		
Global Other-Misc. MJH Adjust					<del></del> -	<del>-:=:</del>			***			<del></del>		
Total SPD	53,435	4,454	8,908	13,362	17,816	22,270	26,724	31,178	35,632	40.D86	44,54D	48,994	53,435	53,435
rown arv	<u> </u>	-1/444	21228			تنصت	لتجييد	- 11114						

LIGROUPPLANNING/2001 PLAN/2001 FINAL Operat WK

HIGHLY

23

PPRO SERVICES PURCHASED - S RECONCLIATIONS MONTH - S 2001 PLAN									· 	<del></del> .	<del></del> .	<del></del> ,	CONTROL SE OT AM	
FIXED CHARGES	TOT PLAN	JAN	FEB	MAR	APR .	MAY	TIME	JULY	AUG	SEPT	ост	NOV	DEC	TOTAL
PASS THROUGH CHARGES; Protesse 2nd Gen (ABT 378) Macrolide (ABT 773)	5,562	464	 454	454	464	484	 454	464	464	464	464	454	458	5, <i>5</i> 62
Macrolide (ABT 773) Pediatric		-	•••	-	-	-	_	-			-			-
Macrolide (ABT 773) LV. Cholinergic Charmel Modulator	-	_	_	_	_		=	_	-		_			-
BPH Backup	490	41	45	41	41	41	41	41	41	41	41	41	39	490
Endothelin NPS-1776	490	41	41	41	41	41	41	41	41	41	41	41	38	490 3,302
Quinciane	3,382	28D 76	280 76	290 78	280 76	280 76	280 76	280 76	280 76	280 76	290 76	280 76	262 71	907
Cancer - Anti Mitolic (Essi-7010) Clari 140H	907	10	10	_	_	_	_		_	_	_			_
Cancer - Angiogenesis	2,085	174 102	174 102	174 102	174 102	174 102	174 102	174 102	174	174 102	174 102	174 102	171 103	2,085 1,225
Ctari IV Ctari Process Improvements	1,225 748	• 62	62	62	62	82	62	62	62	62	62	62	66	748
New Products	-	-	-	-	_		_	_	_	<u>-</u>		_	_	Ξ
Mise Procest Impv (ery Danisco) Subtotal Pass Through	14,869	1,240	1,240	1,240	1,240	1,240	1,240	1,240	1,240	1,240	1,240	1,240	1,229	14,869
DISCOVERY														•
Natural Products Discovery	-		_	_	=	_		=	· -		-	_	_	_
Patents & Trademarks Miscollanaous (Depr adjusted here)		_	_		_	_			-		_	_	-	2001
Discovery Special Labs	2.621	218 218	218 218	21B 218	218 218	218 218	218 218	218 218	218 216	218 218	218 218	218 218	223	2,621
Sublotal Discovory	2021	272	<u> </u>	z	-12						_			
OTHER Dom Other-Eny Proc Imp	359	31	31	31	31	31	31	31	31	31	31	31	28	589
Global Other - Clari I	-	_	_	_	-	-	-	-	-	-	-	_	-	_
Global Other - Clari IV Global Other - AET 378 IV	-	_	_	-	_	_		_	_	_		_		_
Global Other - Misc PMP		-	-		=	=	- 2	 Z	2	 2	 2	- 2	ī	ā
Global Other - Misc (Add't Wareho Protesse 2nd Gen to PPNC	u 23	2	2	2	2	,	-		_		_		***	_
New Projects	6,390	448	449 102	449 102	449 102	449 102	449 102	448 102	102	448 102	449 102	44B 102	451 103	5,390 1,225
New Projects Excess Capacity	1,225 11,610	102 968	968	968	968	968	968	968		968	968	968	962	11,610
Unit of Activity Charges	·		_	-	-	-	-		. :	_	_	_	_	_
Global Other-Misc. NLIH Adjust							<u></u>				2 242	3.010	2,997	36.107
Total SPD Fixed Charges	<u>36,107</u>	3,010	3.010	2.01Q	3,010	3. <u>P1P</u>	<u>2.010</u>	3,010	3.010	2,010	2.010	3701A	2331	547157
	· ——							·			<u>·</u>			
DIRECT CHARGES	DI PLAN	MAL	FEB	MAR	APR	MAY	TUNE	JULY	AUG	SEPT	OCT	NOV	DEC	TOTAL
PASS THROUGH CHARGES:						_				_	_		_	_
Protesse 2nd Gen (ABT 378) Macrolide (ABT 773)	9,4D8	784	784	784	7B4	784	784	784	784	784	784	784	784	9,408
Macroscie (ABT 773) Pediatric	_	. –	-	-	-	-	_	_	. <u>.</u> .		_		: =	=
Macrotide (ABT 773) I.V. Chotinergic Channol Modulator	_	_	_	Ξ	=	_	_	_		-				-
BPH Backup	193	18	18	18	16	15	16		10	16	16	16	17	193
Endothelin NPS-1778			***		_	_						_		2,400
Quinolone Cancor - Anti Mitolic (Elsal-7010)	2,400 265		200 22		200 22	200 22								
Circl 14OH		-	_	_	-	-						55	63	668
Cancer - Angiogenesis Cizri IV	658 3,072											256	256	3,072
Clari Process Improvements	852					BC	) B	81	98 0	) BI	) 80	) BC	,72	952
New Products Miss Process Impy (ary Danisco)	-	_		<u> </u>	_						· <u> </u>	<u>-</u>		<u> </u>
Subboal Pass Through	15,956	1,413	1,413	1,413	1,413	1,4%	1,41	1,41	3 1,412	1,41	1,41	1,410	3 7,415	16,958
DISCOVERY												_		
Natural Products Discovery Priorits & Tradomarks	370	31	31	31	31	3	i 3	1 3	ī 5	3	i 3	i 3	1 2	
Miscellaneous (Depr adjusted hor				-	-		- •				. <del>.</del>		-	· -
Discovery Special Labs Subtotal Discovery	370	2 2	<u> </u>	<u> </u>	3	1 2	1 3	<u>i                                    </u>	1 2	1 2	i a	1 3	1 2	370
OTHER														
Dom Other-Ery Proc Imp	_				. <b>-</b>						• ·			
Global Other - Clari I Global Other - Clari IV						/								=
Global Other - ABT 378 IV	-	<del>-</del>												<u>-</u>
Global Other - Misc PMP Global Other - Misc (Add'6 Wareh						: :		<u>.</u>			_ :	_ :	- :	
Protease 2nd Gen to PPNC	-		: -					-				. ,		
New Projects	-		-				- :	-	<u> </u>	- :	- :			- <del>-</del>
New Projects Excess Capacity	-					_ :	_	_	_ :	_				- ~
Unit of Activity Charges Global Other-Misc. MJH Adjust	-					. :	_ :		_ :	-		- 	·	
Change Carric Licens and London														
Total SPD Direct Charges	17.32	<u> 1,44</u>	4 1.44	4 1.44	4 1.44	4 1,44	4 14	4 14	4 1.44	4 1.44	4 1.44	4 5.44	4 14	4 17,325

MGIILY CONFIDENTIAL ABBT 0037536

PPRD SERVICES PURCHASED - S RECONCILIATIONS YTD - \$ 2001 PLAN	PD												EUTHET DEST/AN	
FIXED CHARGES	01 PLAN	TAH .	FEB	MAR	APR	MAY	JUNE	JULY	AUG :	SEPT	<u>ост</u> -	NOV	DEC	TOTAL
PASS THROUGH CHARGES: Proteoso 2nd Gen (ABT 378) Macrolido (ABT 773)	5,562	464	EZ8	1,292	1,858	2,320	2.764	3,248	3,712 	4,175	4,640 —	5,104	5,562 	5,562
Macrolide (ABT 773) Pediatriç Macrolide (ABT 773) I.V. Cholinerpic Channel Modulator	-	-	-	-			=	-	_		-	=		=
BPH Backup Endothelin	490	45	82	123 123	164 164	205 205	248 248	287 287	328 328	389 389	410 410	451 451	490 490	490 490
NPS-1776 Quinolone Cancer - Anti Mitolic (Elsai-7010)	490 3,362 907	41 260 76	82 580 152	840 228	1,120	1,400 380	1,680 456	1,960 532	2,240 608	2,520 584	2,800 760	3,080 838	3,362 807	3,352 907
Ciari 140H Cancer - Angiogenesis	2,085	174	348	522	696	870	1,044	1,218	1,392	1,568 102	1,740 102	1,814	2,085 205	2,085 205
Clari IV Clari Process Improvements	1,225 748 748	107 02 62	102 62 124	102 62 186	102 62 248	102 62 310	102 62 372	102 52 434	102 62 495	62 658	620	62 682	185 748	165 748
New Products Misc Process Impv (ety Danisco) Subtotal Pass Through	15,617	1,302	2,440	3,578	4.718	5,854	6,992	8,130	9,26B		11,544	12,682	14,014	14,014
. DISCOVERY													•	
Natural Products Discovery Patents & Trademarks	=	-	=	-	_	=	=	-	_	=	-	• =	=	, Ξ
Miscellaneous (Deprinducted here) Discovery Special Labs Subtotal Discovery	2.521 2.521	218 218	438 436	654 654	672 872	1,090	1,308	1,528	1,744	1,962	2.180 2.180	2,398 2,398	2.021 2.621	2,621 2,621
OTHER Dom Other-Ery Proc Imp	. 369	31	62	<b>6</b> 2	124	155	186	217	248	279	310	341	369	369
Global Other - Clari I Global Other - Clari IV	Ξ	=	-	=		-	=			=		Ξ	_	-
Global Other - ABT 378 IV Global Other - Misc PMP Global Other - Misc (Addril Wareho		- 2		·- 6	-	10	12	14	18	18	20	22	23	23
Protesse 2nd Gen to PPNC New Projects	6,390	449	898	1,347	1,796	2,245	2,694	1,143	3,592 816	4,041 918	4,490	4,939	5,390 1,225	5,290 1,225
New Projects Excess Capacity	1,225 11,810	102 968	204 1,536	306 2,904	408 3,872	510 4,840	612 5,808	714 5,778	7,744	8,712	8,680	10,648	11,610	11,810
Unit of Activity Changes Global Other-Misc. Milh Adjust					=						<u> </u>		·	
Total SPD Fixed Charges	36,855	3.072	5,980	8,888	11.796	34,704	17.612	20,520	22,520	26,236	29,244	37,152	35 <u>,752</u>	25,252
DIRECT CHARGES	101 PLAN	JAN	FEB	MAR	APR	MAY	JUNE	JULY	AUG	SEPT	ост	NOV	DEC	TOTAL
PASS THROUGH CHARGES:	DI PLAN	JAN I	FBB	MAR		MAY	JUNE			SEPT				
PASS THROUGH CHARGES: Prolonze 2nd Gon (ABT 378) Macrolide (ABT 773)	9,408			MAR 2,352		MAY 3,820	JUNE 			<u>.</u>	7,B4D	8,624	9,408	TOTAL 9,408
PASS THROUGH CHARGES: Protome 2nd Gen (AST 378) Macrolide (AST 773) Podiatic Macrolide (AST 773) Podiatic Macrolide (AST 773) IV. Chollengic Channel Modulator			1,568		APR		·	JULY	AUG 8,272	SEPT				
PASS THROUGH CHARGES: Protoine 2nd Gen (AST 378) Marcridde (AST 773) Pedutric Macrolide (AST 773) I.V. Chellengie Channel Modulator BPH Backup Endotwen	9,408	764	1,568	2,352	3,138	3,820	4.704	JULY 5,488	B,272	7,056	7,B40	8,624	9,408	9,408
PASS THROUGH CHARGES: Protoine 2nd Gen (ABT 378) Macrotide (ABT 773) Pediatric Macrotide (ABT 773) Pediatric Macrotide (ABT 773) IV. Cholinergic Channel Modulator BPH Backop Endotwein NPS-1776 Outnotion	9,408	784	1,568	2,352	3,138	3,920 	4.704   98	JULY 5,488	B.272 	7,056	7,840	8,624 	9,408 	9,408  - 193 2,400
PASS THROUGH CHARGES: Protome 2nd Gen (ABT 378) Macrolde (ABT 773) Pediatric Macrolde (ABT 773) Pediatric Macrolde (ABT 773) IV. Crecknergie Channel Modulator BPH Bascher MPS-1776	9,408 9,408 193 2,400 285	784 	1,568 	2,352 	3,138	3,920 	4.704 	5,488 5,488 112 1,400 154	B,272 1,800 178	7,056 	7,840 	8,624 	9,408 	9,408   193 2,400 265 668
PASS THROUGH CHARGES: Protosee 2nd Gen (ABT 376) Macrolide (ABT 173) Macrolide (ABT 173) Pediatric Macrolide (ABT 173) I.V. Cholinergic Channel Modulator BPK Bactoop Endothelin NPS-1776 Outhrolone Cencer - Anti Mitotic (Essal-7010) Casi 140H Cancer - Angiogenesis Cast IV Casi Process Improvements	9,408	784 	1,568	2,152   48 600 68	3,138	3,820 	4,704 	5,488 5,488 112 1,400 154 385 1,792	8,272 	7,056	7,840 	8,624 - - 178 2,200 242 - 805 2,818	9,408 	9,408 
PASS THROUGH CHARGES: Protoine 2nd Gon (AST 376) Macrotide (AST 773) Podiatric Macrotide (AST 773) Podiatric Macrotide (AST 773) IV. Cholinenjic Channel Modulator BPH Banker HPS-1776 Outnotone Cancer - Anii Mitotic (Eizai-7010) Clasi 140H Cancer - Angiopenesis Cast (V	9,408 193 2,400 265 3,072	784 784 10 200 200 200 200 200 200 200 200 200	1,568 	2,352   48  600 68 768	3,138	3,920 80 1,000 110 275 1,280	4,704 	JULY 5,488	B.272 	7,056 	7,840 	8,624 	9,408 	9,408 
PASS THROUGH CHARGES: Protosee 2nd Gen (ABT 378) Mastrolide (ABT 1773) Mastrolide (ABT 1773) Profestive Mastrolide (ABT 1773) IV. Chollensylice Channel Modulator BPK Bandon Endetheein PRS-1776 Outnotono Center - Ansi Mitotic (Essai-7010) Class 14CH Center - Angiogenesis Cast IV Can Process Improvements New Products Nüce Process Improvements Nüce Process	9,408 193 2,400 285 3,077 852	784 784 10 2000 20 20 20 20 20 20 20 20 20 20 20	1,568 	2,152 	APR 3,138 64 80 88 82 220 1,024 320	3,920 80 1,000 110 275 1,280	4,704 	JULY 5,488	B.272 	7,056	7,840 	8,624 	9,408 	9,408 
PASS THROUGH CHARGES: Protosee 2nd Gen (ABT 378) Masrolide (ABT 173) Masrolide (ABT 173) Pediatric Masrolide (ABT 173) IV. Chollensylic Channel Modulator BPK Bandon Endothelin PRS-1176 Outholono Cancer - Ansi Mitotic (Essai-7010) Class 14CH Cancer - Angiogenesis Class IV Carlor - Angiogenesis Class IV Carlor - Angiogenesis Class IV Miss Process Improvements New Products Miss Process Improvements Nice Process Nice Proc	9,408 193 2,400 283 3,077 16,950	784 16 200 200 25 25 25 25 25 25 25 25 25 25 25 25 25	1,568	2,352 	3,138	3,820 	4,704 	35,488 112 1,400 154 1,792 500 9,691	8,272 	7,056	7,840 	8,624 	9,408 	9,408 
PASS THROUGH CHARGES: Protoma 2nd Gen (ABT 378) Macrolde (ABT 773) Pediatric Macrolde (ABT 773) Pediatric Macrolde (ABT 773) Pediatric Macrolde (ABT 773) IV. Crecknergic Channel Modulator BPH Basich FPS-1776 Outnotone Cencer - Anii Mitotic (Essal-7010) Clari 14CH Cencer - Aniiopenesis Clari IV Clari Process Improvements New Products Miss Process Improvements New Products Statistical Pass Through	9,408 193 2,400 283 3,077 16,950	784 16 200 200 250 250 250 250 250 250 250 250	1,568	2,352 	APR 3,138	3,920 60 1,000 110 279 1,280 400	4,704 	5,488 5,488 1,400 154 1,792 560 9,891	8,272 8,272 128 1,800 178 440 2,048 640 11,304	7,056	7,840 	8,624 	9,408 	9,408 
PASS THROUGH CHARGES: Protores 2nd Gen (AST 378) Macrolde (AST 773) Pediatric Macrolde (AST 773) Pediatric Macrolde (AST 773) Pediatric Macrolde (AST 773) IV. Cholinergic Channel Modulator BPH Basing Endothelin APS-1776 Outnotono Cancor - Anii Mitotic (Ensi-7010) Casi 14CH Cancor - Aniiopenesis Carl IV Cast Process Improvements New Products Misc Process Improvements Misc Process Improvements New Products Misc Process Improvements Misc Process	9,408 193 2,400 2,400 3,077 85 3,077 85 16,950	784 16 200 200 250 250 250 250 250 250 250 250	1,568	2,352 	3,133 3,133 64 60 68 88 83 720 1,024 320	3,920 60 1,000 110 279 1,280 400	4,704 	5,488 5,488 1,400 154 1,792 560 9,891	8,272 8,272 128 1,800 178 440 2,048 640 11,304	7,056	7,840 	8,624 	9,408 	9,408 
PASS THROUGH CHARGES: Protoma 2nd Gen (ABT 378) Macrolde (ABT 773) Pediatric PHE Basile (ABT 773) Pediatric PHE Basile (ABT 773) Pediatric Carlor - Anniopenesis Carlor - Anniopenesis Carl IV Carlor - Anniopenesis Carl IV Carlor - Anniopenesis Carl IV Carlor - Anniopenesis Nice Process Improvements New Products Nice Process Improvements New Products Nice Process Improvements New Products Subtrail Pass Through  DISCOVERY Natural Products Discovery Palents & Trademarks Miscellanous (Depra agicsted her Discovery Special Lebs Subtroid Discovery  OTHER Dom Other-Ery Proc Imp Global Other - Charl I	9,400 193 2,400 2,400 3,077 853 16,950	764	1,568	2,352 	3,133 3,133 64 60 68 88 83 720 1,024 320	3,920 60 1,000 110 279 1,280 400	4,704 	3/488 5,488 112 1,400 3/55 1,792 500 9,691	8,272	7,056	7,840 160 2,000 220 2,550 800 14,130	8,624 	9,408 	9,408 
PASS THROUGH CHARGES: Protome 2nd Gen (AST 378) Macrolde (AST 773) Pediatric Macrolde (AST 773) Pediatric Macrolde (AST 773) Pediatric Macrolde (AST 773) Pediatric Macrolde (AST 773) IV. Crecknergie Channel Modulator BPH Baside Marys-1776 Outholone Cencer - And Mitotic (Essai-7010) Claid 14CH Cencer - Angiogenesis Carl IV Carl Frocess Improvements New Products Mise Process Improvements New Products Subtotal Pass Through  DISCOVERY Natural Products Discovery Patents & Trademarks Misectaneous (Depr adjusted her Discovery Special Lebs Subtoud Discovery  OTHER Dom Other-Ery Proc Imp Global Other - Carl I Global Other - AST 378 IV	9,400 193 2,400 2,400 3,077 853 16,950	784 784 784 784 784 784 784 784 784 784	1,568 1,568 1,32 1,32 2,44 1,10 1,51 1,51 1,51 1,51 1,51 1,51 1,51	2,352 	3,133 3,133 64 60 68 88 83 720 1,024 320	3,920 60 1,000 110 279 1,280 400	4,704 	3/LY 5.488 5.488 1121 1121 1.4000 154 154 154 157 159 107 107 107 107 107 107 107 107 107 107	8,272	7,056	7,840 	8,624 	8,408 	9,408 
PASS THROUGH CHARGES: Protosee 2nd Gen (ABT 378) Macrolide (ABT 173) Macrolide (ABT 17	9,408	764	1,568 3 2 3 2 3 2 4 6 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4	2,352 	3,133 3,133 64 60 68 88 83 720 1,024 320	3,920 60 1,000 110 279 1,280 400	4,704 	3/488 5,488 112 1,400 3/55 1,792 500 9,691	8,272 128 1,800 440 2,048 640 11,304	7,056	7,840 	8,624 	8,408 	9,408 
PASS THROUGH CHARGES: Protosze 2nd Gen (ABT 378) Masrolide (ABT 1773) Masrolide (ABT 1773) Masrolide (ABT 1773) Profustric Cancer - Angiogenesis Cast IV Cancer - Angiogenesis Cast IV Cancer - Angiogenesis Cast IV Carlor - Angiogenesis Cast IV Carlor - Angiogenesis Masc Process Improvements New Products Nation Process Improvements Nation Process Improvements Nation Process Improvements National Pass Through  DISCOVERY Natural Products Discovery Patents & Trademarks Missedaneous (Depr adjusted her Discovery Special Labs Subtotal Discovery  OTHER Dem Other-Eny Proc Imp Global Other - Cast II Global Other - Alts T 378 IV Global Other - Misse (AddT Warel Probass 2nd Gen to PPMC	9,408	784	1,568 3 2 3 2 3 2 4 6 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4	2,352 	3,133 3,133 64 60 68 88 83 720 1,024 320	3,920 60 1,000 110 279 1,280 400	4,704 	JULY 5,488 112 112 1,400 20 154 154 1,782 500 1,782 500 1,782 1,78	8,272 128 1,800 440 2,048 640 11,304	7,056	7,840 	8,624 	8,408 	9,408 
PASS THROUGH CHARGES: Protoses 2nd Gen (ABT 378) Mastrolide (ABT 1773) Mastrolide (ABT 1773) Mastrolide (ABT 1773) Pediatric Mastrolide (ABT 1773) Pediatric Mastrolide (ABT 1773) Pediatric Mastrolide (ABT 1773) IV. Cholinersije Channel Modulator BPK Bandon Endethelin PRS-1776 Outholono Cancer - Angiogenesis Cari IV Carlore - Angiogenesis Mice Process Improvements New Products Mice Process Improvements New Products Mice Process Improvements Nice Products Subtotal Depar Agriculture Discovery  OTHER Dom Other-Eny Proc Imp Global Other - Alex PMP Global Other - Alex PMP Global Other - Alex PMP Global Other - Mice PMP Global Other - Mice PMP Global Other - Mice PMP Global Other Protects New Projects New Projects	9,403	784	1,568 8 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	2,352 	3,133 3,133 64 60 68 88 83 720 1,024 320	3,920 60 1,000 110 279 1,280 400	4,704 	JULY 5,488 5,488 5,488 5,488 5,488 5,488 5,488 5,488 5,488 5,782 5,500 5,691 5	8,272	7,056	7,840 	8,624 	8,408 	9,408
PASS THROUGH CHARGES: Protome 2nd Gen (ABT 378) Marcoldo (ABT 173) Marcoldo (ABT 1773) Marcoldo (ABT 1775) Cultor - Antiopenesis Cartor - Antiopenesis Cartor - Antiopenesis Cart IV Cartor - Antiopenesis New Products New Products Mace Process Improvements New Products Marcoldo Discovery Patents & Trademarte Miscedances (Dopra adjusted her Discovery Special Lubs Subtotal Discovery  OPHER Don Other-Eny Proc Imp Global Other - Cart I Global Other - Cart I Global Other - Cart I Global Other - ABT 378 IV Global Other - Marc PMP Global Other - Marc Ladd't Warel Protesses 2nd Gen to PPNC New Projects	9,403	784	1,568 8 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	2,352 	3,133 3,133 64 60 68 88 83 720 1,024 320	3,920 60 1,000 110 279 1,280 400	4,704	JULY 5,488 5,488 5,488 5,488 5,488 5,488 5,488 5,488 5,488 5,782 5,500 5,691 5	8,272	7,056	7,840 	8,624 	8,408 	9,408 

HIGHLY

PPRD SERVICES PURCHASED - RECONCILIATIONS MONTH - \$ 2001 PLAN	SPD												02/19/01 01:07 AM	
	'01 PLAN	MAL	FEB	MAR	APR	MAY	JUNE	JULY	AUG	SEPT	ост	NOV	DEC	TOTAL
SUMMARY SPD Total Pilot Plant/PMP Stack Card Total Bulk Drug Direct Total Excess Capacity Stack Card Total SPD	24,497 17,328 11,610 53,435	2,042 1,444 968 4,454	2,042 1,444 968 4,454	2,042 1,444 968 4,454	2,042 1,444 968 4,454	2,042 1,444 968 4,454	2,042 1,444 968 4,454	2,042 1,444 968 4,454	2,042 1,444 968 4,454	2,042 1,444 968 4,454	2,042 1,444 968 4,454	2,042 1,444 968 4,454	2,035 1,444 962 4,441	24,497 17,328 11,610 53,435
SUMMARY GLOBAL/DOMESTIC Total Global SPD Total All Other Domestic SPD Total SPD	47,069 6,366 53,435	3,823 531 4,454	3,823 531 4,454	3,923 531 4,454	3,923 531 4,454	3,923 531 4,454	3,923 531 4,454	3,823 531 4,454	3,923 531 4,454	3,923 531 4,454	3,923 531 4,454	3,823 531 4,454	3,916 525 4,441	47,069 6,366 53,435
Ligrouppelayericzon plangom fral o	ocost.WW4										KEY	CHECK (	s/u u/⊸>	
PPRD SERVICES PURCHASED - RECONCILIATIONS YTD - \$ 2001 PLAN	SPD													
RECONCILIATIONS YTD - \$	SPD DI PLAN	JAN	FEB	MAR	APR	MAY	JUNE	JULY	AUG	SEPT	ост	NOV	DEC	TOTAL
RECONCILIATIONS YTD - \$		JAN 2,042 1,444 968 4,454	4,084 2,888 1,936 8,908	6,128 4,332 2,904 13,362	8,168 5,776 3,872 17,815	10,210 7,220 4,840 22,270	JUNE 12,252 8,664 5,808 26,724	14,294 10,108 6,776 31,178	16,336 11,552 7,744 35,632	SEPT 18,378 12,996 8,712 40,086	OCT 20,420 14,440 9,580 44,540	22,462 15,884 10,648 48,994	24,497 17,328 11,610 51,435	TOTAL  24,497 17,328 11,810 53,435

LIGROUPPLANNING/2001 PLAN/2001 FINAL Openst WK4

HIGHLY CONFIDENTIAL ABBT 0037538

96

PPRO AFFORDABILITY RECONCILIATIONS MONTH - \$ 2001 PLAN									·	٠.			02/19/01 05:07 AM	
	2001 PLAN	JAN	FEB	MAR	APR	MAY	JUNE	JULY	AUG	SEPT	ост	NOV	DEC	TOTAL
SDG/Other				٠.				•••			•••	•••	•••	•••
HIV/Knol/QD/Other			•••	•••			•••			•-•		•••		
Aegis Insurance		•••	•••		•••	•••	•••	•••	•••		•••	•••	•••	
Gensel #1	***			•••	***	-**		•••	•=	•	•••	•••		
Genset #2	•••	•••	•••		•••	***	•••	•••	•••		•••			
Neurosearch FTE \$2530, depr \$200		•••	•••	•••	•••	•••	•••		•••		***	•••		
Coactinon	•••	•••	•••		•••	•••	•	•		•••	•••	•••		
SPD IDV Liponavir	•••	•••	•••	•••	•••		***			•••		•		
Thrombolytics to HPD (Ovrhd & Grants)		•••	•••				•••	•••	•••			•		
Data Management Absorbtion	***	•••	•••		•••						•••			
Other New Products		•	•••		*		•••	***			•••			
Quinolone Payment	•••				•••	•••	•••		•••	•		•••		
Division Task		•••			•••			***	***	•		•••		
		•••			•••	•••	•••	•••	-	•••		•••		٠
Total SDG/Other	***				•••	-		-		-	•			

HIGHLY

шашл

### Pharmaceutical Research & Development Key Plus/Minus List 2001 (\$MM's)

Description	Сотпепсиу	Probability	Pavi(Unfav)
DPI Agreement	Licenaing agreement with Diecovery Pertners international. Accounting to be clarified with Corporatio.	High	2.0
SPD Buik drug (or Kelolide	Discussions are currently on-going with SPD to drop the number of bulk menulacturing campelign runs from 6 to 4 for the April Update.	High	1.5 - 2.0
Kaletra FDA Stralegy	The current Kaletra budget easumes all date that is scheduled to be submitted as part of the FDA Accelerated Approval Unistable will be authorist. In the event that the date is incontitueive (as determine by the FDA) additional dollars will be needed to conflitue existing studies.		
	Subiotal for High Probability Scenarios	lly Scanarios	2.3 - 2.8
CCM Milestone Funding	GorNo go decision is acheduled for May/June 2001. If the decision to confirm development is made, additional funding will be needed to confirm the program.	Medium	(8.8)
Kelolide Jepen	Japan Phase (I/III atudies have been milesions funded. If positive data it available in the 4Q (this is the projected slart date of the study), funding will be needed to stay on target with the expectations of Japan regulators.	Medium	(4.0)
Oulnolone Milestone Paymen!	Currently, Phease lib mileatone psyment is unfunded. If current enrollment levels are achieved for Phease lib, additional funding will be necessary to eatify our contractual additional funding will be necessary to eatify our contractual colligiations. There is a light probability that the contract will be repeated and the mileatone psyment will then curre due in 1Q 2002.	Medium	(5.6)
	Sublotel for Medium Probability Scenarios	Ility Scenarios	(17.3)
i Immunosuppresant Sale	Sale of this compound is expected in 2001. Global Pharmaceulical RAD Division could potentially receive the fevenue from this sale.	Ē	0.0
Кат Вю ООС	If Karo Bio does not produce a DDC, we will not owe them a milestone payment in 2001.	Ľġ.	1.0
Bimoclomol Funding	GorNo go decision is expected in lais 10 or early 20 2001. If the decision to confinue development is made, Phase III studies will require funding.	Low	(11.7)
	Subtotal for Low Probability Scenarios	ility Scenarios	(6.7)
	<u>。地域地震和光层结构和影响的变态的运动,对于10.00元素,是一个10.000元素,是一个10.000元素,</u>	Malliscontros	antonal billouin

нісніх CONFIDENTIAL ABBT 0037541

99

2001 PLAN PHARMAĊEUTIGAL PRODUGTS RESEARCH A DEVELOPMENT

		,
Depakole	On going extivition eldenty equation, imputative aggression, psychoels     New extivities: polycyetto ovary, new DR form, 26ting ER definitive bia	New formulations: apilopsy & regarded     Bjoots in pediatio manks     Dose Proportomality     Pediatio Patent Extension - Paych     Acth Migman Extension - Paych     Dose Person - Paych
ABT-584	- Milestone funded to GaNo Go decision June 2001 for neuropattio pain.	Funding for Srt and 4th qt # Go decision is made - Phase IIS Chrotic Penislam Pah
	- Completion of work started in 2000 bringing It to a logical stopping point	· Continuation of pre clintal and Phase (
ABT-089.	- Completion of work started in 2000 britiging It to a topked stopping point	- Single Multiple rising dose Ph I study
A89-103	<ul> <li>Completion of work started in 2000 bringing if to a foolest stopping point</li> </ul>	- Pre dinkal audier - Single feins dae Pri i Andu
NPG-1776	- Completion of work started in 2000 bringing it to a lagical etopping point	Pre clinical studies     Bingle sand risting multiple dose Ph I study and formulation bio saudies
Нучтосодопельнуюль	- Repld dissolvs and controlled release forms	
ANTINERGINE	-	<del>-</del> .
Clarithnamycia	- Extended Release Onca/Day - Pitaus IV Int	- Cyalio Fibrosia - Asbuna
Ketelide	- Tablet FDA delayed mylaw forcing ABT De add new effec and redo lissue-studies to maintain NDA filling dels. Cost = \$5.5MM Drug Internation studies: Warfarft,	- I.V Pediatro - Japan Pri Ivili - Diug inieracion etudies: Loratidine, Carbanzepine & Syclosporina
Quinolone	- Tabial - \$3MM milestons payment tor inflating Ph IIA	• Milastons psyment for intlation of PTI ITS \$3.5MM
Noumantinidase (ABT-877)		2 week foxbology study elingle rising dose study rutiliple rising dose study
Omnice/	- Olula Modia	- AECB & Phuyngilds

HIGHLY

••	LI .	Out
UROLOGY/CARDIOLOGY Foncilbrate (Fournist)	- Medical Alitaire ( Ph IV base level aupport	- Diabette - PM Women
		- Feno Post Mi
KCO	. Pre Clinicale	
ЯIV	·	
Ritonavír	Nords / Rochs Combo Effes A & B	
Kaleira	- Kroll (SEC reformutation) - Kroll (SEC reformutation) - HAAFT Metabolio compuleations - Stord Phase IIII 8 Which & Surfive - Expanded Accoss - Ph II Pediatric - Ph II Pediatric	- Current assumption is that long larm salery data from compiles of portion of Ph II Pedative and Ph III Native reduction will make the Third of a The Application of the Third of a The Application of the Third of the Third of the Third those studies we will need about \$1.2MM.
Cyclosporine	. PREFER - European Britch Kidney plus Extension - Padisulio PK	
CANGER		
Endothelln (ABT-627)	- Ph II phyotal study \$1 - Inhiste Ph II phyotal study \$2 - GTO - Bloegulvalance - Drug interaction studies; Fexoferadine	• Eany Stage Pca • Ph Il explanatures • Drug hisparkon studies: Midazolam, Kstocomazole & Pifaripin
TBP #1 (ABT-610)	- Multiple doss in cancer patients - IND study	- Manufacturing & Toxicology
Metalloproteintee	- Muliple dose in cancer patients - IND study	- Manufacturing & Toxicology
· Anti-Mitotle (ABT-781)	- Multiple dose in cancer patients - IND study	
K-5		- Pre clinical / Ph I studies
FILE		- Pre clinical (Ph i studies
Other New Products		- DDC's & in - licensing
ज्य <b>म</b> ा		• ADF, Exploratory, AEGIS Medre, productivity projects • Binecional
Discovery		- Gensal

 $\mathbf{H}\mathbf{G}\mathbf{H}X$ CONFIDENTIAL ABBT 0037543 Analgesia Venture ABT-594 2001 FLAN KEY STATISTICS Pass II (\$000)

The Section

770) 1

il nicotinic receptor antagonist (Milestone Funded to Garko Go June, 2001)  lesiones / Assumptions Tiling  to Phase II - U.S.  to Go Clinincal Efficacy (Phase IIa)  to Go Clinincal Efficacy (Phase IIb)  to Phase III - U.S.  to A U.S./ EMEA EU  to A U.S./ EMEA EU  to Management Support  to Hishing  to Management Support  to Total  to It is to AGU until July, 2001, ABT-594, Gorno Go Decision, then 11 headcount after  and contact Heads: Flat to AGU until July, 2001, ABT-594, Gorno Go Decision, then 11 headcount after  to Contact Heads: Flat to AGU until July, 2001, ABT-594, Gorno Go Decision, then 11 headcount after	9,300 14,411 00,400 2,01 2,01 9,01 9,01 5,03 1,	9,307 017LAN 298 799 6/01 4/02 9/03 9/03 6/01 6/01 6/01 6/01 6/01 6/01 147 6/01 145 145 145 145 145	Status (on target, pending or delayed to x)  Completed C	Status (on target, pending or delayed to x)  Completed  Completed  Completed  Completed  Completed  Completed  Completed  Delayed  Last patient enrolled 1/5/01, n = 269  Delayed  Delayed  Analysis F, Support Milaunobu Cham & Process Justification  Formulation scale-up and process optimization  Completion of MSP-114, Egging 3 Ph is though supplies  Completion of MSP-114, Egging 3 Ph is though supplies
(Phase IIb) (Phase IIb)  milestone funding 3U undi July, 2001,	00 AGU 7198 7198 9199 2/01 9/01 5/03 00 AGU 879 745 745 745	01 FLA 2798 7798 9799 6701 4702 9703	Status (on u Completed Completed Completed Completed Delayed Delayed Delayed Analysis P., Support Milsun Formulation scale-up and pr Completion of M99-114, Pk Coordination of activities as	interuped, pending or delayed to s)  Interupled 1/5/01, n = 269
(Phase Lia) (Phase Lib)  Indication of funding and and July, 2001,	2/98 7/98 9/99 2/01 9/01 5/03 7/03 7/45 178 178 178	2098 7/98 9/99 6/01 4/02 9/03	Completed Completed Completed Delayed Delayed Delayed Delayed Analysis F., Support Milsun Formulation seeds-up and pr Completion of M99-114, Pk	nt enrolled 1/5/01, n = 269 nobu Cham & Process Justification tooss optimization kglog 3 Pt 1 and y nipplies demons of roles or master and
ring of Ociocidal Efficacy (Phase IIa) o Go Clinincal Efficacy (Phase IIb) o Go Clinincal Efficacy (Phase IIb) te Phase III - U.S. UDA U.S./ EMEA EU ulation Dev & Support ulation Dev & Support to Management Support (D Total enture Management enture Management feature Management	7798 9/99 2/01 9/01 5/03 7/03 7/45 178 178	7798 9/99 9/03 9/03	Completed Completed Delayed Last patien Delayed Analysis F., Support Misun Formulation sede-up and pr Completion of M99-114, Pk Coordination of extivities as	nt enrolled 1/5/01, n = 269  nobu Cham & Process Justification rocess splinkastion kplag 3 Pt 1 and ynspilies de strong of rollen and propelles
ic Pinese II - U.S.  o Go Clinincal Efficacy (Phase IIa)  to Phase III - U.S.  (DA U.S./ EMEA EU  rides Dev & Support  ulation Dev & Support  en Hnichting  of Management Support  U Total  sare: \$3,988, reflecting milestone funding  nese: \$3,988, reflecting milestone funding	9/99 2/01 9/01 5/03 00 AGU 879 745 607 1748	6/01 4/02 9/03 9/03	Completed Delayed Last patien Delayed Delayed Analysis P., Support Misun Formulation scale-up and pt Completion of M99-114, Pk Coordination of activities as	nt enrolled 1/5/01, n = 269 nobu Cham & Process Justification rocess spidmization kplog 3 Pt i study supplies
o Go Clinineal Hileacy (Phase Ila) o Go Clinineal Efficacy (Phase Ilb) te Phase Ill - U.S. UPA U.S. EMEA BU  ulaion Dev & Support  al Finishing et Management Support UD Total  feature Management	2/01 2/01 9/01 9/03 5/03 7/45 6/09 6/07 178	6101 6101 6101 6101 6101 6101 6101 6101	Delayed Last patient Delayed Last patient Delayed Delayed Analysis F. Support Milsum Formulation seale-up and pt Completion of M99-114, Pt Coordination of estivities as	nt enrolled 1/5/01, n = 269  robu Chan & Process Justification rocess optimization katog 3 Ph 1 andy supplies at surror of roton or mesting as a
o Go Clinineal Efficacy (Plase IIb) te Phase III - U.S.  4DA U.S.I EMEA EU  vices Dev & Support  ulation Dev & Support  at Flinkling  et Management Support  (D Total  enture Management   9/01 9/01 5/03 5/03 871 745 60 60 60 60 60 60 60 60 60 60 60 60 60	4/02 9/03 9/03	Delayed Delayed Analysis F. Support Milsun Formulation seals-up and pr Completion of M99-114, Pk Coordination of ectivities as	nobu Cham & Process Justilication rocess optimization kiping 3 Ph I andy supplies	
te Phase III - U.S.  ADA U.S./ EMEA BU  Ales Dev & Support  al Fluiching  et Management Support  ID Total  enture Management  e	5/03 5/03 00 AGU 879 745 178 178 178	9/03 9/03	Delayed Delayed Analysis Ft, Support Milsun Formulation seale-up and pr Completion of M99-114, Pk Coordination of ectivities as	nobu Chem & Process Justification cocess optimization kptog 3 Pt 1 and y supplies charmond of references
rites Dev & Support ulation Dev & Support al Flinishing et Management Support (D Total enlure Management enlure Management enlure Management orized Heads: Flat to AGU until July, 2001,	874 745 607 178 178	01 PLA	Analysis F, Support Milaus Formulation scale-up and pt Completion of M99-114, Pt Coordination of estivities as	nobu Chent & Process Justification rocess optimization kping 3 Ph 1 study supplies
vius Dev & Support ulation Dev & Support eal Finishing of Management Support U Total enture Management enture Management nse: \$3,988, reflecting milestone funding orized Heads: Flat to AGU until July, 2001,	00 AGU 879 745 607 178 2,409	01 PLA	Analysis P., Support Milaum Formulation scale-up and pr Completion of M99-114, 2b Coordination of activities as	nobu Cham & Process Justification cocess optimization kplog 3 Pr i study supplies d surround of refer on maximum
viles Dev & Support ulation Dev & Support al Flaishing et Management Support UD Total enture Management enture Management enture Management ore: \$3,988, reflecting milestone funding orized Heads: Flat to AGU until July, 2001,	745 745 607 178 1,409		Analysis P., Support Misum Formulation scale-up and pr Completion of M99-114, Pk Coordination of activities as	nobu Cham & Process Justification roccess optimization kglog 3 Ph I andy ruppiles at surround of rothing or master resi
milestone funding GU undi July, 2001,	745 607 178 2,409		Formulation scale-up and pr Completion of M99-114, Pk Coordination of activities an	roces application of the control of
milestone funding GU until July, 2001,	607 607 178 2,409		Completion of M99-114, Pk Coordination of activities an	kglag 3 Ph I study supplies
ri rnilestone funding AGU until July, 2001,	178		Completion of M99-114, Fig Coordination of activities as	kging 3 Ph i study supplies ad suppose of reduc no must be men
rt ; milestone funding s.GU until July, 2001,	2,409		Coordination of activities ar	
milesione funding AGU undi July, 2001,	7,403	-		day dimension of complete pro-
milestone funding AGU undi July, 2001,				
milestone funding AGU undi July, 2001,			SPD Requirements	
. Authorized Hends: Flat to AGU until July, 2001, ABT-594,Go/No Go Decleion, then 11 headcount atk			Kgr Heads	Mat Cost Total Cost
	er July, 2001	2001 PLAN	+ :	_
	ROSS	RVoss	AN	Cost
1	Start End	Start	End Total	00 AGU 01 PLAN Varlance
		,		337
771 Human Metaboliam 3H		Apr-01	New-01 300	
fMRI Aug-01		Mar-01		
Tirration Optimization			•	
Mar-02 Apr-00 Mar-02 Apr-01 Mar-02 Ma	Apr-00 Nov-00	0 Apr-00	May-01 3,100	3,000 100 A
Total			4,065	3,000 1,065

 $\Pi G \Pi L X$ 

34 141 INIX

Page 12 of 26

3

•		Ħ.	
Discovery	ABT-963	2001 PLAN KEY STATISTICS Pass II	(000\$)
		•	

Project		Z001 Targef	2000 AGU	Z001 PLAN	Ta .	Target vs PLAN Fay(Unfay) Var		·	
Cox II Inhibitor		1,200	4,000	1,186		14			
Ker Milestones ( Assumptions - Initiate Phase I SD Study - Beyond Phase I SD Go/No Go Decision			0002/2 12/2000 00 V 00	01 FLAN 12/2000 2/2001		Surus (on targ	Sutus (an Ergel, pending or delayed to s.)	layed to x)	
PARD  Analytics Dev & Support  Formulation Dev & Support  Clinical Finishing  Project Management Support  PAND Total			00 AGU 195 147 33 29 404	01FLAN 21 11 18 18					
Total Venture Management . Cox it is presently not assigned to a venture and managed by Dr. George Carter in Discovery	r in Discovery			2000 AGU 2001 PLAN	Ker Ker	SPD Requirements	Mat'l Cost	Total Cont	
Clinical Granis	lot Pattent Last Dosed CRF	2000 Start	R/058 2000 AGU rt End	Ross 2001 PLAN Start	S LAN End	Total	Cost 00 AGU 0	I PLAN	Variance
	Nov-00 Jan-01	. Nov-00	Peb-01	Oct-00	Feb-01	261	131	151	•
HIGHLA CONFIDENTIAL ABBT 0037545	. •	,							
	a 3 v.J. ed. 17 St. St. of					261	131		7,7
MINI 141 AN L'OROUPBart an Mailgals Vindondiani de Parlage Voltria vindo parags pau annais ao ray amin									3

33

Analgesia Venture Abr-089 2001 PLAN KEY STATISTICS Pass II (\$000)

Project		2001 2000 Target AGU	2001 T	Target vs PLAN . Far(Unfav) Var	
Neuronal nicotinic receptor modulator (Unfunded)		9,000	619	(13)	
Key Milestones ( Assumptions Transistion Team Go/No Go		00 VCO	OI PLAN TBD Unfunded	Snau (on target, pending or delayed to x) Unfunded, program on hold	
				٠	
PARD  - Analylics Dev & Support  - Formulation Dev & Support  - Clinical Fluishing  - Project Management Support		156 147 147 147 147 147 147 147 147 147 147	OI PLAN		
· PAKU total			בובי	CDD Born framen (a	
Total Venture <u>Management</u> - Expense: \$3,988, reflecting milestone funding - Authorized Heads: Flat to AGU until July, 2001, ABT-594,Go/No C	ABT-594,Ga/No Go Decision, then 11 headcount after July, 2001	after July, 2001	X :	Heads Mail Cost Total Cost	
Clinical Grants	1st Patient Last Dored CRF	Ross 2000 AGU Start End	Ross 2001 PLAN Start End	Cost Total 00 AGU 01 PLAN	Variance
Phase I.				· ·	i
Total				74 74	
LidROUP&Laber\Andreis Verturation (budge Parka) unit men werden 241.41016 Key Suu	o packeg pan ICLANOIP Key Suu			-	

HIGHEY

Analgesia Venturo ABS-103 2001 PLAN KEY STATISTICS Pass II (\$000)

		2001	Target vs PLAN	
Project	Target	FLAN	Fav(Omay) Var	
ABS - 103 (Unfunded)	i	ī	1	
Key Milestowes / Assumptions - DDC Meeting	OD V GO	01 PLAN 4/2001	Status (on terget, pending or delayed to x)	Ť
<u> </u>		`.		
	:	•		
PAID	00 VO	01 PLAN		
- Anniyucs Dev & Support	I. 1		•	
Clinical Finishing	1			
- Project Management Support				
· PARD Total				1
Total Venlure Management - Expense: \$3,988, reflecting milestone funding	ount often July 2001	Non AGU	SPD Requirements  Hepdi Mail Cent Total Cost	
- Authorized neutal: filst in AGO data (total total to			: 1	
1st Pateni		Ross		1
Clinical Grants Dosed CRF	Start End	Start End	Total 00 AGU 01 PLAN	Variance
Lings I.				
	•			
IDI			٠	
	•			
1141 547				
Total				
en issi pas Lighourdschendadigeta Yeadhiddiga padagaying pagaman padag per 122 Lighus Key Siess				·
		•		34

35 Cost 00 AGU 01 PLAN Variance Total Cost Status (on target, pending or delayed to x) Mat I Cost SPD Requirements Target vs PLAN Fav(Unfav) Var 33 i : 2001 PLAN Koga 2000 AGU 2001 PLAN . 537 OI PLAN Start 01 PLAN 4/2001 2001 PLAN 00 AGU Analgesia Venture NPS 1776 2001 PLAN KEY STATISTICS Pass II (\$000) USA 00 2000 AGU 2000 AGU Total Venture Managrement

- Expense: \$3,988, reflecting milestone funding

- Authorized Heads: Flat to AGU until July, 2001, ABT-594,Go/No Go Decision, then 11 headcount after July, 2001 Z001 Target 8 E E L-OROUP Barbara Malgria Yenner United Badga Pachager (OIP) en renter pochage pau 212 stejl MF Kay Stax 1st Patient Clinical Finishing Project Management Support PARD Total Key Milestones (Assumptions DDC Meeting Analytics Dov & Support Formulation Dev & Support NPS-1776 (Unfunded) Clinical Grants Total HIGHLY CONFIDENTIAL ABBT 0037548

## AKTHINFECTIVE FRANCHISE CLARITHRONYCH · 2001 FLAN KEY STATISTICS (\$000)

			•												
				_				2001 PLA							
						2000	2001	Favi(Uniov)	Y5.					ļ	
	indication					10,688	Plan 5,465	AGU 5,223	-						Ĺ
	Extended Release Once/Day					107	3,40	, 523,65 1 65							•
•	Pediatric New Strength (MiriC) XL /MR Patent Protection work	d wide (PARD/IDC)				883	153								
	A) Padiatric	a mide (: salesie e)				4,573	30								
	Phase IV intl.					3,091	9,399								
	Al 1 Grem Tablet					2,985	11								
	Japan 400MG Tablet					1,881									
	Other					2,109	584 15.676								
	Total Clarity on your	•				26,400	14,900								
	Plan Target Variance Favi(Uni) vs. tarpe					E3	1778							١.	
	Variance Partition) Vac Laste	<u> </u>						, ,,,,,	<del></del>					, .	
	Key Milestones / Assumption	ns .				TO AGU	TO PLA	N .			Status			)	
	Extended Raiguse Once/Day		•			•								ŀ	
	<ul> <li>Initiate BAL study Label add</li> </ul>	Olion for Blacks XI.				-	6/00 9/00	Complete						ł	
	• Initiate Mucotylic -Private In	ID Studios (Investig. Initiated) Program - Private IND Studies (Investig. Irillials	160			_	9/00	Complete						[	
	Indiana Primunomoculatory     Indiana Perturais study (Invited Invited In	riginals: Initiated)	,			Ξ	TED							Ī	
	PARD					AGU	TOT PLA	N			Status			)	
	· Patent protection effort for	CL and MR formulations .	•			1/00	1/01	Crigolag						1	•
	1						2001	2001 vs A0	·		PARD Vari	inera be		1	
	Designation of Control					AGU	PLAN	. EndiUni			Proje			1	
	Budget (\$000)     Analytical Development & E	Surport.				879	33				ER Onco/Day	1,264		1 '	
	Formulation Davalopment	Support				2,D61	23	1 1,830	)		Ped New Stre	107		1	
	Clinical Faishing	•				299	35		*)		Al Pod 1/Day	449		1	
	Project Mgt.	•				3,559	1,06				Patent Otiver	631 47		1	
	Total					3,339	1,00	1 2,450	,		Duka	2.498		ĺ	
					<del></del>									-	
	Venturo Management (Total	Dopartmenti				1 '			PD R	edn)teit				1	
	• Exponse:	•						Kgs	_	Hoods	Mati Cost 0 326	Total Cost		]	
	STZ,820M (Increase of \$3,554M	va 2000 Actual; includes ART-412 Milestope payun	cq eξ ±3 m	9.		1	AGU 2001	0		•	0 D	- 326 X		}	
	Tatel Heads - 41 , unchanged	actt. Abbett full time - IL				1		budget does to	n inci	uda Pha			ocuados i	<del>1.</del>	
	unchanged vs. ACU.	,_,				1	(proces	memeyand se	) of \$-	LTMIK;	5326M Include	ed in AGU for	14-OH		
						J	motebo	office.						2001	
			st Potior			. Broce	2000 AGU	R/DSS	7004	MI A37	Study	Cost(\$	non)	2001 Favi(Unf.)	
	Domustic Studies		Dosed		RF	Start	Erid		2001	End	Total	'00 ACT	DI PLAN	VŁ AGU	
	Accrual Adjustments - Com	niated Studies			_		<del></del>					(2,529)	0	(2,529)	
	Extended Release Once/Da	<b>;</b>													(
	. MRS-CEE Biarin XL vs. A	uromentin in AECB (300 pat)			00	3/33	- 4/00	8/99	-	4/00	3,900	1,277 2,333	0	1, <i>21</i> 7 2,333	•
÷,	1693-077 Black XL vs. (	avaquin in CAP (replace Trave 300 pats)	. E/99 1/00		00	9/99 1/00	- 7/00 - 12/00		-	7/00 12/00	4,000 500	2,313 357	500	(143)	
	1299-083 Biasin XI. +Ce 1299-066B Biasin XI. tmm	ph. IV Step Down study vs Lov. (150 pate) unomoctulatory Claim	1/00			1/00	- 12/00			12/00	500	527	Q	527	
	NGO-205 Blazin XI. Mus	ciytic -Private IND Studies (lov. init.; 30 pats.)					•	8/00		12/01	180	8	160 *		
	MOS-208 Blacks XL Mus	ctylic -Private IND Studies (lov. init.; 50 pats.)	6100				•	9/00	-	12/01	180	D	180 *		
		unconnectatelory - Privata (ND (line, Init. pat. TB		- 12	<b>702</b>			3/00	-	12/01	680	0	880 *	(880)	
		I, MOD-207, MOD-208 continuations of M99-060	6/00 B/00	. 41	ms			8/00	_	4/01	350	350	0	350	
	M00-214 BAL study Let TBD Persusula linve	el addillon for Blook XL (45 patients) stigator initiated study (patients TBD)		- 11				CBL	-	TED	150		150	(150)	
	N/A Counter Resis	tance - Animal in Vitro studies CAP registry			ĽĄ			NA		NA	500	0	1,050	(1,050)	
					-	-	~~~~		e h			AND MARKETON	- n n 46*-		
	an rotal Domest Children			7169			T L		THE STREET			( <u>12,73</u> 15)	41.4490.X	\$31926(349)	
	International							-							
	W89-317 PRSP/DRSP I	R	11/99	- BJ	700	11/99	- 8/00	11/99	-	8/00	3,249	2,500	749	1,751	
	Pediatric (international)												0		
	Muttiple Al Ped Once-	Daγ	1/00	- 12	202	1/00	- 12/0	1/00	•	12/02	6,707	1,300	0	1,300	
	Other (International)		1/00	- 12	2/02	1/00	- 120	o inco	_	12/02	2,790	850	0	650	
	Multiple Al 1 Grem PK Multiple Al Japan 4007	SC Tubial	1/00		2/02	1/00	- 120		-	12/02	3,488	1,033	Ď	1,033	
	Multiple Al Japan 4007 Multiple Clari MR	100 p 100 H 101	1/01		2/01	71-0		1/01		1201	0	Ö	. 0	Đ	
		L MR	4/00		2/02	400	120			12/02	9,056	550	5706	(5,156)	
	Minimple Central VI. A											D	848	(848)	
	MECAPP												•	in in	
	MECAPP	(included in Domestic - immunomodulatory)										D	0	C	
	MECAPP haly Whoeze	·	24/52/2	SELECTION	arester Tester			<del></del>	a wa	ray.	25,290				Į
	MECAPP haly Whoeze	included in Demestic - Immunemediantary) Jama Trocson (4 Essay 17, 00,15215.117 (0) File						<del>ADMOTE</del>	- L			343 <u>5733</u> 5	7,203	124-(17 <u>440)</u>	_
	MECAPP haly Whoozo	·										343 <u>5733</u> 5	7,203		_
	MECAPP haly Whoozo  STEELING THE BEAUTY							<b>西</b> 森 (100 m)				343 <u>5733</u> 5	7,203	124-(17 <u>440)</u>	_
	MECAPP haly Whoozo  STEELING THE BEAUTY	·										343 <u>5733</u> 5	7,203	124-(17 <u>440)</u>	_

шеньх

2000	2001	2001 PLAN VI. TO ACTUAL
Actual		FevrjUntav)
67.887	80,574	(20,607)
2,552	6	2,574
2.957	7,528 0	1,329
1.000 A	. 54	1236 I
74.525	90.274	(15,748)
		13,900
BI Verlante experi	med for her reach	used in APU by reduction of one SPO bulk drug compalion (\$1.5MM) and
. 0) 400,000,000	and the state	proof to Japan posistration 13 4MMD.
C leave Desister	na nationala f	or 2001 easternos delay in Phase IVIII studios to 2002.
		N 2001 4330103 010) 211 1234 1211 123-1-1
		Complete
		Complete: Protocol changes will delay Europe start.
		Phase III delayed: Sudies will start 4Q DQ, Europe 1Q 01
1100		Additional siles to actions required patients by NDA filing date
		No harding for Pediatric in 2001.
		Discussing with SPO the possibility for reduction of one delivery
		On terpet (Bused on CAP / Sinusitus 150mg CD vs. 150mg BiD results).
		NDA Filing delayed to 3Q 2002
TBD	TED	No bunding for Pediatric or IV in 2001 Phon.
		Statussy (un target, pending or delayed to x)
		Complete
12/99-2/00	12/98-5/00	Complete
		<del></del>
-		2001 Pian vs.
		AGU FrontUnt)
		228
2,723		767
1,545	1,478	<b>367</b>
547	567	
6,676	5.724	
	Actual 67.83   7.832   7.832   7.832   7.832   74.100   7	Actual PLAN  67.867 60.574  2.862 90.574  1.000 A 64  74.100 80.000  74.100 80.000  80.0000  80.000  80.000  80.0000  80.0000  80.0000  80.0000  80.0000  80.0

 $\binom{n}{2}$ 

Venturs Managatinam Expense: 312,000M (Increase of S3,554M vs 2000 Actual; Includes AST-452 Milestone payment of S3MM.

Total Heads - 41 , unchanged vs. AGU. Abbitt full time - 32, unchanged vs. AGU.

ŀ	Kgs	Heads	Direct Cost	Task	Total Cost	•
2000 AGU	2520	A 25	15,509 B	(2,100)	22,612	
2001 PLAN	1,675	9 22	9,403	<del></del>		9
A) 2198 Km	for Tablet F	omutation, 242	Kps for Pediatric	, 80 Kgs bri	V mt \$7,500 /Kg.	
Total CV	bei ztees O'	hade hwedcowal	related changes o	X 57,3-CIUL		
B) 2,520 Kg	E @ \$7,500/	ty for \$18,000M	less not prespon	ang \$2,1MK	. (16,667/cg pet i	al party
C) 1,575 Kg	25,000	kg + basekouni	and presponding	charber of g	8,595ML Does no	d reflect
pizmed	reduction o	f one bulk drug	campaign.			

		tat Patien Doseti			2000 AGU	nee	ZOM PLAN	Study	Cou	effS000%	2001 FawiiUnday.]
		DOM	UNT	Start	End	Start	End	Tetal	2000 Att	ZDO1 PLAN	VL AGU
	ACPRU STUDIES (Inhland in 2001)					- 5441					
	Fig 2001-1200L	5-01				5-01	12-D1	216		215	(215)
	8ic 3001=5001 BE	11-01				11-01 -	6-02 .	231		221	(231)
	Drug Internation Landbirns - (delayed to 2002)	TBD				TED	TED	175			_
	Onus Interaction Warterin	2-01				2-01	6-01	214		214	(214)
	Drug Interaction Olympia	1-01				1-01	7-01	372		372	(372)
	Drug Interaction Carbernatrophe (delayed in 2002)	TED				TED	TBD	215		-	_
	Drug interaction Cyclosporis (delayed to 2002)	Œ				TBD	TBD	280		_	_
	Drug Interaction Genistric #17	19-01				10-01	10-02	162		152	(162)
	ABT-773 Ste BSL to 300L	5-01				5-01	10-01	175		175	(175)
	ACPRIL Total New 2001 Studies					-•				1,370	[r,370)
•	PHASE DB SYUDIES			•							
MB9-054	CAP	P-99	£100	0-99	6/00	0-69	6/00	4,089	1,637	-	1,537
M99-053	Situation	0-99	6/00	9-99	6/00	0-33	5/00	3,172	1,558	_	1,559
M99-048	AECD	B-89	6/00	8-58	6/00	8-99	6.00	3,885	2,212	-	2,212
	Writing	•						210	157		157
	TOTAL PHASE OF STUDIES							11,356	5,564		£564
	2000 External Blo Studies								790		790
M39-119	Japan Phase I		- 400	12/99	- 4/00	12/91	- 4/00	957 459	120	_	469
M99-142	Tixtue Shides		- 12/00	ממעכ	- 12/00	3/00	- 12/00	500	-	500	(500)
	Tissue Study - Conf - L50cmg	701	12/01			201	12/01	500	-	500	isou
	Thoma Study - Gottlad - 150mg CD vs. 150mg BID	2/01	12/01			. DOI	1201		89	135	\$25) \$25)
	Recet		- 2/01	8400	- 2/01	9/00	- 2/01	300		62	109
M99-125	Hapatic	3/00	- 3/01	2/00	- 2/01	3/00	- 3/01	213 2,529	- <u>251</u> (573	1,200	373
	JAPAN STUDIES (New Formulation)		<u>.</u>				- 5/01	1,500	1,600	_	1,500
	Japan Phase I	10/00	- 5/01	1000	- 5/01	10/00	4/03	22,000		-	, ***
	Japan Phase Billi			-	-	9/01	4/03	23,800	1,500		1,600
	PHASE II STUDIES										1,306
Multiple .	Phase III Surf-Up		• 6/D0	4/00	- 6/00	6/00	- 8/70	1,306	1,305	236	2343
MOC-221 (MSG-089)	CAP - Levo 500mg (10, NA/SA (450 pet.)		- 3/02		- 3/02	11/01	- 5/02	8,200			(9,198
UDO-219 (UDO-152)	CAP - Open Label NA (800 pet)		- 603		- B401	11/00	- 9/01	18,258	3,535	12,731	(1,629
MDG-220 (MDG-151)		9/01	- 3/02	201	- 3/02	1 1/01	- 5/02	5,700	-	1,529	(1,023
M00-225 (M00-149)			- 3/02	9/01	- 3/02	11/01	- 5/02	4,400	=	1,257	(1,257 (5,162
MDD-225 (MDD-087)	Simustine - Open Label, NA, SA, EU (600 pats.)		- 6/01	11,00	- 6/01	11/00	- 9/01	9,258	2.037	7,219	
MDG-218 (MDG-150)		201	- 3/12	9/01	- 3/02	11/01	5/02	5,300	_	1,514	112,17 112)
LIDO-260	Simishus Double Tep	4/01	6402	•		4/01	eath	n30	-	510	(SIL
MDG-218 (M99-088)	ABECB - Leve 500mg QD, HA	11/00	- 6/01	1100	- 6/01	11/00	- 6/01	7,721	1,930	6,791	(2,881
M00-217 (M99-143)		11/00	- E/O1	11/00	- 6/01	11/00	- 8/01	5,224	1,100	4,036	(2,848
M00-223 (M00-090)	Programitis - Penicilla 250 TTD, HASA (520 pat)	11/00	- 6/01	- 11/00	- 6/01	11/00	- 6/01	4,739	1,185	3,554	12,359
K00-222 (M00-157)		11/00	- 6/01	11/00	- 6/01	11/00	- 201	4,629	1,054	3,575 64,153	(2,521
	Other Studies							• •		(5	•
	A.D. Little Pediatric Taxle Textley	7/00	- 2/01	3/00	- 2/01	2/00	- 2/01	270			[250
	Completed Pediatric Prototype Studies	6/00	- 12/09	6/00	- 12/00	6/00	- 12/00	225	(250)		
	Migratiology PK/PO Studies	1,00	-,12/01	1/00	- 12/01	1/00	- 12/01	3,500		2,000	
	Pedatric PK/PD , Press 8	6/00	- 800	6/60	- 6/00	6JUD	• 8/00	1,500	331	-	33
	GRAND YOTAL (EXCLUDING ACPRU)							115,581	21,095	47,404	134,20
	sacorermentalis Albertalistand CD			31-let	D2: 12 PM						

HIGHLY CONFIDENTIAL ABBT 0037550

31

÷.

## ANTI-INFECTIVE FRANCHISE QUINOLONE ABT-492 2001 PLAN KEY STATISTICS (\$000)

	Payment (Phase IIA)		_	2000 Actual 7,063 0 7,063	2001 PLAN 21,341 3,000 24,341	2001 PLAN Few(Unfav) v Actual (14,276) (3,000) (17,276)	L.		٠.		(
Total Quinok	⊇n6			5,800	25,000	(18,200)				1	•
Variance Fin	A(Chrit) vs. temped			(263)	659	822		·		]	
			<u> </u>	'00 AGU	101 PLAN		St	ahrs		ו	
	s / Assumptions			40,700	40 100	Complete				,	
	IASE I STUDIES IASE IIA SAFETY STUDY:			_	30 '01	On tarpet			M-11	1	
· NDA Filed				40 703	40,104	Delayes o	as your out	त्यां कृत्येक्ताओं व्य	MEGOL.	_	
PARD				DO AGU	101 PLAN	•			-		
• Formulation IDC Press 0				<b>-</b> .	1 <i>R</i> 01 5/01	On barget					
PARD Comm	norcial			-		On terpet				I	
Budget (PAR				'00 AGU 225	01 PLAN	Fav/(Unii) (290)			•		
Formulation	evelopment & Support Development & Support			274 38	341 1D	(67) 26	ı			l	
Clinical Finis Project Mot.				59	95	(36				1	
Total				594	. 961	. (357)	i		_	1	
• Expense: \$12,020M (Inc \$2MM Mileski	gement (Total Robertmont) crease of \$3,54M vs 2000 Actual lockufes AET-432 MI sits Phymant) - 61, suchamped vs. AGU. Abbott his time - 23, - a AGU.	Destone pay	ment of SSA	esu.	AGU 2001 PLAN A) CAPD I B) CAPD I	Regularmenta Kar Hoads 0 0.5 600 6.0 Piot Plant 12 week Filet Plant 44 week	Pilot Piani 480 1892 cs @ \$40Mh	Personnel 116 1,470 week and 1 persons to the perso	Total Cost 598 5,762 orsen for 6 m count @\$245	E entens	
L	·	1st Patient		ט	-	al bulk drug.					2001
		Dosed	CRF	R/OSS Start	2000 AGU End	R/OSS Z	End End	Study Total	2000 AcL	(\$000) 2001 PLAN	Fav/(Unfav.)  £ 2000 Act
Prazo I Single C Multiple	Dosal Food Effect in Headiny Volumeers (100 pat) Rising Dosas in Healthy Volumeers (60 patients)	11/00 01/01	01/01 03/01	4Q 2000 4Q 2000	4Q 2000 4Q 2000	.9700 62701 •	01/01 06/01	850 500	680 0	170 500	510 (500)
-, Phase I	A / Bio Studies (3 studios)			04/01	03/01	04/01	10/20	700		700	(700)
: PHASE	TOTALS							2,050	680	1,370	(690)
Microbia	ology Studies					•		710	0	710	(710)
Phase HA											
CIMAG NA	AECB (250 patients)	06/01	04/02			OBJÓ1	04/02	3,750	0	2,063	(2,083)
•	SUBTOTAL PHASE I/ PHASE IIA							6,510	680	4,163	(3,453)
Phase II B						11/01	07/02	3,750	0	. 837	(837)
•	CAP (250 patients) Uncomplicated UTI (300 patients) Skin and Skin Structure Infection (300 patients)	11/01 01/02 01/02	07/02 09/02 12/02			01/02 01/02	09/02 12/02	1,650 2,100	. 0	0	D D
•	PHASE II B TOTAL	•				-	•	7,500	- 0	837	(ES7)
Total								14,010	680	5,000	(4,320)

MIGHLY CONFIDENTIAL ABBT 0037551

ANTI-INFECTIVE FRANCHISE OMNICEF

2001 PLAN KEY 5 (\$000)								
indication Development Total Target Vertence Fav(Uni) vs. target	2000 AGU 0 0 0	2001 PLAN 4,843 4,843 5,000	2001 PLAN Fav/(Unfav) va AGU (4,843) 0 (4,843) (5,000) . 157			·		
Key Milestones / Assumptions	'00 AGU	'01 PLAN		St	alus		i	
BALITATE ACUTE OLIUS MENY ZLIDA		09/01	On Target					
	<u>.</u> .						<u>}</u> .	
PARD.  • To be defined	'00 AGU	'00 AGU			ztus		1.	
Budget     Glinkad Finishing     Project Migl.     Total	USA 200° 0 0	100 AGU 82 0 92	AGU WE APU Eav/IUm) (92) 0 (82)	_		•		•
Venture Management (Total Department)  • Expense:  \$12,0200 (Increase of \$2,644) vs 2009 Actual; includes AST-422 Milestons payment of \$3,644,  \$3,700 Milestons Payment)  • Total thesians 41, unchanged vs. AGU. Abbort full time -22,		CAPD F AGU 2001 PLAN	Kos Heids 0 D 0 0.0	Pilot Plant 0 0	Personnei 0 0	Total Cost U D		
oncharged vs. ACU.  1st Patkint Lost Dosed CRF	R/OSS:	2000 AGU End	R/OSS ZOC Start	n PLAN End	Study Total	Cost 2000 AGU	(\$000) 2001 PLAN	2001 Favijunfav. Vs. AGU
<u>Phane</u> IV Acute Ottis Media 1 Am 50 QD HID ya. Zishoomox (250 pas) 06/01 07/02			08/01	115/02	6,000		3,000	(3,000
PHASEIV TOTALS			•		6,000		3,000	(3,000
				e e e	## F 6:000	25 N. 740.		:4 :(3,000

## UROLOGY KCO ABT-598 2001PLAN KEY STATISTICS (\$000)

ANTI-VIRAL NORVIR ABT-638 2001PLAN KEY STATISTICS (\$000)  \text{Z001} \text{Z000} \text{Z001} \text{Z001} \text{Z001} \text{PLAN vs TARGET}  \text{Z,000} \text{8,530} \text{1,780} \text{2,240} \text{2,240} \text{2,240} \text{2,240} \text{4,700} \text{2,240} \text{2,240} \text{2,240} \text{2,20} \text{2,240} \text{2,20} \text{2,240} 2,2	2001  DD AGU 381 289 893 332 1,686	Table   Tabl	750 0 9,580 2,507 1
Project Venture Programs Phase-IV Programs Total  Key Milestones / Assumptions Continue combination studies	ARD  - Analytice Dev & Support  - Formulation Dev & Support  - Clinical Finishing Project Management Support  - PARD Total  - Otal Venture Management  - \$983M: \$283 for Venture \$710 for PHASE IV  - Authorized Heads: Total 6 heads: 1 Venture	Inical Grants Protocol Study Nama SIVITHE STUDIES MB8-885 RTVIIDV Combo Study M88-882 RTVIIDV Combo Study M88-824 Erica A M88-03 Rica A M88-047 NICE ITAL PHASE IV STUDIES M88-03 Floa B M88-047 NICE M8	HIGHLY CONFIDENTIAL ABBT 0037554

	•			(2002)							
				Terrori	2000	P. 2001	5.5	PLAN to TANGET Fewillnier) Ver	ון פון		
Venture Programs				44,100	73,054	45,005	:	. 1			
Phase-IV Programs (M Total Project	Phase-IV Programs (Metabolic and Switch)			50,800	78,600	508,18		(908)			
										1	
Key Milestones / Assumptions - Commists International EAP program	<u>lplignt</u> EAP program				100	500	Extended	nother year	Extended another year		
· Conlinue Regulatory requirements	quirements				12/02	12022	On Tarpot	1. m600 face	5		_
- Continue Knoil formulation - Start Phase IIIS Switch and Salvage Kalatra	ion and Salvage Kalein					1001	Approved	Approved in 2001 for \$6.4MM	BAMM.		
PARO					20 AOU	WITTEN		observations (C)	i		
. Analytics Day & Support					2,813	1 2		d support	ŀ		
. Ppelitve controls					3,000	200		٠.			
- Carical Falshing - Project Management Support - PARO Telet	uppart				12,854	2,909					
To least the same							100	10000			ſ
Talel Vanlus Management Expense: \$13,780 whi Authorized Heads: 65 sw	<u>l Gjej Yanliya Mangebnani</u> Expones: \$12,780 whoth Include \$1.5KM Bulk Drug and \$1.5kM exclinat agreement . Aufonteed Heads: 65 ezme za AGU	FI.SMM conita	A agreeme			2000 AGU 2001 FLAN	2,800	Bodylemen	4,500	Total Cont. B,R10	
		1st Petland	1 5	Ross		Rigare Til	.:		ě	.	
Cilnical Grants Protocol Study Name		2000	5	Stri	Bud	Blari		Total	OD AGU OF PLAN		Variance
				. 100	1907	1001	1900	7 308	-	0	i
	Prese II Relyd	88.9	, 25 25 26 27	<b>8</b>	126	4/88	12/02	3,831	757	8	32
_	Phasa II Gustiva	B24	5	8	12/02	5	ğ	1.787	100 E	<b>3</b>	- ;
	Experience in Date	<u> </u>	25	<b>§</b> §	158 158 158 158 158 158 158 158 158 158	8	12021 100	200,		9 8	2 5
MGB-840 PEDS PI	PEDS PRESS (M)	ž	<b>2</b> ×	8	125	8	1804	120	12.	물	E
	Acute Seroconvention	180	瓦	8	1202	8	12/02	419	<u>5</u>	蓋.	(148)
Photonii Phoso III Naive	) Naive	3738	12/01	11/88	12/01	11/86	12/01	28,176	000,0	4,176	3,824
	Phase III Experience	6 00 E	2 362 20 120	11/09	<u> </u>	11/50	1201	1,495	<b>3 3 3</b>	629	156
	Fernanded Access	86/8	340	8780	1048	80/8	1202	22,525	10,720	4,723	5,885
NEW VENTURE & TUDIES	10 17 17	100	<b>4</b> 003		•	So	4703	1,820	•	880	(880)
MOC-257 Salvage	Selvans of K2	ŝ	19			10.5	<b>403</b>	1,180	•	3	9
TBD: Deelpray	Designantins Interaction	<b>5</b> 8	<u>0</u>			<u> </u>		8 2	• •	2 2	000
٠.	Hepaic Impliment Stemmin foliated for	<b>2</b> 5	<b>1 2</b>			<u> </u>	3	1.1	•	8	(900)
	avir Interaction	1001	402			5	ĝ	2	•	88 E	(350)
	Pi Interaction	<u>5</u>	200			5 5	3 5	\$ 8 8		3 25	(350)
TBD Abban F	eig stuny Japan Abbait France/DuPont(BiKS)	25	ğ			30	<b>g</b> .	285	•	<u>5</u>	(130)
Knell Studios			10/2			Ð	101	. 82	•	Z	(220)
TBD Pharmapel	. led	107	102			£	훋.	ž	ı	ត	£23
Phase IV Program MOD-267 Swith Study THD Metabolica THO Metabolica	110 Swith Budy Melabolica - Consorbun / EMEA Melabolica - Covide Budds	180 181	180 180	in the second	; 1208 ::	2/01 01/01 180	1/02 12/03 180	5,424 704 TBD	`æ.	4,915 265 368	(4,915) 38 (356)
Total								17,867	27,883	22,848	4,847
. 10-W-01									•		

ίÇ

ĺ

нсных CONFIDENTIAL ABBT 0037555 ONCOLOGY GROUP
ATTASENTAN (ABT-627)
2001 PLAN KEY STATISTICS
(\$000)

Project			2001 Target	2000 AGU	2001 PLAN	74 EE	PLAN vs Target Fay(Unfay) Var	<u>-</u>		
Endothelin Antagonist	•		39,200	13,000	38,843		299			
K <u>óy Milegtones / Agsumptjons</u> - Phase III Pivolal Study (M00-211) - iniliate Phase III Pivolal Study #2 (M00-244) - Oto, Bloequivalence and Drug Interactions				00 Agu 40/00	01 PLAN 6/01 8/01 20/01	Status Delayed to 6/01. Delayed to 6/01. On target	Status (on targ E/01. 6/01.	Status (on larget, pending or delayed to x) E/O1. B/D1.	delayed to x)	
	•							•		
				-						
PARD Analylin Day & Simond				00 AQU	01 PLAN	Note: NDA tots and	sebility supp	Note: NDA tots and stability support, plus clinical study	· Apala	
- Formulation Dev & Support				. 440	833	eupply and re-eupply.	-eupply.			
. Clinical Finishing				67	1,019					
. Project Management Support	•			1,158	3.602					
Total Venture Menagement - Expense: \$7,246M of \$11,712M - Authorized Heads: 38 Regular and 9 Other					ZDDD AGU ZDD1 PLAN	Kut 30	SPD Regulramente	MATICORI 116	Total Cost 350 683	
	1st Patlent	Last	R/oss	98	No balt defraite us planned process full facton work confined. F/O 88	a planned process	Authorition work	panguner		
Clinical Grants	Dosed	E E	2000 AGU	AGU	2001 PLAN	AN		ō١		
			Start	End.	Start	End	Total	OD AGO	o PLAN	Variance
European PCa Study	2/88	TBD	26/8	12/99	78/8	12/00	9,858	ī	Į	:
	4/88	180	1/88	12/00	1/98	12/00	3,200	.1	: ;	7
Olin Pharm QTo	4/01	901	rı/a	17/8	4/01	12/01	281	:	281	(281)
Clin Pharm Bloaquivalence,	6/01	8/01	n/a	n/a	6/01	12/01	321	•	321	(321)
Clin Pharm Drug interaction - Midazotam	10/02	20/01	a/i	n/a	.10/02	30/02	0,	i	:	I
	10/02	20/01	5	n/a	10,02	30/05	0	i	!	1
Clin Pharm Drug Interaction - Fexofenadine	4/01	8/01 20/01	7/a	7/a 1/a	10/02	30,02	182 0	: 1	182	(162)
			!	!				i	ŧ	•
Phase III Phase III Photes #1	5/01	8/03	12/00	8/03	12/00	1/04	39,338	1,850	12,420	(10.470)
	6/01	12/04		;	8/01	12/04	85,000	;	6,888	(5,698)
Mod-244 Filese III Fisher #2 Mod-258 Mod-21 & Mod-244 I T Extention			1	: <b>:</b>	10/01	12/04	11,000	:	848	(846)
Compassionale Use	TBD	081		i	7/01	12/04	2,000	i	288	(288)
Less Clin Pharm studies							(784)	į	(784)	784
Total							100,394	1,950	19,252	(17,302)
28-Jan' 1110-111 3.			ί.			•				 L
Health										

1.00

ONCOLOGY GROUP TSP (ABT-510) 2001 PLAN KEY STATISTICS (\$000)	2001 2000 2001 PLAN vs Turget Target AQU PLAN Fav(Unfav) Var mbospondin 8,000 6,600 9,881 (981)	nptions  Dose Study   00 AQU 01 PLAN NDIB 391 625 211 855 74 165 311 765 1,150	2000 A 2001 Pi	1st Pallent Last Hoss Hoss Cost Cost Cost Start End Total 00 AGU 01 PLAN Variance	ose in Cancer Patients of Texas - Dr. Fidier of Texas - Dr. Fidier	HGHLA 1281 1281 1281 1281 1281 1281 1281 128	
	<u>ject</u> rilangiogenesis Thrombospondin	(Milestones / Assumptions vitate Phase I Multiple Dose Study vre-IND Meeting vitate IND Study	ADnalylics Dev & Support ormulation Dev & Support linical Finishing roject Managament Support	<u>al Ventura Management</u> xpense: \$825M of \$11,712M ulhorized Heads: 38 Regular and 9 Olher	losi Granis	156 <u>I</u> 100-153 Multple D. 1/A University 1/A University 1/A University 18D IND Study	otal


ONCOLOGY GROUP
MMPI #2 (ABT-518)
2001 PLAN KEY STATISTICS
(\$000)

ONCOLOGY (ABT-761) ANTI-MITOTIC *EISAI* (ABT-761) 2001 PLAN KEY STATISTICS (\$000)

		•	•							
1000			2001 Target	2000 AGU	2001 PLAN	Fa.	PLAN va Target Fav(Unfav) Var			
4nti-Miotic	•		10,000	3,000	6,331		1,669			<del> </del>
iv Milestones / Assumptions				OD ACT	Of P! AN		Status fon fam	Status (on fame) pending or deleved to v)	lalayar to v)	
Delivery of Clinical Supplies		•		ı	4/01	Delayed - due	Delayed - due to Pilot Plan limitations	limitations		T
Initiate Phase I Multiple Dose Study	÷	,		ī	6/01	On Target				
Pre-IND Meeting	-			ı	4/01	On Target				_
Intilate Phase II Safety & Efficacy				, <b>t</b>	2/02	On Target	,			
•										
Las				1000	. 10	Mala				
Analytics Dev & Support				1	630	Developmen	l of Phase II (	naise. Development of Phase II formulation, pending encourading	nding encour	adina
Formulation Dev & Support				:	432	MTD results.	, 	•		 )
Clinical Finishing				i	112					
Project Management Support					126					
ייותו מודין					201					
stal Ventura Management Expense: \$2,812M of \$11,712M						SPD F	SPD Requirements 8 Heads N	lari Cost	Total Cost	
Authorized Heads: 38 Regular and 9 Other		•			2000 AGU .	:	:			
					2001 PLAN	5	m	250	1,172	<del></del>
Halon Commence	1st Patient	Last	R/oss		Hose	, NA				
	2000		Start	End	Start	End	Total	00 AGU	O1 PLAN	Variance
hage / Mon.931 Mullinia Dasa in Cannar Pallanta	. 6/01	3/02	į		4/01				(928) 828	(876)
	8/01	1/02	; ;	: 1	6/01	1/02	9 9	: :	320	(320)
	•									
=1	2/02	11/02	;	:	1/02	11/02	1,000		;	;
TBD Safety & Efficacy #2	2/02	11/02	i	;	1/02	11/02	000,	:	:	:
	700	1707	i	ŧ	7,05	707	000	į	:	:
TEO Salety & Efficacy #4	2005 2005	11/02	:	ŧ	1/02	11/02	000,	:	:	:
Salety & Cilicacy #3	20/2	11/02	ŧ	;	707	11/02	3 5	i	:	÷
Sailety & Elithacy #0	2002	2011		;		7011	200		:	:
							7,300		1,025	(1,025)
EN'										
TIAL '559	:				٠	•			•••	//
										72

2000 Actuals

# &D Spending by Phase



HIGHLY CONFIDENTIAL ABBT 0037560

Global Pharmaceutical Research & Development Funding by Phase 2001 PLAN	
---	--

2001 PLAN 1.2 0.5  5.0 10.0 7.4 8.4		88.0 2.3 44.2 38.8 173.3	24.1 4.1 6.4 6.0 7.4 6.0 8.8 8.8 8.4 6.4 6.4 6.4 6.4	192.0 B6.1 Z78.1
2000 - Actuals 2.3 1.8  7.1 7.0 7.0 7.0 7.0 7.0 7.0 7.0 7.0 7.0 7.0	31.7 31.7 14.3 55.9 1.9 1.8 88.8	18.6 31.5 80.8 13.5 14.4	33.6 23.4 2.2 10.1 10.1	180.6 34.4 226.0
nedy ChCM)	Subioial PC/Phass I	Subtotal Phase III	Subtrate Phese IV	Subtotal Other Affordability
Proclinical/Phase L COX-II ABT-099 (cmm/r ChCN) ABS-1776 NPS-1776 Quincione Neuraminidase NCO TSP #1 MARP!	K-5 Ehase II ABT-594 Kelolide Quinciona NS-49 'Endothelin'	Ehasse III Ketolide BFH Backup Kaletra Cyclosporthe Endothelin	Depakote Gablini Hydrozodna Glarithromych Omnicaf Ferofibrate Richary Kaleita Cyclosporine	Olher Discovery Global Olher

以下,而是是在10年的中央的时间中的时间,在10年的时间中的10年的10年的10年的 Excluding Sister Divisions

HIGHLY

HIGHLY

2001 PLAN Global Pharmaceutical Research & Development R&D/Medical Expenses Summary (\$000)

	Memo: Global R&D	192,000 328,307 520,307		208,124	
	2001 PLAN Favi(Unfav) va 2000 AGU	(7,250) (9,742) (A) 3,454 (13,538)	10,461	(10,637)	(15,441) (527) (902)  (1,030) 8,701 (A) 6,122
_	2001 PLAN	192,000 328,307 61,729 572,036	57,348	. 629,384 385,367	222,483 8,327 9,901 5,074 22,924 370,439 (9,764)
	2000 AGU	184,750 318,565 55,183 558,498	62,809	626,307 374,730	207,042 7,800 8,999 5,074 21,894 379,140 (3,642)
	2000 Actual	190,618 313,302 55,441 559,361	65,275	624,636 375,593	204,133 8,452 9,274 5,074 21,869 375,834 375,834
		Discovery Global Development Domestic Development Gross PPD	TAP and Sister Division	Total Gross Expense Net PPD	Expense by Classification: Salaries/Fringe/Contract Travel/Meetings Other Employee Related MIS Corp Allocation Other Affordability Total Expense

Commentary: (A) Primarily due to increased support for Quinolone, Ketolide and Endothelin.

HIGHLY CONFIDENTIAL ABBT 0037563

LIGROUPPLANNING 2001 PLANExec Summary R&DIGSpense Summary\_ Page R1.123

7

2001 PLAN (FINAL)
PHARMACEUTICAL, PRODUCTS RESEARCH & DEVELOPMENT
GLOBAL/DOMESTIC SPLIT
(\$MM)

C	2
Ц	7

PPD	63 905 30 (A) 1.4 1.4	6.8 (8.2) (C) (4.2) (10.6) (D) 1.6 (4.9)	19.0 (B) (0.4) 2.2 (4.0) 16.8	5.4 18.1 (E) 8.8 78.4	(15.5) (C) (2.0) (1.4) (0.2) 0.8	3.7	(4.3)
PLAN VE AGU FAVIUNFI GROSS PPD	8.3 0.8 2.8 2.4 2.4	11.5 (13.9) (17.0) (17.7) 2.5 2.5 (4.9)	31.7 (0.4) 2.7 (5.0) 28.0	8.0 28.6 9.2 43.7	(25.8) (3.4) (2.4) (2.4) (3.0)	(35.9) 9.2 (6.3)	(7.3) (13.8)
DEED NI	24. 1.0.0.0.1.1.4.	8.8 52.8 14.7 14.7	4. : 0.8 6.8	30.8 30.8 34.6	6.0 4 8.0 6.0 4 6.0 6.0 1 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0	78.7 (5.9)	115.2
2001 PLAN	24.1 1.2 1.2 1.2 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0	40.00 14.8 88.0 .:. 24.5 4.9 132.3	1.4	4.0 51.0 2.5 57.6	38.8 10.0 7.4 8.4	 88.1 (9.8)	192.0 <b>577.9</b>
· GE	06.7 8.8 8.8 1.8 1.8	45.0 44.5 44.5 4.1 1.5	22 22 23.8	7.8 46.7 8.4 82.9	7.8 9.0 9.0 9.0 9.0 9.0	62.8 (2.2)	110.8
ZUUD AGU GROSS	30 444 0.20 0.20 1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.	28.4 74.1 (7.0) . 26.8 . 26	34.0 1.0 2.7 37.7	13.0 76.6 11.7	0.51 8.8 8.6 5.0 0.1 5.1 5.1 5.1		184.8 <u>558.8</u>
FRANCHISES	NEUROLOGY Depakate Gashiri ABT-589 (formenty CCM) COX - II ABT-088 (formenty ChCM) ABT-098 (formenty ChCM) ABT-098 NPG-1778 RP Schieret / Alza (Hydrocodone)	Subtotal NEUROLOGY  ANTILINEECTIVE Clerithromycln Katolide Katolide Katolide Katolide Coulnotone Ounicial Subtotal ANTI INFECTIVE	URQLGSVCARDIOLOGY BH Bector Fanoticisis (Founist) Nippon Shinyaky (NS49) KCO Subiotal UROLOGY/CARDIOLOGY	HIV Kalloravir Kalora Cyclospoine Subtorial HIV	CANCER Endathelin 1878 #1 Melainsproleinere Anti-Micolo Fr. 5 Rubtotal CANCER	Other Now Products Other Affordability Total Development	Olecovery Total Gross/Nat PPD
1000 EED	179,9 122,8 37,3 1,6 1,0	342.7 238.3 92.3 7.0 7.0	61.4 14.1 7.4 72.9	178.8 129.4 36.6	57.6 8.5 2.3 0.6	rva rva rva rva	ועפ מעפ
Actuals through 2000 GROSS PPD	179.9 138.5 62.2 2.7 2.1 1.8	382.8 393.8 153.8 11.6	85.7 14.1 12.3 12.3	298.3 215.7 81.0 676.0	88.4 11.0 5.6 3.9 1.0	7.7.7.7.8.8.8.8.8.8.9.9.9.9.9.9.9.9.9.9.	r/a r/a

HIGHLY

	Total Park	5	1001	1001 PLAN
NEUROLOGY	l		Cigha	Domestic
Depthoto				
Gebleil	5	-	1	74
ABT-594 (formerly CCM)	15.0	}	1 2	2
Con-II		ı	2 :	•
ABT-089 (fermerly ChChn	ı	ī	77	I
ABS-101	I	ı	9,0	ī
NFS-1776	I	i	i	Ī
RP Scherer / Alza (Hydrocodone)	1	ŧ	1	ī
	1	-		\$
ANTI INFECTIVE	}	Y.	3	COT.
Chithranycia	37.0			
Ketolide		I	5.	•
Quinolone	2 5	:	68.0	1
Neuranfoldas	2 ;	i	2,52	1
Onnier	7.	į	2	
	1	1		9
WAC TOTAL STATE OF THE STATE OF	7	1	127.4	5
Batt Backer				1
T-de-fr	3,0	ŧ	2.3	
Lincor (Femalibrate)	1	20	1	13
Nippon Shinyalya (NS-49)	77	2	ı	-
KC3	. 1		1 !	ı
	129	-		
HIV.		•	3	3
Nitonavir	13,0		;	
Kaletra	74.6	I	3	i
Cyclospodne	7.9	Ę	0.16	•
	5 50	· 非	7	
CANCER	•	į	575	1
Endothalin	Ç			
Metalloprorease (MMPI)	; 5	i		i
Funcylmoterus (F33) #2		i	7.	1
TSP At	3 5	ı	1	1
T3P #2		ı	0'01	:
Anti-Missoc	3 5	ŧ	1	ı
22	3	ı	7	!
		1	1	1
	ì	ī	9.	;
Other New Products	72			
Other	373	! <u>Y</u>	! ;	1
:		•	6	17.2
Total Development	357.5	1	3368	100
Discourse			!	3
- Translation	145,0	ı	192.0	;
Total PPD (Without Risk)	138			
		3	3770	80
All MA Hordabilly	(43.7)	(5.3)	(6.5)	3
Total PPD (With Bink)		į		
	477.	295	510.3	51.7
Application procedure and the contraction of the c	<b>非在台屿的</b> 的新期的			
2. 14. 14. 14. 14. 14. 14. 14. 14. 14. 14	ARTHUR STEEL SPECTO	ANGESTON	NAME OF TAXABLE PARTY.	O THINKING
At Split as Colonisted @ 40%				
		B. 861		208.1
A Spili pér IDV		183.8	į	186.7
Underf (Over) Charge				
Non-silve Services		250		21.4
The state of the s	Allend			

шсшу

PHARMACEUTICAL PRODUCTS RESEARCH & DEVELOPMENT

	•
	7
	_
١.	_
٠,	7

	Corporate Submission	Finel 2001 PLAN	Final vs. Corp Sub Inc(Dec)
NEUROSCIENCE Depakole	29.0	24.1	(6:1)
Gablul ABT-694	; <b>6</b> 8	4. B.	v v :
COX - 11 ABT-089	3.0 7.0	1.2 0.6	(1.8)
ABS-103	100 E	Į	(6.3)
RP Scherer / Alza	4.0	4.0	(16.3)
ANTIINFECTIVE Claithromyoln	20.0	14.8	(5.1)
Ketolide Quinolone	91.0 25.0	88.0 24.5	(3.0)
Neuraminidase Omnicef	5.0	4.9	(0.1)
· Subtotal ANTI INFECTIVE	141.0	132.3	(8.7)
UROLOGY/CARDIOLOGY	26.4	23	(23.1)
Fenothers (Fourier)	4.0	*1	(2.6)
Nippon Shiriyanya (NS48) KCO	9.0 9.0	6.0	(1.0)
Subtotal UROLOGY/CARDIOLOGY	36,4	8.7	(26.7)
HIV	0.8	4.0	
Kaletra	. 41.5	51.0	5.63
Cyclosporine	47.6	67.5	10.0
CANCER		;	
Endothelin . TSP #1	23.0 8.0	38.8 10.0	15.0
Metalloproteinase	0.7	7.4	0.4
Anti-Mitolic K-6	9.8 8.8	97. } D	(8.8)
FTI #2 Subtotal CANCER	61.9	84.6	(4.1)
Other New Producis	. :	:	
Other Affordability	78.5 (25.1)	88.1 (8.8)	7.6
Total Development	385.1	380.0	(15.1)
Discovery	197.0	182.0	(6.0)
Total Gross PPD	692.1	672.0	(20.1)
TAP & Sister Division	69.2	. 67.4	(1.8)
Total Gross	851.3	629.4	(21.9)

шешл CONFIDENTIAL ABBT 0037566

PRELIAMANAY harmacautical Rossarch & Development Expense Breskdown Z001 PLAN	•
Рћаги	

XX buen to Hekansiy Consutano on AliaJacol xx

Contract And Old	Total Expense Savings	111	1111		72.4  3.8 78.3	2.7	1 1 1 1	6.8 4.2 4.9 	
Strategic	Mondetory R&D Expenses	(18.7) (0.7) (5.2)	(6.6) (5.8)	(25.5)	(10.9) (15.9)	(1.1)	(38.8)	(29.1)	(43.7) 4.9 (183.1) (88.2)
	Potential Expense Savings**	18.7 0.7 5.2	9.0 0 1 1	26.6	10.8 72.4 15.9 3.8 103.1	1.1 0.7 7.7 4.8	2.6 38.8 1.7 41.1	28.1 6.8 4.2 4.8 44.0	(4.9) (4.9) 257.0 88.2
	•				· .			. • .	
	2001 PLAN Targets	24.0 2.4.1	0.8	40.6	14.8 88.0 24.5 4.8 132.3	2.3 1.4 8.7	61.0 61.0 2.5 87.6	38.9 10.0 7.4 8.4	98.1 (9.8) 380.0 192.0
	Other Fixed Costs	7.4 0.7 1.1	0.3	15,1	4.0 45.6 4.8 1.0 1.1	1.2 0.7 2.3 4.2	1.4 (4.2 0.8 16.4	9.7 4.2 3.2 3.5 3.5	42.4 (4.8) 123.0 85.8
· ·	Other Variable Costs*	5.04	6.0 6.0	14.8	18.6 8.0 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8	1.1 0.7 2.3 4.1	14.2	8.6 4.2 3.1 1.5 1.5 1.0 2.0 4.0	42.3 (4.0) 122.1 95.8
	9PD Direct Coxts	111	111	:   :	2.4 2.4 2.4 16.8	. ! ! ! ! !	: :   :	0.3	16.8
NABEAIENT	Grants	3 12	511	10.6	9.2.4 9.7.4 9.0.0 9.0.0 6.00	1 1 4	1.2 22.6 1.0	81 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	118.0
Needs to Be Review's By Likyadenevi	Birategici Mandatory R&O Program	, 70 % % % % % % % % % % % % % % % % % %	Yes	S 29.	8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8	Yes No No	Yes Yes Yes	* 2 2 2 2 2 )	No Yes Yes
— (M	ERANCHISES	NEUROLOGY Dopakote Gabiril	ABI-289 (formerly Cont) COX - II ABI-089 (formerly ChCM) ABS-103	NPS-1778 RP Scherer / Abra (Hydrocodona) Subtotal NEUROLOGY	ANTI INFECTIVE Cletifuromydin Relative Quinctione Neurominidass Ommicat Subtata ANTI INFECTIVE	<u>UROLOGY/CARDIOLOGY</u> BPH Bretynp Fenolibralia (Formela) Nippon Shiryakyu (NS48) KCO Subiolal UROLOGY/CARDIOLOGY	HIV. Rilameri · · Kaletea Cydosporine Subtebal HIV	CANCER Endothein 15 P #1. Menalioproleinsse Anti-Milotic . K-5 F1 R2 Sublotal CANCER	Other Naw Products Other Affordsbilly Total Development Disovery Total Gross PPD

• Cataulated using the retionale that 60% of remaining costs could be cut via headcount reductions, PPD melental reductions, leb supplies, etc. \*\* Includes all costs that are considered variable (Grants, SPD Direct Costs, and Other Verlable Costs).

HIGHLY CONFIDENTIAL ABBT 0037567

54

# Pharmaceutical Products Division - R&D Summary of R&D Projects 2001 PLAN

				1000
Project/Description .	Cost thru	2000 Actual	2000 Actual 2001 PLAN	NDA 2001 and Formers
Depaktofe Development programs to enhance the Depakote Depacen product position in the treatment of migrate headerbet and the treatment of manic spleodes associated with bipolar disorder. This includes a new extended release formulation in seat of latest treatment areas and studies to expend the market for treating impolitive aggression, psychosit, edicity agilation, a comparator has a subject in prediction manial. Additionally, the Depacen Rapid Intarion Study will assess the safety of rapidly leading Depacen in patients with Epilepsy. Two new formulations are being developed-2250 mg Eta tables and DR Spinning Disk.	\$179.9	\$33.6	\$24.1	ψ'n
ABT-394 [Milestone: Go/No Go Clinical Efficacy, 2001, NDA Date: 2003] ABT-394 is a non-opioid, non-NSAID analgeis that it a potent and selective natural alcoint receptor modulator. It is effective across all pain conditions, noticeptive puln and neuropublic pain. Preclained data shows ABT-394 to be 30 to 100 times more potent and equally efficacious to morphise in treating moderate to sweet pain in averal released residual models of more more patent and equally efficacious to morphise in treating moderate as well as monobrerapy. Indicated for the management of recumpabilic pain accident with ablestic polynearic pathy. Indication or publication for specific chronic moderapy and candidate (cat. OA). Oral formulation expected. Desirable active and/or neuropeptive pain econolision (cat. OA). Oral formulation expected.	\$62.2	\$14.3		0.172
ABT-089 [Milestone: Transition Team Go/No Go, 4Q01] ABT-089 is potent and selective neuronal messing receptor modulator with cognition enhancing serivity in rodent and primate preclinical models of cognitive dysfunction. It does not appear to have incomined into a perfect of the contract of the contra	\$1.6	9'18	\$0.6	\$102.3
Clarithromycin The ANDA for clarithromycin extended release (Biswin XL) was approved March 3, 2000. New studies planned for the U.S. Include Authma and Cyrtlo Fibrosin. International Projects for 2001 include OD XL registration studies and the Japan 400mg tablet.	\$393.8	\$23.5	\$14.9	NIA
Ketolide (ABT-773) [Milestone: Phase III CAP/AMS dose range data 2001, Tablet NDA 3002)  ABT-773 is a potent keolide with trong activity against most marcellala restoant strains while also maintaining the broad spectrum coverage of clutiviourycin. Product will be available as about a second strain and injectable form dependent on timing of funding. ABT-773 will advers the most council metaleusing restoances to construct copied agents and weak activity against key problem pelibogan, especially 8, protimoniae. Maintains claim of "Spars the proctorm" (Or. O., appicals). Cover key Or restinant subta (S. procuronia, S. program). Tabled doing will be QD or BID based on severity of indications. Five days for ABECB, Pharpagina, 10 days for AMS and CAP. COGS on more than \$2,500% at Issueh, Pediatio and IV currently not finded.	\$153.8 (Tab)	\$74.5 (Tab)	(Tab)	S42.0 (Tab US/EU)
Quinolone (ABT-492) [Milestone: GofNo Go PK/Satety (Phase Ia) 2001, NDA Date: 4004) ABT-492 is a broad-spectrum and-ineffective agent with potential application across a range of indications, including respiratory infections, gentrourinery infection, and stativof titure infections. Product will initially be available as ubled-capault followed by an injectable form approximately one year later. The in view potent is a bound of the pass to be more potent than constituting to the production of the suggested that ABT-492 was in a potentially effective at dozes comparable to acvallonation. Must have a safety profile comparable to level constitution and IV. Five stay for most indications.	\$11.6	17.7	\$24.5	\$227.6 (Tab)
Omnice [Milestone: Initiate Clinical Studies Q301, SNDA Q402] Cafdinir (Omnica) is a potent explasopoun indicated for the full range of expiratory text and skin infections, and has 5 day BID indications for AOM, pharyngists, and AECB. The suspension is pleasant testings Cafdinir (Omnica) is a potent explasopoun indicated for the full range of expiratory text and skin will in 2 studies, and better than 2 this has a charge than 2 this master in 1 of 2 studies. A new roady will pursue claim for 5 day, once daily doing in AOM, and generate comparative data va.	\$0.0	20.0		NIA
Linconne with word street and part of the street of the st	585.7	\$31.5	123	50.0

 $\Pi G \Pi Y$ 

55

## Pharmaceutical Products Division - R&D Summary of R&D Projects 2001 PLAN


				Cost until
Project/Description	Cost thru 2000	2000 Actual 2001 PLAN	2001 PLAN	NDA.
Kaletra 481-318 is second generaliun protease inhibitor which will be coformulated in one captual-tablet with ritonevir. It is potent against purified HIV protease with a Ki of form. Phase I studies adjease that ABT-378 is safe and well tolerated at all dozes studied. AST-378 words only in combination with ritonevir sets are a potent binder of the 1459 system to chance the PK profile AST-378 to eather which the student into our term, defeated at it including protease inhibitors the symple in the ST part of the 1459 system and tituse concentrations. AT AST-378 to eather which a blood protein student. Designs BID, QD possible, Will be writible in one colorantical pill with ritonevir.	5215.7	\$80.8	\$51.0	YN .
Endinella (ABT-627) [Milestone: Initiate Phace III Clinicals I Q/01] ABT-621 About leading and other surgeoist reveptor. ABT-621 is exesting an indication for the treatment of homone reflectory provide cancer. ABT-627 is only utministered and well tolerated as chronic ABT-627 is about leading and other and other and the surgeoist revenue of the surgeoist compared to place to. It has also demonstrated improvement of times to disease progression compared to place to. It has also demonstrated improvement in time to PSA progression compared to place to.	\$96.4	\$16.8	\$38.8	\$51.0
ISP #1 (ABT-510) [Milestone: Go/No Go Cilulent Safety, 2Q01] ABT-510 is guented themborpordin mimeric. TSP is an angiogenesis inhibitor that may preven the prevent the spread of measures by inhibiting the growth of the prevent and appear to provide blood to growing umnor. With a retailvely benign to skiely profile, this class of agond may be used to prevent measuring classes in patients who have received surgery, adjustion or when ondor as primary therapy to reat center patients. As chronic, fong-term theripy, there is patient to commercial oportunity.	\$11.0	87.0	\$10.0	\$80.5
Metalloprofelnase (MMPI) (ABT-518) [Milestone: Go/No Go Clinical Safety, 4QUI) ABT-518 is an unative metalloproteinase inhibitor and a systotatic agest, MMPI's may preven the growth of metashile tesions and inhibit primary tenes agents will most likely be used with current therapy or post-definitive therapy such as surgery, radiation and chemotherapy. As chronia, long-term therapy, there is significant commercial upside.	\$5.6	\$5.6	\$7.4	\$86.3
Anti-Mitotic (Eisai) (ABT-751) [Mitestanet Go/No Go Clinical Safety, 2001] ABT-18 is an ond synotace agant but labilita town by inhibiting the polymerization of tubulis into microtubles, a necessary step in cell dirition. This mechanism of scalion is somewhat similar to mechanism of scale towid produce clinical benefits equal to or superior to comen towarts and could be as commercially necessifi as the protect of scale produce clinical benefits equal to or superior to other spent of the scale of the scale of the special to be affective in patients experiencing reditants against including toward.	53.9	\$3.9	<b>28</b> .4	578.0
Other Dies projects Include Cabinil, COX-11, ABS-103, NPS-1776, Hydrocodone, Fenolibiate, KCO, Ritonovir, Cyclosperine, CAPD Excess Capacity Charges, and CAPD Clari process improvements.	Y <sub>N</sub>	\$68.6	\$105.6	N/A
4 Trortachilly tellen Risk	ΥN	\$0.0	(8.6.8)	N/A
Discovery Imaging provides for five Discovery Development Candidates (DDCs) to be brought forth in 2001. Reflects Discovery costs in Infectious Discoust, Metabolio Discous Research, Vestelopical part Viological Discovery Canter Research, Includes Neurosearch, Karo Bio, ICABen, IDUR, Incyte and ISIS collaborations.	NA	\$190.6	\$192.0	N/A
Total Gross PPD	NA	\$559.4	\$572.0	N/A
C V CONTRACTOR CONTRAC				

шена

OFIDENTIAL BT 0037569

Pharmacoudeal Producte Division RAD Plan Galding Rollioward Gross Expense

32



HIGHLY CONFIDENTIAL ABBT 0037570

 $m_{GHIA}$ CONFIDENTIAL ABBT 0037571

Pharmacsutteri Producti Civision R&D Pian Galding Rollforward Nei Expenie	
---	--

	(151.1) (100) (100) (100) (100) (100)	12121) 121210	(1,16)	(1,169) (017)	(012.1)		400	(1281)	T8C 11	(1,220)		
PRY Gares  COM Course  COM Course  Total Reductions  Color Epp Avenue  Total Additions  Adjustment  MUNIMAGENERAL SERVICES SERVIC	(1987) (1987) (1987)			-	15851	(515)	(688)	(410)	60	1784	E	(10 m)
Corper Course  Total Reductions  Christophy (111.2 to \$12.3)  Agruthmy (111.2 to \$12.3)  Agruthmy (111.2 to \$12.3)	- (1916.1) - (1916.1) - 105	(vea)	20	610	(014)	600	() ()	( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( )	(26.4) (26.4)	(200)	(30)	(2,900)
Total Reference  David District Control Addition  Total Addition  Total Addition  Total Addition  Adjustment  MUNICAL STATES CONTROL  Total Addition  Total Ad		- <u>6</u>	. 65	(5)	6	100	5	割	9		1	13,101
OTHE Test Addition Test Addit	265	(1,247)	(1,304)	(t)	(2306)	(2,613)		į		:		
DOWN Teu Jadohum Agurum Teu Jadohum Teu Ja	SOR	į		202	203	ŝŝ	202	50	8	8	25	2,482
,	E E	E 16 3	: 215 215	n s	E 5	FIFE TO SERVICE SERVIC	日号	6 5	1 5	1	\$	1,162
			,	ŧ	\$	8	8	Ħ	ğ	9	92	oog'c
	R	R I		1	1	: :	Ę	=	115	110	95	1,314.
	- (		1		TANKE TERRET			Statistands.	STATE OF THE STATE OF	MANIE MANIE	त्रासंस्थान्यस्यान्यस्य	HINE
	96	(1, 528)	(1,526)	(1,528)	(1,526)	(1,528)	(rest)	(FEST)	(1,874)	6 1624'1)	(1,525)	(18,201)
Other Functional Experient (1,119)	12			•	00	<b>.</b> .	D P	•	•	o	٥ ۾	200
	- ₹	.65	8	E.	E	2	65	E	E E		Ē	Ę
	E		E 60			2	Ē	5	E 5	<u> </u>	6	(120 (120)
		(210)	2	- [	- 5	66		20	(8)	9	2	(ביצון)
	<u> </u>		E	[2	E	Ξ	Ē	Ê	25	£ 8	100	(ogri)
		- [	<u>e</u> e	(200)	E	Ē	E	E	£	Đ	<u> </u>	(4,025)
	īĒ	Ē	9	2	68	Ēā	92.0		1 2	5	8	2
Cod htt Menponet 0 1781)	- Imil	liter in	(2,773)	1 (1)	in a co	lno'c)	ltiqt)	(100°t)	(1,144)			
•									i	;	780	4.10
	P	•	0 8	• 5	° E	\$ E	₽E	2 6	2 E	22	E	40,
	2 22	131	9	3	21	9 7	E #	មិ ម	5 8	3 8	7	8
	R =	g •	# °	a -	9 5				<b>.</b>	<b>-</b>	F ~	2 2
Elmination of Sangstal Cratil	•				0	- 0	ا 	- 0	8		Ē	14716
Gebief teinfruntman from Commercial 0 101	111	Į.	i i	l E	940	1,720	1,720	arri	7,186	<u>.</u>	į	•
	į		130	1761	178	J,	1,380	1,314	1,214	1,284	1,284	19,400
Change in Nat Affordability (111.3 to 16.5)		<b>]</b>	ļi	•		5	9	(8)	(828)	(111)	(100)	(1,257)
Adjustment 191	2		١		THE PERSON STATES		TENT TO THE PERSON		Secondon		THE REAL PROPERTY OF THE PARTY	COURTER
THEORIGINAL PROPERTY OF THE PR	STATION SERVICES		Carolina Manager	THE PARTY OF THE P	23 ST. 12							;
		· Ounter 1			Durder 3			Quarter 3			Sicolary 2	
Quededy Dallon.		88.072			100,246			. 163.0%			10.05%	26,36 2.44
Final Plan K. venes 2000 AGU		A38%			200						93,528	363,437
Bast 57		102,598			401214 -6.36%			10.62%			18.224	4,83%
A versus 2000 AGU		102.054			104,163			98,314 44,874			102,000 27,34%	410,EST 9,42%
Book #1 St. resourt 2000 Agu		476%			¥17						80.478	374,738
100 600		91,448			110,606						į	
								•			•	

HIGHLY CONFIDENTIAL ABBT 0037572

2001 Project Funding by Phase

	Ī	/KMMI	Dhade I	(SMM)	Phase if			_'	1	SMM	FIBRICALISE LOTERS	2000	
Franchise Neuroscience	COX-II COX-II ABS-103 NPS-1776 ABS-103		50 B	1	euro euro Milestorie Isteo	9.3 70.1	Hydrocodone	4.0	Depakole: Ongoing Depakole: New Incremental Depakole Gabitrii	24.1 2.0 9.0 1.4	40.6 51.3	Pro	<del></del>
Anij-inlectiva			Quino: Tablel Quino: Tablel	24.5	Keto: Japan Reg Keto: IV Form	88.0 3.0 7.0	Omni: Onitis Media Omni: AECB Omni: Pharyngilis	224 5.0	Clari: TBD Clari: Cysilc Fibrosis Clari: Asikma Incremental Clari Clari: International	14.9 0.7 0.0 0.0	132.3 26.8	102.8	
Uralogy/Cardialogy	KGO	5.0					Вітосютої ВРН Вескир		Feno: Diabelics Feno: Diabelics	2. 8g	14.3	37.7	
HIV/immunosdence	Gengral: PAEFER Gengral: Peds PK	0. 0.					Rijonavir. Combo 2nd Gen: HIV, BID, Oral 2nd Gen: Imp Form Gengraf: Organ Fiel G 2nd Gen: Organ Fiel G	4.0 32.0 4.0 2.0 2.5	Znd Gen: Ph IV Susika Znd Gen: Ph IV Swiich Olher Znd Gen	0.0 0.0 0.0	57.5 19.0	2 10 2	<del></del>
Oncology	MMPI KS FTI	7.4 8.8 4.1	YSP-1 Anti-Mitolic	10.0 8.4			Endo: Prositie Ca Endo: Breasi Ce Endo: Eorly Pca Endo: Endo: Endo: Endo:	37.8 1.0 11.0 5.0			84.8 29.9	31.6	
	000-1 000-2 01scovery 000-3 000-4	5.0 5.0 192.0 5.0 5.0	Olher In-licensed**	30.0			·				278.1 60.0	235.0	
2001 Altordability 2001 Total Eunded 2001 Total Unlunded 2000 Altordability 2000 AGU	ppc-g	(9.8) 205.8 55.7 (3.6) 201.4		129.6 36.9 72.0		97.3 36.1 124.1		94.5 49.7 77.0		21.7 21.7 84.0	(9.8) 572.0 201.1	(3.6)	

All fixed costs in "other" arbitrarily placed in phase 1.
 in-licensed compounds may very in both franchise and phase.

шеніл

Pharmaceutical Products Research & Development R&D/Medical Expenses Summary (\$000)

,	2001 PLAN	192,000 328,307 520,307 3.1%	186,670 35.9% 1.6%	333,637 64.1% 6.5%	51,729 572,036	57,348	629,384 385,367
	2000 AGU	184,750 318,565 503,315 -2.7%	183,768 36.5%	319,547 63.5%	55,183	62,809	626,307 374,730
	2000 APU <sup>:</sup>	185,000 327,300 512,300 4.9%	183,768 35.9%	328,532	55,183 567,483	65,459	632,942 383,815
	2000 PLAN	185,000 312,126 497,126 25.6%	183,768 37.0% 10.8%	313,358 63.0% 23.7%	553,416	52,694	606,110 369,648
	1999 ACTUAL	170,792 248,486 419,278 -5.5%	165,911 39.6% -2.5%	253,367 60.4% -0.8%	63,876	58,301	541,455 315,443
	1998 ACTUAL	162,565 263,041 425,606	170,242 40.0%	255,364 60.0%	66,861	58,700	551,167 322,225
		Global Discovery Global Development · Subtotal Global % growth vs. prior year	A.I. \$ share A.I. % share A.I. % share growth	PPD \$ share PPD % share `PPD % share growth	<ul> <li>Domestic Development Gross PPD</li> </ul>	TAP and Sister Division	Total Gross Expense Net PPD

LIGROUPWIKe Comille/A.I. tracking.123

HIGHA CONFIDENTIAL ABBT 0037574

Detail	of	٠.	Hhi	-
200	٠.	×	A NJ	

				-	2001 PL	AN							
				Adiust			7001	PLAN	t	2000	AGU		Variance
	Global C	omestic	Total	Global Dor		Total .	Clottal Don		画   -	Global Dom		녜	FayiDiniavj
Miss PPD RED							***		110	2,603	_ 2	1003	1,893
Alternate Dosage	110 400	-	110 403 ·	-	-	=	110 403	=	400	1,751		1,761	1,350 457
ia Licensing Exploratory Effort	451		458	٠:.	-	-	458 123	-	451 123	925 927	-	1725 1727	604
Personiption for Growth	123 71	=	123 71	_	-	=	71	Ξ	וז		-		(71)
Birmoctoruol NS-49 AUT-232	57	-	ឆ	-	-	-	sı		57 26	-	-	=	(22) (23)
Attentioner & Recordinard Pro-LCC	-	3B	34	ī	-	7	7	-	7	7	-	7	
Molecular Probes Drug User Feets	_		Ξ		1,207	1,207	-	1,207	1,207	-	1,855 1 200	1,951 200	744 200
Patest to Operations	-		-	3,165	-	1,153	Z 168	-	1,165	Z.209	:	2.259	(857)
Dept & Picoropece not in land inventory Transler ABT 378	-	=	=	-		· 🕳		-	200	(5,726) 200	- f	5,720) 200	(2,720)
Cárical Bupplies (Operations)	-	••	-	200	_	500	200	_	-	2440	_ :	2,440	2,443
Cornécco	-	=	_	=	_	_	_	-	-	1,520 .	- '	1,500	1,500
IT Productily Projects	-	-	-	· -	=	=	_	=	=	1,000		1,000	1,000
KanilAtiVIQDIOther General III	-	-:	=	-	=	=	-	-	-	500	-	500	600
Genset #7	-	-	=	Ξ	=		· <u>-</u>	=	-	=	-	Ξ	_
Coaction Ci cherpe from Dps (Citc Val MgF)	_	-	-	_	-	_	-	-	-	171 607	-	171 807	671 607
SPD EV - Lipotavir	-	-	-	-:		-	=	_	= 1	823	-	823	253
Angis Insurance Data Management Absorption		-	=	=	-	-	-	-	-	1,178 2,650		1,07s 2,050	1,078 2.650
Other Heal Products	-	-	-	-		-	_	-	- <u>-</u>	145		148	148
Al Marpower	1,212	ū	1270	2,272	1,207	4,580	4,605	1,245	5,850	12,412	2,151 1	S.FED	6,713
Non-Promoted Products			Z 480				_	2,480	2.487	_	2,450	2,480	_
Cherl MACC	-	2,480 2,564	2,565		_	=	=	2,529	2,509	-	154	, <b>858</b> ,	(1,710)
Heat Candidates		-	-	-	-	-	<b>E</b>	2.073	B.100	1,592	10,5311	12,283	4,117
All Other (Datal Below)		12,121	13,214			<del></del>	22		13,214	1,552	14,000	6,627	2,407
SPD Mes	_								- 1	657	_	553	557
Cutsourcing	-	_	-	=	_	-	_	=	= 1	_	-	-	-
Perchasing Alto/Other Hazants Lati										552		557	e <u>e</u>
	-	-	-		-	-	-	-	-		-		-
SPD Process Unit of Activity Charge	72	_	23	-		-	73		20	23	638	23 239	6 270
Ery A for Charl Improve	ເສລ	369 .	369 1,973	_	_	=	1,973	369	1,973	2,507	_	2,507	534
Card Process Ingrow H2G	_	=	-	_	-	-	<del>.</del> .	-	7,152	-	-:	=	(7.152)
New Project Support	7,157	-	7,152	-		=	7,152 —	-	- T	-	-	_	(270)
Discovery Patents & Trademarks	310	=	פלב	-	-	-	370	_	270	-	-	-	
Float Cost to EPO (PARO)	-	=		-	-	_	-	Ξ	- 1	1,725	_	5,725	5,726 403
Protesse 2nd Gen (Mily Chy) Clari IV	<b>4297</b>	-	(297	-	••	-	4,297	-	4,2787	4,700	-:	4,700	
HQB-Flad MCPP		_	_		_	Ξ.	=	=	=	Ξ	_	151	151
Angiopenesis - Fixed HCPP Miscelleneous Adjustment							13.815	327	14,104	12,112	675	T3,751	(453)
m m	13,015	344	15,184	-	-	-	14012						
Excess Capacity - SPD PPD RAD Key Cornel	11,610	-	11,510	-	••		11,510	-	11,510	8,100		9,150	(2,450)
PPD RAD Suspense	-	-	=	_	-	_	. =	_	Ξ.	=	-	_	-
Corp Key Consol ATIS Suspense		<u></u>					11,010		11,010		<del></del>	9,160	(2,450)
	11,010	-	11,610		-	-	11,010	-	,,,,,,,				357
Expens Capacity - PPD  Decovery	_	-	-	-	-	-	_	-	- 1	332 634	25	257 ES4	104 104
Drug Safety	-	-	Ξ	=	=	_	_	=	= 1	35	=	25	25
Development Ops Venture Menagement (Thrombo)		••	_		-	_	-	-	- 1	-	1,102	1,162	(,1 <u>62</u>
Venture Myrri	-	-	_	_	-	=	Ξ	=	= 1	_	69	53	59 2.000
PARD Date Management (Sale president)									— <u>-</u> - i	2,000	1,745	2.000 4.447	4,447
•	-	-		-	-	-	-	-	-	4,44		-	
Other Miscellameous Credits CRO Rebales			_	(0,000)		(3,000)	(3,000)	-	(3r,000)	(1,500)	-	(t,500)	3,000 . (1,500)
Horo Betterment	-	-	=	-	_	=	_	_	_ :	(815)	=	(# 18)	(#10)
FLAPIVacquard Ydangio Psymento	-		_	_	-	-	-	-	-	2,914	Ξ	2,914 2,400	2,814 2,400
Bangstat (Cyclosporine)	-	-	_	-	=	-	=	_=_		(888)		F# 553	
					O-MATE CONTRACTOR	skamen)y	227-107-10-	Kaneagara	LOSEW	H-WATER TO BE			
Subrocal DTHER	24,79	17,52	40,271	373	1,207	1,560	27,123	14,735	41,150	41,127	18,045	2,320	78,344 (6),942
Absorption/Unidentified							88,900	2,485 17,220	84,130	45,457	18,065	83,522	(22,598)
TOTAL OTHER													•
"Should be equal.										<b>\</b>			
Show Text = Impute										1			
All Other													•
	0	5 27	5 341		_	_	05	275	341	82	275	157	10 25
Hytria Macrosida AHTTUT	,			:-	-	-	-	-		- 25	-	25 U	18
Prokinstic Macroscie AETZ29		· :		=	7	- =	5	_	5	97	-	97	₩2
H2G ASTEOS Taxana ASTZ/1				-	-	-		-		114	-	19 114	14 92
FLAP ABTOMO		2.		_	:	_	77		22	1,242	-	1,20	1,742
Girnodernol ABT422 Ciscovery			: -	· -	-	_	_	=	-	-	-	-	-
DALT.					-	_	-	_	_		=	_	-
HAART Membolo Complications Miss		_ :			_	_	=	=	=	-	 00	-	
FenoStrate (Vestaller)					-	-	=	8,097	5.097	1 :	6.277	0,278	122
Compliance Initiative								1,701	1,701	\	4,041	4,041	2,540
Pasamacogenetics								6,073	8,106	1,502	10,591	12,213	4,117
Total All Other	1	20 6,01	T) E, 105		••	-		2,14,0	9,140	1 1,000			

 $\mathbf{HIGHI}X$ 

CONFIDENTIAL ABBT 0037575 (D)

ą.

2001 PLAN Rollforward

Affordability	(25.1)	(2.6) B	(27.7)	17.9 D	(8.8)
Other	71.5	9.4 A	80.8	5.2 C	86.1
Bottom	592.1	0	592.1	20.1	572.0
	Book II	Re-prioritization	Subtotal	Task Exercise	Final Plan

Added \$12MM in grants and cut \$18.8MM in other. Projects cut (\$6.8MM) and functionals added \$2.6MM This means absorption went up \$9.4MM. ⋖

Functional impact was up \$12MM in grants and down (\$18.8MM / 2) = (\$9.4MM) in functionals œ

\$12MM - \$9.4MM = \$2.6MM

Projects cut \$55.0MM which translated into functional cuts of \$40.3MM. \$55.0MM - \$40.3MM = \$14.7MM of unabsorption a change in the CMIS IDV for (\$0.4MM), elimination of Ketolide task 7.0MM, elimination of International Clari. charges for \$3.9MM, absorption changes of (\$13.1MM) and a change in affordability of (\$8.5MM). in addition to the unabsorption, relief was given by Commercial for Gabitril/Corp. Altoc for \$1.6MM, the Cyclosporine deal with SPD was terminated for an \$0.4MM, FTI #2 switch to KCO for (\$0.4MM), O

Of the \$40.3MM in functional cuts, we took \$20.1MM to the bottom line, therefore \$17.9MM went to reduce affordability ۵



HIGHLY

CAGROUPWike ComillayPage 100 Reviseduls)Changes

шещх

2001 Fran Task Exercise
Pharmaceutical Products Division
Research and Development
(\$MM)


	ą.	Project \$MM		Func	Functional \$MM	-
Project Name	Grants	Other	Total	Grants	Other	Total
- ABSINPS	•	7.0	7.0	•	3.5	13
- Ketolide	•	6.0	5.0	•	2.5	. 25
. врн	4.6	18.0	25.4	6.4	9.5	15.9
Kaletra	(7.8)	(1.6)	(9.4)	(7.9)	(0.8)	(8.8)
- Endothelin	(10.6)	(5.6)	. (16.2)	(10.6)	(2.8)	(13.4)
. КСО	, 0.5	5.5	6.0	0.5	2.8	3.3
- Depakote New Formulations	•	1.9	1.0		1.0	1.0
- K5	•	8.8	8.8	•	4.4	4.4
- Cox II		3.0	3.0	•	τ. π:	1.5
- Clarithomycin: Cyetir Fibrada	2.0	•	. 0.7	0.7	,	7.0
Asthma	2.4	,	2.4	2.4		2.4
International	7.	•	? <b>N</b>	1	•	i
- Tricor - Diabelics	•	4.0	4.0	, .	2.0	2.0
- ChCM	1.6	5.4	7.0	1.8	2.7	4. 6.
- Discovery	•	5.0	5.0	•	5.0	5.0
- IMET	•	•		r	1.0	1.0
- Project Expense	•	•	•	ı	1.0	1.0
Total Task	(4.8)	57.4	62.6	(4.8)	33.2	28.4

HIGHLY

# Headcount

# 63

# &D Regular Headcoun



2001 FLAH Finel Plan ya Agu Year end Headcount analysis

•	
	2001, PUAD
(tava	HEAD COUNT
Iner I (Decr)	
Final PLAN VE.	Commentary

					. Final		Decity	
		Final	Book 1	Book #	(ORACLE)	Floui Pi	LAN VE.	
	Book# AGU	(Oracie) AGU	PLAN	PLAN	PLAN		AGU	Commentary
MET								
Nat	296	292	264	254	257		(35)	435 Regulat, -f Yeorp, -70 SciPre
Gross	298	298	264	264	257	_	(41)	
						•		
		• • •					•	•
VENTURES							•	
Cardiovascular & Diabelos			•		_		_	
Net	D	6	0	0	0		0	
Gross	0	0	D.	. 0	Đ		٠	
		. •						
Macroöde Het	· 41	41	· '48	48	42		1	e1 SdPm
Free: Gross	41	. 41	48	45	42		1	•
			•					
Anti-Virei		48	· . δ1	51	55		7	47 Regular
Hat	51 55	48 55	의 중	55	<u> </u>		ž	•
Groce	-							•
Analgesia							-	-2 Repose, -1 8ctPro
Net	18	·. 44	35 35	35 35	11 11	·· :	(3) (5)	of Leibnet at any in
Giora	18	.18	33		•••		1-7	
Display	• .	:	•					
Net	. 19	17	23	. 23	14		(2)	-1 Regulat, -4 Controls, -5 Ediffre
Gross	21	21	24	· 24	14		(1)	
	•							
Oncology (Transplant	35	3:8	38	38	-47		11	of Regular, of Years, of Contractor, 43 SciPto
Net Gross	<b>2</b>	42	43	43	47		5	
Total Ventures	40.4	450	193	193	169		13	
Net Gross	184 . 177	. 158 175	203	203	171		(4)	
Gross ·	•••	***		•				
•								
DISCOVERY	778	776	778 **	775	770		(B)	-6 Regular, -6 Yerop, +3 Contract, +1 ScPre
Net Gross	BUZ	802	803	803	803		ï	,
						٠.		
DRUG SAFETY				208	189	•	(8)	-3 Reguler, -3 Contractor
Net	· 205	105 205	208 208	208	205		Ö	
Great	200							
PARD	•						_	+9 Requier, -2 Contractors
Not '	344	220	344	344 380	227 259		7	ed Habrier' -c colmanne
Gross	358	356	360	200	3-40		•	
PHASEI								
Not ·	হ্য	58	76	. 78	-62	•	В	+3 Regulat, +3 Contractor
Gross	<b>57</b>	57	76	76	62		. 2	
								-
DEV OPS Net	215	197	. 218	218	181		(15)	42 Regular, -2 Terror, 45 Contract, -21 ScPys
Gross	213	213	220	720	188		(27)	•
		•				•		
RA				619	88		4	+6 Regular
Net	67 68	64 69	59 53	63	88		40	
Cross	00						• • •	
NA.							_	
Het	143	138	145	145	137		1	ed Regulat, -3 Contractor,
Gross	145	145	148	148	146		•	
ADMIN .				•				•
Het	96	82	`B5	85	113		31	+14 Repuber, -1 Temps +18 SciPro
Group .	88	62	85	85	, 113		31	
_			•					
JUDGMENT		٠		141	90		2	-26 Reputer, +4 Temp, -4 Contract, +18 ScP19
. Net	23 36	87 41	. 35 51	(4) 7	73		32	
Grani	35	-1	u)	•	.•			
TOTAL								
Hed	2,575	2,373	2,412	2,373	2,573		D	
Gross	2,443	2,443	2,487	2,443	2,443		D	
			•					

HIGHLY

CONFIDENTIAL ABBT 0037581

64

			>					R&D							
•	~						PERSONN	IEL - 2001	PLAN					12-Mo	<del></del>
	DEC	JAN	FEB	MAR	APR	MAY	JUNE	JULY	AUG	SEPI	DCT	NOV	DEC	Ayo	13-Mp
Ÿ	Common	arad.		4444	ست	,									
* IL REGULAR	1.968	2,180	2,170	2,175	2,167	2,162	2,146	2,145	2,153	2,181	2,178	2,174	2,194		
GROSS UNFILL	1,000	· (193)	(168)	(143)	(118)	(68)	(40)	(35)	(50)	(63)	(53)	· (43)	(70)		
NET	2,069	1,987	2,002	2,032	2,049	2,094	2,106	2,110	2,103	2,118	2,125	2,131	2,124	(62)082	\$2081
TEMPORARY															
GROSS	13	21	21	21	21	34	56	56	50	22	22	22	22		
UNFILL					<u>÷</u>										
NET	13	21	21	21	21	34	56	56	50	22	22	22	22		
CONTRACT		20	70	79	76	78	76	77	73	74	73	75	75		
GROSS UNFILL	67	80	78	18		70	70		,,,		/3				
NET	87	80	7B	78	76	78	76	77	73	74	73	75	75		
SCIENTIFIC													J		
GROSS	295	162	174	168	179	169	165	165	167	166	170	172	152		•
UNFILL		944				400			407	400			152	•	
NET .	296	162	174	168	178	169	165	165	157	165	170	172	152		
TOTAL EQUIV						204	227	800	500		265	200	249		
GROSS . UNFILL	396	263	273	268	276	281	297	298	290	262	200	259	248		
NET	396	263	273	268	276	281	297	298	290	262	265	269	249		
GRAND TOTAL				•	•										
GROSS	2,364	2,443	2,443	2,443	2,443	2,443	2,443	2,443	2,443	2,443	2,443	2,443	2,443		
UNFILL		(193)	(16B)	(143)	(118)	(6B)	(40)	(35)	(50)	(63)	(53)	(43)	(70)	The second of	esservation and
NET	2,364	2,250	2,275	2,300	2,325	2,375	2,403	2,408	2,393	2,380	2,390	2,400	2,3/3 g	6-04-158 <sub>7</sub>	255
Div Contract	383	242	252	247	255	247	241	242	240	240	243	247	227		
				•		Monthly	Changes	<del></del>		<del></del>				Total	
•		J	F	M	A	М	J	ل ٠	Α	5	0	N	D		
•	Republic	182)													
	Soleman					SECTION .							in profi		
	1161首用器	25回182回	<b>些制度25</b>			E36250#			33 E (3D)#		THE PROPERTY.	SESSION UNITED SESSIO	ALC: VAL	Range At a	
															ı
					n,-	Qu	arterly Cha		. 11.			Total Add: Repular			
. •	2001 PLA	N			Beg_ 2,364	. (64)	103	(23)	(7)	End 2,373		Cohmit			
• • • •	2000 ACT				2,308	(78)	. 17	(15)	132	2,384					
•	1999 ACT	UALS			2,457	(311)	31	44	67	2,308			. [		
	1998 ACT				2,535 2.532	(80) (239)	13 44	(71) 88	70 110	_2,457 2,535		Equivalen Unfills	1		
	1997 AC	UNLO			2,032	(400)	***	60	110			0.111110		- Number	•

01/31/2001 16:03 L-tGROUPPEANNING\2001 PLAN\Headcount\[Funana\_pb.xls]\Heads

Pharmaceutical Produ 2001 Plan Headcount	(Manmon	aron & L th) Sum	marv Jevelobi	nent	•			ADRICUPIPILANK	MUZIUI PLANI		1/31/200		j
2007 Plan neadcodite	(marimon		1	İ	1	1	1	1	1	ł	1	ľ	Total Man
	Jan	Feb	Mar	Арг	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Months
ຼ່າ ຕາກສປິດກ Managem	ent & Tec	hnolog:	, }				1	1	· }			l	ı l
" ' Regular	177	179	180	180	181	183	186	. 186	189	189	189	191	2,216
Temp/Summer				·									,,,,
Contractors							l		\	}			
Sci/Pro	78	79	74	.72	72	72	71	71	70	69	67	66	861
Net Total	255	258	. 254	252	253	255	257	257	259	258	256	257	3,071
Unfills		]			.,,								
Gross Total	255	258	254	252	253	255	257	257	259	258	256	257	3,071
Ventures	)	}	1			l		1	[	٠			
Regular	138	140	140	143	146	147	147	147	147	147	147	147	1,736
Temp/Summer	3	3	3	3	3	3	3	3	3	3	3	3	36
Contractors	6	6	6	6	6		6	5	5	5	5	. 5	67
Sd/Pro	16	. 16	16	16	16	16	· 16	14	14	14	14	14	. 182
Net Total	163	165	165	168	171	172	172	169	. 169	169	169	169	2,021
Unfills	11	11	11	9	6	5	5	2	2	2	2	2	. 68
Gross Total	174	176	176	177	177	177	177	171	171	171	171	171	2,089
Discovery	}		•		•	} . }	_		Į				
Regular	747	. 745	746	746	· 747	74B	748	748	748	748	748	749	8,968
Temp/Summer	2	. 4	4	4	16	, .	23	17	. 4	3		3	106
Contractors	20	20	20	19	19	19	18	17	17	17	17	17	220
Sci/Pro	1	1	1	1	1		. 1	1	1	1	1 1	1	12
Net Total	770	770	771	770	783		790	783	770	769	1 1	770	9,306 392
Unfills Gross Total	33 803	33 803	. 32 803	. 33 803	32 B15		31 821	33 816	33 803	34 803		33 803	9,698
Gross rotal	303		)		0.0		<b>J_</b> .						
rug Safety		400	454	40,4	404	184	. 184	184	184	184	184	184	2,199
" Regular	179	180	184	184	ļ	40	13	, , ,			1		39
Temp/Summer	5	5	5	5	. 5	1	5		5	5	5	5	
Contractors . Sci/Pro	. "	Ð	1	ì	"	Ί							
Net Total	184	185	189	189	189	202	202	202	189	189	189	189	2,298
Unfills	21	20	I .		E .		16		16	16		16	
Gross Total	205	205					21B		205	205	205	205	2,499
Pharm Analytical R&									-4-	318	318	318	3.816
Regular	318	· .318	I .	1			318	I	318				1 '
Temp/Summer	2	2					2			•		ı	,
Contractors	17	17	17	17	17	17	17	17	<u> </u> ''	i ''	' ' '	1	]
Sci/Pro				000		337	337	337	337	337	337	337	4,044
Net Total	337	337 22											
Unfills Gross Total	22 359												-
								}				}	}
Phase-I Center									53	5	3 53	53	624
Regular	.4B	49		1	ł.		ı .	١ .	į.		2 2		1
Temp/Summer	` 2	2				2 4	•	1			7 7	1	T1
Contractors	8	8	7	7	7	7 . 7	1	7	]	ı	'l'	1 '	] .
Sci/Pro					<del>:</del>		- =		64		2 62	6	74
Nel Total	58	59	1	. l	1	1	1	1	1	}	_	1	
Unfilis	1								64				74
Gross Total	59	67	4 62	i 02	دا ک	دا م	יו סי	יו אי	<u>د</u> ا	ין י	-1 "	-{	1

me estant Bando	fr Boos			nant				HOROUPPLANK	SACTORNAL DE AUGU	in a second	over the stablement	estical.	į.
Pharmaceutical Produ 2001 Plan Headcount	(Manmon	arch & L thi Sum	marv Jevelopi	nent				20004270	SACTORIS ACTORIS		1/31/200		
ZUUT Platt neadcount	(181631111011		1.00.3	1	. 1	1	. 1	Ī	- 1	1	1	ľ	Total Man
	Jan	Feb	Mar	Арг	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Months
	ļ	- 1	1			İ	1	1	)	1		1	}
~~velopment Operation	ons	l	- 1	1	1	1		1		455	4.50		
Regular	148	148	148	148	148	150	150	150	150	150	150	150	1,790
Temp/Summer	1	1	1	1	1	1	1	1	1   8	1 8	1 B	1 B	12 96
Contractors	В	В	8	8	8	8) 22	8 22	8 22	22	22	22	22	264
Sci/Pro	22	22 179	22 179	22 179	. 22 179	181	181	181	181	181	181	181	2,162
Net Total	179		7	7	7	5	5	5	5	5	5	5	70
Unfills Gross Total	186	186	186	186	186	186	186	186	186	186	186	186	2,232
Gross (dia)	100	100	,,,,	. "00	,,,,,	,,,,	,,,,			,,,,			
Regulatory Affairs	1	. }	i	l	1	1	1	1			]	- 1	1
Regular	57	58	. aa	62	62	62	62	62	62	62	62	62	733
Temp/Summer	1	1	1	1	1	1	1	1	1	1	1	1	12
Contractors	4	4	4	4	4	. 4	4	4	4	4	4	4	48
Sci/Pro	1	1	1	1	1	1	7	1	1	1	1	1	12
Net Total	63	64	66	68	68	68	68	68	68	68	68	68	805
Unfills	2	1					<u></u>			<del></del>			3
Gross Total	65	65	65	68	68	68	68	68	68	68	68)	68	808)
	1	1	1	. ]	- 1	}	1	1	1	- 1	- 1		
Medical Affairs	445		119	122	122	124	125	125	125	125	125	125	1,464
Regular .	112	115	3	3	3	5	5	5	1	1	1	1	30
Temp/Summer Contractors	1 7	7	7	7	7	7	7	7	7	7	7	7	B4
Sci/Pro	5	là	6	a	Б	5	4	4	4	4	4	4	58
Net Total	125	129	135	13B	138	141	141	141	137	137	137	137	1,636
Unfills	17	13	10	9	.9	9	9	9	9	9	9	9	121
Gross Total	142	142	145	147	147	150	150	150	146	145	146	146	1,757
^dministration	.								- (		- 1		
Regular	88	88	вв	88	88	88	38	88	· BB	88	88	. 88	1,056
Temp/Summer	2	2	2		2	2	2	2	2	2	2	2	24
Contractors	5	3	5	2	5	3	5	3	4	3	5	5	49
Sdi/Pro	18	18	18	18	18	18	. 18	18	1B	18	18	18	216
Net Total	113	111	113	111	113	111	113	111	112	111	113	113	1,345
Unfills					.:.								
Gross Total	113	111	113	111	113	111	113	111	112	· 111	113	113	1,345
								l	į.		. [		1
Judgment				_		l		اء. ا	_,[	61	67	57	385
Regular	(25)	(18)	(1)	5	45	49	49	42	54 4	7	7	7	53
Temp/Summer	- 4	5	3	3	4	2	2	i i	- i				
Contractors	21	31	30	43	33	30	32	35	- 36	41	45	26	404
Sci/Pro Net Total	3	18	32	51	82	. 81	83	8D	94	109	119	90	842
Unfills	79	58	42		(24)		(53)	1 1	(24)	(35)	(45)	(17)	(82)
Gross Total	82	76	74				30		70	74	74	73	924
				1									<u>ا</u> ا
Total Plan Detail	ļ			]							0.454	0 404	24,981
Regular	1,987	2,002	2,032				2,110		2,118	2,125		2,124 22	1
Temp/Summer	21	21	21	21	34		56	•	22	22	22 75	75 75	1
Contractors	80	78	79		1		77		74	73		152	1 1
Sci/Pro	162	174					165		166	170		2,373	
Net Total	. 2,250	2,275	2,300				2,408		2,380	2,390 53		.70	
Unfills	193	16B	143				35		63			2,443	
Gross Total	2,443	2,443	2,443	2,443	2,443	2,443	2,443	2,443	2,443	2,443	امبياح ا	-1170	

Pharmaceutical Product 2001 Plan Headcount (N	ts Rese	arch & D	evelopm	ent			. 1	VCRCRPVPLAKK	NGCOOT PLANS				
2001 Plati neadcodik (i	.	. J		1	- 1	I		j	- 1	- 1	i	- 1	Fotal Man
	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Months
****	1	. 1	1	1	. !	1	ı	,	1	1	,	'	}
(T)													i,
•													
From Heads Tab								- 400	0.440	2 425	2 424	2 424	24.004
Regular	1,987	2,002	2,032	2,049	2,094	2,106	2,110	2,103	2,118	2,125 22	2,131 22	2,124 22	24,981 368
<ul> <li>Temporary/Summ</li> </ul>	21	21	21	21	34	56	56	50	22 85	84	85	85	
Contractors	85	83	85	85	85	84	86	84		159	162		1,016
Sci/Pro	157	169	162	170	162	157	156	156	155			142	1,907
Total	2,250	2,275	2,300	2,325 ·	2,375	2,403	2,408	2,393	2,380	2,390	2,400	2,373	28,272
Unfils ·	193	168	143	118	68	40	35	50	63 /	53	43	70	1,044
Total	2,443	2,443	2,443	2,443	2,443	2,443	2,443	2,443	2,443	2,443	2,443	2,443	29,316
Detail > Corp Submissio	n						•						
Regular			,,,,		-	•••	•••	***		***	***		•••
Temporary/Summ	₩1		***			***	***	***	***	•••	•••	. *	•••
Contractors/Sci Pr		***			•••	••••		-	. ***	***	-47	• •••	***
Total	-	***	•••	***	***	•••	***			•	***	***	
Unfills	•••	•••		***	***	•••	***	***				•••	***
Total		•••	•••	•••		***	•	· •••		•••	***	•••	
2001 Corp Submission													
Regular	1,987	2,002	2.032	2,049	2,094	2,106	2,110	2,103	2,118	2,125	2,131	2,124	24,981
Temporary/Summ	21	21	21	21	34	56	56	50	22	22	22	22	368
Contractors/Sci Pr	242	252	247	255	247	241	242	240	240	243	247	227	2,923
Total	2,250	2,275	2,300	2,325	2,375	2,403	2,408	2,393	2,380	2,390	2,400	2,373	28,272
Unfills	193	168	143	118	68	· 40	35	50	63	5 <b>3</b>	43	70	1,044
. Total	2,443	2,443	2,443	2,443	2,443	2,443	2,443	2,443	2,443	2,443	2,443	2,443	29,316
		•			•			٠	•				
Oracle Report 01/31/01				•••									•
Regular	2,012	2,020	2,033	2,051	2,049	2,057	. 2,069	2,061	2,061	2,064	2;064	2,057	24,608
Temporary/Summ	14	16	18	18	30	54	54	54	48	18	15	15	354
Contractors	80	78	79	76	78	. 76	77	77	73	74	75	75	918
Sci/Pro	141	143	138	135	136	135	133	133	131	130	127	126	1,608
Total	2.247	2.257	2,268	2,280	2,293	2,322	2,333	2,325	2,313	2,286	2,281	2,283	27,48
Unfills	114	110	101	B9	92	. 88	. 79		87	87	88	87	
Total	2,361	2,367	2,369	2,369	2,385	2,410	2,412	2,413	2,400	2,373	2,369	2,370	28,598
Check figure Oracle vs	details b	efore iud	igement						-			•	
Regular				7		***	В		(3)	***	•••	•••	. 17
Temporary/Summ		•••			•	•••	•••	6	30	3	•••	•••	. 39
Contractors	-	•••		•••		•••		. 4	(1)	1	•••	•••	
Sci/Pro		•••		(1)		***	•••			1		•••	
Total				6		•••	8			5	•••		, 5
Unfills ·	***			· (n)			(9)			(1)		•-	
Total	•••	•••		(1)	***	•	(1)			• •		••	. 4
LOM		***		117	•••	***							


HIGHLY

CONFIDENTIAL ABBT 0037585

HIGHLY

CONFIDENTIAL ABBT 0037586

## 69



29


2001 PLAN Capital Pharmaceutical Products Research & Development

 $i_{i,j}^{(\gamma)}$ 

	2000 AGU	PLAN	Fav/(Unfav)	Fav/(Unfav)
Authorizations				
IMAT	6.672	4,748	1,924	28.8%
Discovery	11.268	7,628	3,642	32.3%
Dain Safety	3.520	3,125	382	11.2%
PARD	3.486	5,805	(2,320)	-66.6%
Admin	12,380	3,480	8,910	71.9%
Dev Ops	9	9	0	0.0%
Madical Affairs		23		0.0%
RA/QA	우	9	0	%0'0
Other	283	2,000	(1,717)	-606.7%
Total	37,778	28,944	10,834	28.7%

•	•		
8,831 1,095 272 272 425 1,498 1 11 4 4 4			
1,095 272 272 425 1,498 8 11 4 4 4 4		6,541	75.8%
272 425 1,498 9 11 11 4 4		203	18.5%
425 1,498 9 11 4 4 4 7,722)	•	255	83.8%
1,498 9 11 4 4 4 7,722)		(403)	-94.8%
11 14 4 4 7,722)		758	50.4%
11 4 4 4		0	0.0%
4 4 (1,722)	11	0	0.0%
4 (1,722)	. 4	0	0.0%
(1,722)	. 4	<b>-4</b>	100.0%
		(2,122)	123.2%
10.228	0.228 4,894	5,234	51.2%

LAGROUPPLANNINGICAPITALX2001plan\Z001Gaphal-1s/PassaxajTNle



HIGHLY CONFIDENTIAL ABBT 0037589

3

PHARMACEUTICAL PRODUCTS DIVISION RESEARCH & DEVELOPMENT PROPOSED CAPITAL PROJECTS <\$250M

	2000 AGU	200 Requests	2001 Authorizations Funded Ur	ons Unfunded	01 Funded v. '00 AGU
IM&T *	. 3,196	3,787	2,538	1,249	658
Development Ops	, 100	100	100	0.	0,
Discovery	4,670	4,027	4,027	0	643
Drug Safety	2,050	2,809	2,050	759	0.
PARD	2,455	3,092	2,455	637	
Medical Affairs	50	45	. 20	(2)	.0
RA/QA	10	50	10	10	0
Other	283	. 0	2,000	(2,000)	(1,717)
Total	12,814	13,880	13,230	650	(416)

\* Includes \$1,545M for PC refresh and new employees.

LAGROUP/PLANNING/CAPITAL/2001 plan/2001 Capital-1stPass.xis]RD Summary

	1				Cante	Cantal Authorizations		4	Prol Experiso	
i	Zoot Pign 1886 Exercing					7.250	Total	> 250	4250	Total
보	Pharmaceutical Products Division	IS Division		!	2000			1	970	2 000
	Research and Development	opment	•	Mar	2,210	Z,034	7.628	537	355	885
•	(mwt)			Draw Salah	1.075	2.050	3.126	10	다	11
	Capital Profests			PARD	3,350	2,465	6,805	98	168	828
-		1		Admin	3,480	•	3,480	743		743
	•		-	Dev Ops	•	5	<del>S</del>	•	0	<b>CP</b>
	Capital	Project		Med Affalm		8	20	•	Ξ,	₽.`
-Project Name	Auth	Ехр	Commentary	HADA	•	2	2 6	•	• 6	f
				Other	. 12.	2,000	24 PA	3 037	1 857	7 884
· Admin.				<u> </u>						į
- Delay AEGIS Wave III to 2002 - Reduce lab renovations Subtotel Admin	2,000	. 2 2	-Pharmacology Labs & APB/G19 Renovellens				·			
IM&T.				•						
Reduce PC Refresh / Asset Mgmt     NT Storage Mgmt     Under S250 project expense reduced Subboat M&T	400 684	164 442 688	Assume 4 year refresh vs. 3 year Pending IM&T's approval. There is \$377 of functional expense associated with this project.	donal oxpense	ssociated with t	his project.				•
Piscovers								•	٠	,
Therapoullo Asea Projects Support     HTS Expansion     Ganornics Expansion     Afing under \$250 back to original request amount     Linder \$250 project expense reduced Subiolal Discovery	1,030 580 643 -2,401	1,882 300 480 2,820 2,822	Listed as an IMAT project for capital file. There is \$544 of functional expense essociated with this project. Pending D. Norbeck's approval Pending D. Norbeck's approval Pending D. Norbeck's approval Pending D. Norbeck's approval	ls \$544 of functio	199 estados (1981)	aocialed wilh	this project.			
Drup Saleix										
- LCANS - Lab Renovation AP13A - Lab Renovation AP13A - Gene Expression - Under \$250 project expense feduced Sublotal Drug Salety	1,910	120				,				
PARD										
- Potent Drug Encapaulator - Under \$250 project expense reduced Subtotal PARD	500 500	100 400 600				•				
Quben			•							
- Ellminate judgment - Unideniilled Reverse Teak	283 (2,000)	478 (400)								
Total Impact	6,659	0,600								

memy

CONFIDENTIAL ABBT 0037591

HIGHIN

CONFIDENTIAL ABBT 0037592

578

158 ST	sance Sheet Galling Bu. note this is exactly as it appears in the J-Orive	Leith fresty	t/Orive	٠					PHARMACEU F ACCOUNTS	PHARMACEVTICAL PRODUCTB DIVISION "IAIL OF ACCOUNTS PAYABLE, ACCRUED EXPENSES.	CTB DIVISION CCRUED EXP	ENSES		ភ	מספוג דד	)     	2	
<u>1</u>	CATEGORY	Actual 12/31/87	Actual 12/31/88	Actual 12731/89	AGU	¥	FEB	HAH	APR	YVX	NA NA	Ę	AUG	SEP	Į.	NO.	DEC	13 MO AVO
<b>.</b>	SALARIES, WAGES & COMMISIONS Mgml incentive plans - R&D	(1961)		(1,631)	(330:0)	(5,272)	(5,524)	(181)	(1,005)	(1,289)	(1,810)	(1,762)	(2,014)	(2,264)	(2,618)	(2,770)	(3,022)	(2,440)
000	OTHER ACCRUÈD LABILITIES Contest grants - RAD Drug Briety Grant Accrusi - RAD Miso RAD	(75,627) (409) [9,621)	(67,704) (608) (6,611)	(38,647) (673) (8,742)	(54,789) (584) (19,007)	(68,150) (580) (11,102)	(62,259) (589) (10,037)	(84,128) (888) (10,900)	(82,837) (588) (9,381)	(81,981) (888) (11,027)	(10,101) (158) (10,041)	(63,816) (685) (01,520)	(40,468) (588) (12,784)	(40,121) (688) (10,161)	(42,523) (588) (170,21)	(44,717) (588) (11,621)	(43,761) (585) (7,675)	(53,284) (591) (10,286)
	OTHER ACCRUED LIABILITIES	(88,247)	(63,845)	. (48,382)	(64,357)	(90,636)	(72,878)	(79,104)	112,774)	(73,264)	(72,150)	(121/50)	(02,616)	[54,670)	(67,462)	(50,024)	(51,922)	(04,109)
	TOTAL AP & ACCRUED EXP.	(89,207)	(66,481)	(48,383)	(67,370)	(73,110)	(76,403)	(76,658)	(73,770)	(74,623)	(73,640)	(67,483)	(64,632)	(69,144)	(80,040)	(59,684)	(84.944)	166,602
																		•
									PHARIMACEU	PHARMACEUTICAL PRODUCTS DIVISION	ICTS DIVISIO	<b>z</b>						

				٠			DETAI	DETAIL OF PREPAID EXP. AND OTHER RECEIVABLES	EXP. AND O	THER RECEN	/ABLE8				
	Actual 12/31/97	Actual 12/31/88	Actual	UDA 1221/00	JAH	FEB	MAR	APR	MAY	NO.	111	AUG		팅	NOV
															•
E	797	717	ę	ij	<b>25</b>	432	, .	432	432	3	\$	12	ą	3	4
3	•			٥	•	· •	0	0	0	0	0	•	•	0	
,	•	-	-	٥	0		0	٥	•	0		<b>D</b>	-	<b>.</b>	
	•	٥	•	0	0	•	0	0	0	0		0	•	-	
<b>11</b> 5	2	414	428	42		432	432	\$	Ą	. Ħ	432	ę	432	432	~
,	673	36	170	325	55	676	879	878	578	576	578	878	978	. 678	<b>#</b> 0
0 4 7 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1			809	747	1,000	1,008	1,003	1,008	1,008	1,008	1,008	1,008	1,008	1,008	2

9999

IOI PLAIN										•			
•	Jan	Eeb	March	Apdl	Max	anni	XITI*	Aug.	Sept	Oct	· Mov	Dec	Total
iglining G/L Balance	(23'000)	(58,150)	(62,256)	(64,128)	(62,837)	(61,651)	(61,501)	(53,815)	(48,466)	(46,131)	(43,825)	(44,717)	
iyments	8,945	8,867	11,077	11,788	11,421	10,647	12,283	9,231	9,461	6,393	8,781	10,754	122,558
alled Grents (per P&L galting) Grent Galting Adjustments	(14,095)	(12,973)	(12,948)	(10,606)	. (10,235)	(10,397)	(4,597)	(4,884)	(8,124)	(7,087)	(6,673)	(8,798)	(113,317)
ljusted Grants	(14,095)	(12,973)	(12,948)	(10,508)	. (10,235)	(10,397)	(4,597)	(4,884)	(6,124)	(7,087)	(9,673)	(9,798)	(113,317)
her	;	;		;		:	į	:	ŧ	:	:	į	:
iding G/L Balance	(58,150)	(62,258)	(64,128)	(82,837)	(61,851)	(81,501)	(53,815)	(49,468)	(46,131)	(43,825)	(44,717)	(43,781)	
indposlings : Jebit Balances Viher	;		11	::	11	. ! !	: :	1.1		<b>! !</b>	: :	• •	: :
ıding MFRP Balance	(68,150)	(82,266)	(64,128)	(62,837)	(61,651)	(61,501)	(53,815)	(49,468)	(46,131)	(43,825)	(44,717)	(43,761)	
28-59p-00 02:07 PM 3ROUP\PLANNING\Z001 PLANBelence Sheek\Bel_eht.XW grents	nce Sheel\Bel_shi	Lxiw]grants			• • •								
96 Actual Pay as % of BB 97 Actual Pay as % of BB 98 Actual Pay as % of BB 98 Actual Pay as % of BB our year average	22.25% 12.28% 3.62% 10.49% 12.16%	19.15% 8.62% 7.21% 10.81% 10.95%	30.89% <sub>1</sub> 10.12% 6.93% 8.18% 13.78%	15.59% 14.99% 7.71% 19.70% 14.50%	. 20.20% 22.46% 9.64% 4.48% 14.20%	10.84% 11.49% 10.15% 19.73%	25.05% 11.21% 8.46% 17.90%	12.60% 5.78% 12.52% 12.51%	20.28% 7.44% 8.98% 19.59% 14.07%	13.89% 9.08% 11.18% 25.64% 14.94%	21.79% 6.81% 8.88% 18.05% 14.33%	22.13% 14.55% 16.24% 20.81% 18.46%	
96 Actual 97 Actual 98 Actual 99 Actual 'our year averaga	18,915 ,40,699 ,78,671 ,67,702 ,48,897	25,781 46,087 78,485 67,392 61,936	25,749 48,433 78,324 58,501 53,252	26,740 48,752 78,977 51,012 51,370	25,881 44,188 75,397 49,767 48,808	31,230 47,680 70,808 47,310 48,235	28,251 50,515 69,331 39,852 47,237	27,202 65,855 66,581 33,259 45,749	25,838 62,751 65,681 34,582 47,238	25,579 64,406 66,716 36,331 46,256	24,839 67,079 62,790 40,172 48,720	24,988 75,827 60,600 43,640 51,264	

HIGHLY CONFIDENTIAL ABBT 0037594

75

Pharmaceutical Products Division K&U 2001 Depreciation Estimate vs. 2000 Depreciation By Division

шешү

03/01/01

CONFIDENTIAL ABBT 0037596

 $m_{CHIX}$ CONFIDENTIAL ABBT 0037597

27

PPD R&D FLOOR SPACE SUMMARY 2001 PLAN

				1st Pass	88	2nd Pass	8
Items	2000	1st Pass 2001	2nd Pass 2001	VARIANCE INCRI(DECR)	%	VARIANCE INCR/(DECR)	%
CED	36,807,916	38,691,048	38,777,826 1	1,883,132	5.1%	1,969,910	5.4%
J23/J25- Amhurst	457,449	480,322	464,991 2	22,872	5.0%	7,542	1.6%
J35 -Carriage pt	351,680	369,264	343,466 4	17,584	5.0%	(8,214)	(2.3%)
J28/MIS	408,769	429,207	406,341 3	20,438	5.0%	(2,428)	(0.6%)
Unidentified Space	40,058	42,061	41,860	2,003	n/a .	1,802	n/a
Plug (s/b zero)	0,	0	ci		%0.0	0	0.0%
國位何里經濟學	TA STROBERED TO	**************************************	ar (Diges) keep a see	100 00 00 00 00 00 00 00 00 00 00 00 00			William 02.00

Input per CED Report Pass #1 dated 6/23/00 and CED Report Pass #2 dated 9/1/00 plus the adjusiment for D-472. This adjusiment was detailed in John Uni's memo dated 1/28/2001.
The adjusiment equals \$21,424 for additional space in D-472 es requested by J. Hammerin.

per S. Schaefer 10/1/98.

4. Carraige Point charges to be allocated, calculated as follows:
Lease charge from Legal (R. Polocek) of 5470, 832 for 2001

Total expenses of \$716,833 allocated between Marketing and R&D besed on equare feet occupied.

31,400 (5,97 <i>6</i> )	25,425
\$478,832 (\$138,368)	\$343,468
Total lease charges Less Slackcard to T. Thompson	Net charge to Discovery

<sup>2</sup> Per CED Report (dated 91/100) and Division Summary from P. Kadish (dated 9726/00).
Note: Amburst rates for 2001 PLAN went up by 1.65% versus 2000 PLAN. (Sq. ft. are obtained from CED memo, while \$4's are obtained from Division memo.

<sup>&</sup>lt;sup>3</sup> Per memo received from Sareh Schaeler on 8/21/00 per S. Schaeler 10/1/89.

28

PPD R&D DIVISIONAL VARIANCE SUMMARY 2001 PLAN FLOORSPACE

		Total Dollars (\$000's	180007.01			Total Sa	Total Squere Feet			Average Rate	a Rate	
	2000	2001	inc/(Dec)	* Inci(Doc)	2000	2007	Inc/(Dec)	% inc/[Dat]	2000	2001	Inc/(Dec)	% Inci[Dec)
									-			
1	F 700 F	1 928 8	5 P P	2.4%	50.847	50.792	(55)	(0.1%)	\$37.08	\$37.88	\$0.82	2.5%
1000		7 200	25	135.67	800.00	28 878	10 2501	(7.8%)	\$38.34	\$38.10	51.76	4.8%
Ventures	5.1cu,r	1,010,1	0.50	(errir)	20,020			20.0	8507B	FE3 41	A3 63	404
Discovery	18,525,8	19,520.7	BR3.8	0.41	ž.	010,000	2	0.4.0				
David Colonia	7 583 0	7.009.3	328.4	4.3%	146,938	144,747	(1,191)	(0.8%)	\$61.88	\$57.62	\$2.88	527
Sing Select		A 15.4 B	288.4	5.1%	144,865	144,689	(278)	(0.2%)	240.42	\$42.57	\$2.15	6.3%
PARD	4.000 p		***	90.0	1 900	A 600		0.0% (a)	\$81.17	\$84.23	8	3.0%
Phase I Center	7007	7100			201	200	14 7001	(42.4%) (b)	16.753	840 00	22	7.5%
Davelorment Ope	1.441.1	1,357.7	(83.5)	(2.0.4)	38,734	07,77	(4,130)	(m) (m > 7)	7. 12.			
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	0 7 7 7	4844	202	288	12.135	12.375	240	2.0%	\$35.62	337.62	51.71	4.8%
Hegunatory Missis	o c	200		26.34	17.704	10 058	1.852	10,8% (b)	\$32,52	\$35,81	\$3,08	8.5%
Madical Alleira	0.900	0.010						1	57.0	00 774	24.30	200
Administration	443.1	702.7	259.6	59.6%	10,164	15,656	5,492	D) #0.40	BC:28	294.00	9	2.0%
ESTAGRACACCERTAGEREDIRE	和安全的14年的16月	E SUN CO'ON STREET		THE REAL PROPERTY.	<b>ELECTRICIES</b>	THE STREET STATES					100000000000000000000000000000000000000	1000
The state of the s												
Less Carriage Point	(351.7)	(343.5)	6.2	(2.3%)	i	1	•	N.A	¥2	W.	N.	N/A
	Constitution of the Constitution of	PARTER SHAPE STREET	P020340144	STATESTALISM STUDIES	TENT A THE REPORT	SPECIFICATION OF THE STATES	DELECTION OF STREET	RECOMMON SERVICE	STRIETS HOLDERS	THE REAL PROPERTY.	HINE THE	STATE OF THE PARTY.
HALPHINING CONTROLLING					W. C. C. C. C. C. C. C. C. C. C. C. C. C.			TOWN TOWN TO THE TANK		Name of the last o		

(a) Primarity due to Clarical Phermacokinatic (D-4PK) recolving 1,107 aq. 11. in APS for 2001 PLAN. (b) Primarity due to Statisfica (D-458) re-aftecating basif space to Coutomas nassath (D-42); Med. Affairs) and Descision Analysis (D-4NP; Admits). -(c) Primarity due to R&D Ope (D-477) recalving and additional 644 aq. It it APBA and due to Outoomes Research (discussed in footinols (f) above).

79

		Tetal Dollars (\$000's)	* (S000's)			Total Square Foot	Jaro Foot	•		Average Rate	Rate	
Bullding	2000	2001	Inc/(Dec)	% Inc/(Dec)	2000	2001	Inc/(Dec)	% Inc/[Dec]	2000	2001	(ne((Ose)	% inc/(Dec
	+	128	0.7	808	384	384	0	0.0%		\$32.88	\$1.86	6.0%
ē 3		2636	+13	4.8%	6.358	6.358	0	¥0.0		\$38.10	\$1.75	4.8%
,	4 403 3	5 124 0	220.8	4.5%	101,288	101,284	(4)	(0,0%)	\$48.41	\$50.5B	\$2.18	4.5%
2 5	2400	1 8128	2.5 B	4.7%	35.611	35,503	(108)	(0.3%)		551.06	\$2.20	4.5%
71.5	1,000	4 723 8	222	20.8	73.560	73,529	(16)	(0.0%)		\$84.23	\$3.06	5.0%
FISA	4540	466.4	14.4	10 Ket. (w)	11 931	12.273	36	2.9%		\$13.48	\$0.82	8,5%
716	0,10	100	: i	(*) 6.0.0	200		100	143 7461 (b)		\$29 A7	53.18	12.0%
P18A	34.6	131.1	() (3) (3)	(2.2%)	ממח	7.	3	(14.1.4) (15)		277	2	20.00
P20	163.5	172.5	9.0	2,6%	3,861	3,861	5	£0.0		444.00	36.33	200
Ed	863.2	928,5	46.3	6.2%	25,885	25,885	0	50.0		\$35.01	51.79	5.27
250	830.2	975.2	45.0	4.8%	25,598	25,598	0	0.0%		\$38.10	\$1.76	4.84 3.84
	881.5	807.8	48.4	5.4%	14,784	14,764		0.0%		561.49	£.	5.4%
	7 796	25R.4	706	8.7%	9.542	6,782	240	3.74		\$38.10	\$1.78	4.8%
5 [	0 400 4	R 175 A	2787	***	89,763	85.753	0	20.0		\$62.89	\$3.28	5.5%
707	C 500	2000	200	77.7	13 825	13,868	(69)	(0,4%)		\$38.10	\$1,76	4.8%
¥84	900	22.0	} {	70 7	22 897	799 66		#00	\$38.34	\$38.10	\$1.78	4.8%
100	176	570		17 130 007			(478)	(40,0%) (4)		80.00	(\$28.34)	(100.0%)
PEC	93.6	n. ;	(0.50)	fal (worm)		2	1	(a) (a) (b) (b) (b) (c) (c) (c) (c) (c) (c) (c) (c) (c) (c		44B 4D	41.78	4 8%
084	25.3	32.3	6.9	27.4%	ñ	160	2	לוים ומיוד		2 10 10	,	
60	3,606.8	3,823,1	218.3	80%	83,202	83,202	-	£0.0		440.44	92,90	200
AP8A	4,368,3	4,627,3	259.1	5.8%	100,767	100,690	Ε.	(0.1%)		545,38	\$2.64 \$2.64	200
866	468:1	484:1	28:0	8,0%	10,752	10,752		\$0.0 \$		\$45,85	52,60	6.03
1	40.3	42.7	2.4	90°6	2,789	2,789	0	0.0%		\$15.32	\$0.87	6.09
23 (Ambiral)	185.1	188.2	3.1	1.7%	7,323	7,323	-	0.0%	\$25.28	\$25.70	50.42	17
25 (Amhirati	277.3	278.8	4.5	1.8%	10,777	10,777	0	0.0%		\$29.68	\$0.42	1.84
28 (North Polet MIS)	408.8	408.3	(5.4)	(%8'0)	12,282	12,262	D	0,0%		533.14	(\$0.20)	(0.6%
Contract Contract	2617	3.63.6	(B 2)	12.3%)	N/A	N/A	¥2	NIA (e)		Y.	Ą	ž
o (carriage roun)		305	ď	77.6	1,168	1.169	0	0.0%		\$28.13	\$1.65	8.7%
N .	2 7		ų	424	692.02	31 970	6110	(2.4%)		\$19.03	\$1.28	8.78
ra Va	6.110	7 170	6.0	177		A 0.74	(364)	17.04	•	274 47	\$1.33	4.0%
_	168.9	161.0	(0.6)	(RO.)	0,000	10,0	•	400		584 54	\$2.78	4.5%
2	353.9	369.8	8,0	100	2 4	20,0	• •	300		\$65.4B	\$7.82	4.00
13	2,854,5	2,983.0	128.5	E) MO'T	10,01	10,01	•				7	100
7	678.9	937.3	58.5	47.6	12,637	12,596	(A)	(0.3%)		4.4.4	20.7	
. #	1.041.3	1,219.8	178.4	17.1% (8)	28,860	28,807	2,147	8.1% (g)		\$42.34	\$3.28	
÷,	331.4	357.4	29.1	7.8% (3)	9,549	908'8	259	2.7%		\$38.44	\$1.74	5.0%
, ,	8 20 8	873.5	33.7	4.0%	15.914	15,916	2	¥0'0	\$62.77.	\$54.88	\$2.11	4.0%
Ų								İ				
OPPOSITE THE PROPERTY OF	<b>你所言和999级</b> 条	SECOND CONTRACTOR		STATE OF THE STATE	NAME OF THE PARTY	SENDERGIES.	<b>罗斯斯斯斯</b>					620000
Less Carriege Point	(351.7)	(343,5)	8.2	(2.3%)	1	i	;	NA	NIA	NIA	MA	Ž

MEMO	•	
CED Rate	increased by 5,3%	
Amhural Rate	Increased by 1.6%	
North Point Charges	Decreased by 0.8%	
Carriage Point Charges	Decreased by 2.3% due to commercial assuming	
	responsibility for 800 sq. ft. more over year 2000.	

шешл

CONFIDENTIAL ABBT 0037600

 $\Pi G \Pi N$ 

CONFIDENTIAL ABBT 0037601

8

PPD R&D 2001 Fixed Allocations/Charges GROSS (\$000)

Direct to Departments (Stack Card)	2000 AGU	2001 Pjan	2001 APU	2001 AGU	01 Plan II(D) vs. '00 AGU \$ %	3. '00 AGU %	Notes	
PPNC Allocations 11 Wisdom to Product Development and RA/Q. 12 Other to Product Development 13 Housekeeping 14 Whse. Handling Fixed Allocation	328.7 2,031.0 187.1 0.0	322.7 3,044.6 187.1 86.5	322.7 3,044.6 187.1 86.5	322.7 3,044.6 187.1 88.5	-6.0 1,013.6 0.0 86.5	-1.8% - 49.9% 0.0% #DIV/0I	PPD Ops Fixed (T. Dee / J. Truex) PPD Ops Fixed (T. Dee / J. Truex) Pulls from Milso. Fixed Tab Pulls from Milso. Fixed Tab	i.
Other  15 Amortization Sva Loaners  16 Utilities  17 Corp Copier Fixed Costs  16 R&D Infernal Allocation  19 ARC Allocation	26.5 99.6 0.0 0.0	26.5 99.5 0.0 0.0	26.5 99.5 0.0 0.0	28.5 99.5 0.0 0.0	0.0 0.0 0.0	0.0% 0.0% 0.0% 0.0%	Pulls from Misc. Fixed Tab Pulls from Misc. Fixed TabPulls from Misc. Fixed Tab Pulls from Misc. Fixed Tab Pulls from Misc. Fixed Tab	
Subtotal PPNC/Other	2,672.9	3,766.9	3,766.9	3,766.9	1,094.0	%R.04		
Corporate Reallocations s Subtotal Other Cost Expense Pools	n/a	n/a	n/a	n/a	#VALUE!		NA	
	32,662.6 37,329.0	31,308.5 40,013.1	31,308.5 40,013.1	31,308.5 40,013.1	-1,354.1 2,684.1	4.1%	L:IGROUP!PLANNING\\Zoo1 PLAN\\Flactrapsce\01\\frac{1}{1}\rightarrow\rightarro	
Total Fixed (Group 40 for Functionals)	72,664.5	75,088.5	75,088.5	75,088.5	2,424.0	3.3%		
20 Total Cost Assignments Absorbed in Overh	42,244.5	40,081.1	40,081.1	40,081.1	-2,163.4	-5.1%		
Total Fixed/Overhead	114,909.0 115,169.6 115,169.8 115,189.6	115,169.6	115,169.6	115,169.6	260.6	0.2%		

. L'GROUPPLANHINGZOOI PLANFLad Expenssiflendroi). LipMin Flad 21400 E21 PM

IIIGIIII)CONFIDENTIAL ABBT 0037603

ľ

B

	일	***************************************		115.0 -24.376				-4.87		134.0 20.7%	22/10- 0.524			4,166,0 -1.3% .			840.0 7.7%	2003	,		4,0 0.0%		000	104.0 -3.7%	. 0.0	-33.0%	6,050.0 B.7% Varieties man CHAD" is Add (File-1800).	267.0 0.0	37.6 0.857		2,308.0 20.9%	214.0 -8.1%		1,283.3 -3.0%	0.0 6,345.3 8.3%	78 6	12,100,000	16,452.6 In the Charles to well pubmented according to the following the filters married at \$2070.0 In the companied and the pubmented at \$2070.0 In the companied at \$20.00 In the com
	APU AGU			115.0 115	-		0.0	1,875.3 1,878				2.784.0 2.784.0		4,155,0 4,15			840,0 84	8,870.3 6,97							0.0		6,050.0 8,0	-	7 0.857	343.0		481.0		1,283,3	6,345.3		12,700.2	18,469.6 1
>	AGU Plan	005	14.0 17.0	_	1,200.0 1,219.0		1	1,829.8 1,875.3				28200 77840		₹.	687.0 747.0		873,0 840,0	7,013.0 6,870.3		43.0 43.0			0.0	108.0 104.0	0.0	7,	8,05	7,387.0 7,257.0	717 0 738.0		N	388.0 481.0	0.0 0.0		4,890,9 6,345,3		12,365.9 12,706.3	17,578.9 18,469.6
to a sea din	Increase		ip/AiG# .	0.0%	* #00	0.0%	7600	0.0%	%0°0	2.0%	0.0%	%0'0	300	#600	40.0	0.0%		%0.0			0.0%	0.0%		#0.0 #0.0	I III/NIU	0.0%	0.0%	0.0%	3	\$0.0	20.0	0.0%	#0.0 #UVVIU#	450.0			0.0%	-
raup (PPD UIN. FF	Total	Olv. FP&A1	0.0	×	1184.0			4,1857.4	0.000					0 2,282.0			110.0	A 107.A		urke (PPD Div.		•		0.025	5	ğ		1.0 2781.0		120.0	N		583.0 693.0	1878.0 1878.0	7940.0	* -	16.0 23,126.0	
Note: These charges are obtained from K. O'Rourks's group (PPD Div. FPAA; usu	1988 Total	Other Cost Expense Pools • Kavin O'Rourke (PPD Div. FP&A)	Other taxes on purchases		Insurance Auto/Truck 1184.0		Security Admin 738.3	튵	0.408	Saleina Coprers		7 CHMB -OSS Fixed Admin Svcs 548.0		Other Fixed from PPD Comm 2,282.0		a Other Tele&Mail(CHMS) - MIS Telecomm 178.0	to PPD Meliroom (UPS) Sublobe Fixed from CHMS & PPD Ops 1,888.0	W101-8		pense Assigniments - Kevin O		Community Trainfold     138.0	1 College Relations	Other Unit of Activity Sub-Tries Unit of Activity 810.0	Ī	181	m Orug User Feder Pelents & Trademark 3819.0	Other Pass This Charges		Bu.	Account Psyable	Affolia		General Ledger System 187	,	2 Sub-total Corp Admin Fixed	Subtotal Corp Admin 23,128.0	Key Chack: Overhaed - Burden

HIGHLY

CONFIDENTIAL ABBT 0037604

											•																							
<b>6</b>			×	(0.00%)	(0.00%)	(0.00%)	(6.92)	FUNDA 170 PACE	0.00%	(0.00%)	#DIVIO!	#DIVID!	(18.67%)	(4.7%)	DAIG#	(-50.91%)	1.55%)	(49.28¥)	(0.00%)	(0.00%)	(0.07%)	(0.00%)	0.00%	(0.04%)	1766 077								٠	
98 V 89	Verlances		3	(0)	0	6	9		į	9	(30.1)	(-78.1)	(18.3)	(14.13)	9	(-1013.8)	11	(-1089.3)	Ð	€	(0.05)	<u>e</u>	9	(0.08)	10 1001									
ł	١		Total	28.40	28.40	0.80	0.20	4.7	5 5	25.50	30.10	78,10	91,50			-	- [	3,486,46 (	71.10	7.10	74.68	39.29	23.77	139.66		U.VU 3,100.01 1-1003.01								
	8				00'0					00.0				~		3,0	- 1	P.0 3,4	- 1	0.00			-	0.00		200	B							
	794300		Alloo		0.00			1	00'0	00.0								0.00		00'0				0.00		0.00	B							
	780300	. R&O	Alloc.														į			0,00				00'0			B E	þin	•					
,	790012	Copier.	Con		9.9			١	6.00	000				_		_		0000								١		hose show						
	792007	2000			000				0.00	000	000			40.00		3,004.60		183,00 3,044,60		00'0				00'0		희	8	diractly (L				•		
2001	704336	E P	Alloc		600				6.9	98	ŝ		91.50	91.50				183,00		000	74.59	39.29	25.77	139.85		322.86	를	Srosfek						
į	782410		Kaina		100				00'0	18	900	26.43	! !	153.67			6.89	187,08		000				0,0		167.09	8	om Steva						•
	780162	_		ı	0.00			4.70	4.70	0	20.00	5.6		0.00				81.77		00.0				0.00		98.47	BY	н сошо в						
	789100 7		Syte -	I		0.80	0.20		1.00	25,50	20.02									00.0	;			0.00	٠.	28.60	8,5	эвирация с						
	ł			I.	28.40	ţ			0,00		86.9						80	900	3 5 5	2 5	<u>:</u>			0.00		99,60	16.00	All PARI					•	
•	Yannay		- Intition	1	1		_											1		1			١.	 .io	•	ĺ		s binder.						
		•	į	i Color	20,45	080	0.20	8.8	1.00	25,50	26.60	3 8	3 6	100.00	20.00	3 50	7.50	ŀ	ŧ.			39.29	7.57	139.70		2,672.90		Expense				•	;	
	207705		ABC	Alled	200	3			0.00		0.00								3	900	3			900		0.00	B.91	the Fixes			•			
•	00000	R&D	Internal	Alloc.	1	3			0.00		0.00								0.00		3			=	ì	0.00	B	refelled in						
:	Γ	Copler		5		0.00			0.00		00'0								8		6.0				3	0.00	178	mos era						
	1		٠	Allon		0.00			0.00		0.00			:	40.00		1,991.00		2,031.00		6.0			00.0	00'0	2,031,00	<u> 5</u>	These me						
,	- 1	794355 78	_	Alloc		0.00			0.00		0.00			109,80	79.20	. •	<b>~</b>	- 1	188,00 2,		9	74.84	38.28	26.77	138.70	328.70 2		Ops).						
1	1			1		0.00			0.00	<b>;</b>	0,00					9.6			187.10		0.0			ł	0.00		13.00	ly from Pi						
	ı	12 782410 1. FPD	_	Kplng		0.00			300		0,00				₩			1	0,00		0.00				0.00	0.00	8	nism) sor	ruen).					
	1	790152 Whee.		Alloc			2		١										0.00		0.00				0.00		W.00	four men	ivia J. T	Į				
		789100 Amort.		Loaner			9.9	ö	100		29,50							_									l	, tou	ubmitte	WANG ALL STATES				
		700007		Villilles .	28,40	28.40			200	5. 5	00'0							0.10	0.10	71.10	71.10				00'0	0	10'AA	anness	hole: ittese cristian of the committee (vis J. Truex).	bend in ship and the result is secured to be about 1 100000 Hinde State of the second security of the second secon				
		•		Oeot.	472	-	41C	477	405	920		4P8	4P7	4P4	4P5	418	£.	492		433		<b>4</b> 91	44F	44.					wet PPD	TARPER				
				0	ľ			4						۲	*	•	•	•					•	•	<u>.</u>			į	ne with w	PLANMINGUE	F			
				Ž	Ę	Sublotal	4		•	gubiotal	Sublotal	19							Subtate	2	Bublotal	E			Subtotal		ole e	Ashietes	Nore: De in il	A TOTAL DE	D1401 821 FM			

HIGHIA'
CONFIDENTIAL
ABBT 0037605

83

岛

Fixed Allocations from Operations (via J. Truax memo)

	2000	00	2001	6	PD Variances	ances	RD Variances	1088
6	Product. Develop	Research. & Develop	· Product. Develop	Research. & Develop	લા	প্ল	₩)	នុ
11 WISDOM(On-Going) EDMS (On Going)	189,000 255,000	138,700	183,000 255,000	139,650	-8,000	-3.2%	-20	%0.0
EDMS Project Expense	85,000 75,000	440,400	75.000	524,800	0	0.0%	84,400	19.2%
a) Differ Stabilities	48,000	235,000	104,600	168,800	. 56,600	117.9%	-46,200	-19.7%
A CHEN Maintainance	208,000	947,000	472,000	899,000	264,000	126.9%	-48,000	-5.1%
22 PA ABC Allocations	682,000	68,675	778,000	68,600	000'96	14.1%	-75	-0.1%
27 OA ABC Allocations	978,000	1,438,000	1,320,000	1,942,000	342,000	35.0%	504,000	35.0%
23 CAPD Warehouse/Waste		83,648		81,773	0		-1,875	-2.2%
28 CAPD Prolect Exp. Transfer	<u> </u>	105,000		105,000	0		<b>o</b>	0.0%
25 D-55A Engineering Support		268,000		375,000	0		107,000	39.9%
21 Corp. Eng. Proj. Expense		1,428,000		1,993,000	0		567,000	39.8%
D-55T Calibration Servic	40,000		40,000		0	0.0%	0	•
		0		0	0		0	
20 CHEN Envir Health & Saf		558,000	0	597,000	0		39,000	7.0%
Total	2,560,000	2,560,000 6,709,423	3,227,600	3,227,600 6,914,623	667,600	26.1%	1,205,200	21.1%

a) Not included in overhead; charged directly to projects.

L:IQROUPIPLANKINO2001 PLANIFked Expensex|Burden01.xlsPMsin Flxed 21:401 6:21 PM

шешу CONFIDENTIAL ABBT 0037606

# PPD - Research and Development 2001 PLAN . Key Unfunded Projects (\$MM's) (As of (As of 115/2001)

	, (35 %) 113/4001	/
Drug/Compound	Project Description	2001 PLAN
NEUROLOGY		
Depakote	New Proceedables of B	
Depakote	New Formulationis (Epitepsy & Acuto Migraine)	1.9
nchakote	Bipolar in Pediatric Mania	1.4
ABT-594	Post Milestone Funding (3rd and 4th Quarter)	8.8
ABT-594	Phase IIB Osleogichidis Study (assumes 1/1/01 start date)	5.8
ABT-594	Additional Acute Peln Study (Phase IIB Molar Extraction Etudy)	3.0
COX-II	Ongoing Pre-Clinical Studies	
		3.0
ABT-089	Single/Mulliple Rising Dose Phase I Study	7.0
ABS-103	Pre-Clinical Studies	
ABS-103	Single Rising Dose Phase   Study	3.3 2.4
NPS-1776	•	
NPS-1778	Pre-Cimical Studies Single and Rising Multiple Phase I and Formulation Blo Studies	3.7
•	Samuel Company of the Company of Samuel	24
	Subtotal NEUROLDGY	43.7
ANTLINEECTIVE		
Clarithromycin	Azilumz/immunompitulatory Studies	24
ABT-773	ABT-773 IV Development Cost	
		8.0
Quinolone (ABT-492)	Phase II Acceleration/Expansion of Ctinical Studies	9.7
Quimione (ABT-492)	LV. Formulation	4.0
Quinolone (ABT-492)	Japan Phase I Study	1.0
Omnicer	Pharynpilis/Tonsilits Study: Pediatrics, Suspension, 5D 810 vs. Zithromax	4.0
Omniced	ABECB - Two Arm Study 5D QD vs. Comparator	24
	A	
•	Subloal ANTHNEECTIVE	31.5
UROLOGY		
Fenolitrate	Diabelica	4.0
Elmociomo!	Phase III Studies	10.0
	•	10.0
KCD	Pre-Clinical/Phase   Studies	6.0
	Subtotal UROLOGY	20.0
		20.0
HIV/MMUNOLOGY Kaletos	Phase IIB Program (unfunded portion)	
Kaletra	Kajepa CID  Lunge into Lindiani (miminosa botilori)	5.6
Kaloba	Post Approval Contribinants	42
Kajotra	Kaleba Salvage	4.2
Kaletra	Kaletra Firatilne	2.8 2.6
Kaletra	Expanded Access Program	. 1.6
Kaleba	Phase IV RTI	1.3
Kaleira	19HSC Cdram	1.0
Kaletra	Molabolics Program	0.8
Kaletra	Miscellaneous Phase IV Studies	0.7
•	Subtotal HIV/IMMUNOLOGY	24.5
ONCOLOGY ABT-627	Early Stage Pca Cancer	
	contraction contractions and a second	11.0
K-5	Pre-Clinical/Phase I Shuffes	B.B
•	Subtotal ONCOLOGY	·19.8
DISCOVERY	-	
DDC's	Development of DDC's /	77
IN-LICENSED COMPOUND	5	
Various	Funds to Acquire New Compounds	77
DUDDII CTD TTT	·	•••
PRODUCTIVITY 30% Reduction in Capital	Developments that Partie and	
meason at capta	Productivity Projects  Progetty Gone Expression	
	Resetta Gene Expression Genomics/HTS Expansion Program	0.3
	AEGIS MedDRA	
	· · · · · · · · · · · · · · · · · · ·	
	THE PROPERTY OF THE PROPERTY O	

CONFIDENTIAL ABBT 0037608

# PLs' MX

į į	bbott	Labora	atories
		aceutical	

Thomas Lyons Controller Abbott Laboratories 100 Abbott Park Road Abbott Park, Illinois 60064-6049

November 26, 2001

RECEIVED BOND & CORPORATE FINANCE DEPT.

NOV 27 2001

Dollars &

Mr. Steve Blewitt
John Hancock Life Insurance Company
200 Clarendon Street, T-57
Boston, MA 02117
Attention: Bond & Corporate Finance Group

Fax 617-572-1628

Re:

Research Funding Agreement dated as of March 13, 2001

2002 Preliminary Annual Research Plan

Dear Steve,

We haven't had the chance to meet face to face yet. I hope this can happen in the near future. Enclosed is the 2002 Preliminary Plan information for the program compounds. Please note that the preliminary plan funding for the program compounds is increasing \$43mm or 23% over 2001 APU (April Update). We are in the process of finalizing our internal functional costs and chargeable rates for 2002. Please review this and feel free to contact me with any questions you may have.

Regards.

Tom Lyons

Abbott Laboratories

Global Pharmaceutical R&D

Controller

(847) 937-5618

CONFIDENTIAL JH 000787

EXHIBIT

A-10-67

John Hancock Portfolio Summary R&D Costs and Development Timelines 2002 Plan

Compounds	ds	2001 APU (\$MM)	2002 Plan (\$MM)	Comments
ABT-773	Ketolide Oral & IV	7.68	79.3	
ABT-627	Endothelin	37.8	52.9	
ABT-594	Neuro Pain	8.7		
ABT-510	TSP	10.8	. 26.3	-
ABT-492	Quinolone	24.3	42.4	
ABT-518	MMPI	4.3	3	
ABT-751	Anti-Mitotic	8.3	15.6	
ABT-100	FTI ITS	. 1.2	6.6	
ABT-724	Dopamine Receptor Agonist	0.6	5.9	
	Total	185.7	229.0	
	Abbott: JH Funding Ratio	3.7	4.2	
•	Contract Floor Funding Ratio	£.6.	3.1	·
Limeline	Timeline (Launch Dates):	Original Deal	2002 Plan	Comments
ABT-773	Ketolide Oral & IV	10 2004	3Q 2004	Slow patient accrual impacted dosing decision (QD vs BID). ART-773 will be developed for BID dosing.
ABT-627 ABT-594	Endothelin Neuro Pain	4Q 2004	4Q 2004 N/A	
ABT-510	TSP	10,2006	10, 2006	
ABT-492	Quinolone	4Q 2005	4Q 2006	FDA IND review delayed phase II program beyond original targets. Phase III, originally scheduled to begin in the Fall of '02. is delayed until Fall '03.
ABT-518	MMPI	2Q 2006	N/A	
ABT-751 ABT-100	Anti-Mitotic FTI	1Q 2006 4Q 2007	1Q 2006 4Q 2007	
ABT-724	ABT-724 Dopamine Receptor Agonist	4Q 2007	3Q 2008	ABT-724 is a recently approved DDC. In the original deal model, assumptions for ABT-100 were used as the benchmark for all pre-DDC assets. 2002 Plan reflects ABT-724 specific data, rather than generic modeling assumptions.

CONFIDENTIAL JH 000788 Ketolide Oral & IV (ABT-773) 2002 Annual Development Plan

							1		
2002 C'Unical Proprin Objectives. Phase III program consisting of pivotal trials to support NDA and Liuropean filing for four indications: AUCII, CAP, AUS, ASP Phase I and III intravenous program to support CAP indication	otal trials to su n to support CA	pport NDA and E	uropean Ming	for four indicatio	18: AI:CB, CAP, ABS, ASP			2002 PROGRAM COST	5MM 79,3*
Phase I program to support pédiatric program Phase I / II program supporting Japanese bridying strategy	ic program mese bridging	strutegy				:		* See next page for detail.	
Other Clinical Support:	, in the second	I manufil	dea (AC 1910)	Summit					
Venhire Management, Dan Managementannares, Finse F. enel (2017) in programments	າເອການເຄື່ອນການການ	manes, ranse i v	cuici ton i mi	maddina					
Chemistry, Manusacturing, and Controls (CMC)	Controls (CM	6		ė					
Formulation & Analytical:	Tablet:	Support clinical	program, Regis	stration Activilie	CMC, Bulk drug lot support	Tablet: Support clinical program, Registration Activities CMC, Bulk drug lot support of validation runs, 1200 L support, Process Characterization Scale-up	Characterization	n Scale-up	
	IV Form	1V Formulation: Support clinical program	clinical progra	E		•			
	Continue	Continue to optimize pediatric and intravenous formulation	atric and intrav	enous formulatic	_				
	Jupun Re	Japan Kegistration Bridging support	րթվար չու						
Process Chemistry:	Deliver	Deliver 700 kg bulk drug substance (Cumpaign 17	substance (Can	17 and 18	and 18)for stability testing and formulation sculcup activities	rlation scalcup activities			
	Qualify,	Qualify Abboit Puerto Rico (AFP) for final step of drug substance	so (AFP) for lin	al step of drug s	ibstance	•			
	Complet	Complete Process Justification experiments and reports	ation experime	nts and reports		,			
	Analytic	Analytic Methods Validation	tion		•				
	Manufac	Manufacture starting materials to support Process Validation Runs	criuls to suppor	1 Process Valida	ion Runs				
Drug Safety Support									•
Metabolism	Drug un Lacteal	Drug analysis to support Phase I studies and plasma PK in Phase I studies Locteal & placental transfer studies; Protein binding studies; P456 studies	Phase 1 studies fer studies: Pro	and plasma PK. Tein binding stud	Druy analysis to support Phase I studius and plasma PK in Phase 3 studius to correlate with ECCI's Lacteal & placental transfer studies: Protein binding studies; P450 studies	with ECO's			
Toxicology/Pathology	Imonth	Imonth Rat and Gene Tox study to support impuity qualification	ax study to supp	oort impuity qual	ffcation				
Other Support Activities:									
Medical Services support (IND / Post-Murketing Salety, Epidemiology, Medical Information & Review)	ND / Post-Murk	eting Salèty, Epi	demiology, Me	dieal Information	n & Review)				
Investigational Drug Quality Assurance support for production of clinical supplies	/ Assurance sup	sport for producti	on of clinical s	upplies					
Regulatory Affairs / Research Quality Assurance	ch Quality Assu	ırance						٠	
Microbiology						٠		٠	-
Program Spending by Year:									
2007 2007	2003	. 2004	2002	2006	Total				
89,7 7,93	88.1	12.7	<del>.</del> .	0.0	273.9				•
					,				

LANKUNIPELINIANIH HERROEALKIRI Reserch Piendiasculve Kommonespaliti-1717 stojkilter, idili ANF-773

				. 2002 Plan	Deve	ast Summery	-					Γ
Part of		2000	2001	1 92 93 94 91	5	1 92 93 94	01 02 03	20 10 40	9			
The color of the		1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1			l	<b>4</b> —	٠	•				
Internation   Track   Secret		<u></u>			VON	Launch						
Thirty   T	laine Develoiment Activities and Costs		Translad					II APU Costs		002	72 PLAN Cost	
11   11   11   11   11   11   11   1	Halest Program	Pairets	As of 8/2001	Shirt	End		Internal	External	Total	Internal	Externni	Total
11.00   10.0	Phase (II (4 Indications)			]								
100   552   New-40   New-70	MIII-219 CAP QD vs 1HD	KOO	419	Nov-Off	Mur-02		ŧ	17715	512,231	i	. 54'39Z	7/10"14
10   10   10   10   10   10   10   10	MOU-225 ABS QD vs BID	009	223	Nav-00	Nuv-01		:	V12,72	. 17'75	1 1	: :	; ;
10   10   10   10   10   10   10   10	M00-223 ASP vs Pen US	250	<b>7</b> 6	New-00	Deriot.		I :	\$5,791	55,791			:
Marie   Mari	M00-216 ABECB vs Azi US	B6 5	8/8	Nov-00	Darell		<b>:</b>	\$1,575	\$75.63	:	:	:
March   Marc	M00-222 ASP vs Pen EU	P. S.	961	OD-AGN	Dec-01		: :	\$4,036	\$4,036		ì	;
Main   Main	MUU-217 AUUL B VS LAVO 1:U.		•						٠;	:	I	:
Marion   M	MIIII-2211 ("Al" vs Anny 1911	. dela	5	Clyt 01	May-01			11,629	11,629		56,270	16,270
1,000   0   1,000-92	MINI 121 CAP vs Lavo US/So Hem	ento.	=	E 15	May-01			12,12	7. H		77,274	- 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
100   014-01   May-01     11,177	MUI-XXX CAP Open Label	ODF .	5	Jun-02	Mny-UJ		:	;			OF THE	54.184
10   64	MIDD-218 ABS vs 1,evu [:1]	(199)	<b>.</b>	0-t-01	Miny-01 .		:	51.257	757 18	· · !	\$1,518	\$15.53
13   64   0   0   0   0   0   0   0   0   0	M00-226 AUS vs Aug US	000	<b>&gt;</b>	10-la0 .	Mav-03		1 1	5510	\$310			. 1
172   0   14mo22   Diceol2     1520   5250	M00-260 ABS Double 1sp Study			Oct-01	Dec-01			ı	:	!	.i	1
172   0   10m-02   Dace-02     \$250   \$750     \$500	Pedintic PK/PD/Tasia Testing Studies						i	. 545	. \$45	1	ì	:
172   Nov-01   Due-01     5250   5250       5500   5500     5500	Pediatric Pirase ! Clinicals (Phase I Center	•	0	Jun-02	Dec-02				į	9653	i	963
NA	1.V. Phase I Single Dase (2001)			Nov-01	Dec-01		:	2230	65 E	; —	: 5	: 55
Main Content   MA	External Special Population Studies			Sop-00	Dac-02		:	2002	0025	:		3
NIA Inn-01 Dec01 \$2,000 1 \$2,000	External Tissue Studies	N/A		70-un/	0-20	6.9	SE 449	5714	52.163	52,349	: 1	\$2,349
134   120-03   134   130-04	Internal Bio Studios (Phase I Center)			10-line .	Dec-01	•			:	i	ì	i
134   Jun-01   Dac-04   39,3   5,372   5,477   5,477     37,510     13	Phase I/III EUG Kerrends Microbiology Grants	Y.	•	Jun-02	Dec-02	•		\$2,000	. \$2,000	:	\$2,000	\$2,000
19.5 \$6,172 \$5,124 \$5,127 \$5,137 \$1,275 \$1,2	Janan Studies	374		Jan-01	Dec-04			2600	2000		\$2,630	\$2,630
1,	Venture Munagement			,		39.5	\$6,372		56,372	56,877	:	118,04
28.7 \$\$1734 \$\$6,877 \$\$15,118 \$34,298 \$\$  28.7 \$\$5,224 \$\$5,724 \$\$5,101 \$\$2,845 \$\$  20. \$\$11,770 \$\$11,770 \$\$5,110 \$\$5,110 \$\$2,845 \$\$  20. \$\$11,770 \$\$1,770 \$\$5,110 \$\$5,116 \$\$1,400 \$\$1,725 \$\$  20. \$\$11,770 \$\$1,770 \$\$5,110 \$\$1,400 \$\$1,325 \$\$  20. \$\$11,770 \$\$1,770 \$\$1,730 \$\$1,430 \$\$\$1,	Europeun Venture Research			·		- ;	2632		2665	C 1/2	1	124.97
28.7 \$5,724 \$5,724 \$56,703 \$7,2445 20.0 \$11,770 \$11,770 \$55,216 \$1,410  21,791 \$1,791 \$51,011  21,791 \$1,791 \$1,011  21,702 \$1,791 \$1,011  21,703 \$70,785 \$70,785 \$1,125  21,704 \$1,096 \$1,096  21,705 \$1,096 \$1,096  21,804 \$1,096 \$1,017 \$1,018  21,907 \$1,006 \$1,006  21,500 \$1,006  21,500 \$1,006  21,500 \$1,006  21,500 \$1,006  21,500 \$1,006  21,500 \$1,006  21,500 \$1,006  21,500 \$1,006  21,500 \$1,006  21,000	Data MungentendStatistics			-		7:00	\$12,083	\$48,345	\$61,877	\$15,318	\$34,298	\$49,616
28.7 \$5,224 \$5,324 5.40 \$5,400 \$52,445 20 \$11,770 \$11,770 \$5,101 \$1,480  \$1,791 \$1,791 \$5,101 \$1,480  7.1 \$708 \$708 \$708 \$1,562 \$41,325  7.1 \$71,086 \$71,08 \$1,562 \$1,315  1.4 \$1,096 \$1,096 \$1,917 \$5,466  2.7 \$4100 \$5,946 \$1,464 \$1,597 \$1,562 \$1,562 \$1,562 \$1,562 \$1,562 \$1,563 \$1,564 \$1,565	Subtolial											
28.7 \$5.224 \$7,524 \$5,724 \$7,021 \$1,770 \$1,710	Chemistry, Manufacturing, and Contr	rels (CNIC)					:		į		ž	20 6.12
1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1,	Formulation & Analytical		•			28.7	\$5,224	1	P27'53	\$6,703	\$1.480	\$6,54
11. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1.	Process Chemistry					2	\$1.79	: !	51,791	160,63		\$3,031
1, 4 51,096 5768 5316 5410  1, 4 51,096 51,864 5139 532  1, 4 51,096 51,864 5139 5339 5339  1, 51,864 51,864 51,917 5346  1, 51,864 51,864 51,917 5346  1, 51,864 51,864 51,917 5346  1, 51,864 51,864 51,917 5346  1, 51,864 51,864 51,917 5346  1, 51,864 51,864 51,918 51,809 51	Olher CMC Subtotal CMC Custs		•		•	i	\$20,785	7.	\$20,785	\$14,950	\$4,325	\$19,275
1, 1, 1768 1768 1316 .	Drug Safety Support											
1,1 5768 5166 591 591 591 591 591 591 591 591 591 591	none Metabolism									\$1,562	2430	266'15
14 \$1,096 \$1,096 \$1,096 \$239 \$340 \$340 \$34,000 \$1,096 \$1,	Toxicology/Pathology					1.7	£368	ł	\$768	5316	<u>s</u> i	5407
1,264 31,094 31,717 3340  9,7 52,801 51,268 51,268 51,500 5400 51,5	· Other					I	\$1,096	-	21,090	A L		FALCE
9.7 52401 51,268 51,268 51,509 5400 51,509 5400 51,509 51,509 51,509 51,509 52,519 52,519 52,519 52,519 52,519 52,519 52,519 52,519 52,519 52,519 52,519 52,519 52,519 52,519 52,519	Subioisi Drug Safely Support						51,864	i	\$1,654		1	corps
Thirs	Other Support Casts							l		5		101 63
Sylo   Sylo	Discovery					7.6	1	i	, ,	24,807	:	170'76
To State of Guolity Assurance 1,12 State 1, 5969 51,579 Coals 1,299 52,839 52,839 51,579 51,839	Medical Affairs .					6'0 .	2946	:	2740	905,12		21,500
\$2,839 \$2,839 \$1,837 \$2,839 \$10,170 \$39,169	O#II	,				: ;	9000	;	6365	\$1,599		\$1,599
\$19,206 \$48,34\$ \$89,700 \$40,170 \$39,169	Regulatory Affairs / Rusonsch Que	ifily Assurance		•		<b>!</b> :	\$2,839	: :	\$2,839	2817	١	5817
CALLOS ALLIAS DAL'AGE ENTRES DISTAGE									9			570 330
	Total Program						\$39,906	П	38%,/00	340,170	П	,,,,,,

1. (Bastie inc. John (See of 2012 See on 12 on Inceptual the 110 101 111 111 this beat

CONFIDENTIAL JH 000790 Endothelin (ABT-627) Annual Development Plan

				:	•		·		
2002 Clinical Program Objectives: Complete enrollment of two registration studies Complete drug interaction, QTC, and Bioequivalence studies	Objectives: two registration, QTc, and	tion studies Bioequivulen	ce studies				2002 PROGRAM COST	'IN COST	SMM 52.9*
initlate Ph I study for Japanese registration	ipanese regis	dration					* See next page for detail.	for detail.	
Other Clinical Support: Venture Management, Data Management/Statistics, Phase I Center (ACPRU)	t: ent, Data Ma	เกลgemenVSเล	listics, Phuse J C	enter (ACPRU	) Support				-
Chemistry, Manufacturing, and Controls (CMC)	ıring, and C	ontrols (CMC	0						
Formulation & Analytical:	nalytical:	- Resupply 2 Phase - 2.5 mg lot for Jap - Impurities Qualif - Methods transfer - UK/R8 Pilot Supp	- Resupply 2 Phase III studies - 2.5 mg lot for Japan studies - Impurities Qualification - Methods transfer - UK/R8 Pilot Support	SS SS		<ul> <li>NDA Stability</li> <li>Support of GMP bulk lot for stability studies</li> <li>Formulation manufacturing; support for GMP lot</li> <li>Stability of drug product and drug substance</li> </ul>			
Pracess Chemistry;	æ	Process ju	Process Justification Process justification Qualification runs at second drug substan	nd drug substin	nee manufacturing facility	ring facility			
Drug Safety Support									
Metabolisın.		NDA preparation	paration						
Toxicology/Pathology	logy	Clenetie to Three mo	Genetic toxicity to qualify drug substance impurities Three month rat (axicity to qualify drug substance impurities	t drug substanc o qualily drug	e impurities substance imp	urities			
Other Support Activities:	ties:								
- Medical Services support - IND Safety (safety support) / Epidemiology - Regulatory Affairs / Research Quality Assurance (Phase III site audits)	support - INI s / Research	D Safety (safet Quajity Assur	iy support) / Epi ınce (Phuse III s	demiology (out ite audits)	tcomes), Medi	- Medical Services support - IND Safety (safety support) / Epidemiology (autcomes), Medical Information & Review - Regulatory Affairs / Research Quality Assurance (Phuse III site audits)	.·		•
Program Spending by Year:	y Year:								
7007	2002	2003	F007	2002	2002	Cotal			
37.8	52.9	30.6	37.1	8.9	0.0	165.2			
	\   	1							

CONFIDENTIAL JH 000791 .

			11.7 70.07	2002 Plan Development Cost Summiry	COST SUITING	1					
Program Status	2000	2001	2002	2003	2004	2005	20 10	2006 Q3 Q4			
			7		-	]		4	•		
Phase III	N. (0 1.04 . 1.4 1.4 1.4.				HIN AUN	t Launch					
Mulac Development Activities and Costs	Total	Enrolled as of				ñ	2001 APU Costs			2002 PLAN Costs	
Clinical Program	Pulients	10/2/01	Start	End	FTE's	Internal	External	Total	Internal	External	Total
Plumes III Divising II (MOID-211)		7	10/5	12/03		:	\$10.288	\$10.288	; 	\$10,452	\$10,452
Pinac III Pivala #2 (MOD-2-1-)		. =	10/3	100		: :	Se (172	50,022	: i	311,496	\$11,4%
L.T Extension (M00-258)	1400	: <b>-</b>	10/6	13/0/1		: [	5840	SH4c		ST, 184	53,384
Long Term Safety Study (MOI-304)	250	;	10/6	. 1/05			\$288	SZBB .	:	. \$516	5516
Bisphosphonete Combinetion	200	ŧ	1/02	1/05	•	:	ŧ		:	959'18 .	\$1,656
Early Prostate Cancer	200	. :	7071	1/03		:		ŀ	1	57,076	\$2,076
Phase I Japan Study	32	į	4/02	12/02	•	ŧ	ı	£	;	\$800	2800
Ph II Pilot/Investigator IND Studies	40 per study	4	10/11	6/03			;		;	\$425	\$425
Four Drug Interaction Studies	12 - 18 per study	•	4/02	7/02		ŧ	1	;	\$320	2440.	2760
Bioequivalence (M00-318)	60	ī	70/1	8/03	•	\$55	997\$	1268	250	\$200	2250
Q1'c (M00-283)	36	i	4/02	20/6	•	2227	\$500	1185	\$53	\$203	5256
	•	•			;		•				
Phuse I Center Support					6,7	\$315	:	. 5115	6665	;	\$886
Venture Management					32.0	57,636	<b>:</b>	57,636	\$6,195	; ·	56,195
Data Management/Statistics					23.0	\$2,583	:	\$2,583	\$3,739		\$3,739
Subtotal						\$10,816	\$18,900	\$29,716	\$11,356	531,648	\$43,004
Chemistry, Manufacturing, and Controls (CMC)	(CMC)										
					:	į	į		£	OFE	5
Formulation & Analytical					- : -	54,000	100	167,56	611.0	0707	×10,10
Process Chemistry				•	0.1	F803	;	2083	970'14	ncie.	8/1,1/6
Const Cont.					•	\$1.516	5874	54.420	S4.788	Syyd	\$5.778
	•								-		
Drug Safely Support					·						
Toxicology/Páthology					9.1	1965	260	2401	\$383	\$24	\$437
Orng Membalism	•	•			P*C	\$935	2180	\$11,115	\$748	5370	\$1,118
Other					0.2	\$28	22	530	\$69	54	267
Subtotal Orag Safety Support						\$1,304	\$ <b>2</b> 42	\$1,546	51,194	2428	\$1,622
Other Support Costs											
Discount					9	\$129	573	PZ 15	5289		5280
Remintory Affairs / Recontrib Omility Assertance	Assumuce				1.0	157.18	;	167.13	2669	: ;	2669
Medienl Affiniss	1			•	9.1	. 1	\$195	\$195	\$868	\$200	\$1.068
Other						8188	:	. 8183	*	\$493	\$493
Total Program						517,544	\$20,256	\$37,800	\$19,164	533,759	\$52,923
the second section of the second section of the second section of the second section s	100	-									

TSP (ABT-510) Annual Development Plan

	•							==	
2002 Cilutan Program Objectives: Initiate 3 phase II dosc ranging/efficucy studies to demonstrate efficucy Selection of dose regimen and tumor types	ts cucy studies to demonstrate eff or types	lcuey			·			2002 PROGRAM COST	SMM 26.3*
Selection of surrogate markers of efficacy	Nicacy .						-	* See next puge for dotail.	
Other Clinical Support: Yenture Management, Data M	r Clinical Support: Venture Management, Data Management/Statistics, Phase I Çenter (ACPRU)	Center (ACPR	(U) Support			·	•		. •
Chemistry, Manufacturing, and Controls (CMC)	Controls (CMC)								
Formulation & Analytical:	Support drug substance and chemical synthesis Method development/validation as needed to support Plasse II requirements	ind chemical s idution as nec	rynthesis ded to support	Phuse 11 requ	irements				
	Evaluate erystalline drug substance for formulation	substance for	- Formufation	• •		•			•
Procuss Chemistry:	Process optimization with crystallized drug and increuse scale (23 Kg)	h erystullized	drug and inere	use scale (23	Кв)				
Drug Safety Support				·					
Metubolism	Absorpțion Distribution l	Metubolism l	xeretion studio	s in non-rode	Absorption Distribution Metabolism Exerction studies in non-rodent species to support taxicology				
Taxicology/Pathology	Initiate 6 mouth rat and 9 month monkey	9 month monk	ey loxicity stu	toxicity studies if requested by FDA	ed by FDA				
Other Support Activities:									
Medical Services support - IN Regulatory Affuirs / Research	Medical Services suppon - IND Safety (sulety support)/ Medical Informatio Regulatory Affitirs / Research Quality Assurance (Phase II site audits)	dical Informa ite audits)	tion & Review ·		-: -: -:			٠.	• .
Program Spending by Year:									
2007 7007	2003 2004	2002	2006	Total					
10.8 26.3	47.8 28.0	0.61	14.0	145.9	-		•		
CAURUSTYCE TO THE TRANSPORTED TO THE STATE OF THE STATE O	Ulve Stormuck-Althrechay; S.Jeff TI II (AIIT: 110)		CONFIDENTIAL JH 000793		Hibbit r.29				
		٠	-						

				FUGE	2004	2006	7	2006			•
Program Status	2000	2001	2007	2007			5	2			
<u></u>	PO 03 ZO.	01 02, 03 04 01	92 93 94 91	02 03 04	Q1 Q2 Q4	<b>5</b>	5	╂	•		
Pluse I			10 Total (20) 1888	E3 14			<del></del>		•		
Mass III						VON	Launeh				
And the second of the second o											
FIGURE TANKER AND AND AND AND AND AND AND AND AND AND	Total	Eurolled as of	•			1	2001 APU Costs	į	77	2002 PLAN Custs	- 1
Clinical Program	Patients	10/2/01	Start	End	FTE's	Internal	External	Total	Internal	External	Total
	į		į	£1971			£894	2883		713	217
Abditible Dase in Cancer Pts (MOD-15.1)	₹ ;	=	II.	· · · · · · · · · · · · · · · · · · ·		: .	2750	\$250	: :	\$308	\$368
IND Study (M01-302)	<u>.</u>	:	IDÁ	. F0/E		ŧ	,			\$3.753	\$3,753
Phase II Dose Ranging/Ellicney #1	051	:	4/07	, 0/i.		i	1	:	: 	53.753	\$3.753
Phase II Dose Runging/Effency #2	130	:	4/07	50/6		ī	:	ŧ	:	51.13	137.13
Phase II Dase Ranging/Efficacy #3	150	•	70/1	3/03		1	I	1	:	20,100	20100
Preclinical/PD Markers			. 10/E	2/02		i	. 667\$	2299	:	196	705
Cancer Models			3/02	. 2/03		;	:	:	;	\$330	2330
NCI Pediatric	<b>8</b> 2	:	1/02	12/03		:	ī		:	i	:
•					-	17.53		1223	12(3	:	1718
Plase I Center					2	7	£				200
Venture Management	•				0, ; 7	5858	ŧ	5858	690'75	ŧ	32,009
Data Management/Statistics				•	4.7	5227	:	7775	0//6		2
Subtotal						31,306	51,444	\$2,750	829'638	\$12,101	\$15,739
Chemistry, Munufacturing, and Controls (CMC)	(CIMC)						] 				
Formulation & Analytical					6.5	5987	\$228	\$1,212	81,519	. \$280	\$1,799
Procuss Chemistry					10,0	: . ·	\$3,383	\$3,383	\$4,029	\$1,355	\$5,384
Other CMC					.1	:	=	:			ā
Subtotal CMC Costs	•					2987	\$3,608	\$4,595	55,548	\$1,635	\$7,183
Drug Safety Support									<del></del>		
Try fen louv/Patholony	•				0,7	\$184		. 5184	5173	51,100	\$1,273
Drug Metabolism			٠		Đ.,	\$972	\$209	\$1,181	\$1,078	\$280	\$1,358
Other		(		•		1	i	:	527	\$6	\$33
Subtotal Drug Safety Support	٠.	co ,				\$1,156	\$209	\$1,365	\$1,278	\$1,386	\$2,664
Other Russian Charles		NF JH				].		ŀ	<u> </u>		
Omer support Costs		FID 00	٠			351 13	ž	. 1 860			PFIX
Discovery		EN 07			}		3	013	9113		\$116
Medical Attairs	Australia	NT. '94	•		. 14	: Ξ	} :	: ::	2457	i i	\$457
Office Custs	3011 Electric	IAI				615	:	579	.	. E	S43
. 1		-					. !				,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Total Decome									֡		

Quinolone (ABT-492) Annual Development Plan

										_
2007 Chaisal Program Objectives. Plase II trials to be completed and further Plase I safety studies to determine drug characteristics to be completed. Feasibility and formulation of IV farmulation in progress ( Casts in buyny program)	her Phase I safety studies I utation in progress ( Coste	to determine drug, chur. s in buyup program)	acteristics to	o be completed				2002 PROGRAM COST	5MM 42,4*	
								* See next page for detail.		
Other Clinical Support: Venture Management, Data Management/Studistics, Plasse 11 'enter (ACPRH) Support	, pement/Statistics, Planse 1	Center (ACPRH) Supp	part	,		-			·	<del></del> -
Chemistry, Munufacturing, and Controls (C'MC') Formulation & Analytical: Support ong	nirols (C'DAC) Develop and manufineture supplies for commercial formulation lensibility biostudy Support ongoing stability - Phase I supplies, Phase II supplies, Phase II placebo, Ph	e supplies for commen y - Phase I supplies, Ph	cinl formulat use II suppli	ion l'ensibility les, Phase II pl	r bíostady Incebo, Phase III pilol	rnis (C'IMC') Develop and manuliacture supplies for commercial formulation l'ensibility biostudy Support onyoing stability - Phase I supplies, Phase II supplies, Phase II placebo, Phase III pilot scale, Levofloxacin, Bulk Drug	· Drug		·	
	Bulk drug tesling, Folymorph screening Selection of Commercial formulation Positive controls cost based on \$120/paient x 3,500 patients x 2	norph sereening I formulation sed on \$120/patient x I	3,500 patient	18 x 2						<i>:</i>
Process Chemistry:	Support campaigns that deliver bulk drug for formulation, toxicology, and Pluse III clinicals Sopport PARD in firmulation and physical properties studies Determine vendors for commercial supply	deliver bulk drug for R Intion and physical pro connecetal supply	onnulution, 1 speries studi	toxicology, am ies	rd Phuse III cliniculs		-	··		· T
Drug Safety Support Metabolism	Metubolism support planned	pauli								
Toxicology/Pailiology	Tablet: 1Saudies including Sugment 1,2 and 3 studies. FDA requests jovenile dog study to Investigate possibil	ling Segment 1,2 and 3 fog study to Investigate	3 studies. 3n e possibility	In nd 6 month  mt and ( ity of pediatric program	In nd 6 mouth rnt and dog studies, ity of pediatric program					· 
Other Support Activities:  Medical Services support (IND / Post-Marketing Safety, Epidemiology, Medical Information & Review) Investigational Drug Quality Assurance support for production of clinical supplies Regulatory Affairs / Research Quality Assurance/Microbiology Milestone payment due to Waukanaga upon enrollment of 20 patients in the Ph HB trial. Payment of S3.	/ Post-Markeling Safety, E syrance support for produ uality Assurance/Microbii canaga upon enrollment of	ipidemiology, Medical ction of clinical suppli- ulogy 720 patients in the Ph I:	l'Information es HB (riul. Pay	1 & Review) yment of \$3.5h	ion & Review) Pnyment of \$3.5MM is expected to be made in Q1/02.	s mude in Q1/02.			·	<del></del>
Program Spending by Year: 2001. 2002. 24,3 42,4	2003 2004 54.8 86.9	2005 2006 67.3 11.0		<u>Total</u> 286.6	C					
Littitit Chiedra Ilment, 1713 Record Hosbacores S	o demonstrate de la company de	(Chireces)			ONFIDENTIAI JH 000795					,

Program Status	1000	- 1902				2007	1000				
	20 03 03	10 02 03 04 01	QT Q3 Q4	01 02 03 04 0	92 93 94 91 92 93 94 91 92 93 94 91	01   02   03	6	Q3 Q4	٠		
Phise 1			Wilesself.cogs.lagselfer	अभास्तरम्				<b>←</b>			
Plase II					مامدا مامدا	Stales P.	··		•		
Mase M					 	¥ :	. • • • • • • • • • • • • • • • • • • •	- 1			
· .		!									
Maior Development Activities and Costs						F	April Charles	-	<b>F</b>	2007 PLAN Chate	
	Total.	Enrolled As of 8/2001	Shri	End	FFE3	Internal	External	Total	Internal	External	Total
Clinical Program	- Buchts							-  -			
Pinase.	3	071	(ii)	Marchi		•	0298	0293		;	
Single Dose / Mulliple Dose	981		00-ADA	Musel			21.000	00015		: 1	
Metetox	e i	.7	Wi-Anki			ŧ	<u>.</u>		\$729	\$2,300	\$3.029
QTC Study		:	70-Wif	20-mm		:			\$302		2302
Oral Contraceptive	e :	ŧ	7 cll-47	20-in-		: ;		<del></del> -	\$345	: 1	\$345
Thenphyllin		1	Mar-07	Anre07		\$723	\$136	SAII	\$267	. :	\$267
Bio-Shidy	•	:	70-10141			\$275	\$1.806	\$2.081	\$1,643	\$2,300	\$3,943
Total Phase I					•	<u>;</u>	, 1				
Phase II	: ;	ŧ	ă		•		\$2.291	. \$2,291	:	\$1,909	\$1,909
Bronchilis	976		- i-i-i-i-i-i-i-i-i-i-i-i-i-i-i-i-i-i-i	701-407 7: 4: 03			2993	2993		060 PS	000 PS
CAP	300	:	70-1116	-cn-n-1		:	1005		•	22,400	009 63
5	300	;	Apr-02	Nov-02		ŧ	ŀ	:	:	004 <b>77</b>	200
Acute Prostatitis		:	Mur-02	Dec-02		:		ı	: -	31,108	901,10
Simsitus	300	Ŧ	Mnr-02.	Feb-03		:	3	1	:	080,64	33,080
Miero Studies			,	•			S4 [4	54 14	: ;	inne	1000
Venture Minngement			•		15.5	\$1,226	:	51,226	869.25	£	32,098
Europenn Venture Resenreh			•		0:1	256		20	5115	i	1116
Dan Management/Statistics				•	13.5	NC/C		0016	007.75	£16.403	£21 g04
Subtorul					•	)0¢ <sup>1</sup> 7¢ .	971.00	Cor. /*		2	274120
Chemistry, Manufacturing, and Controls (CMC)	ntrols (CMC)										
. Formulation & Anglotical					15.1	\$1,815	:	\$1,815	\$3,529	\$11,15	\$4,644
Process Chemistry					10.0	\$7,348	I	\$7,348	\$4,029	2900	\$4,929
Ollier CMC	•				i	. :	:				3
Subining CMC Costs					•	\$9,163		59,163	\$7,558	\$2,015	\$9,573
Drug Safety Support											
Denn Metaholiem					5,4	\$957	ŧ	5957	\$1,177	:	51,177
Toxicolouv/Patholouv					5.3	. S704	\$833	\$1,537	\$1,296	\$906	\$2,202
Olher					0.7	265	\$2\$	5117	\$273	\$75	. \$348
Subtotal Drug Safety Support						\$1,753	\$858	\$2,611	\$2,746	186\$	727,62
Other Support Casts					1,1	\$1.420	:	51.426	.52,188	ŧ	\$2,188
Madical Athles					:	\$45	ı	\$45	5128	i	\$215
Regulatory Affairs / Research Omility Assummer	nility Assummer			٠	1,7	\$477	:	· 5477	\$1,043	:	\$1,043
Milestone Poyments					:	1	\$3,000	000,62	1	\$3,500	53,500
Other Costs		•		·	;	\$135	:	\$135	\$250	<b>=</b>	\$250
							Ì	:		. 1.2	200
Total Program			•			513,300	39,030	2+6-476	350,450		344,007

•

Anti-Mitotic (ABT-751) Annual Development Plan

		٠							-		
2002 Clinical Program Objectives: Determine dose und regimen for Phase II Initiate 6 Phase II studies to demonstrate safety und efficucy Initiate pediatric studies for potential accelerated upprovail (drug unly)	sos II strate safety unc al necelerated n	d efficacy pproval (drug o						·	2002 PROGRAM COST	RAM COST pe l'or detail.	SММ 15.6*
Other Clinical Support: Venture Management, Data Management/Statistics, Phase I Center (ACPRU)	ตกลgement/Sta	Histics, Phase I	Center (ACPR	U) Support		•					
Chemistry, Manusacturing, and Controls (CMC)	Çontrols (CMC	6	  - 				<b>.</b>				•
Formulation & Analytical:	Support P Capsule fi Clinical sr Evaluate	Support Phase II studies with capsule formulation Capsule formulation for lower dose (25 mg Peds) Clinical supply manufacturing (4 lots) Evaluate tablet leasibility	with capsule F Jower dose (25 sturing (4 lots) ly	ormulation 5 mg Peds)			·				
· Process Chemistry:	Process o Selection	Process optimization through increase scale (10 Kg) Selection of vendors for starting materials	rovgh increase r starting maler	scale (10 Kg) iuls					-	:	
Drug Safety Support									,		
Metabolism	Absorptie	on Distribution	ı Metabolism B	scretion studi	Absorption Distribution Melabolism Excretion studies in non-radent species to support toxicology	es to support toxico	logy	•			
Toxicology/Pathology	Conduct	Conduct multi-cycle cardiovuscular toxic	rdiovuscular (o	xicily study in	ity study in dogs if requested by PDA	FDA .					
Other Support Activities:					-			٠			
Medicul Services support - INDS (safety support)/ Medicul Information & Review Regulatory Affairs / Research Quality Assurance (Phase II site audits)	4DS (safety sur 1 Quality Assur	ppnrt)/ Medieul rance (Phase H	l Information & site audits)	t Review			·		·		
Program Spending by Year:								•			
2007	2003	F007	2002	<u> 2006</u>	· Total						
. 8.3 . 15.6	47.6	26.0	25.0	.18.5.	. 141.0	•					
19 John St. 11742 & committee from the committee of the c	ntere Standards (Price)	101-1116 54 117[2]: 284		-	ath prizzil					•	

			1 7007	2002 I fall Development Cost Summary		۱					
Program Status	2000	2001		2003	2004	2005	2 2	2006	•	٠	
_	01 02 03 05	5 6 70 10	7 57 67 67	02 03 04 01 07 03 04 01		100 70 101	3 5	_	٠		
Plase			<b>新四十四年</b>	F#		<b>←</b>	<u>.</u>				
Plase III		•	THE RESERVE OF THE PARTY OF THE	<b>整张 医骨髓膨胀影</b>	(A) (A) (A) (B)	VON TOTAL	Lawneh				
							ı				
Major Development Activities and Costs	- Liberit						2001 A PH Costs			2002 PI.AN Costs	
Clinical Program	Patients	10/2/01	Start	End	FTE's	Internal	External	Total	Internal	External	Total
MID in Cuneer Policins (MIO-231)	۲. د	~1	10/6	7/07			\$500	\$500		\$500	\$500
Metronomics Study (M01-303)	36	:	10/01	20/5		:	2445	\$445	:	\$600	.\$600
Six Safety & Efficacy Studies - Ph II	30 x 6		2/02	4/03		ŧ				\$4,422	\$4,422
NCI Pediatric	. 18 - 24	ï	70/1	12/03		ŧ	ï	ŧ	:	Ē	ŀ
Phase I Center					6'0	\$135		\$135	\$136	:	\$156
· Venture Management					0.7.	\$2,812		\$2,812	81,708	:	\$1,708
Data Management/Statistics					4,6	\$177	:	\$177	982\$		\$786
Subtotal			•			53,124	5945	\$4,069	\$2,650	\$5,522	58,172
	•										
Chemistry, Manufacturing, and Controls (CMIC)	(CMC)							•			<b>.</b>
Formulation & Analytical					11.3	\$1,155	\$135	\$1,290	\$2,641	\$275	\$2,916
Process Chemistry	•				3.0	\$922	\$250	\$1,172	\$1,033	\$75.	\$01,18
Other CMC						:	::		-	:	:
Subtotal CMC Costs					_	\$2,077	. \$385	\$2,462	\$3,674	\$350	\$4,024
Drug Safety Support											
Toxicology/Pathology					4,3	\$216	ž	\$216	\$1,044	ŧ	\$1,044
Drug Metabolism					5.1	S794	:	P6LS .	\$1,122	\$220	\$1,342
Other	•		•		6.0	\$110	. \$7	\$117	\$277	\$27	\$304
Subtotal Drug Safety Support						\$1,120	2.5	\$1,127	52,443	. \$247	\$2,690
Other Support Costs		cc 									
Discovery		NI JH	•		0.7	\$205	ß	\$208	\$202	\$100	\$302
Medical Affilirs		=1E 00	•		ŧ	:	\$10	. 015	\$39	3.	\$59
Regulatory Affairs / Research Quality Assurance	Assurance	)0: )0:			4.	\$137	Ę	\$137	\$308	Ē	\$308
Other Costs .		NT 798	•			2387		\$287		:	:
Total Program	•	IAL B	•			\$6,950	\$1,350	. \$8,300	\$9,336	56,219	\$15,555
	]	  - 								Ш	

FTI (ABT-100) Annual Development Plan

٠					٠		-							Ī
1902 Clinical Program Objectives: Initiate Phase I studies in cancer patients to assess salety and pharmacokinetics	Objectives:	15 Esasso oj sjui	afety and pharm	acokinetics							2002 PRO	2002 PROGRAM COST	SMIM 6.6*	₩ .5
		•				٠					* See next	* See next puge for detail.		
Other Clinical Support: Venture Management, Data Management/Statistics, Phase I Center (ACPRU) Support	l: ent, Data Mai	ពេញខ្មាកមារ/Stati	istics, Phuse I Co	enter (ACPRU)	) Support		•.						·	
Chemistry, Manufacturing, and Controls (CMC)	ring, and Co	ontrols (CMC					٠.	:	•		•	. •		
Formulation & Analyticul:	alyticaf:	Support pr Support of Formulatic Stability o	Support preformulation/polymorph studius Support of GLP/GMP drug substance for tox and Formulation manulacturing: support for GMP lot Stability of drug product and drug substance	olymorph studie g substance for ig: support for C ind drug substan	es GMP lot nee	Support preformulation/polymorph studies Support of GLP/GMP drug substance for tox and clinical/stability study Formulation manulacturing: support for GMP lot Stability of drug product and drug substance								-
Process Chemistry:	e-	Deliver G	MP material to s	support taxicole	ogy and clinic	Deliver GMP material to support taxicology and clinical supplies (6 Kg.)	•					-		
Drug Safety Support								٠						
Metubolism		Provide 11	retubolie dutu.fo	r toxicology su	pport to initia	Provide metabolic data for toxicology support to initiate first-in-man trial			•			-		
Toxicology/Pulhology	logy	Conduct t	week and or	ne-monilı toxici	ity (if needed	Conduct two-week and one-month toxicity (if needed per 2-week results) studies in two species to support Virst-in-man	lies in two species	s to support	irst-in-man		·		·	
Other Support Activities:	ties:							•		•				
Medical Services support - INDS (safety support)/ Medical Information Regulatory Affairs / Research Quality Assurance (Program overview)	support - INI s / Research	DS (safety sup Quality Assura	port)/ Medical II ance (Program o	₽	& Review									
Program Spending by Year:	у Уенг:		-											
2001	. 2002	2003	- F007	2005	<u> 2006</u>	Tetal .								
<u> </u>	9.9	15.9	33.6	26.0	28.0	111.3								
I. WHUTEK İnzönin Hansıx Alğınğ İteresit Plenif sernine Sammerte Yenden örgi Asif H. P. HAHI Alkit	Stewarth Planffree	iği niği heriminining ə tili	क्ष क्षांसाम क्षांतानाक		. ≝	Hizoni Kay	•			· .·		•		

FTI (ABT-100) 2002 Plan Development Cost Summary

			101 7 7007	2002 i dii Detelopinen esse dumini	Cost Dammer						
Program Status	2001	2002	2003	2004	2005	2006	2007 Q4 Q1 Q2 Q3	00 to		•	
Plase I							<b>←</b>	ł			,
Phase II	•						vg.	Launch			
								•		:	
Major Development Activities and Costs	its Traini	Enrolled				707	2001 APU Costs		97	2002 PLAN Costs	
Clinical Program	Patients	As of 9/01	Starf	Knd	SALA	Internul	External	Total	Internal	External	Total
Phuse I First-in-Mun	36	. : .	20/1	7/03						. \$525	\$525
IND Study	<b>e</b> .		12/02	12/03	٠	:	:	F-	:	<del>57   5</del>	67 IC
Phase I Center					9.6	ï.	÷		\$104	i	\$104
Venture Management					2.0 0.6	ŧ	ı	:	\$165	Ε	\$165
Data Managemeni/Statistics Subtotal ·					?	: :			1762	\$649	\$1,020
Chemistry, Manufacturing, and Controls (CMC)	rols (CMC)										
Formulation & Analytical					3,5	ï	;	:	\$807	210	\$817
Process Chemistry					6.0	\$600	009 <b>\$</b>	. \$1,200	165'15	\$200	162'1\$
Other CMC Subtotal CMC Costs					: .	\$600	\$600	\$1,200	\$2,398	\$210	\$2,608
Drug Sufety Support											
Toxicology/Pulhology	·	٠.			5.1	Ē	:		\$1,236	66\$	\$66,18
Drug Metubolism					4.4	į.	. :	I :	\$957	\$70 	51,027
Subtotal Drug Safety Support		С			i		<b>!</b>		\$2,193	691\$	\$2,362
Other Support Costs		ONF JH									
Discovery		FID) 00			Ξ	ŧ	·	:	\$303	:	\$303
Medical Affairs	ile.				: 3	1	:	:	88 52	ŧ	<b>88</b>
Other Costs	mny Assandance				§ :	•	: :		3	\$20	\$20
Total Program		L				8600	2600	S1,200	\$5,578	\$1,048	\$6,626

Dopamine Receptor Agonist (ABT-724) Annual Development Plan

2002 Clinical Program Objectives:						
Transition ABT-724 from DDC and prepare a Development Plan including the design and conduct of a (First in Man) study Por of solution administered sub-lingually; Part 2 - single dose of solution administered orally to determina relative bioavallability.	a Development Plan ir ! • single dose of soluti	icluding the design on administered o	n and conduct rally to deterr	Transition ABT-724 from DDC and prepare a Development Plan including the design and conduct of a (First in Man) study Part 1- single dose escalating of solution administered of solution administered or solution administer	2002 PROGRAM COST	5,9*
	·	•			* See next page for detail.	
Other Clinical Support: Venture Management, Data Management/Statistics, Phuse I Center (ACPRU) Support	n/Slatistics, Phuse I C	enter (ACPRU) S	upport			
Chemisiry. Manusacturing, and Controls (CNIC)	(CNC)					
Formulation & Analytical: Deve	Develop und formulate elinical study supplies to for intranasal administration.	nlaal study supplic m.	s to support s	support sub-lingual administration. Explore formulation and administration options		
Process Chemistry: Sym	hesize and provide 3 k	ys, netive drug an	d recommend	Synthesize and provide 3 kgs, active drug and recommendation as to appropriate salt form selection and formulation selection.		
Other CMC: Anal	Analysis of salts synthesized by Process Chumis Analytical support for formulation development	ed by Process Chu nuIntion developn	mistry. Prepa tent, stability	Analysis of salts synthesized by Process Chumistry. Preparation of solid phase characterization for polymorph screening. Analytical support for formulation development, stability assessment, dissolution testing. PARD project management support.		
Drug Sniety Support						
Metabolism Met	Metabolism suppurt includes; in-v support tox range finding sludles.	les; in-vitro metat studies.	oolism, proteir	Metabolism support includes; in-vitro metabolism, protein binding (definitive assessment), rat ADME, CYP 450 Inhibition, support tox range finding studles.		
Toxicology/Pathology Tox	Tox activities include acute tox battery, gene Anding, primury dermal and ocular irritation.	ie tox battery, gen nd ocular irritatio	e tox battery. 1.	Tox activities include acute tox battery, yene tox battery, 2-week doy range finding, I month and doy/rat, pregnant rat range Inding, primury dermat and ocutar irritation.		
Other Support Activities:						
Investigational Drug Quality Assurance support for production of clinical supplies. Regulatory Affairs to provide consulting support on IND.	e support for producti ng support on IND.	on of clinical supp	lies.			:
RQA to provide GLP compliance assessment at study sites as well as GLP training and QA consulting	ssment at study sites a	s well as GLP trai	ning and QA	ı consulting.		
Program Spending by Year;						
2007 2003 2003	7007	2005	2006	Total		
. 0.6 5.9 7,4	31.8	50,6	48,1	144,4		

RHIPATINAMIN Herenakutat Research Plendissentre Sammanselfatt 12.3 stejtwit AMINY (A)14-7---

Comparison of Comparison of							• •				ū		
Part   Part				Dopamine 2002 Flan	e kanaptor Agor Development C	nist (ABT-724 Jost Summary						. [	
Triang   Enrolled   Start   End   FTEs   Start   Total   Tot		2000	2001	2002	2003 :-	2004 1 Q2 Q3 Q4	2005 QZ Q3	75 19 25	19 19	07 09 01 0	8 G	•	
Tiest   Enrolled   Start   End   TTPs   Literal   External   Total   Literal   Literal   External   Total   Literal   Literal   External   Total   Literal		5 3								<b>∢</b>	4		Cas
Total   Enrolled   Sinrt   End   TYPE's   Internal   External   Total   Internal   External   Total   Internal   External   Total   Internal   External   Total   Internal   Internal   External   Total   Internal   Inte	Phase I Phase II Phase III									NDA liling	Lumei		se 1:05
Full line   Full	Major Development Activities and Costs		:				. 700	II API Costs	-	2002	PLAN Costs		5-CV-
120   15   15   15   15   15   15   15   1	Clinical Program	Foth)	As of 9/01	Start	End	FTE's	Internal	External	Total ·	Internal	External	Total	1115
10	SD Esculating Dose	. 30		. 10/31/02	£0/1£/1			i i	: :	; ;	\$400	\$400	50-DF
12   13   14   15   15   15   15   15   15   15		•	ŧ		٠					97.		07/ 13	٧
1.5	Venture Management Phuse I. Center Support					8.0 0.4	: :-	įį		57.12	: I	\$73	D
13	Data Management/Statistics Subtotal	•						1		\$1,907	\$400	\$2,307	ocun
1.3   2.00   2.000	Chemistry, Manufacturing, and Controls (	CMC)		٠.									nent
1.0   1.0	Formulation & Analytical					3.5			: 4	5817		\$817	23
1.3	Process Chemistry					3.0	2600	: :	0004	\$173	: :	5173	4-7
1.3	Subtotal CMC Costs						. 009\$		2600	\$1,766	:	\$1,766	
1.3	Drug Safety Support												Filed
1.2       5264     5264     5264     5451       5451	Toxicolopy					<u></u>	:	:	` :	5487	\$50	\$537	0 t
Salety Support	Experimental Science					1.2	:	:	:	\$264	÷	\$264	1/2
HAN BOOM State Support Commerce Commerc	Clinical Drug Analysis				•	- 12 - 12	7	;	:	\$451 \$334	: .	3401 \$334	8/2
HAN 0014 Manuality Assurance Columbia Assurance Columbia Manuality Assuran	Pathology Subtotal Drug Salety Support		CO			·	1	ľ		\$1,536	\$50	\$1,586	008
833 \$13 88 00 1.0 \$215 \$215 \$215 \$215 \$215 \$20 \$20 \$20 \$20	Other Support Costs		NFI H 0										3
\$20 \$212 \$213			DE 000			. 60	.•			E. S.	:	\$33	Pa
\$520 \$220 \$200 \$2477 \$450 \$5,927	Medical Allaits  Requisitory Affaire / Research Ounlity A	Saurance	NT 302		•	0.1	: :	: ;		\$215	: I	\$215	ge
\$600 \$600 \$5,477 \$450 \$5,927	Other Gosts		IAL P			ŧ				\$20		\$20	9 o
	Total Program						2600	411	2600	55,477	\$450	55,927	f 9
	I Willittiff Trishfelin [Sea in Mint] Resentli, Plantse chament Create	ment Consposit 124 shift maked		•									

I Williaffett healfelin féan in Marit Hossiets, Plantos chquincit

# PLs' MZ

## Abbott Laboratories Global Pharmaceutical R&D

Thomas J. Lyons Controller Abbott Laboratories D-R404, Building AP9 100 Abbott Park Road Abbott Park, IL 60064-6120

BOND & RECEIVED
CORPORATE FINANCE DEPT.

DEC 26 2001

Blewiff
EXHIBIT NO. 44
SHOW MICHELLE KEEGAN

December 18, 2001

Mr. Steve Blewitt
John Hancock Life Insurance Company
200 Clarendon Street, T-57
Boston, MA 02117
Attention: Bond & Corporate Finance Group
Fax 617-572-1628

Re: Research Funding Agreement dated as of March 13, 2001 2001 Program Status Report and Related Cost Summary

Dear Steve,

In accordance with section 2.5 of our agreement, enclosed is the 2001 Program Status Report and Related Program Costs for the program compounds. Please note that both the YTD and total year LBE costs exceed the minimums as per the agreement. As such, we'd appreciate receiving payment of the 1<sup>st</sup> installment of \$50 million no later than January 17<sup>th</sup>, 2002.

I hope you have an enjoyable holiday season.

Sincerely,

Torn Lyons

Abbott Laboratories

Global Pharmaceutical R&D

Controller

TJL/jlb

cc: Daphne Pals

encl.

#### John Hancock Development Portfolio Annual Progress Report

#### ABT-773 Tablet/ IV

The US, Canadian and European New Drug Application (NDA) is planned for August 2003, with an NDA in Japan shortly thereafter. Six Phase III clinical studies were initiated in November 2000 and have been actively enrolling in 2001. Study results will be available by the 3<sup>rd</sup> quarter of 2002. All required drug interaction and special population studies are on track for completion 2002 and 2003.

In Japan, Phase I dose ranging and food effect studies were completed during the 1st quarter of 2001. Based on the BID dose decision for Community Acquired Pneumonia (CAP) and Acute Bacterial Sinusitis (ABS), a Phase II open label CAP study was initiated in Japan in December 2001 to complete by May 2002. The strategy for the Japan NDA is to conduct a Phase III bridging study in CAP to bridge US/European data with the Japanese data.

With respect to the IV formulation, an initial Phase I single rising dose study is scheduled for Q1 2002 to evaluate dose levels, concentration and rates of infusion. Based on the results of this study, further Phase I studies will be conducted in 2002. Phase III studies for the IV formulation are planned to initiate in the 1st quarter of 2003 with an NDA planned for the 4th quarter of 2004.

Given study results recently received, initiation and continuation of further studies for ABT-773 Tablet/IV is currently under review.

#### ABT-627

ABT-627 is still on track to launch in the 4th quarter of 2004. During the course of the past year, ABT-627 has:

Received fast track and rolling NDA status from the FDA.

- Presented positive phase II efficacy results at both the American Society of Clinical Oncologists (ASCO) and the American Urological Association (AUA).
- Implemented 2 worldwide pivotal phase III trials in metastatic and nonmetastatic hormone refractory prostate cancer.
- Initiated clinical work in non-prostate cancers: renal cell, glioma, ovarian, breast, pancreas, lung and colorectal.

CONFIDENTIAL JH 001066

#### ABT-510

An Investigational New Drug (IND) application was filed with the FDA for clinical trials in the United States on August 24, 2001. Currently, two Phase I clinical trials have been initiated with 18 patients enrolled. The 2002 plan includes the initiation of multiple Phase II trials in various cancers, as well as collaborative studies in pediatric cancers and non-cancer indications.

#### ABT-492

An Investigational New Drug (IND) application was submitted to the FDA on June 22, 2001. As well as the filing of the NDA, the Phase I "super protocol" study was completed in March and a Phase IIA study in Acute Exacerbation of Chronic Bronchitis (AECB) began in 2002 Plans include the initiation of a Phase IIB program with the following November. objectives:

- Confirm a dosing strategy with a desired safety/tolerability profile while achieving efficacy goals in RTI indications. .
- Establish activity in uncomplicated UTI.
- Provide both a dosing selection and proof of principle.

#### ABT-751

An Investigational New Drug (IND) application was filed with the FDA for clinical trials in the United States on April 23, 2001. Currently, 2 Phase I clinical trials have been initiated with 6 patients enrolled. The 2002 Plan includes the initiation of multiple Phase II trials in various cancers, as well as collaborative studies in pediatric cancers and adult leukemia.

#### ABT-100

Current activity is focused both on the preparation of drug substance, necessary to complete the toxicology studies, and the development of a protocol for the first-in-human study. The first-in-human study is expected to initiate in August 2002.

#### ABT-724

ABT-724 was presented and approved as a Drug Development Candidate (DDC) in July 2001. Work has since commenced on the manufacture of the bulk active pharmaceutical ingredient to support process chemistry analysis, as well as to provide material for initial toxicology studies and formulation development. In addition, work has been completed on preclinical pharmacokinetics that allows for predicting dose ranges for the first-in-human study. The 2002 Plan includes conducting both pre-clinical toxicology and metabolism studies, as well as initiating the first-in-human study scheduled for the 3rd quarter.

Abbott / John Hancock Funding Collaboration 2001 Y/E Estimate for JH Development Portiolio (5MM)

	2001 Actuals			2001 LBE	2001 Plan	Variance	
Compounds	October YTD	November LBE	December LBE	Projected Y/E	JH Submission	Fav/(Unfav)	Comments
ABT-773 Kelolide Oral & IV	65.4	8,8	9.9	83.2	91.5	en en	Program Delays
ABT-627 Endolhelin	26.2	5.5	75.	37.3	38.0	0.7	
ABT-594 Neuro Pain	6,8	0.1	0,7	6.8	35.0	28.1	Program Terminated
ABT-510 TSP	7.3	1.6	1.6	10.6	9.0	(1,6)	
ABT-492 Ouinglone Tablet	19.9	2.9	2.9	25.6	25.0	(0.6)	
ABT-518 MMPI	3,4	0.4	0.4	6,4	7.0	2.7	Program Terminated
ABT-751 Anil-Milatic	5.0	1.3	£.	7.7	10.0	2,3	
ABT-100 FT!	8.0	6'0	0.9	8.6	6.0	(3.8)	
ABT-724 Dopamine Receptor Agonist	6.4	0.7	0.7	7.8	6.0	(1.8)	
Tota	148.5	23.3	23.3	195,2	. 227.5	32.3	

# PLs' NK

### Abbott Laboratories Global Pharmaceutical R&D

Thomas J. Lyons Controller

Abbost Laboratories D-404, Building AP9 100 Abbost Park Road Abbost Park, IL 60064-6120

December 20, 2002

Mr. Steve Blewitt
John Hancock Life Insurance Company
200 Clarendon Street, T-57
Boston, MA 02117
Attention: Bond & Corporate Finance Group
Fax (617) 572-1628

Re: Research Funding Agreement dated as of March 13, 2001

- (a) 2002 Program Status Report and Related Cost Summary
- (b) 2003 Preliminary Annual Research Plan

Dear Steve,

In accordance with section 2.5 of our agreement, enclosed are (a) the 2002 Program Status Report with Related Program Costs and (b) the 2003 Preliminary Annual Research Plan for the program compounds. Please note that for 2002 both the YTD and total year LBE costs exceed the minimums as per the agreement. As such, we'd appreciate receiving payment of the 2<sup>nd</sup> installment of \$54 million no later than January 19<sup>th</sup>, 2003.

The \$2MM management fee should be wired to you early next week (week of December 23<sup>rd</sup>), if not sooner. Please let me know if you have any questions.

1/21 Tubb (mik Fr)
Poul Holding (mik Fr)
1/20

I hope you have an enjoyable holiday season.

Sincerely,

Tom Lyons
Abbert Laboratories

Global Pharmaceutical R&D

Controller

TJL/jlb

Cc: M. Johannesen

Abbott Stationery

Someway Reads - Mg. Hodges He would par to M. Hodges

CONFIDENTIAL AL 001469

#### John Hancock Development Portfolio Annual Progress Report (November 2002)

#### ABT-627

Key 2002 landmarks in the development of atrasentan include:

Two worldwide pivotal phase III trials in metastatic and nonmetastatic hormone refractory prostate cancer are on going. Enrollment was completed in 3Q02 for the clinical trial in men with metastatic disease. Enrollment in the trial for men with nonmetastatic disease is scheduled to complete at the end of 2002.

A phase II study of atrasentan in early prostate cancer (biochemical relapse following radical prostatectomy) is underway

A pilot study of atrasentan in combination with Zometa (Zoledronate) is underway as a prelude to a randomized phase II trial

Exploratory phase II trials in non-prostate cancer have begun in glioma and study initiations will occur in 4Q02 for renal cell and non-small cell lung cancer. ABT-627 is still on track for a Q4 2004 approval.

#### **ABT-510**

Currently there are no ongoing Phase II studies. By the end of the year, five Phase II studies will have been initiated, including studies of renal, lung, and breast cancer, lymphoma and sarcoma. These were postponed 3 months due to delay in bulk drug supply. The 2003 plan includes the continuation of these studies.

#### ABT-751

Currently, two Phase I studies are ongoing with a total of 45 enrolled patients, twelve of which are active. In addition, three Phase II trials in renal, colorectal, and lung cancers have been initiated, as well as collaborative studies in pediatric cancers and adult leukemia with six patients enrolled. The 2003 Plan includes the initiation of a fourth Phase II trial in breast cancer.

#### **ABT-100**

Due to neurotoxicity indicated in animal studies, decision was made to terminate this program in Q2.

۲.

#### ABT-773 Tablet/IV

As a result of FDA concerns with safety requirements of the Anti-Infective Therapeutic Class, the FDA made clear to us its expectation regarding additional clinical work required to complete the development of ABT-773. Due to the magnitude and duration of the additional investment required, a decision was made 7/02 to seek a licensing partner in the U.S. and Europe and to not independently advance the compound in these markets. We are currently in late stage negotiations with a partner and have been also working with John Hancock to that extent.

#### <u>ABT-492</u>

A Phase I QTc study was completed in October and a Phase IIA study in treating community-acquired pneumonia began in March. The Phase IIA study in Acute Exacerbation of Chronic Bronchitis (AECB) initiated in November 2001 is ongoing. Enrollment for both Phase II studies will be completed by February 2003 with results anticipated by the end of the second quarter 2003.

At this time, no further clinical trials are planned for ABT-492 and all current CMC activities have been brought to a close. Options for the future of the drug will be evaluated based on the results of the existing Phase II clinical trials. No safety issues have been identified in the existing Phase I study data, and the ongoing Phase II studies remain blinded.

#### **ABT-724**

Currently there is one Phase I study ongoing with 32 patients enrolled. An extension of this study is expected to begin in December of 2002 and continue into 2003. In addition, 2002 completed studies include both pre-clinical toxicology and metabolism studies. Due to overall funding constraints as well as strategic priorities, no new studies/work are currently funded in 2003 for ABT-724. If additional funding does become available, ABT-724 will be considered.

Abbott / John Hancock Funding Collaboration 2002 Y/E Estimate for JH Development Portfolio (\$MM)

Comments	See progress report.  Program terminated in 2001. Studies postponed 3 miths. due to builk dug supply delay. See programs report. Program terminated in 2001. Aggressive plan spend. No change in timeline. Program terminated in 2002.	
Variance Fav/(Unfav)	6.02 : 14	97.0
2002 Plan JH Submission	79.3 62.9 26.3 26.3 42.4 15.6 6.8 5.9	229.0
2002 LBE Projected Y/E	19.7 50.4 1.4 1.2 30.8 9.8 9.8 5.5	132.0
December LBE	0.7 4.5 0.9 0.8 1.0 1.0	10.2
November LBE	6.7 6.9 8.9 8.2 1.0 6.0	10.2
2002 Actuela October YTD	18.3 41.4 1.4 1.6 10.3 25.0 7.8 7.8 4.8	111.6
Compounds	ABT -773 Kerokide Oral & IV ABT -627 Endothelin ABT -527 Neuro Palin ABT -510 TSP ABT -482 Quinolone Tablet ABT -518 MMP! ABT -510 FII ABT -724 Dopamina Receptor Agonlat	Total

12/17/2002 8:39

L'AGROUPVPLANNINGVHanoodk/2002 Y\_E JH Estinatios.xia/PR

CONFIDENTIAL AL 001472

John Hancock Portfolio Summary R&D Costs and Development Timeline 2003 Plan

	-1	1		Total	
Compounds	ZOOI ACIUBIS	2002 185	ZUUS PLAN	Cumulative	Comments
ABT -773 Ketolide Oral & IV	80.9	18.7	1.7 1	102.3	Outilcensing being pursued,
ABT -627 Endothelin	34.1	50.4	71.2 65.8		Program progressing on timeline.
ABT -594 Neuro Paln	7.8	1.4	•		Program terminated in 2001,
ABT -510 TSP	9.8	. 12.1	18.3 /8.4		Bulk drug supply delays in 2002 postponed studies 3 months.
ABT -492 Qulnolone Tablel	23.1	30.6	7.2 4	6'09 6'	No new studies to begin at this time.
ABT -518 MMP!	3:7	•	•		Program terminated in 2001.
ABT -751 Antt-Mollo	9. 7.	9.6	2.0/ 10.5		Program Iracking.
ABT -100 FTI	3.6	. 2,4	•		Program terminated in 2002,
ABT -724 Dopamine Receptor Agonist	35	5,5	0.1	8.8	Program on additional funding request list for 2003.
Management Fee and Milestone Payment		10.0	2.0 %	12.0	-
Total	17171	142.0	1112 103.4	3.4 424.9	
Current Year Projected Funding Ratio	3.4	2.6	2.2		
Current Year Target Funding Rallo	2.0	2.0	2.0		
Projected Aggregate Funding Ratio	9.6	3.0	2.6		
Target Aggregate Funding Ratio	2.9	2.9	2.9		

C:DOCUME-1/bonyk/LOCALB-1/Temp(2003 HDCT Analysis v2 for TL.ds)Revisions

12/16/2002 0:30

TBD 4 Q 2004 NA 4 Q 2006 TBD . TBD . NA 1 Q 2008 NA TBD TBD TBD TBD

3 Q 2004 4 Q 2004 N/A 1 Q 2006 4 Q 2006 1 Q 2006 4 Q 2007 3 Q 2008

ABT -773 Kelokde Oral & IV
ABT -627 Endothelin
ABT -594 Neuro Pain
ABT -510 TSP
ABT -492 Quinolone Tablet
ABT -492 AmP!
ABT -751 Anit-Miotio
ABT -100 FT!
ABT -724 Doparnina Receptor Agonist

2003 Plan

2002 Plan

Timeline (Launch Dates);

	ABT-773 Ketolide				
Externali	Total Patients Enrolled Start	nrolled Sta	ri End	2003 Plant 000sl	•
CNC	•			<b>\$</b>	
PARO		101	Total External	\$10	
				FTE (\$000x)	
Internal				•	
Clinical Program					
Global Project Myrni				1.7	_
Phase I Center Bupport					_
Deta Management/Statistics	-				-
Chemistry, Manufacturing and Controls					
Formulation (PARD)				1.4 \$387	
Analytics for Formulation(PARD)					-
Analytics for Process Chemietry (PARD)					
Christian Packaging(PARU)					
Drug Bafety Support					
Other				70	
Other Support Cost	•				
Research Quality Assumence				0.2	
OH.			Total Internal	\$1	
			Total Program:	\$1,703	

{(

CONFIDENTIAL AL 001474

	Exiernali	Total Patients	Enrolled	Steri	End	777	Zuus Plant uuvsi	
March   Marc	New Clinical Activities:						- C81	
March   Marc	Japanese Bridoing Bludy	200	,	200	21/22 22/23		000°	
State   Stat	Phase II that #1	8	Þ	200	10/101		23,34	
International Properties   New Clinical Activities		8		20/1/0	t diam		ST 228	
1000   G1/101   G1/102   G1/101   G1/102   G1/101   G1/102   G1/101   G1/102   G1/101   G1/102   G1/	Bubtotal New Cl							
1990   1991   1992   1993   1994   1995	Ongoing Clinical Activities:			i	200		411 412	
1000   AT   AT   AT   AT	MANDO 11 Phase III (WWW Malacistic Procinis Carbon)	1000		2	(		44 400	
1400   71/101   21/105   1400   140	MDC-244 Phase II (WW repertablished Prostate Carcer)	1000		6179			\$17,100	
Act   Act		1400		1/1/01	21/05		53,672	
1,100 of the control of the contro	MUCCOS PTIMOS III (Ext. No. mourant mourant)	260		10/15/01	3/1/05		\$4872	
1938   Fabre   Parameterization   200	Mol-Soy Frage II Long Jem Serry	200		12/31/02	12/30/04		\$1,788	
A	Phase II - Bisphosphorata Combination	200	O		111/05		\$2,258	
Total External Budy Assumed Part	MO1-358 Phase II Early Produke Cencer	4		11/1/02	1/1/03		\$1,200	
Subjoial Dispoint Claims Such	Japan Phase I Pharmacokinetic Bludy-ALL TUMORB				-		. \$150	
Subtotal Ongoing Clinical Activitias:  Subtotal Ongoing Clinical Activitias:  Clinical Safety Support  T Support Cost  In Sup	Marketing - Outcomes Study						\$33.018	
Clinical Safety Support   Total External   Total Internal   Subjets) Ongoing Clinical Activities:								
Control State	CXC						61 844	
Clinical Safety Support	ON MA						F 55	
Clinical Sariety Support	Proves R&D						3	
File	Dr. Cilpiani Safaty Support							
Figure   F	The Children of the Children						<b>418</b>	
Figure   Cost	Pre-Cultical calley outpoor							
Program   Prog	Other Support Cost						\$2,443	
14.14   14.1	Officer			Total Exte	Tat.		\$44,687	
14.4   2.3   2.4						ETE	( \$0005)	
41.4 2.3 4.4 4.1 2.8 5.6 5.7 7.2 3.4 5.0 3.4 4.7 6.0 3.2 1.8 4.7 7.7 7.0 1.18 7.18 1.18 7.18	ernal .					1		
2.3 4.1 26.5 7.2 3.8 9.8 4.7 6.0 9.5 9.5 1.6 7.7 7.7	Clinical Program					717	48 A54	
4.1 28.5 7.2 7.2 3.8 3.4 4.7 9.9 9.9 9.9 9.5 9.5 9.5 9.5 9.5 9.5 9.5	Clobal Project Mont					2.3	8484	
28.6 7.2 3.4 4.7 7. Total Internal 118.7	Physical Certies Support					7	3554	
6.5 7.2 3.4 1.8 4.7 1.6 1.6 1.6 1.6 1.6 1.6 1.6 1.6	European Clinical Organization					26.6	54'576	
6.5 7.2 3.4 9.6 9.5 9.5 9.5 1.6 7.7 Total Internal 118.7	Data Management/Statistics							
7.7 7.7 7.7 7.7 7.7 7.7	Chemistry, Manufacturing and Controls					8,8	\$1,481	
3.4	Formulation (PARD)					7.2	\$1,852	
3.4 (18.7 Total Internal 118.7 (18.7	Analytica for Formulation(PARD)					3.8	£883	
1.6 4.7 6.3 1.6 6.3 1.6 7.7 Total Internal 118.7	Analytica for Process Chamietry (PARD)					¥ (	\$815	
1.6 4.7 6.3 0.5 Interce 1.6 7.7 Total Internal 118.7						0.a	\$4,433	
1,15 4,7 4,7 1,10 1,10 1,10 1,10 1,10 1,10 1,10 1,	Desir Cafety Compart					,	0074	
1,4,7 (18.7)  1,6  1,6  1,6  1,6  1,6  1,6  1,6  1,		•				ē !	AGE T	
C Discovery)  3.2  1.5  7.7  Total Internal 118.7	Toxicology/Pathology					/· 6	\$1,270	
0.5 3.2 3.2 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5						3	•	
3.2 (1.5 (1.5 (1.5 (1.5 (1.5 (1.5 (1.5 (1.5	Other Bupport Cost					6.0	\$138	
3.2 1.5 7.7 Total Internal 118.7	Discovery (Therapeutic Discovery)						\$175	
1.6 7.7 Total Internal 118.7	Medical Services					3.2	\$874	
7.7 ain Total Informal 118.7	Research Quality Assurance					1.6	\$166	
Total Informal 118.7	Medical Affairs					;	2846	
Total Internal	Hequisiony Author					, ,	4006	
				Total		118.	940,010	

((

CONFIDENTIAL AL 001475

\$1,683 \$1,472 \$1,472 \$680 \$444 \$4,918

**6 5 5 6 5** 

**Subtotal Ongoing Clinical Activities:** 

Process R&D Pre-Clinical Safety Support

Pre-Clinical Safety Support

Other Support Cost

Other

Subtotal New Clinical Activities;

M02-429 Phase II Lang Cancer M02-467 Phase II Lymphone M02-428 Phase II Ransi Cancer Phase II Brasel Cancer Combination.

Phase libili Trist in NSCLO

Ongoing Clinical Activities:

MOZ-534 Phase II Sercoma New Clinical Activities:

\$388 \$35

51.134 ## \$8,212

2003 Plant 000s)

End

Start

4BT-510 (TSP Peptide) Base Program Total Padents Enrolled 8

\$1,322 \$1,322

\$372 \$76 \$448 \$107

\$10,089

Total Program:

\$3,148 \$1,148 \$138

(\$0005)

\$2,824 \$381 \$127 \$1,150

Data Managemen/Statetics Chemistry, Manufacturing and Controls

Global Project Mgml Phase I Center Support European Cirical Organization

Clinical Program

Formulation (PARD)
Analytics for Formulation(PARD)
Analytics for Process Chamistry (PARD)
Carlest Peckaging(PARD)

Drug Safety Bupport Todoology/Pathology

Process R&D

Discovery (Therapeulo Discovery) Medical Services Research Quality Assurance

Other Support Cost

\$239 \$476 \$239 \$1,030 \$978

CONFIDENTIAL AL 001476

	ABT-492 Ouinolone	ile Ile				
External:	Total Patients	Enrolled	Stord	End	2003 Plan( 000s)	Γ
Ongoing Clinical Activities:						-
Phase IA - MOI-344 CAP	300	288	3/18/02	2/8/03	\$1,800	
Subtotal Ongoing Clinical Activities:					\$1.800	
Other Support Cost					1	
Other					\$726	
			Total External	iati	\$2,525	
Internal					ETE (\$000s)	
Clinical Program	•					
Global Project Many					B.3 \$2,021	
Phase I Center Support					0.5 \$101	
Deta Management/Statistics					2.7 \$488	
Chemistry, Manufacturing and Controls						
Formulation (PARD)						
Analytica for Formulation(PARD)						
Analytics for Process Chemistry (PARD)					0.1 \$37	
Chrisal Packaging(PARD)	•					
Process R&D			,			
Drug Sefety Support				,		
Todoology/Pathology					0.1 \$27	
Metabotem Other Green of Park						
Discovery (Therapeutic Discovery)					2.0 4652	_
Macical Berylcas						
Research Quality Assurance					522	
Medical Altain						_
Regulatory Affairs						_
Other					0.5 \$59	
			Total	Total Internal	20.3 \$4,641	_
			Total	Total Program:	\$7,166	


CONFIDENTIAL AL 001477

Cxiernal:	Total Patients Fre	Total Patients Fundled Start	Find	2002	Dian( 000-1
Onnoine Clinical Activities			iii.	2667	COAS LIBRE VOVS
MXZ-447 Phase II (Breed)	9	10/1/02	2 10/1/03		2857
MOZ-448 Phase II (Lung Cancer)	8	11/1/00			475
MO2-446 Phase II (Coloracial Cancer)	: 5	12/14			760
M02-416 Phase II (Renal Cancer)					4704
polocio Jajo	3	=			\$388
				·	\$2,244
PARD					50
Process R&D					5130
		Total E	Total External		\$2,369
hiernal				FTE	(5000s)
Clinical Program					
Cooper Project Agent				9.4	\$2,278
				<u>:</u>	\$228
				7.0	754
Detail Management/Statesics				4.5	\$838
Gremistry, Manufacturing and Controls					
Formulation (PARD)				3.1	5841
Analytics for Formulation(PARD)				3.5	Spec
Analytics for Process Chemistry (PARD)				1,8	\$470
Cinical Psologing(PARD)				0.8	\$217
Process R&D				2.2	\$1,183
Drug Safety Support					•
TodoologyPathology				0.2	2
Metabollen				2.1	\$573
Other				0.2	255
Other Support Cost					į
Discovery (Therapeutic Discovery)				0.5	\$149
Medical Services					828
Research Quality Assuminos				<b>5</b>	\$274
Medical Affaira				0.1	\$17
Other				0.5	B778
		Tot	Total Internal	28.4	\$8,282

ABT-724 Dovamine 4 Aronisi)

((

((



CONFIDENTIAL AL 001479

# PLs' NN

#### Global Pharmaceutical Products Division

James L. Tyree Vice President Global Licensing and New Business Development 200 Abbott Park Road Abbott Park, Illinois 60064-6189

November 12, 2003

VIA FAX (612-572-1628) and U.S. MAIL John Hancock Financial Services, Inc. John Hancock Place Post Office Box 111 Boston, Massachusetts 02117 Attn: Stephen J. Blewitt, Senior Managing Director

Research Funding Agreement Between Abbott Laboratories ("Abbott") and John Hancock Re: Life Insurance Company, John Hancock Variable Life Insurance Company and Investors Partner Life Insurance Company (collectively, "John Hancock") Dated March 13, 2001 (the "Agreement")

Dear Mr. Blewitt:

In accordance with Sections 1.6 and 2.2 of the Agreement, enclosed please find the preliminary Annual Research Plan for 2004 and 2005.

Document 234-10

In addition, in accordance with Section 2.5 of the Agreement, enclosed please also find the research report concerning the status of the Research Program and all Program Related Costs expended by Abbott for the first nine (9) months of 2003, together with good faith estimates for the last three (3) months of 2003. In addition, this report also contains the actual Program Related Costs for the period October 1-December 31, 2002.

Very truly yours,

Global Licensing/New Business Development

CONFIDENTIAL JH 001283

Œ:

VIA FAX (617-572-1628) & U.S. MAIL John Hancock Life Insurance Company 200 Clarendon Street, T-57 Boston, MA 02117 Attn: Bond & Corporate Finance Group

VLA FAX (617-572-9268) & U.S. MAIL John Hancock Life Insurance Company 200 Clarendon Street, T-50 Boston, MA 02117 Attn: Investment Law Division

Giobal Pharmaceulical Research & Development

		Hancock Collaboration	aboration	,			
		Spending by Program	Program				•
				F	. 1	in thousan	in thousands of dollars
				301	r tan	rajecnou	
•		2001	2007	7007	<u> </u>	2005	<b>Tola</b>
ABT-100	FII	3,6	. 24	0'0	0.0	000	6.0
ABT-492	Quinologe	20.1	28.2	4.6	9.0	0.0	50.7
ABT-510	TSF#L	8.8	123	17.4	304	41.6	110.5
ABT-518	NOAP!	7.0	0.0	0.0	0.0	0.0	7,6
ABT-594	Neuro Pain	7.8	7	0.0	0.0	0.0	9,2
ABT-627	Altrasentan Base	3.1	48.1	50.4	31.1	36.1	199.8
ABT-627	Altrication Hormone Naive Prostate Cancer	0.0	7	2.6	2.9	2.2	8.9
ABT-637	Japan	0.0	0.1	53	7.4	9.0	3.6
ABT-627	Non-Produte Caucers	0.0	0.0	08	1.9	10.5	17.4
ABT-724	Departus 4 Agents	3.2	5,5	0.0	00	0.0	8.7
ABT-751	And-Mirotio	. 6.5	9,6	11.1	25.2	50.2	102.6
ABT-773	Васо	80.3	13.0	0.0	9.4	20	<b>2.5</b>
ABT-773	Japan	7	. 1.9	0.0	00	93	33
	Management Fee! Milestones	0.0	10.0	2,0	2.0	8	14.0
٠	Other	2.2	6,8	00	0'0	0.0	6.6
	Total	1717	141.3	91.6	19.1	141.3	6449
Cumulative					٠		
		2003	7007	2002	200	3002	
ABT-100	FIT	3.6	9	6.0	6.0	6,0	
ABT-492	Quindone	20.1	48.3	52,9	23,7	53.7	
ABT-510	TSP#1	10.00	21.1.	38.5	68.9	110,5	
ABT-SIB	MARFI	7.0	3.7	3,7	3.7	7,0	•
ABT-594	Neuro Palo	7.8	9.7	9,3	9.3	8.2	•
ABT-627	Altraseulm Base	34.1	82.3	132.6	163.7	199.B	
ABT-627	Altraculan Hormone Naive Prostate Canoer	0.0	7	. 8	6.7	8,9	
ABT-627	Japan	00	0.1	0.6	3.0	36	
ABT:677	Non-Proside Canoers	0.0	0.0	3.0	6'9	17.4	
ABT:627	Dopamine 4 Agantst.	3.2	8.7	8,7	8.7	B.7	
ABT-751	Antl-Miotic	6.5	16.1	27.2	52,4	102.6	
ABT-773	Васе	80.3	<b>34.1</b>	24,1	84.5	2,5	
ABT-773	Japan	1.4	3.3	E'E	9.3	93	
	Management Fee / Millestones	0.0	10.0	120	14,0	14.0	
	Other	2,2	0/1	9.0	9.0	9,0	
	-		****	A	200	2	

Global Pharmaceutical Research & Development Hancock Collaboration Spending by Program In millions of dollars


•			•				
Total Yr. 2003	0.0	17.4	56.5	11.1	0'0	2,0	91.6
Q4 LBE 2003	0.0	0.0	10.6	2.9	0,0	2,0	20,9
Q3 YTD 2003	0.0	12.0	45,9	8.2	0.0		70,7
Q4 2002	0,1	3.0	14.9	2,5	0.0	2.0	29.7
٠.	ABT-100	ABT-510	ABT-627	ABT-751	ABT-773	Management Fee	Total

L:\GROUP\PLANNING\Hancock\[Hancock Collaboration 2002 & 2003,xis]Sheet\_


CONFIDENTIAL JH 001285

11/13/03

ABT-492 1004 Plan Executive Program Summary



ABT-510 2004 Plao Eteculive Program Summary



Discovery: Condant additional in the fumor undel experiments including combination studies with cytotectics and angiogenesis inhibitors. Continue biomarker development and analysis of clinical namples from Phase 2 studies.

-

PARD: Deliver and support chinical supply requirements for the completion of Phase 2. Identify commencial manufacturing site and commencial commodities to enable timely manufacture of Phase 2b/3 clinical and commencial supplies if excelerated approval is mulcipated. Process R&D: Deliver 30 kg API in 3Q/04. Deug may be considered registration traterial and will support Phase 2b davelopment.

Drug Safety / Metabolism / PKs. Complete 6M rat and 9M monkey studies. Initiate/complete ADME studies including CYP inhibition, protein binding and mouse ADME. Complete drug analysis for precibilical vedices and PK summaries for Pinese 2s official studies.


Regulatory Affairs: Conduct PDA coesting to directs clinical program 3QVA. Continue development of a global regulatory strategy with focus on accelerated approval opportunities.

# rocrem Statu


Clinical. Additional sites are being added to further enhance enrollment in the Phase Za studies. Key to actieving program Lindiuss is the enrollment of patients for the Go / No-Go decision.


Process R&D: Starting materials for 30 kg API will be secuted in early 2004 in amicipation of inclusion of the Pusse 2b program in 4QPO4. In amicipation of a possible accelerated development timeline, the API will be manufactured as registration material.

Atresectur (ADT: 627) 2014 Plan Executive Pregram Summary



ABT 751 2004 Vian Executive Program Summary





MOV.13.2003 4:39PM JAMES L TYREE

Page 9 of 9

## PLs' NO

John Hancock

John Hancock Financial Services, Inc.

Bond and Corporate Finance Group

John Hancock Place Post Office Box 111 Boston, Massachusetts 02117 (617) 572-9624 Fax: (617) 572-1628 E-mait: sblewitt@jhancock.com

Stephen J. Blewitt Senior Managing Director

April 12, 2004

BY FAX (847) 937-6683 CONFIRMATION COPY BY U.S. FIRST CLASS MAIL

Mr. James L. Tyree Vice President, Global Licensing & New Business Development Abbott Laboratories 200 Abbott Park Road Abbott Park, IL 60064-6189

Re: Research Funding Agreement by and between Abbott Laboratories and John Hancock Life Insurance Company, John Hancock Variable Life Insurance Company, and Investors Partner Life Insurance Company, dated as of March 13, 2001

Dear Jim:

Pursuant to § 2.5 of the Research Runding Agreement by and between Abbott Laboratories and John Hancock Life Insurance Company, John Hancock Variable Life Insurance Company and Investors Partner Life Insurance Company, dated as of March 13, 2001 (the "Agreement"), John Hancock Life Insurance Company, John Hancock Variable Life Insurance Company and Investors Partner Life Insurance Company (collectively, "John Hancock") hereby give notice of the exercise of their right to inspect and audit all books and records of Abbot and of any Subcontractor of Abbott with respect to the following matters:

- 1. All Program Related Costs expended by Abbott during each Program Year;
- 2. Compliance by Abbott with its obligations, under § 2.2 of the Agreement, to prepare and provide John Hancock with an Annual Research Plan, and to conduct the Research Program during each Program Year in accordance with the Annual Research Plan for such Program Year;
- 3. Compliance by Abbott with its obligation, under § 2.3 of the Agreement, to use Commercially Reasonable Efforts to conduct the Research Program in accordance with the requirements of § 2.3 of the Agreement;
- 4. Compliance by Abbott with its obligation, under § 4.3 of the Agreement, to substitute Program Compounds in accordance with the requirements of § 4.3 of the Agreement;

Campbell 2 2/20/07 CS

<sup>&</sup>lt;sup>1</sup> Unless otherwise specified herein, capitalized terms used in this letter and in the attached Schedule A shall have the same definitions as those set forth in the Agreement.

- 5. Compliance by Abbott with its obligation, under § 4.3 of the Agreement, to out-license or divest Ceased Compounds to third parties in accordance with the requirements of § 4.3 of the Agreement;
- 6. The stage of development and status of each Program Compound as of March 13, 2001; and
- 7. The current stage of development and status of each Program Compound.

Attached hereto as Schedule A is a preliminary list of those categories of books and records that John Hancock reasonably expects will be made available for its inspection and audit of these matters. The list is provided solely to assist Abbott in complying with this notice, and not by way of limitation. John Hancock requests that all books and records of Abbott and its Subcontractors pertaining to the above-identified matters be made available for its inspection and audit, regardless whether such books and records are described on Schedule A.

John Hancock's inspection and audit of the books and records of Abbott, as set forth herein, shall be conducted by Christopher Martinez, Brian Napper and other employees of the StoneTurn Group, LLP, a firm of independent auditors retained by John Hancock. The audit shall take place during normal business hours commencing on May 12, 2004, and continuing from day to day thereafter until completion, subject to adjournment as may be necessary to accommodate scheduling exigencies. In accordance with § 2.5 of the Agreement, John Hancock reserves its right to designate for copying, at its initial expense (but subject to reimbursement by Abbott in accordance with § 2.5 of the Agreement), any or all of the books and records of Abbott that are subject to its inspection and audit.

Please inform me before the close of business on May 5, 2004 of the specific location at which Abbott will make its books and records available for inspection and audit pursuant to this notice. Please also provide me with the name of the person who the StoneTurn Group's representatives should contact upon their arrival to begin their inspection and audit.

Thank you for your anticipated cooperation.

Very truly yours,

Stephen J. Blewitt

#### Attachment

cc: General Counsel (by fax, 847-938-6277; confirmation copy by mail)

Lawrence R. Desideri, Esq. Peter E. Gelhaar, Esq. Brian A. Davis, Esq.

Michael Arthur Walsh, Esq.

3679391vI

### Schedule A

- All records and documents indicating expenditures made by Abbott related to any compound that is now or ever was a Program Compound, including the following:
  - a. Abbott's standard policies and procedures related to accounting for project/program related expenditures;
  - b. Abbott's chart of accounts as relevant to accounting for project/program related expenditures;
  - c. Summary of costs/expenditures incurred by Program Compound by year delineating expenditures by nature (e.g., direct costs incurred by Abbott, subcontractor costs, allocated indirect costs, etc.);
  - d. Accounting framework for compiling the expenditures presented (i.e., whether cost assembled on an accrual or cash basis of accounting);
  - e. Identification of whether expenditures presented were capitalized or expensed under General Accepted Accounting Procedures ("GAAP") definitions;
  - f. Summary of the timing of expenditures for each Program Compound within each year presented;
  - g. Contracts or other governing documents and information related to all Research Program activities performed by Subcontractors;
  - h. Reconciliations of annual expenditures by Program Compound to the audited financial statements of Abbott;
  - i. Calculations, algorithms, and basis for all allocations included in the total expenditures by Program Compound by year;
  - j. Abbott standard policies and procedures related to allocation of indirect costs;
  - k. Expenditure/Costs summaries and/or reports prepared in the normal course of managing the development of each Program Compound; and
  - 1. Underlying supporting records (e.g., timesheets, payroll records, purchase orders, invoices, etc.) for all expenditures made related to each Program Compound.
- All records and documents discussing or evidencing the implementation and conduct of the Research Program, including but not limited to:
  - a. Reports/Updates/Summaries prepared by Abbott in the normal course of managing the development of the Program Compounds;
  - b. Listing of all reports/updates/summaries typically prepared by Abbott during the normal course of developing an experimental pharmaceutical compound;
  - c. Minutes/Summaries/Notes from all management meetings in which any of the Program Compounds where reviewed or approved for further development funding;
  - d. Analysis and documentation supporting all forward looking projections of expenditures to be incurred for each Program Compound by year;

- e. Abbott policies and guidance as to the appropriate and/or required methods/approaches/procedures for conducting a research program for an experimental pharmaceutical compound;
- f. Abbott's internal approval framework for determining whether or not to continue to fund and develop an experimental pharmaceutical compound, including all relevant thresholds for approval along the compound development process; and
- g. Minutes/Summaries/Notes from all Abbott meetings regarding continued funding of product development for any Program Compounds.
- 3. All records and documents concerning Abbott's obligations under § 4.3 of the Agreement, including but not limited to:
  - a. Records identifying any and all Replacement Compounds;
  - b. Records identifying any and all Failed Early Stage Program Compounds;
  - c. Records identifying any and all Ceased Compounds;
  - d. All documents pertaining to Abbott's consideration or selection of any compound to replace any Failed Early Stage Program Compound;
  - e. Records identifying any and all compounds that Abbott held out as or considered to be "back up" compounds for the compounds that constituted the Program Compounds (i) on the effective date of the Agreement, and (ii) as of the end of each calendar year 2001 through 2003; and
  - f. All documents pertaining to the actual or attempted out-licensing or divestiture of any Ceased Compound.
- 4. All records and documents concerning the status of each Program Compound as of March 13, 2001 and currently, including but not limited to:
  - a. Reports/Summaries/Meeting Minutes which indicate the stage of development of each compound that originally constituted a Program Compound during the first calendar quarter of 2001;
  - b. Records describing the various stages into which Abbott generally categorizes the pre-clinical and clinical development of experimental pharmaceutical compounds;
  - c. Records indicating when each Program Compound reached each stage of pre-clinical or clinical development into which Abbott generally categorizes the pre-clinical and clinical development of experimental pharmaceutical compounds;
  - d. Reports/Summaries/Meeting Minutes which evidence the current status of each Program Compound; and
  - e. Management Reports and/or other documents prepared in the normal course of business which indicate future prospects and development expectations for each Program Compound.

P. 1

 $\star$  COMMUNICATION RESULT REPORT ( APR.12.2004 3:22PM )  $\star$   $\star$ 

TTI JOHN HANCOCK

FILE MODE

OPTION ADDRESS (GROUP) RÉSULT

· †

MEMORY TX

918479376683

P. 5/5

OΚ

REASON FOR ERROR E-1) HANG UP OR LINE FAIL E-3) NO ANSWER

E-2) BUSY E-4) NO FACSIMILE CONNECTION

OND & CORPORATE FINANCE GROUP, T-57 .00 CLARENDON STREET **BOSTON, MA 02117** FAX: 617-572-1628/6454



To: JAMES Tyree	From: Steve Bleevith
Fax: 847 - 937 - 6683	Phone: 617-572-9624
Phone:	# of Pages 5 (including Court)
Date: 4/12/04	CC:
☐ Urgent ☐ For Review	☐ Please Comment ☐ Please Reply ☐ Please Recycle
• Comments: This facsimile	communication is strictly confidential and may be subject to

P. 1

\* \* \* COMMUNICATION RESULT REPORT ( APR.12.2004 3:37PM ) \* \* \*

TTI JOHN HANCOCK

FILE MODE

OPTION

ADDRESS (GROUP)

RESULT

PAGE

427 MEMORY TX

918479386277

OΚ

P. 5/5

REASON FOR ERROR E-1) HANG UP OR LINE FAIL E-3) NO ANSWER

E-2) BUSY E-4) NO FACSIMILE CONNECTION

BOND & CORPORATE FINANCE GROUP, T-57 200 CLARENDON STREET BOSTON, MA 02117 FAX: 617-572-1628/6454





To:	beneral Coun.	Sel From	: Strue	Blue. H
Fax:	847 - 938- 6d	רך · Phone		2 - 9624
Phone:		# of P:	ages: 5 (5	chidung cover
Date:	4/12/04	cci	7	
□ Urgen	nt 🗆 For Review	☐ Please Comment	☐ Please Rep	ly 🛘 🌣 Please Recycle

<sup>•</sup> Comments: This facsimile communication is strictly confidential and may be subject to legal privileges. This communication is intended for the solution.

P. 1

\* \* \* COMMUNICATION RESULT REPORT ( APR.12.2004 4:22PM ) \* \* \*

TTI JOHN HANCOCK

FILE MODE OPTION ADDRESS (GROUP) RESULT PAGE
129 MEMORY TX 96172484000 OK P. 5/5

REASON FOR ERROR E-1) HANG UP OR LINE FAIL E-3) NO ANSWER

E-2) BUSY E-4) NO FACSIMILE CONNECTION

BOND & CORPORATE FINANCE GROUP, T-57 200 CLARENDON STREET BOSTON, MA 02117 FAX: 617-572-1628/6454





□ Urgent	☐ For Review	☐ Please Comment	□ Please Reply	/ Please Recycle
Date:	4/12/04	ĊC;		
Phonet	,	# of Pag	1000 5 (in	duding cover
Fax: 6	17- 248-40	) è Phone:	417-	572-9624
To: Br	ian DAVIS	From:	Stur	Dlaw H

P. 1

 $\star$   $\star$   $\star$  COMMUNICATION RESULT REPORT ( APR.12.2004 4:25PM )  $\star$   $\star$   $\star$ 

TTI JOHN HANCOCK

FILE MODE OPTION ADDRESS (GROUP) RESULT PAGE

130 MEMORY TX 96172484000 OK P. 5/5

REASON FOR ERROR E-1) HANG UP OR LINE FAIL E-3) NO ANSWER

E-2) BUSY E-4) NO FACSIMILE CONNECTION

OND & CORPORATE FINANCE GROUP, T-57 .00 CLARENDON STREET BOSTON, MA 02117 FAX: 617-572-1628/6454





□ Urg	gent       For Review	☐ Please Comment	☐ Please Reply	☐ Please Recycle
Date:	4/12/04	¢¢;		
Phone	3:	# of Pa	ges: 5 (incl	udia love
Fax	617- 248-400			12-91024
To:	Michael Arthur L	unsh From:	Star bl	w.H

## PLs' OC

John Hancock Financial Services, Inc.

Bond and Corporate Finance Group

John Hancock Place Post Office Box 111 Boston, Massachusetts 02117 (617) 572-9624 Fax: (617) 572-1628 E-mail: sblewitt@jhancock.com

Stephen J. Blewitt Senior Managing Director John Hancock.

December 10, 2004

### BY TELECOPIER AND U.S. MAIL

James L. Tyree Vice President Global Licensing and New Business Development ABBOTT LABORATORIES 200 Abbott Park Road Abbott Park, Illinois 60064-6189

Re: Research Funding Agreement by and between Abbott Laboratories ("Abbott") and John Hancock Life Insurance Company, John Hancock Variable Life Insurance Company and Investors Partner Life Insurance Company (collectively, "John Hancock"), dated as of March 13, 2001 (the "Agreement")

### Dear Jim:

I received your letter of December 2, 2004, which contains various misstatements that I believe require correction.

First, the distinction that you attempt to draw between a "contingent" Annual Research Plan that turns upon the receipt of additional funding from John Hancock, and a non-contingent Annual Research Plan that reflects "planned spending under two scenarios," one of which is dependent upon the receipt of additional funding from John Hancock, is an obvious exercise in semantics. The Agreement provides, in relevant part, that "Abbott shall be solely responsible for the clinical development ... of Products" (see Section 4.1); that "Abbott shall use Commercially Reasonable Efforts to conduct the Research Program ... to achieve the objectives of the Research Program efficiently and expeditiously..." (see Section 2.3); and that "Abbott shall not ... develop ... or otherwise treat any Program Compounds or Products differently, as compared to any other Abbott compounds or products" on account of John Hancock's involvement (Section 4.4). Consistent with the foregoing requirements, Sections 1.6 and 2.2 place upon Abbott the obligation to provide John Hancock each year with an Annual Research Plan containing a "reasonably consistent detailed statement of the objectives, activities, timetable and budget for the Research Program" as determined by Abbott. The amount of funds budgeted each year by Abbott is entirely up to Abbott, so long as it reflects "Commercially Reasonable Efforts" as defined in the Agreement. Taking John Hancock's participation into account in determining the appropriate level of anticipated spending, however, is neither called for, nor permitted.

Letter to Mr. James L. Tyree ABBOTT LABORATORIES December 10, 2004 Page 2 of 3

I understand from the enclosures to your letter of November 16 that Abbott currently expects that its expenditures on Program Related Costs over the four-year Program Term will total \$486.3 million. I further understand from your November 16 and December 2 letters that it is Abbott's intent and reasonable expectation to expend approximately \$62.8 million on Program Related Costs in 2005, which will bring Abbott's total expenditures on Program Related Costs over five years (i.e., the four-year Program Term and the subsequent year) to approximately \$549.1 million. To the extent that Abbott believes that the ments of the Program Compounds actually warrant the expenditure of \$149.8 million on Program Related Costs in 2005 as stated in your November 16 letter, I urge Abbott to engage in "Commercially Reasonable Efforts" and increase its anticipated spending to that level in order to "achieve the objectives of the Research Program efficiently and expeditiously" as required under the Agreement. Abbott's most recent Form 10-O, which was filed on November 4, 2004, states that, as of September 30, 2004, Abbott had on hand cash and cash equivalents and investment securities of more than \$2.1 billion, and shareholders' investment of more than \$12 billion, which reserves are more than adequate to permit Abbott to spend whatever funds are reasonably required in the circumstances. In addition, in each of the last four years, according to Abbott's public securities filings, Abbott has spent over \$1.5 billion on research and development. To suggest that not receiving the \$52 million that John Hancock allegedly owes for 2004 -- which would constitute approximately 3.5 percent of Abbott's annual spending on research and development -- warrants a 58 percent reduction in Abbott's intended spending on Program Related Costs in 2005, is not "Commercially Reasonable." In light of these facts, Abbott's failure to fulfill its funding obligations will constitute a violation of the Agreement and may give rise to additional claims by John Hancock.

Furthermore, your statement that, "under either scenario Abbott's spending will exceed its \$400 million portion of the Aggregate Spending Target independent of Hancock's payments to date" misperceives the spirit and the terms of the Agreement. Section 3.2 of the Agreement provides that "Abbott shall spend on Program Related Costs ... at least the Aggregate Spending Target during the Program Term." Section 1.3 defines the Aggregate Spending Target as "Six Hundred Fourteen Million Dollars (\$614,000,000)," not "\$400 million" as you represent in your December 2 letter. Abbott's voluntary decision in 2002 to spend less than \$614,000,000 over the four-year Program Term automatically terminated John Hancock's "obligation to make any remaining Program Payments for any succeeding Program Years" pursuant to Section 3.4(iv) of the Agreement, but did nothing to change the amount of the Aggregate Spending Target that Abbott is required to exceed.

Finally, Section 2.5 of the Agreement requires Abbott to provide John Hancock with "other information" concerning the Research Program and Program Related Costs "as John Hancock may reasonably request from time to time." The specific categories of other information that John Hancock requests at this time pertain to the details of Abbott's intended and expected spending on Program Related Costs under its current \$62.8 million Annual Research Plan budget for 2005, including the relevant program timelines, clinical program objectives, description of

Letter to Mr. James L. Tyree ABBOTT LABORATORIES December 10, 2004 Page 3 of 3

Abbott's internal activities, and the details concerning Abbott's out-licensing activities and efforts with respect to ABT-492 and ABT-724. Please contact me as soon as possible to schedule a conference call to discuss these matters. As previously stated, John Hancock is prepared to agree that any such call will be subject to, and governed by, the terms of the Non-Use Agreement that currently is in effect.

This letter is sent without prejudice to John Hancock's claims and defenses in the pending litigation and is not intended to, and does not, constitute a waiver of any rights or claims that John Hancock has or may have arising under, or related to, the Agreement.

Very truly yours,

Stephen J. Blewitt

Senior Managing Director

## PLs' OW

John Hancock Financial Services, Inc.

Bond and Corporate Finance Group

John Hancock Place Post Office Box 111 Boston, Massachusetts 02117 (617) 572-9624 Fax: (617) 572-1628 E-mail: sblewitl@jhancock.com

Stephen J. Blewitt Senior Managing Director John Hancock.

April 1, 2005

### BY FAX AND U.S. MAIL

Mr. James L. Tyree Vice President Global Licensing and New Business Development ABBOTT LABORATORIES 200 Abbott Park Road Abbott Park, IL 60064-6189

Re: Research Funding Agreement by and between Abbott Laboratories ("Abbott") and John Hancock Life Insurance Company, John Hancock Variable Life Insurance Company, and Investors Partner Life Insurance Company (collectively, "John Hancock"), dated as of March 13, 2001 (the "Agreement")

#### Dear Jim:

...

Abbott Laboratories and John Hancock Life Insurance Company, John Hancock Variable Life Insurance Company and Investors Partner Life Insurance Company (now known as "ManuLife Insurance Company"), dated as of March 13, 2001 (the "Agreement") to identify certain further disputes that have arisen between John Hancock Life Insurance Company, John Hancock Variable Life Insurance Company and ManuLife Insurance Company on the one hand (collectively, "John Hancock"), and Abbott Laboratories ("Abbott") on the other, with respect to the Agreement. The further disputes of which John Hancock currently is aware are as follows:

- (a) Abbott unreasonably and unjustifiably has hindered, delayed and obstructed John Hancock's attempts to audit Abbott's compliance with the terms of the Agreement as expressly permitted under Section 2.5 of the Agreement, and accordingly has failed to demonstrate that it actually has made expenditures on Program Related Costs as represented in its written reports to John Hancock;
- (b) Abbott misrepresented the development status of ABT-518 to John Hancock prior to, and at the time of, the execution of the Agreement;
- (c) Abbott misrepresented the development status of ABT-594 to John Hancock prior to, and at the time of, the execution of the Agreement:



- (d) Abbott has misrepresented its "in tended and reasonably expected" expenditures on Program Related Costs in the Annual Research Plans that it has provided to John Hancock;
- (e) Abbott unreasonably and unjustifiably has failed to use Commercially Reasonable Efforts to develop the Program Compounds;
- (f) Abbott unreasonably and unjustifiably has refused to provide John Hancock with a copy of its modified 2005 ARP; and
- (g) Abbott unreasonably and unjustifiably has failed to out-license or divest itself of certain Ceased Compounds, including ABT-492, ABT-518 and ABT-594, "as soon as is practicable" as required under Section 4.3(d) of the Agreement.

Please be aware that, as a result of the foregoing violations by Abbott of its representations, warranties and obligations under the Agreement, which John Hancock believes may have been committed willfully and wantonly, Hancock has sustained Losses for which it intends to claim indemnification from Abbott under, inter alia, Sections 1.27, 12.6 and 12.8 of the Agreement.

John Hancock is prepared to participate in an executive meeting within thirty (30) days of this notice for the purpose of attempting to resolve the above-referenced disputes in accordance with the requirements of Section 16.7. I invite you to contact me at your earliest convenience to schedule such a meeting.

Very truly yours,

Stephen J. Blewitt

Cc: President – Abbott Pharmaceutical Products Division (by U.S. Mail)
General Counsel – Abbott Laboratories (by U.S. Mail)
Lawrence R. Desideri, Esq. (by fax)
Peter E. Gelhaar, Esq. (by fax)
Brian A. Davis, Esq. (by fax)

: \* \* COMMUNICATION RESULT REPORT ( APR. 1.2005 2:53PM ) \* \* \*

TTI JOHN HANCOCK

P. 1

FILE MODE OPTION ADDRESS (GROUP) RESULT PAGE
767 MEMORY TX 29268 OK P. 3/3

REASON FOR ERROR

E-1) HANG-UP OR LINE FAIL

E-3) NO ANSWER

E-2) BUSY E-4) NO FACSIMILE CONNECTION

BOND & CORPORATE FINANCE GROUP, T-57 200 CLARENDON STREET BOSTON, MA 02117 FAX: 617-572-1628/6454



Fax

To: $\gamma$	an Minish	i Än From:	Steve 18	lew.H
Faxe	29268	Phone	: 417-572	- 5624
Phone:		# of Pa	ges (3/ now	ding cover)
Dates	4 ilos	CC:		
□ Urgent	☐ For Review	☐ Please Comment	□ Please Reply	☐ Please Recycle

<sup>•</sup> Comments: This facsimile communication is strictly confidential and may be subject to legal privileges. This communication is intended for the sole use of the individual(s) or legal privileges.

\* \* \* COMMUNICATION RESULT REPORT ( APR. 1.2005 2:51PM ) \* \* \*

TTI JOHN HANCOCK

FILE MODE OPTION ADDRESS (GROUP) RESULT PAGE
756 MEMORY TX 21565 OK P. 3/3

REASON FOR ERROR E-1) HANG UP OR LINE FAIL E-3) NO ANSHER

E-2) BUSY E-4) NO FACSIMILE CONNECTION

BOND & CORPORATE FINANCE GROUP, T-57 200 CLARENDON STREET BOSTON, MA 02117 FAX: 617-572-1628/6454





To: K	ren Mata	From Steve Blew. H	
Fax	41565	Phone: 117-573- 163	
Phones		# of Pages 13 ( nulling ca	1
Date:	4/1/05	CC)	<del></del>
□ Urgent	☐ For Review	☐ Please Comment ☐ Please Reply ☐ Plea	se Recycle

<sup>\*</sup> Comments: This facsimile communication is strictly confidential and may be subject to legal privileges. This communication is intended for the sole use of the individual(e) or

\* COMMUNICATION RESULT REPORT ( APR. 1.2005 3:49PM ) \* \* \*

TTI JOHN HANCOCK

FILE MODE OPTION ADDRESS (GROUP) RESULT 96172484000 MEMORY TX ОK P. 3/3

BUSY NO FACSIMILE CONNECTION

BOND & CORPORATE FINANCE GROUP, T-57 200 CLARENDON STREET BOSTON, MA 02117 FAX: 617-572-1628/6454





To: Brim DAVO		From:	<u> Steve</u>	Howitt	· . · · · .
Fax: 617-248-460	)	Phone:	<u> </u>	572- 46	24
Phone:		·# of Pages:	3/in	huding con	w \ _
Date: 4/1/67		cc:	(.		<del></del>
□ Urgent □ For Review	v 🔲 Please Con	nment OP	leaso Rep	ly 🖸 Pis	ase Recycle

<sup>•</sup> Comments: This facsimile communication is strictly confidential and may be subject to legal privileges. This communication is intended for the sole use of the individual(s) or

## PLs' OZ

Abbott

Global Pharmaceutical Licensing and New Business Development D-R50J, AP34 200 Abbott Park Road Abbott Park, IL 60064-6187

Tel: (B47) 937-1438 Fax: (847) 937-1771 Email: suzanne a lebold @abbott.com



January 20, 2006

## VIA EMAIL AND FEDERAL EXPRESS

Mr. Stephen J. Blewitt Senior Managing Director Bond & Corporate Finance Group John Hancock Life Insurance Company John Hancock Place Post Office Box 111 Boston, Massachusetts 02117

Re:

Research Funding Agreement Between Abbott Laboratories ("Abbott") and John Hancock Life Insurance Company, John Hancock Variable Life Insurance Company and Investors Partner Life Insurance Company (collectively, "Hancock") Dated March 13, 2001 (the "Agreement")

Dear Steve:

Per my e-mail yesterday, enclosed please find Abbott's preliminary Annual Research Plan for 2006, in accordance with Sections 1.6 and 2.2 of the Agreement.

In addition, in accordance with Section 2.5 of the Agreement, please also find the research report concerning the status of the Research Program and all Program Related Costs expended by Abbott for the first eleven (11) months of 2005, together with good faith estimates for the last month of 2005.

Sincerely

Suzanne A. Lebold, Ph.D. Divisional Vice President

Scientific Assessment and Technology Licensing

Cc:

Via Federal Express

John Hancock Life Insurance Company

200 Clarendon Street, T-57

Boston, MA 02117

Attn: Bond & Corporate Finance Group

John Hancock Life Insurance Company

200 Clarendon Street, T-50

Boston, MA 02117

Investment Law Division

CONFIDENTIAL

CONTIDINTIAL

Global Pharmaceutical Research and Development
Hancock Funding Agreement
Spending by Program in millions of dollars

<u>L'</u>	Tetal 1006	6,0	27.4		_	_	_	2144 31,3	8	2	77	3 6		<u></u> -	2 :			671																			
	9001	0'0	0.0,	16.7	6	2 6	_	43.1	0.0	ב	TO	6	; <u>;</u>		3 6	2 6	2	0.0		ļ	2002	6,0	27.4	£02	3.7		! ;		3 ;	; ;	1:	6 6	20.5	: 2	96	249.1	į
1	ž	0.0	0.0	3.52	0.0	5	3 ;	¥.	2	2	<u>.</u>	0.0	13.5	6	3 6	. 3	ž	2.0		}	7967	6.0	52.4	63.2	3.7	6.3	1314	9		! :	! ;	1 9	23.5	e.c	0.8	470.7	į
ł	3	0.0	7	3	0.0	00		7.00	ม	<b>1.</b> 0	62	9.6	11.0	8	0	8	17.1	07		l	2002	9.	37.4	39.6	3,7	93	132.9	1	5	20	: :	27.1	23.2	2	9.0	390.1	;
		7	211.7	3	0.0	3		į	=	2.	0.0	3.5	9'6	13.8	1.9	6.8	131.3	10,0		I	2962	Q**	3	21.12	3.7	22	773	1	3	00	<b>:</b> 5	<u> </u>	; ;	3.	2,0	303.0	;
\$	1	3.6	20.5	7	3.7	7.8			0.0	0.0	0.0	3.2	6.5	5	3		177.1	d.		ŀ	1007	3.6	1,04	2	3,7	7.8	34.1	0.0	00	0.0	11	2	Con	3	22	171.7	ć
	E				500	Mento Pala	Althornation Bess		-	•		Dependent Agranis	And-Misorie	1	ļ	Oppe	Total	Mangatant Foe / Milosopa			ł		Quinclose	12 <i>p n</i> i	MAAPT	Nearo Pata .	Abnesentas Buse	Abrestes Homose Naive Protests Cason		Non-Promote Canoury	Dependes 4 Agracia	Anti-Misodo	Base		Odber	196	Management Fee / Milestrans
	ABT-100	ABTAB		DIC-16V	ABT-5)8	ABT-394	ABT-427	ABTAN		9	ABT-617	ABT-724	ABT-751	ABT-773	ABT-773			Memoc	Commission		APT Ind				ABT-518	ABT-SP	ABT-617	ABT-627	VBT-C27	ABT-627	ABT-627	ABT-751		L ET-TEA	-	r <b>-</b>	Maner

J
₹
Ľ
2
Щ
Q
I
Z
Õ
Ū
_

 Month 11
 Month 12
 Total Vear 2005

 2005
 2006
 2006

 2005
 2006
 2006

 15.3
 1.4
 16.7

 39.0
 4.1
 43.1

 0.0
 0.0
 0.0

 1.4
 0.1
 1.6

 0.9
 0.0
 1.0

 11.1
 1.0
 1.2.1

 0.0
 0.0
 0.0

ABT-627 Atrasentan Hormone Naive Prostate Cancer

ABT-627 Atrasentan Base

ABT-510

ABT-627 Non-Prostate Cancers

ABT-751 ABT-773

ABT-627 Japan

Global Pharmaceutical Research & Development Hancock Funding Agreement Spending by Program in millions of dollars


Total Program Spend

CONFIDENTIAL

GPKD 2006 Plan. ABTSI WA' - Servema	Total Tailout	720	902	Body 60th	DATES SOM OF		oal Activities:	ing and Controls		Ct. Landing of the Ct. Ct. Ct. Ct. Ct. Ct. Ct. Ct. Ct. Ct.		Tetal Eriorial	2006 Plea /77Es	671	į	and (Carl) Love (Carl)		2.7 2.0 Chimal working	toold the same of		Todal Pilles 35,0
	T	Control and Place	The COST Philadell 18	MOCCOS Plane II IS	President Colleboration	LECKALING Prince II ABI - 4 (V *: WIP-VEL)*	Subtitue Citrical Activities:	Chemistry, Menutacianing and Controls	GATAS	Pro-Californi Godiff Evaluation	Pro-Chical Epidop	Clecoping	Internal	Clinitial Physicales Contact Project Team	Para Contractual		Chienistan, Manufacturing and Controls (CMC)	GPAS Provent Barn	Pro-Catigated Sented Estational	California Subject Cipel	No.


CONFIDENTIAL

ABT617/E - Horm	SERVICE - Hormone Refrectory Produce Cancer Rescove	er Resouve			
	Total Periods	Zen.	THE STATE OF	2006 Place Hibbled	
Externel and the second and the second sections of the second sections of the second sections of the second sections of the second seco			7	3	
LACO SCO Cambination Printitionals decontains evid 637 4Metry december in	₹-	25	3	憂	
CLOS SOCK Planes III (Cross Version Services Control of the Contro	0001	2742	5	200°11	
MOD SHAPWING nonestablished Prostate Canon Pit 81	Ŧ	18/	Ę	ST(1)4	
STANDED ACCOUNTS				į	
Careton Project There				.0031	
Pro-Clarital Selecty Brahamion				9	
Pistakial Belay	1 label	Total External		\$11,848	
Internal.		2006 Clear Dates, United			
			2		
Chickel Poster Team					
53					
6650					
					<i>-</i>
Chambled by Bernspieler in the second of the common terms of the c					_
Pro-Carrie and Parkety Freedom Co.					
				•	
Discovery Programme 22					
6,15 43171abl					7



	ı
•	ľ
	į
	3
7	ζ
'n,	į
	3
1	ė
1	3
4	4
C	3
E	2
•	_

•	TILL YELL	ABT677/H - Non-Ch Concert Rescope		7.5	PARK Place S/BODE
Probrault	-	Tetal Lationix	) Jane		TAXA CHANGE BEREIT
Conjoy Actibities; VART Corne for Br VART Corne for Br VART Corne for Br VARAN (2006 Deleborator) Pittee Ib VARAN (2006 Deleborator) Pittee Ib VARAN (Biother Corner Frame Ib		282	855 855 855	12-07 10-07 10-07	10 Per 10
Cinical Program  Cinical Program  Dun Stond Menophrisa			٠		8.8
Christ Pined Them		Total Edentral	TITLE		.51,247
letional;	1006 Flax CTEs		1006 Plan Other Chilis	ANO.	
ere. Ject Townk niter (4,2°4,17)	2.1 0.0 0.0				
Experimental functions (per; repeat to:) Establishe Childral Caparitation (is non-EUU) Desirations (Childral Caparitation (is non-EUU) Central Service functions (in the Childral Caparitation)	8.1 1.5				
Pra-Ciferical Baleny Designation Pra-Ciferical Sefety	ទប		•		•
Other Bippowi Cort	0.1				
	Total FIEs. 8.4				



Companies   Comp						4
		GPRD 1995 Zienes IV Straties				-
100   100	Esternals	Their District		First.	24MCTion STREET	
Program	Chindred Activities:  ECOT Children (Air N SWOOD SOLET Children fin N SWOOD SOLET Children fin N SWOOD SOLET Children fin N	00T 86T		# <b>\$</b> .		
Technical Control Co	_				8.2	
Truggers  And Property Teach  And Property Teach  And Property Teach  And Property Teach  And Property Teach  And Property Teach  And And And And And And And And And And		1961	il External		ALT 145	
in the Train of the Page (CA) of the Cap	general contract of the contra	286 Day ITEs	109/ New Oder	AR.		
Contact (APALI)  read building that Press (CA)  read building that Press (CA)  read building that Press (CA)  read building that Press (CA)  read CA	Clinical Programs	3.5				_
Total Files	VACLO GOSpo Speed Phone	<b>9</b> 00	,			
Agent Enthalism	Outsignment Operations Dieg Billiefe standard					
ort Cost	The Control of the Co	3				
	orticols					
	O)					

### John Hancock Development Portfolio Annual Progress Report (January 2006)

### 1) ABT-627

- a) Phase 3 pivotal trial M00-244 in non-metastatic HRPC is expected to complete within the second quarter of 2006. Decision and timing regarding a New Drug Application will be based on the outcome of the trial and the timing of data, respectively.
- b) Study M01-366 in hormone-naive early stage PCa was completed in March 2005. The trial did not demonstrate a treatment effect of atrasentan on PSADT compared to placebo.
- The pharmacokinetic study of atrasentan in combination with docetaxel (Study M03-655) is fully enrolled and a favorable pharmacokinetic, safety and efficacy profile was observed with the combination in patients with metastatic HRPC.
- The SWOG is planning to initiate a Phase 3 multicenter trial of docetaxel with or without Xinlay in men with metastatic HRPC. The trial is planned to start in late second quarter of 2006
- e) The Japan pharmacokinetic trial (M02-466) was completed with a favorable, linear pharmacokinetic profile of atrasentan in Japanese HRPC patients, generally consistent with the PK seen in Caucasian volunteers. There were no safety concerns identified in the Japanese patients in doses up to 20mg. The companion study M03-593 in Caucasian patients has enrolled the 10 mg cohort of patients with the 2.5 mg cohort currently enrolling. The study is expected to end by the end of 3Q06
- The Non-prostate cancer clinical strategy for Xinlay is under review, with clinical and/or preclinical signals identified in ovarian cancer, malignant glioma and bladder cancer. Collaborations are underway with NABTT, GOG and the University of Virginia to develop clinical trials for these indications. Five ongoing investigator initiated trials are expected to be completed by the end of 2006

## 2) ABT-510

- a) Phase 2: Studies in Renal, Lung, Lymphoma and Sarcoma completed.
- b) Randomized Phase 2b study combining ABT-510 with a multi-targeted kinase inhibitor (e.g. sorafenib or sunitinib) in advanced renal cell carcinoma is in preparation.
- c) Data do not warrant proceeding in Non Small Cell Lung Cancer. Small response rate observed in Lymphoma; strategy being developed.
- d) Phase 3: Phase 2 Sarcoma study and Phase 3 sarcoma strategy reviewed with FDA and EMEA. Based upon regulatory agency guidance and a subsequent feasibility study, the Phase 2 sarcoma study showed insufficient separation from historical control to proceed with the Phase 3 sarcoma trial.
- e) Collaborations:
  - Melanoma study stopped after 21 patients did not achieve efficacy target at interim analysis. Follow up studies evaluating a higher dose of ABT-510 and ABT-510 in combination to be initiated.
  - ii) Three studies ongoing in Head and Neck Cancer, Glioma (brain cancer) and in GI solid tumors in combination with Avastin.
  - iii) Two three additional studies in preparation evaluating ABT-510 in combination therapy in breast cancer and prostate cancer.

CONFIDENTIAL

## 3) ABT-751

a) Phase 1:

- Two Abbott-sponsored Phase 1 studies are complete. A total of 112 patients were enrolled. MTDs have been determined for the four dose schedules interrogated in these studies.
- ii) Two Collaborative Phase 1 studies are either completed or ongoing. A total of 93 patients were enrolled to date.
  - (1) Study in pediatric cancer ongoing with 61 patients enrolled; amended to include a neuroblastoma only cohort
  - (2) Study in adult leukemia has been completed after enrolling 32 patients (published)
- b) Phase 2: Four Phase 1 trials enrolled 209 patients
  - i) Renal Enrollment complete, patients active.
  - ii) Lung Enrollment complete, patients active.
  - iii) Colorectal Enrollment complete. No patients active.
  - iv) Breast Enrollment stopped and study discontinued after interim analysis failed to meet pre-specified criteria for efficacy. No patients active.
- c) Collaborations: Four collaboration studies are underway. Two pediatric collaborations studies are in the planning stages.
  - i) Collaborations are underway in colorectal cancer, lung cancer and prostate cancer, with both ABT-751 as a single agent, and in combination.

4) ABT-773

Advanced Life Sciences now controls this asset pursuant to the license agreement executed in late 2004 with John Hancock's consent. The development plan is outlined in the company's S-1 document; they are continuing Phase III development with the Intent to register the asset.

5) ABT-492

Wakunaga approached Abbott regarding the return of rights to the asset so that they could out-license the asset or further develop it on their own. Abbott has successfully negotiated the return of rights agreement and has requested consent from John Hancock in order to effectuate this transaction.

6) ABT-724

A small biotechnology company has expressed an interest in the asset, but it must first secure funding to support the license. The fact that the Phase I data did not demonstrate spontaneous erections has been a challenge to potential licensees. We will continue to discuss this asset with prospective partners as appropriate.

CONFIDENTIAL


# PLs' PC

Shoote President

Filed 01/28/20028937 Fage 2 of 7

Email: suzanne.a.lebold@abbott.com

Scientific Assessment & Technology Licensing Abbott Dept. P50A, Bidg. AP34-2 200 Abbott Park Road Abbott Park, IL 60064-6187



November 20, 2007

## VIA E-MAIL AND FEDERAL EXPRESS

Mr. Stephen J. Blewitt
Senior Managing Director
Bond & Corporate Finance Group
John Hancock Life Insurance Company
John Hancock Place
P. O. Box 111
Boston, MA 02117

Re: Research Funding Agreement Update

Dear Steve:

In accordance with Sections 1.6 and 2.2 of the Research Funding Agreement ("Agreement"), enclosed please find Abbott's preliminary Annual Research Plan for 2008.

You will also find, in accordance with Section 2.5 of the Agreement, a report concerning the status of the Research Program and all Program Related Costs expended by Abbott for the first 10 months of 2007, together with good faith estimates for the last two months of 2007.

Sincerely.

Suzanne A. Lebold, Ph.D Divisional Vice President

Scientific Assessment and Technology Licensing

cc: Via Federal Express

John Hancock Life Insurance Company

200 Clarendon Street, T-57

Boston, MA 02117

Attn: Bond & Corporate Finance Group

John Hancock Life Insurance Company

200 Clarendon Street, T-50

Boston, MA 02117

Attn: Investment Law Division



14.0

Global Pharmaccutical Research & Development Hancock Collaboration

		3	Talence Con							
		S	Spending by Program	Ргодгат						
			in millions of dollars	dollars .						
								LBE		PLAN
		1002	2002	2003	7007	2002	2006	2007	Total	20418
	4	16	7.7	8	0.0			00	6.9	0'0
ABI-100		102	78.7	4.1	00			0.0	52.6	0.0
ABI-NE		90 90	11	18.5	23.6			6.0	85.1	0.0
AB1-510		17	0.0	0.0	00			0.0	3.7	0:0
ABT-518		7.8	4	00	0.0			0.0	9.3	0.0
ABT-594	עודגו טודגו	) - 12 - 12	1.84	50.7	38.4	38.7	22.9	2.4	235.3	8.0
ABT-627	Altrosentan Base	,	2	51	7			0.0	<b>5.6</b>	0.0
ABT-627	Altrentan Hormone Naive Prostate Canori	2 6	! =	0.7	. 15			9'0	4.8	0.0
ABT-627	Japan		; ;	! 5	. 01			0.0	17	0.0
ABT-627	Non-Prostate Cancers	00	3	• •				0.0	5.6	0.0
ABT-724	Dapamine 4 Agonist	7. T	ç.	e ;				717	91.2	13.9
ABT-751	Anti-Mitotic	6.5	9.6	110	13.5				710	5
ABT-773		803	13.8	(0:0)	03			0.0	D. C.	0.00
		-	6:1	0.0	00			00	ว	2
7PI-19V		. 6	8.9	0.0	00	•	,	0.0	9.0	0.0
	כֿפַש	1	12.	87.1	80.6			7.5.7	615.1	14.7
	Total	1/11:	2			_	D			
Mema	Management Fee / Milestones	000	10 0	20	2.0	0.0	00	00	14.0	0.0
Cumulative	ive	•	50	1001	7007	2005		2007		
		100	7007	<b>]</b>	3	1 5		09		
ABT-100	H (	36	9	0 1	9 (	, (		5.5		
ABT-492	Quinolone	- PE	48.3	52.4	52.4	<u>, , , , , , , , , , , , , , , , , , , </u>		) . i		
ABT-510		50 50	1.12	39.6	63,2	76.	Z '	97.		
ART-518		3.7	3.7	3.7	3.7	3.7		). (		
4 DT 504		7.8	9.7	92	93	9.2		9.1		
707.00		34.1	82.2	132.9	171.3	210.0		235.3		
10-10-C		0.0	11	1.7	6.0	93		9.4		
70-194		00	0.1	0.3	8.1	3.3		<b>4</b>		
ABI-62/	lapar	00	0.0	0.2	7	77		13		
VF0-19V		-	7.8	9.5	9.5	9.5		9.5		
ABT-627			19	27.1	907	52.9		91.2		
ABT-751	1 Anti-Mitotic	50 6		91.7	2.19	936		936		
ABT-773	3 Base	2	Ī	) I	; ;	;		1.1		

Memo: Management Fee / Milestones

Japan Odker

ABT-751 ABT-773 ABT-773

Global Pharmaceutical Research & Development

Hancock Collaboration Spending by Program in millions of dollars

2007 2007 2007 2007	0.0 0.0 0.0	6.0 0.1 0.1 0.9	e 2.0 0.2 0.2 2.4	0.0 0.0 0.0	0.5 0.0 0.0	0.0 0.0 0.0	18.1 1.8 1.8	0.0 0.0 0.0	21.4 2.1 25.7
	Quinolone	TSP #1	Altrasentan Base	Altrsentan Hormone Naïve Prostate Cancer	Japan	Non-Prostate Cancers	Anti-Mitotic	Basc	F

ABT-492

ABT-510

Total

ABT-627 ABT-627 ABT-627 ABT-751 **ABT-773** 

**ABT-627** 

		Case (Single)	
Project	Task Name	6,777,8	26.4
60631282 ABT751 Base Program	ine Program		0.0
≤.	ADME/ADME Lacted Tansier in II		0.0
<u> </u>	ADME / ADME Placental I ransier I'n II	0.0	0.0
<u></u>	CMC Ph 11b 2007 NSCLC & Peds / Drug Product Support Pn 11b	0.0	
<u>ں</u>	CMC Ph IIb 2007 NSCLC & Peds / Drug Substance Support Ph 11b	150.0	0.0
<u> </u>	CMC Ph IIb 2007 NSCLC & Peds / Formulation Development Ph III Stage I		0.0
<u>- L</u>	CAN DE HIS DOOR IN SOCIETY & Park / Pren GMP Drug Substance Ph III Stage I	p'o .	•
٠, ٠	The full to control of the first of the firs	320.0	7.0
٠	CALL PRINCIPLE SUPPLIES SUPPLIES SUPPLIES TO A SUPPLIES TO A SUPPLIES SUPPL		7. 0
ੁ	CMC Ph IIb/ III Clinical Support Stage 1 (2008) / Furnituation Levelphine III 5		0.7
یں	CMC Ph 111/ 111 Clinical Support Stage 1 (2008) / Prep Clinical Supplies Ph 111 Singe 2	90	
	CNC Ph 111/ Hi clinical Sunnort Stare 1 (2008) / Frep GMP Drug Substance Ph III Stage 2	3	•
٤	And the state of the state of the State I / Date Product Sumon Ph II State I		3
<b>∠.</b> ,	M. Fri Helli Cineta Supplie Andre Supplies Comment of Histories 1		0.0
<u>~</u>	CMC Ph Ilb/III Clincial Support Adult Stage 1.7 Formanion Conceptions 1.7.	0.0	<del>-</del>
=	Discovery / Discovery 2008	130.0	0.2
	Discovery 2007 / Preclinical Models ROSS (turners and combo agents)		0.8
	Mn1-157 NCI Pediatric Drug safety and supply only Ph 1/ Clinical Trial Support Ph 1		0
	2011-257 NCI Podiarrie Drus cafery and supply only Ph I / sIND related to M01357 Clinical Trial Support Ph I		3 6
	August 1857 Control of the many of the Many of the Many National Country of the Country of the Many of		•
7-	NIO3-780 Adult NSCLE Contro with All Ministers and All All All Alimin Clinical Trial Support Pit (1b		9
	M05-780 Adult NSCLC combo with Alimia for this of victor of section with Alimia front manner of the lib		0
	M05-780 Adult NSCLC combo with Alimia Ph 1/116 / Adult NSCLC combo with Alimia Ph 1/116 / Adult NSCLC combo		Ī
	Mo5-780 Adult NSCLC combo with Alimta Ph (Alb / Adult NSCLC combo with Alimta reporting ra	2.270.6	
	M05-780 Adult NSCLC combo with Alimia Ph I/Ilb / Adult NSCLC combo with Alimia MOS 11 11 11 11 11 11 11 11 11	i	0.0
	N05-782 Adult NSCLC combo with Taxotere Ph I/IIb / Adult NSCLC combo with Taxotere Cunical Supplies for the unio	0.50	7.1
	Mos-782 Achit NSCLC combo with Taxotere Ph 1/11b / Adult NSCLC combo with Taxotere Clinical 11th Support in 11th	001	
	And, 282 Ashir NSCLC combo with Taxotere Ph 1/11b / Adult NSCLC combo with Taxotere Eurollment Treatment Ph 1/11b	2	3 6
	Anna-722 Adult NSCI Combo with Taxolone Ph 1/11b / Adult NSCLC combo with Taxotone Reporting Ph Ph 1/11b	5014.	2
	AND THE ACT IN COMPANY TAXGET PROJECT PARTIES AND ADMINISTRATION OF THE PROJECT PORTION OF THE PROJECT PARTIES AND THE PROJECT PORTION OF THE PROJECT PARTIES AND THE PROJECT PORTION OF THE PROJECT PARTIES AND THE PROJECT P	5,137.3	3 6
	MUSTREE Adult SSCIENCE Control of the Management of the Neurophysical Supplies Ph 2		
	- '		-1
	_		
		\$43.8	
	M06-803 Phase II COG Peds Neuroblastoma Ph 27 C.Ug Feds Neuroblastoma (NOS) 107-71 11.		
	MYY-021 TACI. Pediatric leukemia Ph IIb / TACL Pediatric leukemia Cinitea Supplies fu 110		
	NIYY-021 TACL Pediatric leukemia Ph 11b / TACL Pediatric Jeukemia Clinical I rial Support Fri 110		0.5
	Myy-021 TACL Pediatric feukemia Ph 11b / TACL Pediatric feukemia Eurollment Treatment Ph 11b		50
	NOV. AND CAS Profession solid tumors Ph 2 / COG Pediatric solid tumors Clinical Supplies Ph 2		
	1911 - Constitution of the Constitution of the Constitution of the Clinical Trial Support Ph 2		. ·
	17 1-22 Control control of the Contr		
	NY T-222 COOL Committee and Control and Cooking the Cooking of the		
	MYY-222 COU regarine solutionary files to con-	389.2	
	MYY-021 COO Pediatric Solid Minnis First, Cool Figure Constitution Con		
	MYY-038 CFCR Funded studies Ph II / General Study Support	0.0	
	WYY-039 Ph III Lung combo with Alimia pivotal same of the combo with Taxofere Pivotal Pre ROSS Ph III	0.0	
	MYY-039 Ph III Lung combo with laxetere pivents safely and enteract 7 Lung combo	0.0	2.2
	QA Regulatory and GPT Support ( QA Regulatory and OFT support 11111 2002) The content of the American Onsidification ( TxxxAAO Analysis and Report		0.2
	LAKYAN COMMINING		

SWOG SO421 Collaboration Ph IV

Citaical Activitles:

External

## John Hancock Development Portfolio Annual Progress Report – November 14, 2007

## 1) ABT-751

- a) Two Collaborative Phase 1 studies
  - i) A Phase 1 with an extension cohort of 52 pediatric neuroblastoma patients was completed
  - ii) A study in pediatric leukemia is ongoing with 5 patients enrolled
- b) Two Phase 2b combination studies have been initiated.
  - i) ABT-751 in combination with pemetrexed versus pemetrexed in advanced lung cancer with a total of 165 patients enrolled to date.
  - ii) ABT-751 in combination with docetaxel versus docetaxel in advanced lung cancer with a total of 71 patients enrolled to date.
- c) Collaborations: Four collaboration studies are ongoing
  - i) Collaboration studies are ongoing in colorectal cancer, lung cancer and prostate cancer, with both ABT-751 as a single agent, and in combination.
  - ii) A collaboration Phase 2 study in pediatric neuroblastoma is ongoing with 27 patients enrolled.


## 2) ABT-627

- a) Abbott is providing support for a collaboration study with the Southwest Oncology Group (SWOG) to study taxotere +/- ABT-627 for treatment of men with metatstatic hormone refractory prostate cancer. 54 patients are enrolled as of November 2007.
- b) All monotherapy studies with ABT-627 have been closed. Four patients remain on treatment via a patient-named IND basis. One patient in the pilot study for taxotere +/- ABT-627 remains on treatment.


## 3) ABT-510

a) Data from ongoing IIS studies has not provided clear signals of activity. Preclinical models continue to demonstrate anti-tumor activity. Collaboration is being sought to support continued development.

## PLs' PE





DRAFT - FOR DISCUSSION PURPOSES ONLY



CONFIDENTIAL

ABBT 9006862





## PLs' PH

ITIAL PORT	FOLIO	PRIORITIZATION		C- continue P- pending T- terminate
Project	Priority	Next steps	Responsibility	Timing
Anti-infectives ABT-492	С	Address safety issues (including QTc) with internal/ expert review     Determine how many indications at launch (pay back)	• J. Leonard	-
HSR-903	T	Consider trading with Dalichi     Halt any new expenditure	- J. Tyree	-
ABT-773	С	Assess side effects issues with expert review (QTc and liver tox.)     Ensure all drug interactions are adequately covered     Assess relative to Ketek	J. Leonard J. Leonard I. Loew	-
Urology BSF 420627	Р	Set up task force to address issues and bring back plan to senior management     Reasons for failure of the SKB ETa/b antagonist     Design short (~4 week) PoP trial for symptom relief     Rationale for sustained release formulation     Nature of the Schwarz Pharma relationship	J. Leonard	• By May
Hypothyroidism T3/T4	P	Assess most appropriate ratio     Gain FDA feedback on study design     Determine ex-US market attractiveness (price)	• J. Leonard	• By May
<b>Asthma</b> Hokunalin tape	Р	Conduct market research on acceptance by different patient segments Determine how to position against long acting beta agonists and combination inhalers Evaluate opportunity to gain complete access to the patch technology	A. Higgins/ E. Florentino J. Tyree	• May

 $(\mathbb{Z}_{i})$ 

Project	Priority	Next steps	Responsibility	Timing
Oncology ABT-510	С	Pursue proof of concept     Leverage TAP knowledge of angiogenesis product development (appropriate endpoints)	• Project team	As planned
ABT-751	Ċ	Pursue proof of concept     Use echocardiogram to monitor potential cardiotoxicity     Resolve potent drug manufacturing approach	Project team     CMC group	<ul> <li>As planned</li> </ul>
ABT-518	Hold	Walt for May results from Pfizer (will save ~\$1 mill) and re-evaluate Halt all further expenditure	<ul> <li>Senior</li> <li>management</li> </ul>	• May
Rubitecan	P	Significant clinical rework required (funded by partner)- further in-depth review required     Make a proceed decision when 2Q data available	• J. Leonard	• By May
Theragyn	Р	Negative initial scientific perspective - further indepth review required, e.g.,     Determine if there is a PoC to support claim     Address GMP issues     Determine best control to demonstrate efficacy	J. Leonard	• By May
ABT-627	С	Re-look at partnership contract  Seek alternative funding (e.g., NCI) before starting major trial  If move ahead Determine how to ensure NDA filing in 2004 Get FDA input since survival not primary endpoint Harmonize US and EU study design and inputs Consider partnership (e.g., Bl or established oncology player)	J. Tyree  J. Leonard, P. Nisen  J. Tyree	ASAP     By May

HIGHLY CONFIDENTIAL ABBT0155582

1

TIAL POR	TFOLI	O PRIORITIZATION (CONTINUED)		C- continue P- pending T- terminate
Project	Priority	Next steps	Responsibility	Timing
Cardiology/ thrombosis				
Darusentan (LU 135252)	Hold	<ul> <li>Continue currently budgeted funding for next 6 months</li> <li>Do not start any new trials (e.g., hypertension planned for May)</li> </ul>	Project team	Ongoing
		<ul> <li>If proceed, plan for pilot to look at effects in sperm and tetratogenecity</li> <li>Consider out-license or swap</li> </ul>	• J. Tyree	• ASAP
LU 208075	Hold	Continue currently budgeted funding for next six	<ul> <li>Project team</li> </ul>	• ongoing
		months • Look at Myogen deal • Oul-license or swap	• J. Tyree	
Levosimendan	C	<ul> <li>Conduct detailed expert panel review for trial design</li> </ul>	<ul> <li>J. Leonard</li> </ul>	<ul> <li>May</li> </ul>
PEG-hirudin	P	<ul> <li>Set up expert panel for commercial assessment (is diabetes an option?)</li> </ul>	• E. Ogunto	• By May
Ancrod	T	Identify out-licensing opportunities	<ul> <li>J. Tyree</li> </ul>	• TBD
Urokinase	P	Market research required on open cath     Match versus IPA in dose-ranging studies to determine efficacy	• E. Fiorentino	• By May
Pro-urokinase	С	<ul> <li>Identify opportunities to speed up program</li> </ul>	<ul> <li>Project team</li> </ul>	• TBD
Clivarine	С	<ul> <li>Assessment by HPD (review previous evaluation and new trial data)</li> </ul>	• E. Ogunro	• By May
		<ul> <li>Understand finished product manufacturing cost</li> </ul>	<ul> <li>B. Dempsey</li> </ul>	
Rythmol SR	С	Continue filing     Verify if package is likely approvable     Assess commercial attractiveness in a generic market	Project team	<ul> <li>Ongoing</li> </ul>

## INITIAL PORTFOLIO PRIORITIZATION (CONTINUED)

C- continue P- pending T- terminate

Project	Priority	Next steps	Responsibility	Timing
Neuroscience				
ABT 594	Р	<ul> <li>Awalt results from ongoing PII trial — probable T</li> <li>Project team to develop decision criteria for go/no go</li> </ul>	<ul> <li>Senior management</li> </ul>	<ul> <li>June/ July</li> </ul>
ABT 963	С	<ul> <li>Identify a co-development/co-promotion partner (TAP high on list)</li> </ul>	J. Tyree	• TBD
		Evaluate benefits of the long half life in pain and cancer (including additional physician market research)     Explore cancer prophylaxis and Alzheimer's indications	<ul> <li>Project team</li> </ul>	
BSF 201640	P	Complete review of all schizophrenia NCEs with expert	• I. Loew	- By May
		<ul> <li>Complete staffing of internal project team, but halt further expenditure beyond looking at hepatic tox. and QTc</li> </ul>	• Project team	
		<ul> <li>Understand Novartis contract and level of interest</li> </ul>	<ul> <li>J. Tyree</li> </ul>	
BSF 190555	Р	Complete review as above     Halt further expenditure pending outcome	• I. Loew	<ul> <li>As above</li> </ul>
BSF 74398	С	Allow DevCo to continue development     Re-look at relationship with DevCo	<ul><li>Project team</li><li>J. Tyree</li></ul>	• By May
Diluadid Oros	Hold	Return to ALZA or out-license to other interested partner	• J. Tyree	• TBD
Hydrocodone	С	Assess regulatory pathway     Understand DEA impact on manufacturing	<ul> <li>Project team</li> </ul>	• By May
Bimoclomol (ABT 822)	Р	<ul> <li>Await data from ongoing trial in April before deciding whether to continue - probable T</li> <li>Halt further expenditure pending outcome</li> </ul>	<ul> <li>Senior management</li> </ul>	• April

3

ITIAL PORT	FOLIC	PRIORITIZATION (CONTINUED)	P	C- continue P- pending T- terminate	
Project	Priority	Next steps	Responsibility	Timing	
Gastro-enterology Ganaton	Р	Conduct U.S. commercial assessment with TAP     Assess how to position in Europe versus generics and implications for comparative trial	• E. Fiorentino	• By June	
		<ul> <li>Develop model to assess spend at different termination points</li> </ul>	Bob Funck	• By May	
TU-199	T	Terminate outside Japan	<ul> <li>Project team</li> </ul>	<ul> <li>Immediate</li> </ul>	
AU-224	С	<ul> <li>Develop and pursue a small PoC trial in humans ASAP (consider niche indication first and leverage Marlene's expertise)</li> </ul>	- Project team	• ASAP	
		Conduct market research on IBS versus constipation (including pricing)	• E. Fiorentino		
immunology D2E7	С	Conduct intensive product review     2 day meeting with J. Lennard's group (already in process)	• J. Leonard	By May	
		- ½ day session with senior management group  Important actions include  - Approach FDA for fast track and compassionate use  - Develop strategy for DMARD claim in first submission  - Assess need for Enbrel assay to detect HAHAs  - Assess delivery device options  - Evaluate additional indications (e.g., Psoriasis, Crohns, heart failure) and pediatric program  - Profile Celltech product  - Assess impact of additional IV program on reimbursement	• Various	• By May	
		<ul> <li>Develop list of potential marketing partners for guids</li> </ul>	<ul> <li>J. Tyree</li> </ul>		

## INITIAL PORTFOLIO PRIORITIZATION (CONTINUED)

C- continue P- pending T- terminate

Project	Priority	Next steps	Responsibility	Timing
Immunology (continued) Segard	Hold	Continue filling in EU and Canada Put on hold in US — consider creating a small team in the US to analyse data, propose smaller Pll study Research pricing, marketing and Phase IV plans in Europe Look at TNF-alpha levels retrospectively to see stratification with IL-6 Assess manufacturing strategy Identify potential out-licensing opportunities (Genentech)	Project team J. Leonard  J. Tyree	• Ongoing
J695	P .	Decide on most attractive indications from Abbott and partner perspective     Discuss with partner ways to share the various indications and potential for TNF-alpha combinations     Add commercial person to the project team by this week	<ul><li>E. Fiorentino</li><li>J. Tyree</li><li>Ongoing</li></ul>	• ASAP

5

5

## INITIAL PORTFOLIO PRIORITIZATION (CONTINUED)

C- continue P- pending T- terminate

Project	Priority	Next steps	Responsibility	Timing
PIV programs Clarithromycin	С	None identified	-	-
Omnicef	С	Talk to partners	<ul> <li>J. Tyree</li> </ul>	-
Kaletra	С	None identified	-	-
Norvir	С	None identified	-	-
Meridia	Hold	Conduct commercial assessment for CNS and depression (P&L)	<ul> <li>B. Dempsey,</li> <li>J. Arnott, E.</li> <li>Fiorentino</li> </ul>	• ASAP
		<ul> <li>Assess combination therapy with fibrates</li> <li>Assess outcomes trial design to meet preferred commercial profile; determine payback</li> </ul>	• Project team	
Uprima	С	<ul> <li>Ensure no redundant trials with TAP in Europe</li> </ul>	<ul> <li>Project team</li> </ul>	<ul> <li>Ongoing</li> </ul>
Trandolapril patch	Т	Halt all activities	<ul> <li>Project team</li> </ul>	<ul> <li>Immediate</li> </ul>
Trandolapril "Invest" clinical program	Р	<ul> <li>Review trial in more detail (reduce complexity and risk)</li> </ul>	• E. Fiorentio	By May
Other trandolapril trials	С	<ul> <li>Continue "Create", "Peace" and "Benedict" trial programs</li> </ul>	Project team	<ul> <li>Ongoing</li> </ul>
Fenolibrate	С	<ul> <li>Develop co-formulation ideas with Meridia and statins (including assessment of sales and costs)</li> </ul>	Project team	-
Depakote	С	None identified	-	-
Gengral	С	None identified	-	-
oongra.	-	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		

6

## PLs' PI

## (200~~~ EXHIBIT 444 + FOR I.D. 611 07 1 000 1

New Organizational Plan Roll-Out

Jeff Leiden, M.D., Ph.D.

Executive Vice President Pharmaceutical Officer and Chief Scientific (

y technology-based compan lat fails to reinvent itself ever years is (

— Lou Gerstner CEO, IBM

Filed 01/28/2008

## SUBLEUS ADUSCASUS ARSOL TIOUUOINUT BOINOODUIB

- Mega-mergers creating global R&D giants
- Increased regulatory pressures
- Global scrutiny on pricing
- Rapid pace of scientific innovation

# Abbolt's Internal R&D Challenges

Phase I Time (years) Cumulative

**(1) (3) (4) (4) (4) (5) (1)** 

Phase III

Phase II

6

Depakote (ER) Biaxin (XL)

(Clari repl) • ABT-773

ABT-627 (pr ca)

**ABT-492** ABT-510

ABT-963

9

Kaletra

Flomax

Co-actinon (HIV) Co-viracil (HIV)

• Uprima (ED)

 ABT-594 (pain) • ABT-822 (DIVI)

ABT-751

**ABT-518 ABT-598 ABT-828** 

not yet achieving DDC status 10 compounds

Significant (>\$500 MM) Questionable Viability Commercial Potential Commercially Viable Uncertain Viability

(\$100 - 250MM)

Short-term pipeline gap  $v_{\cdot}$ 

Funding and resource challenges 0.1

More early-stage compounds than we can possibly fund 11.

# Abbotis Internal R&D Chalenges

DPD

AI

HPD

SPD

API (Bulk Drug

Development Discovery

Development Regulatory

Development Regulatory

In-licensing

Development)
Regulatory

rineliketism<u>e</u>

Regulatory

**Bulk Drug** 

Multiple independent pharmaceutical development organizations leading to:

Lack of efficiencies of scale

Lack of critical mass in R&D

Limited Information sharing across organization

Fragmented research and regulatory processes

Not always global in scope of development

## Taking Abbott's global pharmaceutical business Volume Confidential Character Victoria to the next level

# To be a global top-tier pharma player we must:

- Continue to execute sales/marketing in a world-class fashion
- Meet earnings expectations to maintain valuation
- In-license and acquire late-stage compounds to fill short-term pipeline needs 72.
- Build a world-class unified global pharmaceutical R&D program based on scientific innovation to address ong-term pipeline needs

## micensing and Acquisitions Will Be ELLEGOTIETOOM VOUSETUE STALON MOVING FORMAN

Case 1:05-cv-11150-DPW

- More than 50% of big pharma drugs currently under development have been in-licensed
- small pharma, biotech, universities and foreign Increasing opportunities for in-licensing from companies
- Only way to fill late-stage pipeline quickly

## Chold pristal conditions of the conditions of th Building a World-Class

In November, integrated previously separate into a single global licensing group directed pharma licensing groups from PPD and Al by Jim Tyree, reporting to CSO

## Advantages:

- Single voice for Abbott pharma licensing worldwide
- Enhanced sharing of knowledge
- More focus on biotech and university tech transfer
- Broad geographical coverage (U.S., Europe, PAA)
- Integrated contract management
- Highly integrated commercial and tech assessment skills

## Discovery and Development Based on Scientific Intolation and Excellence

## Mission

discovers and develops breakthrough treatments Research & Development group that consistently for important and prevalent human diseases To create a uniffed, global Pharmaceutical

# Our Roadmad for Building a Norld-Class TODE THE TOTAL COLOR TO THE TOTAL TO

- Structure and Environment
- Unify Pharma R&D from HPD, SPD, Al and PPD into one organization reporting to CSO
- Maintain and enhance our innovative and exciting scientific environment
- Resources
- Continue increased investment in R&D
- Create a platform for growth to increase size of pharmaceutical R&D
- People
- Recruit and retain outstanding scientists at all levels
- Technology and Process
- Optimize R&D processes
- (e.g., genomics, transgenics, structural biology, etc.) Build or acquire leading-edge technologies



**Pharmaceutical Development** Community-based

Pharmaceutical Discovery

RPD

ABBT0162932

## Mew Good Prannace Lica

J.M. Leiden, MD, PhD EVP Pharmaceuticals & Chief Scientifc Officer

Discovery, D.W. Norbeck, PhD VP Pharmaceutical

VP Hospital Products Regulatory Affairs, E.A. Ogunro, PhD R&D, Medical &

- · Critical Care · Renal Care
  - Anesthesia/
    - Pain Mgmt.

**VP Pharmaceutical Drug** J.M. Leonard, MD Development,

- Oncology
- Infectious Diseases **Antivirals** 
  - Neurology/Urology
    - Phase IV Group
- International Clinica Support

Neurological/Urologica Science (including API Advanced Technology Diseases/Antivirals Process Chemical bulk drug dev.) Infectious Oncology Diseases

Diseases/Diabetes

Metabolic

# Organization: Pharmaceutical Development Building a Morid-Class Global R&D

- with close alignment to Discovery and Commercial Single Pharmaceutical Development Organization
- utilize them in common tools and processes for the development Pharmaceutical Development will identify best practices and of all pharmaceuticals
- Common development plans and global SOPs
- Common decision-making tools
- Common project tracking procedures
- Common regulatory approaches
- Optimally directed resources and enhanced personnel exchange
- Common performance standards
- Flexibility and responsiveness to commercial needs
- Better sharing of knowledge across the corporation

ABBT0162935

Filed 01/28/2008

## Organization: Pharmaceutical Development Building a Morid-Class Global R&D

- Venture Organizations, including proprietary HPD pharmaceuticals, will be responsible for all Phases of Pharmaceutical Drug Development (Phase I – III) and the implementation of Phase IV
- The Venture Organizations will be comprised of the following:
- Renal Care
- Critical Care
- Anesthesia/Pain Management
- Oncology
- Infectious Disease/Virology
- Neurology/Urology
- nternational Clinical Support Function
- or Implementing Post-Marketing Studies Dedicated Phase IV Operations Group

# Building Synergies and Competitive Advantages The New Global R&D Organization:

- International Development Center (IDC), based in the formulation development and report to Efraim Shek JK, will join PARD to provide global scope to 翻
- be global and consolidated with the Phase I/PK Center Statistics and Data Management (PPD, HPD, AI) will reporting to Rick Granneman
- who will report to the commercial heads of AI and PPD Decision Support Group reporting to Keith Hendricks, There will be a single New Product Planning and

# Building Synergies and Competitive Advantages The New Global R&D Organization.

by Xavier Frapaise, MD and reporting to the VP of Pharmaceutical Drug Development (J. Leonard, MD) will provide international coordination for all oharmaceutical development projects and will also An International Clinical Support Venture directed continue to coordinate international nutritional development projects

# Building Syncrojes and Competitive Advantages The New Global R&D Organization:

- developed by the divisions and the Pharmaceutical A dedicated budget for Phase IV studies will be Executive Management Committee, and will be administered by Medical Affairs
- Post-marketing clinical studies will be designed by Development by a dedicated Phase IV operations Medical Affairs and carried out in Pharmaceutical group 遊

Filed 01/28/2008

ABBT0162939

- Single global pharmaceutical organization for Medical Affairs (AI/PPD):
- **Pharmacovigilance**
- Medical Services
- Health Economics
- Outcomes Research
- Marketed Product Development Phase IV Design and Budgeting
- This organization, headed by Dave Pizzuti, MD, wil report to both the International and Pharmaceutical Division Presidents

## T&U CONTONION OF C

Development and Commercial organization Single Pharmaceutical Drug Discovery Organization with close alignment to

## Mission

nternal and external resources, leads, and partners Discover new therapeutic compounds using both to bring innovative drug candidates into clinical development 2

## Organization: "Drainacettical Discolori

- Discovery will be comprised of the following:
- Process Chemistry Science (including API bulk drug development)
- Cancer Research
- Infectious Disease Research/Antivirals
- Metabolic Disease Research/Diabetes
- Neurological/Urological Research
- Advanced Technology

# Building Synergies and Competitive Advantages The New Global R&D Organization:

unified within Pharmaceutical Discovery to create and to ensure a smooth transition from discovery Development groups from SPD and PPD will be ■ To provide synergies and efficiencies of scale into development, the Chemical Research & a single Process Chemistry Science group

# Building Synergies and Competitive Advantages The New Global R&D Organization:

- to Jill Mueller will provide HR support and report A Human Resources Department reporting to the CSO
- R&D Controller, Steve Cohen will support the VPs of Development and Discovery and report to the CSO
- All Pharmaceutical IT and Regulatory functions will remain within their respective divisions providing support across all functions

## Management Committee to Facilitate Synergies Execute Critical Decision Making Establish Pharmaceutical Executive

- Jeff Leiden, EVP Pharmaceuticals
- and Chief Scientific Officer
- Rick Gonzalez, EVP Medical Products
- Arthur Higgins, SVP & President Pharmaceutical Products Division
- **Bill Dempsey,**SVP & President
  Abbott International Division
- **Chris Begley,**SVP & President
  Hospital Products Division
- Lance Wyaft, SVP & President Specialty Products Division

- John Leonard,
- VP Pharmaceutical Drug Development
- Dan Norbeck,
- VP Pharmaceutical Drug Discovery
- **Ed Ogunro,**
- VP Hospital Products R&D, Medical & Regulatory Affairs
- Jim Tyree, DVP Pharmaceutical & Intl. Licensing and New Bus. Development
- Steve Weger, Jr., VP Corporate Planning and Development

## Pharmaceutical Executive Management Committee Responsibilities

- Review and approval of all proprietary pharmaceutical development projects
- Review and approval of all proprietary pharmaceutical in-licensing deals
- full R&D budgets will remain in each division Project and budget approvals; however

## Abbott Global Pharmacoulical Red. Continuing Our Tradition of Excellence While Reinventing Ourselves

- Turn our challenges into opportunities
- Invest wisely in science as the cornerstone of our future 験
- Retain and recruit the best talent for our corporation
- the best work environment for our people Work together across divisions to build
- Maintain our commitment to science, quality and integrity

## PLs' PJ

Jim,

Greetings.


We had a project review with upper management this Wednesday. During this review their was a concern regarding the continuation with ABT-518 development. Although, we thought that we will be allowed to continue at this time, I and Perry have learned, 45 minutes ago, that we should stop all development activities immediately. As much as I hate to do this to you, I would like to ask you to communicate with Drs. Zonnenberg and Schellen that we are not proceeding with the trial as a result of the projects re-prioritization following the acquisition of Knoll. I will call you on you mobile phone (I do not have your home #) to discuss this further with you and check you comfort level with this very difficult task. If you prefer to call me, my home number:847-382-3818, mobile: 847-380-5830. As you know, at AZU they are expecting a patient Monday morning, so this has to be done ASAP.

I did not have the chance to tell Todd and Diane D. this news since I was informed late in the day and they have left already. So please do not copy others until I have a chance to inform them directly.

Thanks

(::::

Azmi



## PLs' PM



Memorandum To:

File

Re:

Abbott Laboratories ("Non-Recourse")



## Background:

In October 2000, the Committee of Finance approved a \$220 million commitment to fund research and development expenses for a basket of pharmaceutical products currently under development by Abbott Laboratories. During the documentation process, which was completed on March 13, 2001, certain terms of the transaction were modified, although the basic economics were not materially changed. This memorandum describes the significant changes to the transaction compared to the initial report to the Committee of Finance.

## Modifications

The Commitment Amount was reduced from \$220 million to \$214 million.

The <u>basket</u> of pharmaceutical products was modified and increased from eight to nine (see <u>Program Compounds</u> below for further details).

The Program Payments were changed from:

CONFIDENTIAL JH 001103

	Original	Revised
December 2000	\$50,000,000	\$ 0
December 2001	\$55,000,000	\$50,000,000
December 2002.	\$55,000,000	\$54,000,000
December 2003	\$60,000,000	\$58,000,000
December 2004	\$ 0	\$52,000,000

The <u>Program Term</u> was changed from "commencing December 2000 and ending on December 2004" to "commencing March 2001 and ending on December 2004".

The <u>Milestone Payments Upon NDA Approval by the FDA</u> were changed from \$10,000,000 to \$20,000,000 for the first Product and \$10,000,000 for the second and third Products.



The Aggregate Milestone Payments for all "non-NDA Approval" milestones was changed from \$12,000,000 to \$8,000,000:

The Royalty Payments were changed from:

	Original	Revised
\$0 to \$400 million	8%	81/2%
$>$ \$400 and $\leq$ \$1,000 million	4%	4%
$>$ \$1,000 and $\leq$ \$2,000 million	1%	1%
>\$2,000 million	1/2%	1/2%

The Royalty Payments shall cease on December 31, 2015 instead of December 31, 2014.

The Program Compounds were modified as follows:

Program Compound ABT-980 and the Urokinase Program were removed from the basket. Program Compounds ABT-492 and ABT-751 and the ED Program were added to the basket. The assumptions for the added Program Compounds are:

Product	Indication	Peak Sales	Stage of Development
ABT-492	Anti-infective	\$400 million	Phase I/2005
ABT-510	Cancer	\$400 million	Phase I/2006
ED	Erectile Dysfunction	\$400 million	Pre-clinical/2007

In addition, a provision was added that requires Abbott to substitute an additional Phase II compound with no less commercial value than initially expected for ABT-492 and ABT-510 if either ABT-492 or ABT-510 fails to enter a Phase II Clinical Trial. We modeled this contingent additional compound as a Phase II compound with 40% probability of success, \$400 million of peak sales, 2006 launch date. We assumed that the probability of obtaining the contingent additional compound in the basket was approximately 84%.

## Affect of Modifications on Model Results

Our initial model (without adjustments for conservatism) provided a probability of loss of approximately 0.9% and a median return of approximately 17.5% and a mean return of approximately 15.9%. Our revised model (without adjustments for conservatism) provides a probability of loss of approximately 1.3% and a median return of approximately 18.8% and a mean return of approximately 16.2%.

## PLs' PO

## NOMINAL AND EXPECTED SALES FORECAST

ere.	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2040	1000	
										-	10101	4017	בל בל
Protease 2nd Generation	100	450	550	570	670	750	562	750		í			,
prin back-up	:		•	108	203	323	425	) u	2 1	190	2	730	7,690
CCM Neuro/Osteo	,	,	٠,		;		Ì	000	<u>n</u>	979	632	632	4,139
TSP	.1			COX	086	505	1,115	1,248	1,202	1,202	1,202	1,202	1.740
TSP #2	1	•	•			5	160	200	300	395	440	440	7.950
Taxane					٠.	į	15	160	200	300	395	440	200
		•	1		•	168	305	460	099.	909	505	200	01010
: - [		•		•	•		•	,		}	3	2	0,433
F11#2	•	,	,					•				,	ç.
MMPI	,	,			•	٠ .			쥖.	260.	400	455	1,235
MMPI #2		,		, ·			•		•	•	•		<b>(</b>
MMP1#7	•	÷		•		,	120	260	400	455	620	530	ם מצה כ
Antimitation	1	•					120	260	400	455	200	520	272
, manuscript	•		•		,	188	412	. 000			2 .	0.70	6177
. cy		•		,		2	?	070	0 0	. 026	910	910	4,765
Urokinase								120	260	<del>4</del> 0	455	465	1,690
		, ,	•	• .		•••		120	260	400	455	455	1,690
TOTAL NOMINAL SALES	400	YEA	052	2007			-						
-		1004	nec	1,033	1,459	2,347	2,341	3,506	4,581	5,551	6,077	6,157	34,252
TOTAL EXPECTED SALES	400	440		1	111					•			
	2	410	010	8/5	1,057	1,528	1,360	1,564	1,808	1,957	2,031	2,024	15,231
5% ROYALTY	ŧр	74	. 26	44	53	76	. 89	78	98	88	102	101	762
10% ROYALTY	10	42	52	88	. 106	153	136	156	181	, 196 96	203	ė, O, C	1 533
ABBOTT ROYALTY EXPENSE	0.0	8.4	10.2	7.42	22.4	, ,		;			}	1	22
	0.0%	2.0%	200	200	7 6	7,50	7.70	4.4	87.4	99.1	104.9	105,4	656.9
	•		2.4	E 0.4	3.2.7a	3.3%	4.0%	4.4%	4.8%	5,4%	6.2%	5.2%	4.3%
STEP-DOWN ADJUSTMENT	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0		10 097	(F2 0)	10 (3).	5
	0:0	8.4	10.2	24.7	33.4	59.0	540	7.02	1 12	1000	20.07	(07-0)	(0.861)
•								100.0	7.10	20.1	6.26	53.4	503.9

IRR = 20.97% Net of Step-Down Adjustment

CONFIDENTIAL JH 002314

	8%	2%	2%	4.5%
Royalty Percentages	Oncology Portfolio	Protease 2nd Generation	WOO.	HJB



Sensitivities1A.123



## NOMINAL AND EXPECTED INVESTMENT COSTS

	2000	2001	2002	2003	2004	2002	2006	2007	2008	2009	2010	2011	TOTAL
Protesses and Consulting							•	:					
Ello dellerallori	. 42	32	22	.20	ř:	<del>го</del>	15	13	, <del>t</del> ō	2	2	ιΩ	254
orn back-up	. 45	40	72	ø	eo	R	্ব	4	Ç1	ଧ	. ~	0	141
Ira/Osteo	87	73	25	<b>2</b>	우	<b>cc</b>	80	<b>62</b>		823	80	. 👄	273
	ιa	ö	•		0			8		0	0	Q	LO
	8	24	.8.	20	53	8	20	<b>=</b>	ro	un.	rt3	Lt)	168
		~	応	40	8	₽.	9	9	យ	10	ıΩ	Lo	133
	•		٠.	•			•						
	4	<b>~</b> ¢h	¥	37	=	节	ħ	9	m	ю	i.	to	127
	Ħ.	<b>#</b> 1	0	0		Q	0	. 6	9	<b>5</b>	0	0	4
אוואורן וויל אווירן אווירן אווירן אווירן אווירן אווירן אווירן אווירן אווירן אווירן אווירן אווירן אווירן אווירן	Q	₹.	73	32	<u>₽</u>	. 23	<del>1</del> 3	. 16	œ	63	ιċ	ĸ	149
	<del>o</del>	**	73	. 32	49	23	un T	<b>16</b>	œ	19	ю	ıo	149
	<b>ES</b> )	et.	10	40	6	23	2	12	æ	លេ	to	ĸ	165
	ιn	땆	<b>32</b>	35	æ	#	<b>15</b>	40	ო	ın	10	រភ	167
· .	10	<del>.</del>	S2	. 32	. 33	ŧ		10	ପ	10 ·		тЭ	167
TOTAL NOMINAL INVESTMENT	NT 249	225	218	307	211	171	151	104	62	56	. 09	45	1,902
Nominal Batio Analysis Investor Partner \$	sls r \$ 50	. 50	25	50	0	0	0	6	0	0	0	0	200
ABBOTT & ABBOTT RATIO	T\$ 199	175	168	257	211	171	151	104	62	to to	. 09	45	1,702

1,159 200 959 6 33 ដ 27 27 34 56 56 B 63 114 202 152 3.0 20 177 20 127 .153 22 103 1.1 182 3.6 20 Investor Partner R&D INVESTMENT ABBOTT CALCULATED HATIO Expected Ratio Analysis TOTAL EXPECTED INVESTMENT

> CONFIDENTIAL JH 002315

Portfolio S - Onc. + BPH + CCM + Protease

NOMINAL AND EXPECTED SALES FORECAST

Royalty T - Onc. + BPH + CCM + Prolease

TOTAL	•	7,690	4.139	1.740	1.950	1.510	3,293		1 735	onet.	2.275	2.275	4.765	1,690	1,690	34,252		15,658	783	1,566	1,057.5		
2011		730	632	1,202	460	440	800		455		520	520	910	455	455	6,157		2,091	105	209	183.0 8.7%	(91.0)	92.0
2010		750	632	1,202	\$	335	8	,	400		520	520	910	465	455	6,077		2,096	105	210	181.2	(90.6)	90.6
2009		750	929	1,202	386	300	<b>6</b> 00	•	260		455	盘	910	200	400	5,651		2,010	101	204	168.7 8.4%	(84.3),	84.4
2008		150	615	1,202	300	200	260		120		400	400	816	260	260	4,681	1	1,847	35	185	144.9	(72.4)	72.5
2007		150	556	1,248	200	160	460	•			260	260	620	120	120	3,506	2027	1,532	80	159	110.3	0:0	110.3
2006	٠	770	436	1,115	160	45	305	•	•		120	120	413			2,341	7.00	1,001	69	138	83.2	0.0	83.2
2002		150	323	808	5		168	•			,	١,	186			2,347	7 500	1,000	. 42	167	88.6 5.7%	0.0	88.6
2004		9.40	. 602	580	,	,	٠,	,				,	,			1,459	1 002	1,033	55	109	46.1	0.0	46.1
2003	į	9/0	108	255		,				.•						1,033	508	300	45	3	32.1	0.0	32.1
2002	5	000			•	,		• .	•	. •	•			•		550	734	3	27	53	10.7	0.0	10.7
2003	760	707		,			•		•	•					•	450	437		22	\$	8.7	0.0	8.7
zooci			•	i	•	•	•	٠.		•	•	•	•		•.	100	100		ър ,	40	%0°0 .	0.0	0.0
	Professe 2nd Generation	HDH Brok II	of it back-op	TSP TSP	, ch	7# LD-	i axane isti	= I	11.42	WINIT	MMP1#2	NIWIT #3	Anumatotic	1 Inches	CIONIDASE	TOTAL NOMINAL SALES	TOTAL EXPECTED SALES		5% ROYALTY	10% RÖYALTY	ABBOTT ROYALTY EXPENSE	STEP-DOWN ADJUSTMENT	

IRR = 19.80% Net of Step-Down Adjustment

CONFIDENTIAL JH 002316

	15%	2%	%8	6.5%	1
Royalty Percentages	Oncology Portfolio	Protease 2nd Generation	CCM	ВРН	

## NOMINAL AND EXPECTED INVESTMENT COSTS

Protease 2nd Generation BPH Back-Up CCM Neuro/Osteo TSP TSP #2 Taxane FTI ATI #2 MMPI MMPI #3 Antimitotic K6 Urokinase	2000 45 45 78 78 78 78 78 78 78 78 78 78 78 78 78	2001   35 40 40 40 40 40 40 40 40 40 40 40 40 40	2002 20 12 25 0	2003 20 5	2004	2005	2006	2007	2008	2009	2010	2011	TOTAL
aration	7.48 0.02 p. 20 p. 20 p. 20 p. 20 p. 20 p. 20 p. 20 p. 20 p. 20 p. 20 p. 20 p. 20 p. 20 p. 20 p. 20 p. 20 p. 20 p. 20	25 40 40 47 40 40	25 25		15.	U	į	1					!
Protease and Generation BPH Back-Up CCM Neuro/Osteo TSP #2 TSP #2 Taxane FTI #2 MMP! MMP! #3 Antimilotic K5 Urokinase	. * * * * * * * * * * * * * * * * * * *	25 0 25 0 25 0 0 0	2 2 2 2 5 0	20		U,	Ļ		•				
OFFI Back-Up CCM Neuro/Osteo TSP TSP TSP Taxane FTI ATI #Z MMP! MMP! #3 Antimilotic K6 Urokinase	A © иыл ' 4 4 6 6 6 m m	6 tt D 22 r · 4 D	23 12	ဖ		?	2	15	<u>1</u> 5	40	10	u	256
Com redrovoseo TSP TSP TSP Taxane FTI FTI FTI FTI MMP! MMP! #3 Antimitotic K5	° иили ' 4400 ю по п	73	£5 0		က	7	7	. 7	Ŋ	N	? N	) C	144
TSP #2 Taxane FTI = FTI #2 MMP! #3 Antimitotic K5 Urokinase	ими ' 4466 юпр	D \$7 ~ . 4 O		10	10	œ	∞	æ	8	to	. 60	· c	773
Tokane FTI FTI #2 MMP! #2 MMP! #3 Antimitotic K5 Urokinase	ми , ч4о⇔ ш ю	\$ r , 4 D	ŀ	0	9	Ċ	0	0	0	0		. 0	i i
FTI #2 MMP! MMP! #2 MMP! #3 Antimitotic K5 Urokinase	и , ч4000 юю	<b>~ , ∀ □</b>	28	.20	ĸ	20	20	Ŧ	to.	w	i.o	: 147	768
FT1#2 MMP! MMP! #2 MMP! #3 Antimitotic K5 Urokinase	. 4 4 B B B B B	, 4 0	. 16	40	20	10	10		un.	យ	rU.	ı ro	133
MMP! #2 MMP! #2 MMP! #3 Antimitotic K5 Urokinase	44558129	4 <b>o</b>		•	,		,		,		,		C
MMPI #2 MMPI #3 Antimitotic K5 Urokinase	<del>က်</del> ၀က က က က	<b>-</b>	£	37.	. 17	ri.	15	9	m	ιά	ю	ιο	127
MMPI #3 Antimitotic K5 Urokinase	9 9 8 13 10			0	0	0	p	0	0	0	0	c:	. 4
Antimitotic K5 Urokinase	🗅 ထား အ အ	4	77	32	19	23	15	16	<b>1</b> 5	113	10	ı ın	149
K5 Urokinase	Eo Eo Eo	₹.	24	. 32	49	73	15	16	Ф	**	ភេ	ιc	149
Urokinase	us to	4	₽.	<del>4</del>	19	25	N	12	Ф	ιb	ro:	177	165
	<b>to</b>	to to	22	36	33	15	15	ω	ć	ເນ	rto	L LCT	167
		35	52	32	33	13	15	ø		w	រភ	rů.	167
TOTAL NOMINAL INVESTMENT	:NT 249	225	218	307	211	114	151	104	62	25	60	. 45	1 902
											3	?	70011
Nominal Ratio Analysis Investor Partner \$	<u>rsis</u> er \$ 75	75	7.5	75		a	0	0	0	٥	0	D	300
ABBOTT \$	T\$ 174 TIO 2.3	150	143 1.9	232	211	171	151	104	29	99	. 09	45	1,602
	,										٠.		?
TOTAL EXPECTED INVESTMENT	rsis INT 232	148	173	199	413	62	55	34	26	77	22	13	1,143
1 Notes to Fartner R&D INVESTMENT	INT 75	75	75	75		· •	· o	0	0	D	0	0 	300
A BBOTT CALCULATED RATIO	NT 157	73 1.0	98 1.3	124	113	. 62	55	34	26	22	22	ಕ್ಟ	843

## PLs' PT



To Phyllis L Kincaid/LAKE/PPRD/ABBOTT@ABBOTT

D44J, Cheryl D Spencer/LAKE/PPRD/ABBOTT@ABBOTT,

CC Jeanne M Fox/LAKE/PPRD/ABBOTT@ABBOTT, Gregory
Bosco/LAKE/PPRD/ABBOTT@ABBOTT

bcc

Subject Clinical Hold

I received a phone call from Carol Meyer (Anti-Infective) moments ago, informing me that a conference call was held with the FDA and the agency requested that they place the following ABT-773 studies on HOLD. The team is drafting a letter which will be faxed to each of the 80 sites (approx.) with a supplemental telephone call to instruct the sites not to enroll any additional subjects until further instructed. There are 8 subjects who have received drug and will remain in the study and followed during this interim period.

M00-219 (CAP) M00-216 (ABECB) M00-222 (Pharyngitis) M00-225 (Sinusitis)

The team is scheduled to meet with the agency for an *End of Phase II* meeting on Monday (27 November, 2000) and will hopefully discover whether the HOLD is lifted.

Kind regards, Belinda

## PLs' PY

## NON-USE AGREEMENT

WHEREAS, John Hancock Life Insurance Company, John Hancock Variable Life Insurance Company, and Investors Partner Life Insurance Company (collectively, "John Hancock") and Abbott Laboratories ("Abbott") are parties to a Research Funding Agreement, dated as of March 13, 2001 ("Research Funding Agreement"); and

WHEREAS, disputes have arisen between the parties concerning their respective rights and obligations under the Research Funding Agreement, resulting in litigation styled *John Hancock Life Insurance Company, et al. v. Abbott Laboratories*, Civil Action No. 03-12501-DPW, U.S. District Court (D. Mass.) (the "Litigation"); and

WHEREAS, the parties wish to continue to conduct the business contemplated in the Research Funding Agreement (the "Business") while the Litigation is pending without fear or concern that actions hereafter taken or statements hereafter made pursuant to or in furtherance of the Business will be used against one party or the other in the Litigation or in any subsequent action between John Hancock and Abbott,

NOW, THEREFORE, John Hancock and Abbott further agree as follows:

1. No action taken, or statement, writing or other communication hereafter sent, made, or authored by employees of John Hancock or Abbott (collectively, the "Business Representatives") for the sole purpose of out-licensing various compounds in connection with the Business and pursuant to the terms of the Research Funding Agreement, on or subsequent to July 7, 2004, up to the effective termination date of this Non-Use Agreement, shall be discoverable or admissible in evidence for any purpose in the Litigation or in any subsequent action between John Hancock and Abbott.

- 2. Nothing in this Non-Use Agreement shall be construed or applied so as to inhibit or preclude John Hancock or Abbott in the Litigation from discovering or offering as evidence in the Litigation or in any subsequent action between John Hancock and Abbott any action taken, or statement, writing or other communication sent, made, or authored by any of the Business Representatives prior to July 7, 2004.
- 3. This Non-Use Agreement may be terminated by either party by providing written notice of the same, by telecopier and by overnight-mail, to each of the following representatives of the Parties or their successors:

## For John Hancock:

Karen V. Morton, Esq. Vice President and Counsel John Hancock Life Insurance Company 200 Clarendon Street 31<sup>st</sup> Floor Boston, Massachusetts 02117 Fax: (617) 572-1565

Pamela A. Memishian, Esq. Senior Counsel John Hancock Life Insurance Company 200 Clarendon Street 31<sup>st</sup> Floor Boston, Massachusetts 02117 Fax: (617) 572-9269

Brian A. Davis, Esq. Choate, Hall & Stewart Exchange Place 53 State Street Boston, Massachusetts 02109 Fax: (617) 248-4000

## For Abbott:

Kenneth Wittenberg, Esq. Senior Counsel--Litigation Abbott Laboratories

100 Abbott Park Road Dept. 324 AP6D1 Abbott Park, Illinois 60064-6020

Fax: (847) 938-6235

Lawrence R. Desideri, Esq. Winston & Strawn LLP 35 West Wacker Drive Chicago, Illinois 60601

Fax: (312) 558-5700

Any written notice of termination sent in accordance with the terms of this Non-Use Agreement shall be effective ten (10) days after such notice is sent. Upon termination of this Non-Use Agreement by either party, all actions taken, or statements, writings or other communications sent, made, or authored by any of the Business Representatives subsequent to the effective termination date shall become discoverable or admissible in evidence in the Litigation or in any subsequent action between John Hancock and Abbott, provided, however, that termination of this Non-Use Agreement shall not affect the discoverability or the admissibility of any actions taken, or statements, writings or other communications sent, made, or authored by any of the Business Representatives on or subsequent to July 7, 2004, up to the effective termination date of this Non-Use Agreement, which actions, statements, writings or other communications shall remain non-discoverable and non-admissible in the Litigation or in any subsequent action between John Hancock and Abbott.

The signatories below represent that they have authority to enter this agreement on behalf of the respective entity and bind that party to these obligations.

Date: Sopt - 15, 2004

JOHN HANCOCK LIFE INSURANCE COMPANY, JOHN HANCOCK VARIABLE LIFE INSURANCE COMPANY, and INVESTORS PARTNER Case 1:05-cv-11150-DPW Document 234-24 Filed 01/28/2008 Page 5 of 5

LIFE INSURANCE COMPANY

Name:

Title: Address: 200 Claveler Street Bofor Ma 0217

Date: September 9, 2004

-

ABBOTT LABORATORIES

Name: James i

Title: Corporate Vice President, Licensing and New Business Devol Address: 100 About Park Boat, Dept. DRSCA Birth APSHZ, About Park, IL Ga

Fax: 847-937-6683

3732962.1

PLs' PZ

## **NON-USE AGREEMENT**

WHEREAS, John Hancock Life Insurance Company, John Hancock Variable Life Insurance Company, and Manulife Insurance Company (f/k/a Investors Partner Life Insurance Company) (collectively, "John Hancock") and Abbott Laboratories ("Abbott") are parties to a Research Funding Agreement, dated as of March 13, 2001 ("Research Funding Agreement"); and

WHEREAS, disputes have arisen between the parties concerning their respective rights and obligations under the Research Funding Agreement, resulting in litigation styled *John Hancock Life Insurance Company, et al. v. Abbott Laboratories*, Civil Action No. 03-12501-DPW, U.S. District Court (D. Mass.), and *John Hancock Life Insurance Company, et al. v. Abbott Laboratories*, Civil Action No. 05-11150-DPW, U.S. District Court (D. Mass) (collectively, the "Litigation"); and

WHEREAS, the parties wish to continue to conduct certain aspects of the business contemplated in the Research Funding Agreement (the "Business") and detailed in Paragraph 1 below, while the Litigation is pending without fear or concern that actions hereafter taken or statements hereafter made pursuant to or in furtherance of the Business will be used by or against one party or the other in the Litigation or in any subsequent, related action between John Hancock and Abbott,

NOW, THEREFORE, John Hancock and Abbott further agree as follows:

1. No action taken, or statement, writing or other communication hereafter sent, made, or authored by employees of John Hancock or Abbott (collectively, the "Business Representatives") regarding the actual or potential transfer of Abbott's rights 3970641v3

in ABT-492 to Wakunaga Pharmaceutical Co., Ltd. ("Wakunaga") and/or the outlicensing of ABT-492 by Abbott or Wakunaga, or made solely in the context of any quarterly telephonic informational conference(s) between or among the Business Representatives, on or subsequent to August 22, 2005, up to the effective termination date of this Non-Use Agreement (collectively, the "Protected Communications"), shall be discoverable or admissible in evidence for any purpose in the Litigation or in any subsequent action between John Hancock and Abbott.

- 2. Nothing in this Non-Use Agreement shall be construed or applied so as to inhibit or preclude John Hancock or Abbott in the Litigation from discovering or offering as evidence in the Litigation or in any subsequent action between John Hancock and Abbott any action taken, or statement, writing or other communication sent, made, or authored by any of the Business Representatives prior to August 22, 2005. Further, nothing in this Non-Use Agreement shall be construed or applied so as to affect or limit the protection and application of the separate Non-Use Agreement between Abbott and John Hancock that was in effect between July 7, 2004 and June 30, 2005.
- 3. This Non-Use Agreement may be terminated by either party by providing written notice of the same, by telecopier and by overnight-mail, to each of the following representatives of the Parties or their successors:

## For John Hancock:

Karen V. Morton, Esq. Vice President and Counsel John Hancock Life Insurance Company 200 Clarendon Street

30th Floor Boston, Massachusetts 02117

Fax: (617) 572-1565

Pamela A. Memishian, Esq. Senior Counsel John Hancock Life Insurance Company 200 Clarendon Street 30th Floor Boston, Massachusetts 02117 Fax: (617) 572-9269

Brian A. Davis, Esq. Choate, Hall & Stewart Two International Place Boston, Massachusetts 02110 Fax: (617) 248-4000

## For Abbott:

Jeff C. Risher, Esq. Litigation Counsel Abbott Laboratories 100 Abbott Park Road Dept. 324 AP6D Abbott Park, Illinois 60064-6020 Fax: (847) 938-6235

Lawrence R. Desideri, Esq. Winston & Strawn LLP 35 West Wacker Drive Chicago, Illinois 60601 Fax: (312) 558-5700

Any written notice of termination sent in accordance with the terms of this Non-Use Agreement shall be effective ten (10) days after such notice is sent. termination of this Non-Use Agreement by either party, all actions taken, or statements, writings or other communications sent, made, or authored by any of the Business Representatives subsequent to the effective termination date shall become discoverable Hancock and Abbott, provided, however, that termination of this Non-Use Agreement shall not affect the discoverability or the admissibility of the Protected Communications, which communications shall remain non-discoverable and nonadmissible in the Litigation or in any subsequent action between John Hancock and Abbott.

4. The signatories below represent that they have authority to enter this agreement on behalf of the respective entity and bind that party to these obligations.

Date: August 17, 2005

JOHN HANCOCK LIFE INSURANCE COMPANY, JOHN HANCOCK VARIABLE LIFE INSURANCE COMPANY, and MANULIFE INSURANCE COMPANY (f/k/a INVESTORS PARTNER LIFE INSURANCE COMPANY)

SENITR MANAGING

Date: 8/29 , 2005

ABBOTT LABORATORIES

By: Name:

By: Name:

Title: Semior Vice

Address: 100 Abbott

Fax: 847-937-6683

6006Y

## PLs' QQ

John Hancock Financial Services, Inc.

John Hancock Place Post Office Box 111 Boston, Massachusetts 02117 (617) 572-9624 Fax: (617) 572-1628 E-mail: sblewitt@jhancock.com

Bond and Corporate Finance Group

Stephen J. Blewitt Managing Director John Hancock
FINANCIAL SERVICES

May 8, 2000

Memorandum To:

Messrs. Aborn, Brown, D'Alessandro, DeCiccio, Hartz, Nastou

Re:

Proposed John Hancock - Abbott Laboratories Transaction

The attached material is for our meeting on Thursday, May 11th at 2PM.

Steve Blewitt

## John Hancock - Abbott Laboratories Research and Development Transaction

## **Investment Analysis**

1. John Hancock is considering committing [\$50 million] per year for a period of four years to fund the development and commercialization of a specified pool of compounds owned by Abbott Laboratories. During the four year period, Abbott will commit three-to-four times John Hancock's investment for those compounds, and will spend over seven times our investment during the term of the transaction. In return, Abbott will agree to pay John Hancock milestone and royalty payments for each compound that reaches regulatory approval and has commercial sales.

This transaction is valuable to Abbott because it allows them to offset R&D expenditures with research and development income – improving their net income. This transaction is valuable to John Hancock because it allows us to generate equity returns in the form of current (royalty) income for a sizeable investment.

Abbott Laboratories is the eight largest pharmaceutical company in the U.S. Its revenues were approximately \$13 billion in 1999 and its current market capitalization is approximately \$60 billion. Abbott is rated "Aaa" by the major rating agencies.

Our business relationship with Abbott began in 1997 when we funded a \$30 million equity investment in a development stage company called Metabolex and received the right to sell our equity to Abbott at a slight premium. Since then, Abbott has introduced us to a number of other proprietary investment opportunities and we have completed one (Idun).

- 2. Determining the fair economics of the proposed transaction is highly dependent upon the number of compounds included, the characteristics of the compounds (i.e. status of development, potential sales), the structure of the royalty rates, and an estimation of what is a fair return. To help us answer these questions, we have taken several steps. First, we have researched industry standards for likelihood of success and probable sales curves for compounds in different stages of development. Second, we have developed a spreadsheet model that calculates the rate of return for a chosen portfolio and have developed a minimum number of compounds and associated milestone/royalty payments to provide us with returns that adequately compensate us for the risk we are taking. Third, we have tried to determine what rate of return the capital markets would require for the level of risk that we are willing to take.
- 3. The current portfolio of compounds that we are considering consists of five of Abbott's late-stage development compounds and a basket of three pre-clinical cancer compounds. The late-stage compounds range from mid-Phase II to starting Phase-III. Peak annual sales for these compounds range from \$400 million to \$1.2 billion. With the exception of the "cancer basket", the compounds are independent of each other. We have not completed any diligence on the specific compounds yet other than to read Abbott's press releases and analyst reports. Assuming that Abbott has correctly characterized the development stage of each compound, we have assigned probabilities of success ("regulatory approval") and time to success for each compound. Our probabilities of success come from a 1995 study by Dr. Joseph A. DiMasi at the Tufts Center for the Study of Drug Development. Dr. DiMasi's study is generally accepted by the pharmaceutical industry as an accurate assessment of the probability of success and of the time and costs associated with drug development. Dr. DiMasi looked at a random sample of 93

compounds in four broad disease categories from 12 pharmaceutical companies that were first tested in humans between 1970 and 1982.


Dr. DiMasi's results are summarized below:

	-	Probab	ility of Success		
Entering	NSAID	Cardio-	Anti-infective	Neuro-pharm	All
Phase		vascular	·		•
I	22%	26%	30%	20%	23%
П	30%	41%	38%	22%	31%
Ш	71%	72%	77%	51%	63%

Dr. DiMasi calculated the average time to approval as 8.75 years for compounds entering Phase I, 7.5 years for compounds entering Phase II, and 5.5 years for compounds entering Phase III. Embedded in these times was an approximately 30-month review process by the FDA. Due to legislative and process changes, the average FDA review time is now approximately 12 months. A revised timeframe for approval (which was been published by TCSDD in 1999), based on accelerated review by the FDA, and quicker processes within the pharmaceutical companies, is 6.0 years for Phase I, 5.0 years for Phase II, and 3.0 years for Phase III.

During the past four years, we have evaluated many equity investments in emerging pharmaceutical and medical device companies, and we have completed several transactions. During that period, we have established relationships with reliable scientific advisors. If we proceed beyond the current step of working with Abbott on the framework of a transaction, we will test Dr. DiMasi's model for reasonableness and we will engage scientific consultants to evaluate the compounds in the portfolio.

- 4. In estimating sales projections by compound, we start with expected peak sales for the compound. For now, we have accepted Abbott's number for peak sales. In our diligence process, however, we will look at sales for similar compounds, the relative success of first-to-market drugs versus others, and other factors. Our next step is to use a Sales Curve calculated by Lehman Brothers that projects ramp-up and ramp-down for sizeable drugs. In general, this Curve shows peak sales being reached seven years after launch. Ramp-up is achieved by 5% of peak sales in the first year, followed by 13%, 25%, 50%, 80%, and 90%. Peak sales are maintained for three years, and the compound then achieves 85% of peak, 75%, 70%, etc. As expected, every compound has its own unique curve, and Lehman's is only a general estimate. We have compared the curve to IMS data of prescription sales for individual compounds in a number of drug classes from 1981 to 1999. Our analysis indicates that Lehman's curve is a good fit.
- 5. We developed a spreadsheet that incorporates multiple drug compounds (and their specific probability of success, time to launch, and expected sales pattern) and a milestone/royalty structure that is intended to lower our risk in the transaction. Having multiple compounds that are substantially far along in clinical trial, we limit our exposure to the possibility that no compound is approved and that we lose all of our money. Based on the current proposed portfolio, we believe that the risk of losing all of our money is approximately 1%. The second component of our model is to receive a milestone payment from Abbott upon regulatory approval. We have proposed \$10 million per compound. This payment is intended to return cash to John Hancock sooner and to somewhat lower the risk that actual sales do not meet projected sales. The third component of our model is to have a tiered royalty structure such as 8% of the first \$400 million of aggregate annual sales, 4% of the next \$600 million of aggregate annual sales, and 1% of aggregate annual sales in excess of \$1 billion.



6. The last step of our analysis is to determine what a fair economic return for this transaction should be. We have benchmarked this transactions in a number of ways, such as: R&D vehicles for pre-clinical compounds were sold with expected IRRs (over a three-to-five year period) of approximately 40%; Hambrecht & Quist has estimated pharmaceutical IRRs for single phase-II compounds to be 40% and single phase-III compounds to be 25%; the Palisade Partners (Sony movies) transaction that we participated in last year has an expected IRR of 20%; Elan Pharmaceuticals in currently in the market with a pooled transaction with an IRR of 25% (over 18-24 months); and our proprietary analysis of the equity market's IRR for Abbott's entire R&D pipeline of 16-22%. Based on these comparisons, we think that an IRR of 20-25% is reasonable – and Abbott agrees.

We also evaluated the relationship between our investment (and Abbott's) in the entire portfolio and the average royalty rate that we expect to receive – which is approximately 4-5%. We estimate that the current value of the compounds that Abbott is contributing to the transaction is about \$1 billion. During the four year investment period, Abbott expects to invest \$800 million on the compounds, in addition to our \$200 million. Based on these amounts, our investment is approximately 10% of the total invested dollars. Most pharmaceutical companies earn about a 50% pre-tax margin (excluding R&D expenses) on sales. On a net basis, then, our expected royalty should be about 5%.

7. The current proposed portfolio consists of (1) a mid Phase II compound with projected peak sales of \$700 million, (2) a late Phase II with peak sales of \$1.2 billion, (3) an early Phase III with peak sales of \$700 million, (4) an early Phase III with peak sales of \$700 million, (5) an early Phase II with peak sales of \$400 million, and (6) a basket of three cancer compounds currently in pre-clinical trials, each of which may have peak sales of \$400 million.

John Hancock will find [\$50 million] per year for four years. Milestone payments of \$10 million will be paid for each compound that receives regulatory approval. Royalty rates will equal [8%] on the first \$400 million in sales, [4%] on the next \$600 million of sales, and [1%] on sales in excess of \$1 billion. Abbott would also like to build in a provision to limit royalties if our actual IRR exceeds a certain amount.

Based on this portfolio, and running our model 500 times, the probability of losing all of our money is about 1%. There is also about a 1% probability of just getting our money back (with no return). The average return is approximately 20% and tightly bound around that percentage. The maximum return is 25%. Looking at sensitivities to our assumptions, if the \$1.2 billion compound generated only \$600 million in revenues or if all compounds generated only 75% of projected sales, our IRR would be reduced by approximately 1-2%. Our probability of failure would not change.

It is important to note that the expected IRRs are over a long period of time (10-15 years). Assuming that we could sell our future royalty stream after the fifth year, our five-year IRR would be about 24% (and the maximum return would be about 35%).

A one-percent probability of total loss combined with a one-percent chance of not earning a return is approximately equivalent to a 30 basis point annual loss over five years — or a "Baa" credit rating. The expected return of 20% is attractive relative to the risk that we would be taking.

### Estimated Cash Flow (\$ millions)

Year	JH Cash	Milestone	Royalty	Aggregate	班
	Payments	Payments	Payments	Cash Received	Net Cash Flow
2000	(50)				(50)
2001	(50)				(50)
2002	(50)		6	6	(44).
2003	(50)		18	18	(32)
2004		30	35	65	65
2005			48	48	48
2006			58	58	58
2007			62	62	62
2008			65	65	65
2009			65	65	65
2010			66	66	66
2011			64	64	64
2012			61	61	61
2013			32	32	32
2014			14	14	14
TOTAL	(200)	30	594	624	424

#### Accounting Structure

### Anticipated Structure:

We would establish a trust to make the investment and issue one series of certificates backed by the royalty cash flows. Rating agency would rate the certificate to a minimum return (approximately 8 - 10%). In early years, when no cash flow is available, bond would accrete at this minimum return. When cash flow is available it first pays the current period return, then the accreted return, then pays down the bond. If certain targets are hit, some cash flow beyond the minimum return can be designated as excess interest and booked as income.

Balance sheet treatment: Bond, with an NAIC 2 or NAIC 3 rating. This requires we get a rating agency to rate the bond.

Income treatment: Current, fixed return of minimum rated yield. If deal is successful, excess income in later years.

**Downside scenario:** If the program is performing poorly, bond will be downgraded and ultimately rated category 6. Bond will be written down each period as necessary to reflect drop in value. This will spread the loss over several years and many quarters.

#### Issues:

- 1) Can this be considered a bond?
  - Many royalty streams have been securitized in this fashion. The David Bowie bond (bought by Prudential Insurance) is the most visible example, but other musical groups have sold off royalties in bond form and a drug royalty deal is currently being marketed. The SVO will consider it an Asset Backed Security if we get it rated by a reputable rating agency.
- 2) Can we accrete income during the first few years when no cash flow is available? There are plenty of examples of accreting bonds. Corporate bonds can be issued on a zero coupon or pay-in-kind (PIK) basis. In the asset-backed arena, principal only strips allow accretion of income. A recent deal backed by film revenues was rated by Duff & Phelps to a minimum yield. This should allow the accretion of income.

### Alternative Structure:

If we either cannot get a rating agency comfortable rating this bond or E&Y will not buy off on the structure, we can create a RACERS trust. Our accountants and E&Y do agree that a RACERS structure meets the accounting rules (we spent lots of time exploring the possibility of placing our volatile BA assets in a RACERS trust), with the provision that a 3% equity portion be sold to a third party.. The idea behind a RACERS is to put a zero coupon bond and the contemplated investment in a trust. The zero coupon bond ensures the trust certificate can be rated by the SVO and hence booked as a bond. The RACERS would use structured note accounting, which requires all cash flow be booked as income. We'd create cash flow, and hence income, in the early years by including cash in the trust that can be distributed, according to preset rules, as income. We can dampen the volatility of the income in the later years by structuring a maximum coupon paid by the trust. There are several disadvantages of this structure. First, the cash and zero coupon bond drag down the economics. There are ways to mitigate this, but ultimately there is likely to be some drag. Second, structured notes can draw the attention of the rating agencies and security analysts. This could be viewed as a tool to manage earnings. While it is small relative to John Hancock's total assets, it is a large (ultimately \$200 million) transaction. Finally, we would need to find a buyer of the 3% equity. Most buyers would likely demand a very high return for this investment.

# PLs' RQ



### RECEIVED

### **Global Pharmaceutical Products Division**

NOV 2 1 2003

James L. Tyree Vice President BOND & CORP. FINANCE GROUP

200 Abbott Park Road Abbott Park, Illinois 60064-6189

Global Licensing and New Business Development

November 20, 2003

### VIA FACSIMILE (LETTER ONLY) FOR SETTLEMENT PURPOSES ONLY VIA FEDERAL EXPRESS (LETTER AND EXHIBITS)

John Hancock Financial Services, Inc. John Hancock Place 200 Clarendon Street, T-57 Boston, Massachusetts 02116 Attn: Mr. Stephen J. Blewitt Senior Managing Director

Re:

Research Funding Agreement Between Abbott Laboratories ("Abbott") and John Hancock Life Insurance Company, John Hancock Variable Life Insurance Company and Investors Partner Life Insurance Company (collectively, "John Hancock") Dated March 13, 2001 (the "Agreement")

Dear Mr. Blewitt:

I write in response to your November 14, 2003 letter in which you reiterate that John Hancock believes that it has no obligation to make its 2003 and 2004 payments under the parties' Research Funding Agreement ("Agreement"), and assert that John Hancock "continues to have serious concerns" regarding the development status of ABT-594 at the time the parties entered into the Agreement. While I, too, would prefer to continue our settlement discussions orally, I believe a written response to the assertions in your letter is warranted.

First, Abbott strongly disagrees with the assertion in your letter that John Hancock has been relieved of its payment obligations under the Agreement. Section 3.4 of the Agreement, upon which John Hancock relies for its position, relieves John Hancock of its obligation to make Program Payments only for years "succeeding" any in which Abbott does not demonstrate "in its Annual Research Plan" (not preliminary internal estimates) its intent and reasonable expectation to exceed the Aggregate Spending Target. The Agreement specifically states that "[f]or the avoidance of doubt, Program Payments for the Program Year in which such event occurs shall still be due and payable." Section 3.4(iv). Abbott, with John Hancock's knowledge, acquiescence and approval, furnished John Hancock with the Annual Research Plan at issue during 2003, not 2002. Hence, even assuming Section 3.4(iv) applies to the present situation, John Hancock's 2003 payment is due and payable on December 1, 2003 under the plain language of that provision.

Mr. Stephen J. Blewitt November 20, 2003 Page 2

In any event, Section 3.3 of the Agreement expressly provides that Abbott "shall be permitted to change its funding obligation" by choosing to spend the Aggregate Carryover Amount in the fifth year of the Program in order to meet the Aggregate Spending Target. That is all that has occurred here. We believe that John Hancock's position that this permitted change to Abbott's funding obligation relieves it of all further payment obligations is contrary to the parties' intent, the structure and language of the Agreement read as a whole, and simple logic.

Second, as I set forth in my earlier letter, Abbott takes any allegations of fraud very seriously and, after investigating the matter, has concluded that no basis exists for any such allegation by John Hancock. Having now reviewed the November 26, 2001 letter from Abbott to John Hancock, several things are clear. Almost two full years ago, Abbott provided this information to you and Abbott expressly invited any questions you may have regarding the information provided. I am confident that had this information caused John Hancock "serious concern" that it had been defrauded, it would have taken advantage of the limitless opportunities it has had to ask questions or raise the issue with Abbott prior to now. Nonetheless, we are now happy to provide you with information concerning ABT-594.

As we informed you in our 2001 Annual Research Plan as well as in other documents provided to John Hancock, we conducted an ABT-594 Phase IIb Neuropathic Pain Study (internally known as "M99-114") in 2000 and 2001 with more than 300 subjects. As I told you on November 19, while we were awaiting the results of the Study, the project was funded on a Milestone/Go-No Go basis. On April 23, 2001, the Study was "unblinded" for the first time and Abbott learned the results of the Study. See E-mail dated April 23, 2001 from James W. Thomas to Sharon Druker et al (attached as Exhibit A).

Upon receiving the results of the Study in April 2001, Abbott learned that while ABT-594 significantly reduced diabetic neuropathic pain, it had extensive side effects, which included nausea and vomiting. See M99-114 Study Review dated April 23, 2001 (Exhibit B). Abbott analyzed the results more extensively on May 2, 2001. See ABT-594 Phase IIb Diabetic Neuropathic Pain Results: M99-114 Study Review (Exhibit C).

Obviously, Abbott did not embark on the other Studies that had been contemplated to commence after the Phase IIb Neuropathic Pain Study. Had the Study been successful, we would have spent the approximately \$35 million outlined in the Research Plan. Abbott instead conducted further evaluation of the results of the Pain Study and their effect on the future of ABT-594. In August 2001, a presentation was made to the Abbott Pharmaceutical Executive Management Committee Review concerning ABT-594. See ABT-594 Pharma Executive Management Committee Review dated August 21, 2001 (Exhibit D) and ABT-594 Decision Analysis dated August 21, 2001 (Exhibit E).

In September 2001, Abbott investigated whether it had the ability to reduce the side effects via modified titration and lower peak dosing. See ABT-594 Revised Transition

<sup>&</sup>lt;sup>1</sup> I am providing documents to you under the terms of the confidentiality contained in the Agreement.

Mr. Stephen J. Blewitt November 20, 2003 Page 3

Proposal dated September 13, 2001 (Exhibit F). In October 2001, another presentation regarding ABT-594 was made to the Pharmaceutical Executive Management Committee Review. See ABT-594 Decision Analysis, Update: ABT-594 Intermediate Dose (75-125 mcg) Ph. IIb Study dated October 8, 2001 (Exhibit G). It was after this meeting that a final decision was made to terminate the project. Thus, as you will no doubt conclude from a review of these materials, your assumption that in March 2001 Abbott had already made a determination regarding the future of ABT-594 is mistaken. Accordingly, I consider the matter closed and propose that we focus our energies upon attempting to resolve our companies' dispute over their respective obligations under their Agreement.

Towards that end, I am prepared to settle this matter on the following terms:

- John Hancock pays Abbott \$58 million as payment for the 2003 year.
- Should John Hancock wish to continue funding in 2004 in whole or in part, I would be willing to add one or more compounds to the basket in the Program. Please let me know if you want to explore this avenue.

If John Hancock agrees to and does pay the 2003 payment but not the 2004 payment, the Settlement Agreement would provide that each party's obligations and remedies under Articles 3 and 4 of the Agreement would be released. The parties' obligations and remedies under Articles 6, 7 and 8 (relating to Milestones and Royalties on the Program Compounds) would remain.

John Hancock should appreciate and recognize the enormous amount of money that Abbott is willing to release in order to get this matter behind us. If this matter proceeds to litigation, Abbott will prove that the intent of the parties was that Abbott would have five years to spend the Aggregate Spending Target. As I have made clear, if John Hancock refuses to consider a fair settlement now, we will seek both the 2003 and 2004 payments in litigation, as well as any other damages that John Hancock causes.

Stephen, please take this settlement offer in the spirit of compromise and good faith in which it is made and seize this opportunity to spend our time on more constructive endeavors. I would appreciate hearing back from you prior to the Thanksgiving Holiday.


Best regards,

James L. Tyree

## PLs' RU

Abbott

Global Pharmaceutical Licensing and New Business Development D-R50J, AP34 200 Abbott Park Road Abbott Park, IL 60064-6187 Tel: (847),937-1436 Fax: (847) 937-1771 Email: <u>suzanné.a.lebold@abbotl.com</u>



November 15, 2006

### VIA E-MAIL AND FEDERAL EXPRESS

Mr. Stephen J. Blewitt Senior Managing Director Bond & Corporate Finance Group John Hancock Life Insurance Company John Hancock Place Post Office Box 111 Boston, Massachusetts 02117

Re: Research Funding Agreement Update

Dear Steve:

In accordance with Sections 1.6 and 2.2 of the Research Funding Agreement ("Agreement"), enclosed please find Abbott's preliminary Annual Research Plan for 2007:

You will also find, in accordance with Section 2.5 of the Agreement, a report concerning the status of the Research Program and all Program Related Costs expended by Abbott for the first 10 months of 2006, together with good faith estimates for the last two months of 2006.

Sincerely

Suzanne A. Lebold, Ph.D. Divisional Vice President

Scientific Assessment and Technology Licensing

cc: Via Federal Express

John Hancock Life Insurance Company

200 Clarendon Street, T-57

Boston, MA 02117

Attn: Bond & Corporate Finance Group

John Hancock Life Insurance Company

200 Clarendon Street, T-50

Boston, MA 02117

Attn: Investment Law Division

Global Pharmaceutical Research & Development

Hancock Collaboration Spending by Program in millions of dollars

PLAN	2007	0.0	0.0	4.1	0.0	0.0	9.8	0,0	0.0	0.0	0.0	24.9	0.0	0.0	0.0	27.1	0.0																			
	Total	6.0	27.6	84.3	3.7	9.2	236,3	9,4	4,2						•	594.1	14.0																		,	14.0
LBE	2006	0'0	0.1	4.9	0.0	0.0	26.3	0.1	6.0	0.4	0.0	17.8	0'0	0'0	0.0	50.3	0.0			2006	6.0	52.6	84.3	3.7	9.7	236.3	9.4	4.2	2.5	5.6	70.7	93.6	33	9.0 594.1		14.0
	2002														,	73.1																		543.8	•	14.0
	7007														-	80,6				700 700 700 700 700 700 700 700 700 700	6.0	52.4	63.2	3.7	25	1713	6,0	1.8	17	9.5	40,6	93.5	3.3	470.7		14.0
	2003															87.1																		390.1	_	12.0
	2007							-								131.3				7007	6.0	48.3	21.1	3.7	9.2	82.2	1.2	6.1	0.0	8.7	16.1	94.1	5.5	303.0		10.0
ā.	7007	3.6	20.1	8,8	3.7	7.8	1.4	0.0	0.0	0'0	3.2	6.5	€03	1.4	22	171,7	0.0			7007	3.6	20.1	8.8	3.7	7.8	34.1	0.0	0.0	0.0	3.2	6,5	80,3	9	171.7		0.0
			Oninologe	137 #1	Idwa	Nemo Pain	Almsentin Base	Almenton Hormone Naive Prostate Cancer	1444	Non-Prostate Concers	Departite 4 Acquist	Anti-Mitatic	Hace	france	Other	Total	Management Fee / Milestones		N.		EU				Neuro Pain	Altracenton Base	Altrentan Hormone Naive Prostate Cencer							supar Other		Management Fee / Milestones
		ABT-100	ABT-492	ABT-510	ABT-518	ABT-594	ABT-627	AHT-627	ABT.627	ABT-627	ABT-724	ART.751	ALT.773	ABT-774			Memo:	٠	Cumulative		AHT-100	ABT.492	ART-510	ABT-518	ABT.594	ABT-627	ABT-627	AHT-627	AHT-622	ADTAS	ABT.761	AUTOR		611-18V		Memo:

Global Pharmaceutical Research & Development

Hancock Collaboration Spending by Program in millions of dollars

Total Year 2006	. 0.1	4.9	26.3	0.1	0.9	0.4	17.8	0.0	50.3
Month 12 LBE 2006	0.0	0.2	1.0	0.0	0.1	0.0	1.5	0.0	2.8
Month 11 LBE 2006	0.0	0.2	1.0	0.0	0.1	0.0	1.5	0.0	2.8
Month 10 YTD 2006	0.1	4.4	24.3	0.1	0.7	0.3	14.8	0.0	44.7

Altrsentan Hormone Nalve Prostate Cancer

ABT-627 ABT-627

Altrasentan Base

Quinolone TSP #1

ABT-492 ABT-510 ABT-627 Non-Prostate Cancers

ABT-627

ABT-751 ABT-773

Japan

Chemistry, Manufacturing and Controls (CMC)		GP1. ,007			Report Created: 4 .006
Histry, Manufacturing and Controls (CMC)  As Subjoint Cost  covery  Subjoint Externals:  Cal Program  Alea Program		G0631240 ABT510 TS	P Peptide		
ilistry, Manufacturing and Controls (CMC) As Solution Cost Sovery Subtotal Other Externals: Cal Program Postmental Medicine (exc. Phase I Ctr) Postmental Medicine (exc. Phase I Ctr) Postmental Medicine (exc. Phase I Ctr) Postmental Medicine (exc. Phase I Ctr) Postmental Medicine (exc. Phase I Ctr) Postmental Medicine (exc. Phase I Ctr) Postmental Medicine (exc. Phase I Ctr) Postmental Medicine (exc. Phase I Ctr) Postmental Medicine (exc. Phase I Ctr) Postmental Medicine (exc. Phase I Ctr) Postmental Medicine (exc. Phase I Ctr) Postmental Medicine (exc. Phase I Ctr) Postmental Medicine (exc. Phase I Ctr) Postmental Medicine (exc. Phase I Ctr) Postmental Medicine (exc. Phase I Ctr) Postmental Selector (exc. Phase I Ctr) Postmental Medicine (exc. Phase	Homali	Total Patients	Start	End	2007 S(000s)
r Support Cost  covery  Subtotal Other Externals:  Total External  Total External  Total External  2007 Other Units  partners Hospical Team postmental Medicine (excl. Phase I Ctr) postmental Phase I Ctr) postmental Phase I Ctr) postmental Medicine (excl. Phase I Ctr) postmental Phase I Ctr) postmental Phase I Ctr) postmental Phase I Ctr) postmental Phase I Ctr) postmental Phase I Ctr) postmental Phase I Ctr) postmental Phase I Ctr) postmental	Chemistry, Manufacturing and Controls (CMC)		03/03	70/60	828
Subtotal Other Externals:  Following Subtotal Other External  Following Supply Management  Iniestry, Manufacturing and Controls (CMC)  Sees R&D  Clinical Safety Evaluation  e-Clinical Safety  re Support Cost  sovery  Total Files			04/03	03/08	\$26 \$57
cal Program nical Program nical Program nical Project Team perimental Medicine (excl. Phase I Ctr) perimental Medicine (excl. Phase I Ctr) perimental Medicine (excl. Phase I Ctr) ug Supply Management nistry, Manufacturing and Controls (CMC) noses R&D Clinical Safety Evaluation a-Clinical Safety Evaluation a-Clinical Safety ar Support Cost scovery A Total FIEs	Subtotal Other Externals:			Total External	\$57
cal Program nical Program nical Project Team perimental Medicine (excl. Phase I Ctr) perimental Medicine (excl. Phase I Ctr) perimental Medicine (excl. Phase I Ctr) ag Supply Manufacturing and Controls (CMC) nistry, Manufacturing and Controls (CMC) oces R&D coces R&D Clinical Safety Evaluation e-Clinical Safety sovery Total Files	itemati:	2007 Other Units			2007 FTEs
Total FIEs	Clinical Program				5.2
Total FIEs	Cuntal rugest ream Experimental Medicine (excl. Phase I Ct.)				
Total FIEs	Development Operations Ong Supply Management				870
Total FIEs	Chemistry, Manufacturing and Controls (CMC) GPAS				ئ. ئ ئــــ
Total Files	Process R&D				
S <u>크 I J</u> IPIO1	Pre-Clinical Satety Evaluation Pre-Clinical Safety		-		0.1
Total FIEs	Other Support Cost				2.0
	. Liscovery QA			Total FT	

CONFIDENTIAL

Subtotal Clinical Activities:

SWOG SQ421 Collaboration Ph IV

Clinical Activities:

Rxternal

Initial Activities:   Initial Pacisis Connect combo with Taxonian Ph IIb   Initial Pacisis Connect combo with Taxonian Ph IIb   Initial Pacisis Connect combo with Taxonian Ph IIb   Initial Ph	58.7	Total FIEs			QA
### ### ### ### #### #################	1.6				Discovery
Intel   Produito Cancer combo with Toxodano Ph IIIb   Intel   Produit Produito Cancer Combo with Toxodano Ph IIIb   Intel	2.3				Other Support Cost
### ### #### #########################	ŧ				Pre-Clinical Safety
### ### #### #########################	n				Pre-Clinical Safety Evaluation
### Auth Prosists Cancer combo with Taxotiers Ph IIIb ##################################	22				GENERAL TRANSPORTER TO THE PROPERTY OF THE PRO
### ### ##############################	2.7				Cove
Adult Production Cancer combo with Toxotiens Ph IIIb	1				Drug Supply Management
### ##################################	2.9				Development Operations
tivilites:         Total Partients         Start         End         2007 :           4 and Prostatic Cannear combo with Taxolare Ph IIIb         80         0.3077         0.8009         0.8007           IIS Ovariean Cannear Study in Spain PH II         160         1.0706         10.008         12.007           Adult NSCL/C combo with Taxolare Ph IIIb         80         0.2006         12.006         10.008           Adult NSCL/C combo with Taxolare Ph IIIb         80         0.2006         12.007         0.8007           Adult NSCL/C combo with Taxolare Ph IIIb         190         0.1/08         0.1/09         0.1/09           Adult NSCL/C combo with Taxolare Ph IIIb         190         0.1/08         0.1/09         0.1/09           Adult NSCL/C combo with Taxolare Ph IIIb         190         0.1/08         0.1/09         0.1/09           7 (2007         200         0.2008         1.2007         0.2008         1.2007           18 Contract Study in Spain Ph I         200         0.2007         1.1/09         1.2008         0.9008           18 Contract (APILLI) Studies         30005         1.2008         0.9008         1.2009         0.9008         1.2009           18 Contract (APILLI) Studies         0.0005         1.2008         0.9008         1.20	12.0				European Clinical Organization (& non-ECO)
Adult NSCLC cambo with Taxotana Ph IIIb	5.0				Experimental Medicine (excl. Phase I Ctr)
### ### ##############################	n 7				Phase I Center (APILU)
### ### ##############################	24.7				Clinical Program
Activities:   Activities:				2007 Other Units	Internal:
Activities:   Activities:	2007 FT'FC				
Activities:   Activities:	\$9,163	Total External			
Activities:   Activities:					
Activities:         Total Patients         Start         End.         2007 :           AC CIIS Ovarian Cancer combo with Taxotians Ph IIIb         80         0307         0809           AC COG Pediatric solid tumors Ph IIIb         80         0107         0609           762 Adult NSCLC combo with Taxotians Ph IIIIb         160         1206         1206           782 Adult NSCLC combo with Alimia Ph IIIIb         80         0206         1207           780 Adult NSCLC combo with Alimia Ph IIIIb         140         0406         0109           780 Adult NSCLC combo with Alimia Ph IIIIb         190         0107         0508           780 Adult NSCLC combo with Alimia Ph IIIIb         190         0106         0508           780 Adult NSCLC combo with Alimia Ph IIIIb         190         0107         0508           780 Adult NSCLC combo with Alimia Ph IIIIb         190         0106         0508           780 Adult NSCLC combo with Alimia Ph IIIIb         190         0107         0508           780 Adult NSCLC combo with Alimia Ph IIII         1207         0508           780 Adult NSCLC combo with Alimia Ph IIII         1208         0107           80 Adult NSCLC combo with Alimia Ph IIII         1209         0207         11/09           90 Adult NSCLC combo with Alimia Ph IIII </td <td>\$189 \$1 458</td> <td>12/07</td> <td>01/07</td> <td></td> <td>Other Support Cost</td>	\$189 \$1 458	12/07	01/07		Other Support Cost
Activities:   Activities:	•		ğ		Pre-Clinical Safety
Activities:   Total Patients   Start   End   2007 :	\$1,268	19/07	70/07	•	Pre-Clinical Safety Evaluation
Activities:   Total Patients   Start   End   2007 :	٤	12/09	08/08		Development Operations .
Activities:   Total Patients   Start   End   2007   1/1/09     Activities:   Total Patients   Start   End   2007     Activities:   80 03/07 08/09     Activities:	3 8	04/08	12/08		Circles Explore Teach
Activities:   Total Patients   Start   End   2007   1/1/09     Activities:   Total Patients   Start   End   2007     Activities:   80 03/07 08/09     Activities:   80 03/07 08/09     Activities:   80 03/07 08/09     Activities:   80 03/07 08/09     Otto Pedia Cancer Study in Spain Ph II     Activities:   80 03/07 08/09     Otto Pedia Neurobia II   160 12/06 10/08     Otto Pedia Neurobia II   160 12/06 10/08     Otto Pedia Neurobia II   160 12/07     Otto Pedia Neurobia II   160 12/07     Otto Pedia Neurobia II   160 12/07     Otto Pedia Neurobia II   160 12/07     Otto Pedia Neurobia II   160 12/07     Otto Pedia Neurobia II   160 12/07     Otto Pedia II	Ş	09/08	12/08		Clinical Program
Activities:	41,100			-	Subtotal Clinical Activities:
Activities:   End   2007 :   Activities:   End   2007 :   End   2007 :   Activities:   End   2007 :   Activities:   End   2007 :   Activities:   End	57 70F	11/09	02/07		ManAAC IIS Overlan Cancer Study in Spain Ph
Activities:   End   End   End   End   2007 S	3				ghasa I Canter (ADI. II) Studies
Activities:   Total Patients   Start   End   2007 S	\$104	12/07	02/08	22	Masten TACI Decimbration lenkemis Phillip
Activities:   End   2007 \$     Activities:   End   2007 \$     Activities:   Start   End   2007 \$     Activities:   Start   End   2007 \$     Activities:   Start   End   2007 \$     Activities:   Start   End   2007     Activities:   Start   End   2008     Activities:   Start   End   2008     Activities:   Start   End   2008     Activities:   Start   End   2009     Activities:   Start   End   2009     Activities:   Start   End   2009     Activities:   Start   End   2009     Activities:   Start   End   2009     Activities:   Start   End   2007     Activities:   Activities:   Start   End   2007     Activities:   Start   End   2007     Activities:   Start   End   2007     Activities:   Start   End   2007     Activities:   Activities:   Activities:   Activities:   Activities:   Activities:   Activities:   Activities:   Activities:   Activities:   Activities:   Activities:   Activities:   Activities:   Activities:   Activities:	\$138	05/08	01/07	,	M05-760 Adul NSCLC combo with Almea Fit vito
### Total Patients   Start   End   2007 S	\$3,014	09/08	01/06		M05-762 Adult NSCLC combo with Taxolara en vito
### Total Patients   Start   End   2007. Start   End   2007. Start   End   2007. Start   End   2007. Start   End	\$2,572	01/09	2406	140	M06-803 Phase II COG Peds Neuroblastoma Ph Ilb
Total Patients Start End 2007 S if Activities:  Activities:  Activities:  ACTIS Ovarian Cencer combo with Taxotere Ph IIb  ACTIS Ovarian Cencer Study in Spein Ph I	\$235	19/07	12/06	100	MnnAAC COG Pediatric solid tumors Ph IIb
I Activities:  AF Artif Prostate Cancer combo with Taxoters Ph IIb  80 03/07 08/09	\$209	10/08	13707	160	MnnAAC IIS Ovarian Cancer Study In Spain Ph I
Total Patients Start End 2007 S	\$1,133 \$300	08/09	03/07	80	Clinical Activities: ManAAF Artiti Prostate Cancer combo with Taxoters Ph IIb
	1007 - 11000V	Ent	Start	Total Patients	Exernal:
	2007 Stanne				

GPRD 2007 G0631282 ABT751 Base Program

Report Created: 4-Oct-2006

### John Hancock Development Portfolio Annual Progress Report - November 15, 2006

### 1) ABT-751

- a) Phase 1:
  - i) Two Collaborative Phase 1 studies are ongoing. A total of 92 patients were enrolled to date.
    - (1) A Phase 1 extension cohort in pediatric neuroblastoma is ongoing with 23 patients enrolled
    - (2) A study in pediatric leukemia has started enrolling and will expand into a Phase 2a
- b) Four Phase 2 studies are complete. A total of 209 patients were enrolled.
  - i) Renal –Study failed to meet pre-specified criteria as single agent; minor efficacy signal of stable disease observed
  - ii) Lung Study failed to meet pre-specified criteria as a single agent, but a modest overall survival that is comparable to 2<sup>nd</sup> line treatments was observed and supports exploration of a combination regimen
  - iii) Colorectal Study failed to meet pre-specified criteria for efficacy.
  - iv) Breast Enrollment stopped and study discontinued after interim analysis failed to meet pre-specified criteria for efficacy.
- c) Two Phase 2b combination studies have been initiated.
  - i) ABT-751 in combination with pemetrexed versus pemetrexed in advanced lung cancer; enrolling
  - ii) ABT-751 in combination with docetaxel versus docetaxel in advanced lung cancer; enrolling
- d) Collaborations: Four collaboration studies are ongoing. An additional 2 pediatric collaboration studies is in late planning stages.
  - i) Collaborations are ongoing in colorectal cancer, lung cancer and prostate cancer, with both ABT-751 as a single agent, and in combination.

#### 2) ABT-627

- a) The Phase III M00-244 study concluded this summer and demonstrated limited value of ABT-627 monotherapy in the treatment of men with hormone refractory prostate cancer.
- b) Abbott will provide support for a collaboration study with the Southwest Oncology Group (SWOG) to study taxotere +/- ABT-627 for treatment of men with metatstatic hormone refractory prostate cancer.
- c) Other studies with ABT-627 are being closed as appropriate.

#### 3) ABT-510

a) There were few if any responses to single agent therapy in lymphoma, renal cell cancer and sarcoma. In non-small cell lung cancer there was no compelling evidence of any additive activity. In renal cell cancer the competitive landscape changed with the appearance of MTKIs making the possible observation of much less relevance. The situation with sarcoma is similar with few documented responses and the suggestion that time to progression may have been prolonged but only in comparison to a limited historical control. Abbott is considering collaboration options to accelerate the program.

## PLs' RX



Thomas E Woldat/LAKE/PPRD/ABBOT

03/21/2001 04:59 PM

Mike A Higgins/LAKE/PPRD/ABBOTT@ABBOTT, Michael A Comilla/LAKE/PPRD/ABBOTT@ABBOTT, Matthew R Russell/LAKE/PPRD/ABBOTT@ABBOTT, William A To Brown/LAKE/PPRD/ABBOTT@ABBOTT, Kay Rekau/LAKE/PPRD/ABBOTT@ABBOTT, Steve Szostak/LAKE/PPRD/ABBOTT@ABBOTT, Anita P Bakker/LAKE/PPRD/ABBOTT@ABBOTT

cc bcc

Subject Proposed APU Target Adjustments

Attached please find my proposed adjustments to APU targets based on 1) Review of detail budget into in Oracle and 2) based on issues that have come in in the APU Review process(e.g. Kaletra PARD increase, Endothelin CRO savings, etc.).


I would appreciate it if each of you can review (analysts please review your respective projects). I think the most "controversial" proposal is increasing the 773 target by \$1.6MM. Bill I would appreciate it if you could do a scrub of Oracle upon your return from vacation. I noticed that your development cost summary reflects different numbers than currently in Oracle (incidentially the \$1.2MM SPD reduction needs to get dialed into Oracle). At a minimum, we should increase the 773 target for the IV Phase I study.

Let me know your comments.

Tom

2

Page 100proposed.xls



### 2001 APRIL UPDATE GLOBAL PHARMACEUTICAL RESEARCH & DEVELOPMENT KEY PROJECT SUMMARY (SIM)

Actuals		2001	2001	Proposed	2001 APU REVISED	APU vs PLAN	POLITICAL
thru 2000	FRANCHISES	PLAN	APU	Adjusi	HEVISED	Fev/(Unlav)	DOMMENTE
	NEUROLOGY						
179.9	Depakote	24.1	24.1	(0.6)	23.5	0.0	Lower Impulsive Aggression costs
		14	14	10.07	14	0.0	No target last - passame risk of \$0 3MM for CRO payment
156 5	Gabitil		93		9.3		ter to factor - tertains in the same in out of law.
62.2	ABT-594 (formerly CCM)	0,3				(0 1)	PARD stability S. 2UM (SS to confirm arrit), offset by larget edi
27	COX - 11 (ABT-963)	12	12	D.1	13		
1.6	ABT-089 (formerly ChCM)	0.6	ao	0.3	. 0.9	(0.3)	PARD stability (SS to confirm arra)
	ABS-103					•	
	NPS-1776		•				
	RP Scheret / Alza (Hydrocodone)	4.0	4,0		4.0	<u>'</u>	
382.9	Bublotal NEUROLOGY	40.5	40.6	(0.2)	40,4	D.2	
	ANTI INFECTIVE						
393,5	Clarithromycin	14.9	14.9		14 9	-	SO,BMM of task required to achieve target
153.5	Katolide (ABT-773)	0.88	88.0	1.5	8 ¢8	(1.6)	Fund IV form Ph 1 50.51414 and soft target to detail budget
11.6	Quinolone (ABT-492)	24.5	24 5	(0,2)	24 3	02	Adj target to detail budget
_	Neuraminidase (ABT-877)				-		
	Omnical	4.9	4.9	(0.1)	4.8	O.t.	Adj target to detail budgel
559.2	Subtotal ANTI INFECTIVE	132,3	132.3	1.3	133.8	(5.7)	
	UROLOGY/CARDIOLOGY						
85.7	BPH Backup (ABT-980)	23	23		2.3	_	
14.1	Fenofibrate (Fournier)	1.4	1.4	0.6	2.0	(0.6)	Convinue PARD stability work (not in 01 Plan target)
12,3	Nippon Shinyakyu (NS-49)	1,00				,,	
	KCO (ABT-598)	E 6	5.0		5.0		
112.1	Subtotal UROLOGY/CARDIOLOGY	<u> 5.0</u> 8.7	8.7	0.5	93	(0.6)	
112.1	SUBIDIES DROEOG FICARDIOCOG F	0,1	0,1			(0.0)	•
	- <del>ÃÍX</del>	4.0	4.0	02	4.2	(0.2)	Warlarin interaction Study (EU Registration)
299.3	Ritonavir	51.0	9.0 51 D	1.0	62.0	(1.0)	Stobility & Dissolution issued; target still reflects \$1.2MM task
215.7	Kaletra			1,10	2.5	• •	Target reflects \$252M task judgment
61.0	Cyclosporine	2.5	<u>2.5</u> 57.5	1.2	58.7	(1.2)	Initial unione 2505W (SEE Inchine)
576.0	Subtotal HIV	57.5	57.5	1.2	50.7	(1.2)	
	CANCER						
964	Endothelin (ABT-627)	38.5	38.8	(D.4)	38 4	0.4	Printerly Phase III CRO savings .BMM
11.0	TGP #1 (ABT-510)	10.0	10.0	0.6	10 6	(0.6)	SPD increase (offset in Other-Pilot Plant Excess Cap)
5.6	Metalloproteinase (ABT-518)	7.4	7.4	(D 1)	7,3	01	
3.9	Anti-Mkotic (ABT-751)	8.4	8.4	(0 1)	8.3	0.1	
1.0	K-5 (ABT-828)						
	FTI #2						
117.9	Subtotal CANCER	64.6	64.6	(0.0)	64.6	_	
n/a	Other	86.1	86,1	(2.9)	53.2	2.9	
n/a	Affordability	(9,8)	(9.8)		(9.8)	***	
n/a	Total Development	380.0	380.0	0,0	380,0	0.0	
n/a	Discovery	192.0	192.D		192.0	-	
Viewas is	Total Grass Wa KNOLL**	m) (	5720	0.0	572:0	3, <del>00000000</del>	
※ 後度 44 Hote 14 またた							
n/a	KNOLL Projects*	n/a	263 D	263.0	263 0	nia	

Highly Confidential

ABBT364019

"Knoll Project detail is located in the Knoll tab of the Book
""Excludes Sister Divisions

Highly Confidential

ABBT364020